



FoundationOne®CDx

Technical Information

Table of Contents

1	Intended Use.....	7
2	Contraindication.....	9
3	Warnings and Precautions.....	9
4	Limitations	9
5	Test Principle	11
6	Summary and Explanation	13
7	Sequence Analysis.....	13
8	Test Kit Contents.....	15
9	Sample Collection and Test Ordering	15
10	Instruments.....	15
11	Performance Characteristics.....	15
11.1	Concordance – Comparison to an Orthogonal Method	25
11.2	Concordance – Comparison to FoundationOne®	31
11.3	Tissue Comparability	31
11.4	Analytical Specificity	32
11.4.1	Interfering Substances	32
11.4.2	In silico Analysis – Hybrid Capture Bait Specificity	34
11.4.3	Carryover/Cross-contamination	34
11.5	Precision	34
11.6	Analytical Sensitivity: Limit of Detection (LoD) and Limit of Blank (LoB)	43
11.6.1	Limit of Blank (LoB)	43
11.6.2	Limit of Detection	45
11.7	Stability.....	49
11.7.1	Reagent Stability	49
11.7.2	DNA Stability	49
11.7.3	FFPE Sample Stability	49
11.8	Reagent Lot Interchangeability.....	49
11.9	General Lab Equipment and Reagent Evaluation	50
11.9.1	DNA Amplification.....	50
11.9.2	DNA Extraction	50
11.9.3	Validation of Migration from F1CDx HiSeq 4000 to F1CDx NovaSeq 6000	52

11.10	Guard banding/Robustness	56
12	Clinical Studies	59
12.1	FoundationOne®CDx Concordance Study for EGFR Exon19del/L858R	60
12.2	FoundationOne®CDx Concordance Study for EGFR T790M	61
12.3	FoundationOne®CDx Concordance Study for ERBB2 (HER2)	63
12.4	FoundationOne®CDx Concordance Study for ALK.....	64
12.5	FoundationOne®CDx Concordance Study for KRAS	66
12.6	FoundationOne®CDx Concordance Study for BRAF	67
12.7	FoundationOne®CDx Concordance Study for KRAS/NRAS.....	68
12.8	Summary of Clinical Concordance Studies.....	69
12.9	Clinical evaluation of BRCA1/2 classification for treating ovarian cancer patients with olaparib	70
12.9.1	Summary of the Clinical Study – Olaparib D0818C00001 (SOLO1)	70
12.9.2	Accountability of the PMA Cohort	70
12.9.3	Efficacy Evaluation	71
12.10	FoundationOne®CDx Clinical Bridging Study for PIK3CA.....	71
12.10.1	Safety Analysis.....	72
12.10.2	Effectiveness Results	72
12.11	Clinical evaluation of FGFR2 rearrangement detection for treating Cholangiocarcinoma (CCA) patients with pemigatinib.....	74
12.11.1	Summary of the Clinical Study – INCB 54828-202 (FIGHT-202)	74
12.11.2	Accountability of the PMA Cohorts	75
12.11.3	Efficacy Evaluation	75
12.12	Clinical evaluation of MET exon 14 classification for treating NSCLC patients with capmatinib 77	
12.12.1	Summary of the Clinical Study – CINC280A2201 (GEOMETRY-mono 1).....	77
12.12.2	Summary of the Clinical Bridging Study.....	77
12.12.3	Safety Analysis.....	77
12.12.4	Accountability of the PMA Cohorts	77
12.12.5	Clinical Concordance	78
12.12.6	Efficacy Evaluation	78
12.12.7	Conclusions	79
12.13	Clinical evaluation of HRR gene alterations for treating prostate cancer patients with olaparib 79	
12.14	Clinical Evaluation of pembrolizumab in TMB-H solid tumors	81
12.15	Clinical evaluation of VITRAKVI (larotrectinib) in patients with solid tumors with NTRK1, NTRK2, NTRK3 fusions	83

12.15.1	Post-Approval Study (PAS) to Support the Clinical Effectiveness of F1CDx for Treatment with VITRAKVI (larotrectinib)	88
12.16	Clinical Evaluation of KEYTRUDA (pembrolizumab) in patients with MSI-H solid tumors	89
12.16.1	Post-Approval Study to Support the Clinical Effectiveness of F1CDx for the Treatment with KEYTRUDA	93
12.17	Clinical Evaluation of ROZLYTREK (entrectinib) in Solid Tumor Patients with NTRK Fusions ..	94
12.17.1	Summary of the Clinical Studies	94
12.17.2	Accountability of the PMA Cohort	94
12.17.3	Summary of the Clinical Bridging Study	94
12.17.4	Clinical Concordance	94
12.17.5	Efficacy Evaluation	95
12.17.6	Post-Approval Study (PAS) to Support the Clinical Effectiveness of F1CDx for the Treatment with ROZLYTREK (entrectinib)	95
12.18	Clinical Evaluation of ROZLYTREK (entrectinib) in NSCLC Patients with ROS1 Fusions	96
12.18.1	Summary of the Clinical Studies	96
12.18.2	Accountability of the PMA Cohort	96
12.18.3	Summary of the Clinical Bridging Study	97
12.18.4	Clinical Concordance	97
12.18.5	Efficacy Evaluation	97
12.18.6	Conclusions	98
12.19	Clinical Evaluation of AKEEGA® (niraparib + abiraterone acetate) in metastatic castration resistant prostate (mCRPC) Patients with BRCA1, BRCA2 Alterations	98
12.19.1	Summary of the Clinical Study – 64091742PCR3001 (MAGNITUDE, PCR3001)	98
12.19.2	Accountability of the PMA Cohort	98
12.19.3	Efficacy Evaluation	99
12.19.4	Sensitivity Analysis – Impact of F1CDx Unevaluable Set (F1CDx invalid results + not tested by F1CDx) 100	
12.19.5	Safety Analysis	100
12.19.6	Conclusions	100
12.20	Clinical Evaluation of RETEVMO (selpercatinib) in Solid Tumor Patients with RET Fusions ..	100
12.20.1	Summary of the Clinical Trial- LIBRETTO-001	100
12.20.2	Accountability of the NDA and sNDA Cohorts	101
12.20.3	Summary of the Clinical Bridging Study	101
12.20.4	Clinical Concordance	101
12.20.5	Efficacy Evaluation	102
12.20.6	Safety Analysis	103
12.20.7	Conclusions	103
12.21	Clinical Evaluation of Braftovi® (encorafenib) in combination with Mektovi® (binimetinib) in NSCLC Patients with BRAF V600E Alterations	104

12.21.1	Summary of the Clinical Studies.....	104
12.21.2	Accountability of the PMA Cohort	104
12.21.3	Summary of the Clinical Bridging Study.....	104
12.21.4	Clinical Concordance	104
12.21.5	Efficacy Evaluation	105
12.21.6	Conclusions	107
12.22	Clinical evaluation of TRUQAP™ (capivasertib) in combination with Faslodex (fulvestrant) in breast cancer patients with PIK3CA/AKT1/PTEN alterations	107
12.22.1	Summary of the Clinical Study- CAPItello-291.....	107
12.22.2	Accountability of the PMA Cohort	107
12.22.3	Efficacy Evaluation of F1CDx	107
12.22.4	Safety Analysis.....	108
12.22.5	Conclusions	108
12.23	Clinical evaluation of LYNPARZA® (olaparib) in combination with abiraterone in mCRPC Patients with BRCA1, BRCA2 Alterations.....	108
12.23.1	Summary of the Clinical Study – D081SC00001 (PROpel)	108
12.23.2	Tissue to Liquid concordance	109
12.23.3	Efficacy Evaluation	109
12.23.4	Sensitivity Analysis – Impact of F1CDx Unevaluable Set (FoundationOneCDx invalid results + not tested by FoundationOneCDx)	110
12.23.5	Safety Analysis.....	111
12.23.6	Conclusions	111
12.24	Clinical evaluation of OJEMDA™ (tovorafenib) in pediatric low-grade glioma patients with BRAF V600 mutations and BRAF fusions	111
12.24.1	Summary of the Clinical Study – FIREFLY-1	111
12.24.2	Accountability of the PMA Cohort	111
12.24.3	Summary of the Clinical Bridging Study.....	111
12.24.4	Clinical Concordance	112
12.24.5	Efficacy Evaluation	112
12.24.6	Sensitivity Analysis	114
12.24.7	Safety Analysis.....	114
12.24.8	Conclusions	114
12.25	Clinical evaluation of TEPMETKO® (tepotinib) in advanced or metastatic NSCLC patients with MET exon 14 skipping alterations.....	114
12.25.1	Summary of the Clinical Study – NCT02864992 (VISION)	114
12.25.2	Accountability of the PMA Cohorts	115
12.25.3	Summary of the Clinical Bridging Study.....	115
12.25.4	Clinical Concordance	115
12.25.5	Efficacy Evaluation	116

12.25.6	Sensitivity Analysis	118
12.25.7	Safety Analysis	118
12.25.8	Conclusions	118
12.26	Clinical evaluation of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) patients with HRR gene alterations ..	118
12.26.1	Summary of the Clinical Study – TALAPRO-2	118
12.26.2	Accountability of the sPMA Cohort	119
12.26.3	Efficacy Evaluation of F1CDx	119
12.26.4	Safety Analysis	120
12.26.5	Conclusions	120
12.27	Clinical evaluation of ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant in breast cancer patients with PIK3CA alterations	120
12.27.1	Summary of the Clinical Study INAVO120	120
12.27.2	Accountability of the sPMA Cohort	121
12.27.3	Summary of the Clinical Bridging Study	121
12.27.4	Concordance between F1CDx and F1LCDx assays based on INAVO120 trial data	121
12.27.5	Clinical Concordance	122
12.27.6	Efficacy Evaluation	123
12.27.7	Sensitivity Analysis	124
12.27.8	Safety Analysis	125
12.27.9	Conclusions	125
13	CDx Classification Criteria	125
13.1	CDx classification criteria for ALECENSA® (alectinib), ALUNBRIG® (brigatinib), XALKORI® (crizotinib), or ZYKADIA® (ceritinib) for patients with NSCLC	125
13.2	CDx classification criteria for ERBITUX® (cetuximab) and VECTIBIX® (panitumumab) for patients with colorectal cancer	125
13.3	CDx classification criteria for AKEEGA® (niraparib + abiraterone acetate) or LYNPARZA® (olaparib) in combination with abiraterone for patients with prostate cancer, or for LYNPARZA® (olaparib) for patients with ovarian cancer	125
13.4	CDx classification criteria for PIQRAY® (alpelisib) for patients with breast cancer	127
13.5	CDx classification criteria for PEMAZYRE® (pemigatinib) for patients with cholangiocarcinoma	127
13.6	CDx classification criteria for TABRECTA® (capmatinib) and TEPMETKO® (tepotinib) for patients with NSCLC	127
13.7	CDx classification criteria for LYNPARZA® (olaparib) for patients with prostate cancer	127
13.8	CDx classification criteria for PIQRAY® (alpelisib) for patients with breast cancer	128
13.9	CDx classification criteria for ROZLYTREK® (entrectinib) or VITRAKVI® (larotrectinib) for patients with solid tumors	128
13.10	CDx classification criteria for ROZLYTREK® (entrectinib) for patients with NSCLC	129

13.11	CDx classification criteria for RETEVMO® (selpercatinib) for patients with solid tumors	129
13.12	CDx classification criteria for TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant) for patients with breast cancer	129
13.13	CDx classification criteria for OJEMDA™ (tovorafenib) for patients with pediatric low-grade glioma	130
13.14	CDx classification criteria for TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for patients with prostate cancer	130
13.15	CDx classification criteria for ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant for patients with breast cancer	131
14	References	131

FoundationOne®CDx

Technical Information

Foundation Medicine, Inc.
400 Summer Street, Boston, MA 02210
Phone: 617.418.2200

1 Intended Use

FoundationOne®CDx (F1CDx) is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in **Table 1** in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in **Table 1** are not prescriptive or conclusive for labeled use of any specific therapeutic product.

Table 1. Companion diagnostic indications

Tumor Type	Biomarker(s) Detected	Therapy
Breast cancer	AKT1 E17K; PIK3CA R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L, and G1049R; and PTEN alterations	TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant)
	ERBB2 (HER2) amplification	HERCEPTIN® (trastuzumab)
		KADCYLA® (ado-trastuzumab emtansine)
		PERJETA® (pertuzumab)
	PIK3CA mutations	ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant
	PIK3CA mutations (C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y)	PIQRAY® (alpelisib)
Cholangiocarcinoma	FGFR2 fusions and select rearrangements	PEMAZYRE® (pemigatinib)
Colorectal cancer	KRAS/NRAS wild-type (absence of mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146))	ERBITUX® (cetuximab)
		VECTIBIX® (panitumumab)

Melanoma	<i>BRAF</i> V600 mutation-positive	TECENTRIQ® (atezolizumab) in combination with COTELLIC® (cobimetinib) and ZELBORAF® (vemurafenib)
	<i>BRAF</i> V600E	BRAF Inhibitor Approved by FDA*
	<i>BRAF</i> V600E and V600K	BRAF/MEK Inhibitor Combinations Approved by FDA*
		MEKINIST® (trametinib)
Non-small cell lung cancer (NSCLC)	ALK rearrangements	ALECENSA® (alectinib)
		ALUNBRIG® (brigatinib)
		XALKORI® (crizotinib)
		ZYKADIA® (ceritinib)
	<i>BRAF</i> V600E	BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
		TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)
	<i>EGFR</i> exon 19 deletions and <i>EGFR</i> exon 21 L858R alterations	EGFR Tyrosine Kinase Inhibitors (TKI) Approved by FDA*
	<i>EGFR</i> exon 20 T790M alterations	TAGRISSO® (osimertinib)
	<i>MET</i> single nucleotide variants (SNVs) and indels that lead to <i>MET</i> exon 14 skipping	TABRECTA® (capmatinib)
Ovarian cancer	<i>BRCA1</i> , <i>BRCA2</i> alterations	TEPMETKO® (tepotinib)
		ROZLYTREK® (entrectinib)
		LYNPARZA® (olaparib)
Pediatric low-grade glioma	<i>BRAF</i> V600 mutation-positive and <i>BRAF</i> fusions	OJEMDA™ (tovorafenib)
Prostate cancer	<i>BRCA1</i> , <i>BRCA2</i> alterations	AKEEGA® (niraparib + abiraterone acetate)
		LYNPARZA® (olaparib) in combination with abiraterone
	Homologous Recombination Repair (HRR) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>ATR</i> , <i>CDK12</i> , <i>CHEK2</i> , <i>FANCA</i> , <i>MLH1</i> , <i>MRE11A</i> , <i>NBN</i> , <i>PALB2</i> , <i>RAD51C</i>) alterations	TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide)
	Homologous Recombination Repair (HRR) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>BARD1</i> , <i>BRIP1</i> , <i>CDK12</i> , <i>CHEK1</i> , <i>CHEK2</i> , <i>FANCL</i> , <i>PALB2</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RAD54L</i>) alterations	LYNPARZA® (olaparib)
Solid tumors	MSI-High	KEYTRUDA® (pembrolizumab)
	<i>NTRK1/2/3</i> fusions	ROZLYTREK® (entrectinib)
		VITRAKVI® (larotrectinib)
	<i>RET</i> fusions	RETEVMO® (selpercatinib)

	TMB $\geq$ 10 mutations per megabase	KEYTRUDA® (pembrolizumab)
--	--------------------------------------	---------------------------

*For the most current information about the therapeutic products in this group, go to: <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>

2 Contraindication

There are no known contraindications.

3 Warnings and Precautions

1. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
2. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
3. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by F1CDx, in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%¹.

¹HER2 overexpression occurs in 18-20% of breast cancers (Owens et al. 2004 [PMID: 15140287]; Salmon et al. 1987 [PMID:3798106]; Yaziji et al. 2004 [PMID: 15113815]). Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

4 Limitations

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay.
4. Samples with <25% tumor may have decreased sensitivity for the detection of copy number alterations including *ERBB2*.
5. Clinical performance of Tagrisso® (osimertinib) in patients with an *EGFR* exon 20 T790M mutation detected with an allele fraction <5% has not been established.
6. Due to differences in variant calling between assays and technologies, the F1CDx assay may not identify and report approximately 16% (10/61) of copy number alterations and approximately 18% (3/17) of rearrangements.
7. Confirmatory testing using a clinically validated assay should be performed for all copy number alterations and rearrangements not associated with CDx claims noted in Table 1 of the Intended Use but used for clinical decision making.
8. For patients with solid tumors whose samples have MSI scores >0.0041 and <0.0124, an MSI "Cannot Be Determined" result is reported. Patients with this result should be re-tested with a validated orthogonal (alternative) method as these MSI scores represent a range of scores with low reliability. The likelihood of a patient receiving this result is ~3.29% within solid tumors.
9. Patients with solid tumors may also receive an MSI status reported as "Cannot Be Determined" due to a

quality control (QC) failure. When all sample-level quality metrics are met, the rate of MSI “Cannot Be Determined” results due to a QC failure is 8.96%. Patients with this result should consider re-testing with FoundationOne CDx or an orthogonal (alternative) method, if clinically appropriate.

10. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI’s TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut- off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
11. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient’s condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community.
12. The test is intended to be performed on specific serial number-controlled instruments by Foundation Medicine, Inc.
13. Alterations in polyT homopolymer runs may not be reliably detected in *BRCA1/2*.
14. Certain large rearrangements in *BRCA1/2* including large scale genomic deletions (affecting at least one whole exon), insertions or other deleterious genomic rearrangements including inversions or transversion events, may not be detected in an estimated 5% of ovarian cancer patients with *BRCA1/2* mutations by F1CDx.
15. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be reported under the “CDx associated findings” but may be reported in the “Other alterations and biomarkers identified” section in the patient report.
16. Alterations at allele frequencies below the established limit of detection may not be detected consistently.
17. While the overall positive percent agreement between trial enrollment assays and F1CDx was 84% (37/44), thirty percent (30%) (6/20) of patients enrolled in the VITRAKVI clinical studies using RNA-based NGS detection were negative for *NTRK* fusions by F1CDx. Four of the six patients (4/6 or 60%) that were negative for *NTRK* fusions by F1CDx had a response to larotrectinib. Therefore, F1CDx may miss a subset of patients with solid tumors with *NTRK1/2/3* fusions who may derive benefit from VITRAKVI.
18. *NTRK2* fusions per the F1CDx CDx biomarker rules for *NTRK1/2/3* fusions were not well-represented in analytical validation studies.
19. While the overall positive percent agreement between trial enrollment assays and F1CDx was 63.6% (21/33), 52.4% (11/21) of patients enrolled in the ROZLYTREK clinical studies using RNA-based NGS detection were negative for *NTRK* fusions by F1CDx. 36.4% (4/11) of the patients enrolled using RNA- based NGS detection that were negative for *NTRK* fusions by F1CDx had a response to ROZLYTREK.
20. While the overall positive percent agreement between trial enrollment assays and F1CDx was 73.9% (34/46), 30.3% (10/33) of patients enrolled in the ROZLYTREK clinical studies using RNA-based NGS detection were negative for *ROS1* fusions by F1CDx. 50.0% (5/10) of the patients enrolled using RNA- based NGS detection

that were negative for *ROS1* fusions by F1CDx had a response to ROZLYTREK

21. In detecting *ALK* rearrangements, due to differences in technology, F1CDx, FISH, and IHC may identify slightly different populations. 6.5% of negatives by F1CDx may be positive by both IHC and FISH. See Section 3.4 for more information.
22. Certain gene fusions, homozygous deletions and rearrangements including but not limited to *BRCA1*, *BRCA2*, *CDK12*, and indels in *PALB2* were not adequately represented in analytical validation studies and may not be detected consistently by F1CDx.
23. Due to technological differences in detection, patients who are negative by F1CDx for *RET* fusions may derive benefit from RETEVMO when determined to be positive by other test methods.
24. Rearrangement detection relies on the breakpoint of the targeted genes listed in Table 3. Rearrangements reported with genomic partners that consist of genes not targeted by the assay have not been validated by the assay.
25. Additional clinical investigation for *NTRK1/2/3* fusions determined to be negative by F1CDx is recommended for cancers with high *NTRK1/2/3* fusion rates (e.g., soft tissue infantile fibrosarcoma, kidney mesoblastic nephroma, salivary gland secretory carcinoma (MASC), breast secretory carcinoma) such that patients may not forgo a potentially effective therapy.
26. F1CDx may miss a subset of patients with solid tumors with *NTRK3* fusions due to the design of the test not fully covering the *NTRK3* gene and common fusion partners.
27. This assay did not detect 24.3% (9/37) of *BRAF* fusions in the clinical validation study supporting this indication. Reduced sensitivity to detect *BRAF* fusions in the clinical validation samples was attributed to sub-optimal quality metrics, including low tumor purity, observed across the whole sample population. Physicians who receive a negative report for *BRAF* fusions for patients with pediatric low-grade glioma should consider following up with another test such that patients may not forgo a potentially effective therapy.
28. The effect of hemoglobin interference has not been evaluated for the reporting of tumor mutational burden (TMB) with the FoundationOne®CDx assay.

5 Test Principle

FoundationOne®CDx (F1CDx) is performed exclusively at Foundation Medicine, Inc. owned and operated sites using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The assay employs CoExtraction, an automated DNA/RNA co-extraction methodology for DNA extraction from routine FFPE biopsy or surgical resection specimens; 50-1000 ng of DNA will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons (refer to **Table 2** and **Table 3** for the complete list of genes included in F1CDx). In total, the assay detects alterations in a total of 324 genes. Using the Illumina® NovaSeq 6000, hybrid capture–selected libraries are sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data is then processed using a customized analysis pipeline designed to detect all classes of genomic alterations, including base substitutions, indels, copy number alterations (amplifications and homozygous gene deletions), and select genomic rearrangements (e.g., gene fusions). Rearrangements in one of the targeted genes included in Table 3 may be reported along with their uniquely identified genomic partners, which can be any gene in the genome even if not explicitly targeted by the assay. Additionally, genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) are reported.

Table 2. Genes with full coding exonic regions included in FoundationOne®CDx for the detection of substitutions, insertions and deletions (indels), and copy number alterations (CNAs)

ABL1	BRAF	CDKN1A	EPHA3	FGFR4	IKZF1	MCL1	NKX2-1	PMS2	RNF43	TET2
ACVR1B	BRCA1	CDKN1B	EPHB1	FH	INPP4B	MDM2	NOTCH1	POLD1	ROS1	TGFB2
AKT1	BRCA2	CDKN2A	EPHB4	FLCN	IRF2	MDM4	NOTCH2	POLE	RPTOR	TIPARP
AKT2	BRD4	CDKN2B	ERBB2	FLT1	IRF4	MED12	NOTCH3	PPARG	SDHA	TNFAIP3
AKT3	BRIP1	CDKN2C	ERBB3	FLT3	IRS2	MEF2B	NPM1	PPP2R1A	SDHB	TNFRSF14
ALK	BTG1	CEBPA	ERBB4	FOXL2	JAK1	MEN1	NRAS	PPP2R2A	SDHC	TP53
ALOX12B	BTG2	CHEK1	ERCC4	FUBP1	JAK2	MERTK	NT5C2	PRDM1	SDHD	TSC1
AMER1	BTB	CHEK2	ERG	GABRA6	JAK3	MET	NTRK1	PRKAR1A	SETD2	TSC2
APC	C11orf30	CIC	ERRFI1	GATA3	JUN	MITF	NTRK2	PRKCI	SF3B1	TYRO3
AR	CALR	CREBBP	ESR1	GATA4	KDM5A	MKNK1	NTRK3	PTCH1	SGK1	U2AF1
ARAF	CARD11	CRKL	EZH2	GATA6	KDM5C	MLH1	P2RY8	PTEN	SMAD2	VEGFA
ARFRP1	CASP8	CSF1R	FAM46C	GID4 (C17orf39)	KDM6A	MPL	PALB2	PTPN11	SMAD4	VHL
ARID1A	CBFB	CSF3R	FANCA	GNA11	KDR	MRE11A	PARK2	PTPRO	SMARCA4	WHSC1
ASXL1	CBL	CTCF	FANCC	GNA13	KEAP1	MSH2	PARP1	QKI	SMARCB1	WHSC1L1
ATM	CCND1	CTNNA1	FANCG	GNAQ	KEL	MSH3	PARP2	RAC1	SMO	WT1
ATR	CCND2	CTNNA1	FANCL	GNAS	KIT	MSH6	PARP3	RAD21	SNCAIP	XPO1
ATRX	CCND3	CUL3	FAS	GRM3	KLHL6	MST1R	PAX5	RAD51	SOCS1	XRCC2
AURKA	CCNE1	CUL4A	FBXW7	GSK3B	KMT2A (MLL)	MTAP	PBRM1	RAD51B	SOX2	ZNF217
AURKB	CD22	CXCR4	FGF10	H3F3A	KMT2D (MLL2)	MTOR	PDCD1	RAD51C	SOX9	ZNF703
AXIN1	CD274	CYP17A1	FGF12	HDAC1	KRAS	MUTYH	PDCD1LG2	RAD51D	SPEN	
AXL	CD70	DAXX	FGF14	HGF	LTK	MYC	PDGFRA	RAD52	SPOP	
BAP1	CD79A	DDR1	FGF19	HNF1A	LYN	MYCL	PDGFRB	RAD54L	SRC	
BARD1	CD79B	DDR2	FGF23	HRAS	MAF	MYCN	PDK1	RAF1	STAG2	
BCL2	CDC73	DIS3	FGF3	HSD3B1	MAP2K1	MYD88	PIK3C2B	RARA	STAT3	
BCL2L1	CDH1	DNMT3A	FGF4	ID3	MAP2K2	NBN	PIK3C2G	RB1	STK11	
BCL2L2	CDK12	DOT1L	FGF6	IDH1	MAP2K4	NF1	PIK3CA	RBM10	SUFU	
BCL6	CDK4	EED	FGFR1	IDH2	MAP3K1	NF2	PIK3CB	REL	SYK	
BCOR	CDK6	EGFR	FGFR2	IGF1R	MAP3K13	NFE2L2	PIK3R1	RET	TBX3	
BCORL1	CDK8	EP300	FGFR3	IKBKE	MAPK1	NFKBIA	PIM1	RICTOR	TEK	

Table 3. Genes with select intronic regions for the detection of gene rearrangements, one with 3'UTR, one gene with a promoter region and one ncRNA gene

ALK introns 18, 19	BRCA1 introns 2, 7, 8, 12, 16, 19, 20	ETV4 intron 8	EZR introns 9- 11	KIT intron 16	MYC intron 1	NUTM1 intron 1	RET introns 7-11	SLC34A2 intron 4
BCL2 3'UTR	BRCA2 intron 2	ETV5 introns 6, 7	FGFR1 intron 1, 5, 17	KMT2A (MLL) introns 6-11	NOTCH2 intron 26	PDGFRA introns 7, 9, 11	ROS1 introns 31-35	TERC ncRNA
BCR introns 8, 13, 14	CD74 introns 6- 8	ETV6* introns 5, 6	FGFR2 intron 1, 17	MSH2 intron 5	NTRK1 introns 8-11	RAF1 introns 4-8	RSPO2 intron 1	TERT Promoter

<i>BRAF</i> introns 7-10	<i>EGFR</i> introns 7, 15, 24-27	<i>EWSR1</i> introns 7-13	<i>FGFR3</i> intron 17	<i>MYB</i> intron 14	<i>NTRK2</i> Intron 12	<i>RARA</i> intron 2	<i>SDC4</i> intron 2	<i>TMPRSS2</i> introns 1-3
-----------------------------	--	------------------------------	---------------------------	-------------------------	---------------------------	-------------------------	-------------------------	-------------------------------

*ETV6 is a common rearrangement partner for *NTRK3*

6 Summary and Explanation

FoundationOne®CDx (F1CDx) is a broad companion diagnostic (CDx) test for eight tumor indications. In addition to use as a companion diagnostic, F1CDx provides cancer relevant alterations that may inform patient management in accordance with professional guidelines. Information generated by this test is an aid in the identification of patients who are most likely to benefit from associated therapeutic products as noted in **Table 1** of the Intended Use.

The F1CDx platform employs whole-genome shotgun library construction and hybridization-based capture of DNA extracted from FFPE tumor tissue prior to uniform and deep sequencing on the Illumina® NovaSeq 6000. Following sequencing, custom software is used to determine genomic variants including substitutions, insertion and deletion variants (indels), copy number alterations (CNAs), genomic rearrangements, microsatellite instability (MSI), and tumor mutational burden (TMB). The output of the test includes:

Category 1: Companion Diagnostic (CDx) Claims noted in **Table 1** of the Intended Use

Category 2: Cancer Mutations with Evidence of Clinical Significance

Category 3: Cancer Mutations with Potential Clinical Significance

7 Sequence Analysis

Sequence data are analyzed using proprietary software developed by FMI. Sequence data are mapped to the human genome (hg19) using Burrows-Wheeler Aligner (BWA) v0.5.9.² PCR duplicate read removal and sequence metric collection are performed using Picard 1.47 (<http://picard.sourceforge.net>) and SAM tools 0.1.12a.³ Local alignment optimization is performed using Genome Analysis Toolkit (GATK) 1.0.4705.⁴ Variant calling is performed only in genomic regions targeted by the test.

Base substitution detection is performed using a Bayesian methodology, which allows for the detection of novel somatic alterations at low mutant allele frequency (MAF) and increased sensitivity for alterations at hotspot sites through the incorporation of tissue-specific prior expectations.⁵ Reads with low mapping (mapping quality < 25) or base calling quality (base calls with quality ≤ 2) are discarded. Final calls are made at MAF ≥ 5% (MAF ≥ 1% at hotspots).

To detect indels, de novo local assembly in each targeted exon is performed using the de-Bruijn approach.⁶ Key steps are:

- Collecting all read-pairs for which at least one read maps to the target region.
- Decomposing each read into constituent k-mers and constructing an enumerable graph representation (de-Bruijn) of all candidate non-reference haplotypes present.
- Evaluating the support of each alternate haplotype with respect to the raw read data to generate mutational candidates. All reads are compared to each of the candidate haplotypes via ungapped alignment, and a read 'vote' for each read is assigned to the candidate with best match. Ties between candidates are resolved by splitting the read vote, weighted by the number of reads already supporting each haplotype. This process is iterated until a 'winning' haplotype is selected.
- Aligning candidates against the reference genome to report alteration calls.

Filtering of indel candidates is carried out similarly to base substitutions, with an empirically increased allele frequency threshold at repeats and adjacent sequence quality metrics as implemented in GATK: % of neighboring bases mismatches < 25%, average neighboring base quality > 25, average number of supporting read

mismatches ≤ 2 . Final calls are made at $MAF \geq 5\%$ ($MAF \geq 3\%$ at hotspots).

Copy number alterations (CNAs) are detected using a comparative genomic hybridization (CGH)-like method. First, a log-ratio profile of the sample is acquired by normalizing the sequence coverage obtained at all exons and genome-wide SNPs (~3,500) against a process-matched normal control. This profile is segmented and interpreted using allele frequencies of sequenced SNPs to estimate tumor purity and copy number at each segment. Amplifications are called at segments with ≥ 6 copies (or ≥ 7 for triploid/ ≥ 8 for tetraploid tumors) and homozygous deletions at 0 copies, in samples with tumor purity $\geq 20\%$. Amplifications in ERBB2 are called positive at segments with ≥ 5 copies for diploid tumors.

Genomic rearrangements are identified by analyzing chimeric read pairs. Chimeric read pairs are defined as read pairs for which reads map to separate chromosomes, or at a distance of over 10 megabase (Mb). Pairs are clustered by genomic coordinate of the pairs, and clusters containing at least five chimeric pairs (three for known fusions) are identified as rearrangement candidates. Filtering of candidates is performed by mapping quality (average read mapping quality in the cluster must be 30 or above) and distribution of alignment positions. Rearrangements are annotated for predicted function (e.g., creation of fusion gene).

To determine a patient's MSI status, F1CDx employs a fraction based (FB) MSI algorithm to categorize a tumor specimen as MSI-High (MSI-H) or microsatellite stable (MSS). The FB-MSI algorithm calculates the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score) based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. Two FB-MSI score thresholds are applied to classify a tumor specimen as having MSI-H or MSS status. MSI-H status is reported for patients with solid tumors whose samples have FB-MSI scores ≥ 0.0124 while MSS status is reported for patients with solid tumors whose samples have FB-MSI scores ≤ 0.0041 . Per the F1CDx assay, a patient whose tumor has an MSI-H score ≥ 0.0124 is reported as eligible for treatment with KEYTRUDA. For patients with solid tumors whose samples have FB-MSI scores >0.0041 and <0.0124 , an MSI "Cannot be Determined" result is reported. Patients with this result should be re-tested with a validated orthogonal (alternative) method as these MSI scores represent a range of scores with low reliability. Patients with solid tumors may also receive an MSI status reported as MSI-Cannot Be Determined due to a quality control (QC) failure. Patients with this result should consider re-testing with FoundationOneCDx or an orthogonal (alternative) method, if clinically appropriate.

Tumor mutational burden (TMB) is measured by counting all synonymous and non-synonymous substitution and indel variants present at 5% allele frequency or greater and filtering out potential germline variants according to published databases of known germline polymorphisms including Single Nucleotide Polymorphism database (dbSNP) and Exome Aggregation Consortium (ExAC). Additional germline alterations still present after database querying are assessed for potential germline status and filtered out using a somatic-germline/zygosity (SGZ) algorithm.

Furthermore, known and likely driver mutations are filtered out to exclude bias of the data set. The resulting mutation number is then divided by the coding region corresponding to the number of total variants counted, or 793 kb. The resulting number is communicated as mutations per Mb unit (mut/Mb). Per the F1CDx assay, a patient whose tumor has a $TMB \geq 10$ mut/Mb is reported as eligible for treatment with KEYTRUDA:

After completion of the Analysis Pipeline, variant data are displayed in the FMI custom-developed CATi software applications with sequence QC metrics. As part of data analysis QC for every sample, the F1CDx assay assesses cross-contamination through the use of a SNP profile algorithm, reducing the risk of false-positive calls that could occur as a result of an unexpected contamination event. Sequence data are reviewed by trained bioinformatics personnel. Samples failing any QC metrics are automatically held and not released.

8 Test Kit Contents

The FoundationOne®CDx (F1CDx) test includes a sample shipping kit, which is sent to ordering laboratories. The shipping kit contains the following components:

- Specimen Preparation Instructions and Shipping Instructions
- Return Shipping Label

All other reagents, materials and equipment needed to perform the assay are used exclusively in the Foundation Medicine laboratories. The F1CDx assay is intended to be performed with serial number-controlled instruments.

9 Sample Collection and Test Ordering

To order FoundationOne®CDx (F1CDx), the Test Requisition Form (TRF) included in the test kit must be fully completed and signed by the ordering physician or other authorized medical professional.

Please refer to Specimen Preparation Instructions and Shipping Instructions included in the test kit.

For more detailed information, including Performance Characteristics, please find the FDA Summary of Safety and Effectiveness Data at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf

10 Instruments

The F1CDx device is intended to be performed with the following instruments, as identified by specific serial numbers:

- Hamilton STAR/STARlet Liquid Handling Workstation
- Covaris LE220-plus Focused ultrasonicator
- Thermo Fisher Scientific KingFisher™ Flex with 96 Deep-well Head
- Illumina® NovaSeq 6000 system

11 Performance Characteristics

Performance characteristics were established using DNA derived from a wide range of FFPE tissue types; tissue types associated with CDx indications were included in each study. **Table 4** below provides a summary of tissue types included in each study. Each study also included a broad range of representative alteration types for each class of alteration (substitution, insertion and deletion, copy number alterations, and rearrangements) in various genomic contexts across a broad selection of genes as well as analysis of genomic signatures including MSI and TMB. **Table 5** provides a summary of genes and alteration types associated with the validation studies.

Table 4. Summary of tissue types included in validation studies.

Tissue or Tumor Type	Limit of Detection	Precision	Pan-Tumor Analysis	NGS Concordance	Inter-Laboratory Concordance	CDx Concordance	DNA Extraction	DNA Stability (part 1)	FFPE Slide Stability	Interfering Substances	Guard Banding/Robustness	Molecular Index Barcodes	Variant Curation	Reagent Stability
Abdomen or Abdominal wall														

Tissue or Tumor Type	Limit of Detection	Precision	Pan-Tumor Analysis	NGS Concordance	Inter-Laboratory Concordance	CDx Concordance	DNA Extraction	DNA Stability (part 1)	FFPE Slide Stability	Interfering Substances	Guard Banding/Robustness	Molecular Index Barcodes	Variant Curation	Reagent Stability
Adrenal Gland														
Anus														
Appendix														
Bladder														
Bone														
Brain														
Breast														
Cervix														
Chest wall														
Cholangiocarcinoma														
Colon														
Diaphragm														
Duodenum														
Ear														
Endometrium														
Esophagus														
Fallopian Tube														
Gallbladder														
Gastro-esophageal junction														
Glioma														
Head and Neck														
Kidney														
Larynx														
Liver														
Lung														
Lymph Node														
Malignant effusions														
Mediastinum														
Nasal Cavity														
Omentum														
Ovarian														

Tissue or Tumor Type	Limit of Detection	Precision	Pan-Tumor Analysis	NGS Concordance	Inter-Laboratory Concordance	CDx Concordance	DNA Extraction	DNA Stability (part 1)	FFPE Slide Stability	Interfering Substances	Guard Banding/Robustness	Molecular Index Barcodes	Variant Curation	Reagent Stability
Pancreas														
Pancreatobiliary														
Parotid Gland														
Pelvis														
Penis														
Pericardium														
Peritoneum														
Pleura														
Prostate														
Rare Tissues*														
Rectum														
Salivary Gland														
Skin (Melanoma)														
Small Intestine														
Soft Tissue														
Spleen														
Stomach														
Thyroid														
Tongue														
Trachea														
Ureter														
Uterus														
Vagina														
Vulva														
Whipple Resection														

Table 5. Summary of genes and alteration types included in validation studies.

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
ABL1												
ACVR1B												
AKT1												
AKT2												
AKT3												
ALK												
ALOX12B												
AMER1 (FAM123B)												
APC												
AR												
ARAF												
ARFRP1												
ARID1A												
ASXL1												
ATM												
ATR												
ATRX												
AURKA												
AURKB												
AXIN1												
AXL												
BAP1												
BARD1												
BCL2												
BCL2L1												
BCL2L2												
BCL6												
BCOR												
BCORL1												
BCR												
BRAF												
BRCA1												
BRCA2												
BRD4												
BRIP1												
BTG1												
BTG2												
BTK												
C11orf30 (EMSY)												
CALR												
CARD11												
CASP8												
CBFB												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
CBL												
CCND1												
CCND2												
CCND3												
CCNE1												
CD22												
CD274												
CD70												
CD74												
CD79A												
CD79B												
CDC73												
CDH1												
CDK12												
CDK4												
CDK6												
CDK8												
CDKN1A												
CDKN1B												
CDKN2A												
CDKN2B												
CDKN2C												
CEBPA												
CHEK1												
CHEK2												
CIC												
CREBBP												
CRKL												
CSF1R												
CSF3R												
CTCF												
CTNNA1												
CTNNB1												
CUL3												
CUL4A												
CXCR4												
CYP17A1												
DAXX												
DDR1												
DDR2												
DIS3												
DNMT3A												
DOT1L												
EED												
EGFR												
EP300												
EPHA3												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
EPHB1												
EPHB4												
ERBB2												
ERBB3												
ERBB4												
ERCC4												
ERG												
ERRFI1												
ESR1												
ETV4												
ETV5												
ETV6												
EWSR1												
EZH2												
EZR												
FAM46C												
FANCA												
FANCC												
FANCG												
FANCL												
FAS												
FBXW7												
FGF10												
FGF12												
FGF14												
FGF19												
FGF23												
FGF3												
FGF4												
FGF6												
FGFR1												
FGFR2												
FGFR3												
FGFR4												
FH												
FLCN												
FLT1												
FLT3												
FOXL2												
FUBP1												
GABRA6												
GATA3												
GATA4												
GATA6												
GID4 (C17orf39)												
GNA11												
GNA13												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
GNAQ												
GNAS												
GRM3												
GSK3B												
H3F3A												
HDAC1												
HGF												
HNF1A												
HRAS												
HSD3B1												
ID3												
IDH1												
IDH2												
IGF1R												
IKBKE												
IKZF1												
INPP4B												
IRF2												
IRF4												
IRS2												
JAK1												
JAK2												
JAK3												
JUN												
KDM5A												
KDM5C												
KDM6A												
KDR												
KEAP1												
KEL												
KIT												
KLHL6												
KMT2A (MLL)												
KMT2D (MLL2)												
KRAS												
LTK												
LYN												
MAF												
MAP2K1												
MAP2K2												
MAP2K4												
MAP3K1												
MAP3K13												
MAPK1												
MCL1												
MDM2												
MDM4												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
MED12												
MEF2B												
MEN1												
MERTK												
MET												
MITF												
MKNK1												
MLH1												
MPL												
MRE11A												
MSH2												
MSH3												
MSH6												
MST1R												
MTAP												
MTOR												
MUTYH												
MYB												
MYC												
MYCL												
MYCN												
MYD88												
NBN												
NF1												
NF2												
NFE2L2												
NFKBIA												
NKX2-1												
NOTCH1												
NOTCH2												
NOTCH3												
NPM1												
NRAS												
NT5C2												
NTRK1												
NTRK2												
NTRK3												
NUTM1												
P2RY8												
PALB2												
PARK2												
PARP1												
PARP2												
PARP3												
PAX5												
PBRM1												
PDCD1												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
PDCD1LG2												
PDGFRA												
PDGFRB												
PDK1												
PIK3C2B												
PIK3C2G												
PIK3CA												
PIK3CB												
PIK3R1												
PIM1												
PMS2												
POLD1												
POLE												
PPARG												
PPP2R1A												
PPP2R2A												
PRDM1												
PRKAR1A												
PRKCI												
PTCH1												
PTEN												
PTPN11												
PTPRO												
QKI												
RAC1												
RAD21												
RAD51												
RAD51B (RAD51L1)												
RAD51C												
RAD51D (RAD51L3)												
RAD52												
RAD54L												
RAF1												
RARA												
RB1												
RBM10												
REL												
RET												
RICTOR												
RNF43												
ROS1												
RPTOR												
RSPO2												
SDC4												
SDHA												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
SDHB												
SDHC												
SDHD												
SETD2												
SF3B1												
SGK1												
SLC34A2												
SMAD2												
SMAD4												
SMARCA4												
SMARCB1												
SMO												
SNCAIP												
SOCS1												
SOX2												
SOX9												
SPEN												
SPOP												
SRC												
STAG2												
STAT3												
STK11												
SUFU												
SYK												
TBX3												
TEK												
TERC												
TERT promoter												
TET2												
TGFBR2												
TIPARP												
TMPRSS2												
TNFAIP3												
TNFRSF14												
TP53												
TSC1												
TSC2												
TYRO3												
U2AF1												
VEGFA												
VHL												
WHSC1												
WHSC1L1												
WT1												
XPO1												
XRCC2												
ZNF217												

Genes	Substitutions	Insertion/Deletions	CNAs	Rearrangements	Precision	LoD	NGS Concordance	Inter-lab Concordance	In Silico Study	DNA Extraction	Guard Band	Interfering Substances
ZNF703												

11.1 Concordance – Comparison to an Orthogonal Method

The detection of alterations by the F1CDx assay was compared to results of an externally validated NGS assay (evNGS). Overall there were 157 overlapping genes between the two assays. The comparison between short alterations, including base substitutions and short indels, detected by F1CDx and the orthogonal method included 188 samples from 46 different tumors. Additional orthogonal concordance data includes:

- 101 (53 positive, 48 negative by F1CDx) breast cancer samples were analyzed to determine concordance specific to *PIK3CA* base substitutions
- 158 (26 positive, 132 negative by F1CDx) cholangiocarcinoma samples were analyzed to determine concordance to an externally validated laboratory developed test specific to *FGFR2* fusions and select rearrangements with additional samples to be completed in the post-market setting
- 168 (50 positive, 118 negative by F1CDx) NSCLC samples were analyzed to determine concordance for detection of qualifying *MET* exon 14 base substitutions and indels
- 230 (120 positive, 110 negative by F1CDx) samples were analyzed to determine concordance specific to *HRR* gene (*BRCA1*, *BRCA2*, *ATM*, *BARD1*, *BRIP1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *RAD51B*, *RAD51C*, *RAD51D* and *RAD54L*) alterations (including base substitutions, indels, rearrangements and homozygous deletions)
- 218 (76 TMB-H, 146 non-TMB-H by F1CDx) samples were analyzed to determine concordance with a CLIA validated whole exome sequencing (WES) assay for detection of TMB ≥ 10 mutations per megabase
- 626 solid tumor samples were analyzed to determine concordance of *NTRK1/2/3* fusions. These included 588 (96 positive, 492 negative by F1CDx) samples where F1CDx served as the selection assay (subset 1) and 38 (16 positive, 22 negative by F1CDx) clinical trial samples where local clinical trial assays (LCTAs) served as the selection assay (subset 2)
- 188 (84 positive, 103 negative, 1 invalid by F1CDx) samples were analyzed to determine concordance for detection of qualifying *ROS1* fusions.
- 159 unique solid tumor samples with evaluable or valid F1CDx results were analyzed to determine concordance with a PCR-based assay for detection of MSI-High (MSI-H). Additionally, 128 colorectal cancer (CRC) and 50 uterus endometrial cancer patient samples with evaluable or valid F1CDx results randomly selected from the FMI clinical commercial database were analyzed to evaluate concordance between the MSI classification (MSI-H/deficient mismatch repair (dMMR) vs non-MSI-H/proficient mismatch repair (pMMR)) determined by the F1CDx assay and mismatch repair (MMR) immunohistochemistry (IHC) assays
- 105 solid tumor samples with evaluable or valid F1CDx results were evaluated with a PCR-based assay for detection of MSI-High (MSI-H) in a supplementary study
- 410 (153 positive, 254 negative, 3 invalid by F1CDx) solid tumor samples were analyzed to determine concordance of *RET* fusions.
- 237 (126 positive, 110 negative, 1 invalid) breast cancer samples were analyzed to determine concordance of *AKT1/PIK3CA/PTEN* alterations.
- 203 (96 positive, 105 negative, 2 invalid by F1CDx) samples were analyzed to determine concordance of

BRAF V600 mutations and *BRAF* fusions.

- 156 (43 positive, 105 negative, 8 invalid by F1CDx) prostate cancer samples were analyzed to determine concordance of *FANCA* alterations.

A summary of Positive Percent Agreement (PPA), Negative Percent Agreement (NPA) and corresponding 95% two-sided exact confidence intervals (CI) is provided in **Table 6** below. Differences in variants of unknown significance (VUS) alteration calls between the platforms were noted and are expected based on differences in filtering employed by F1CDx and evNGS. Negative predictive value and positive predictive value were also calculated and were found to be different than percent agreement because the two platforms filter VUS differently. Discordant alterations not related to VUS filtering were primarily caused by deletions with low allelic fraction in homopolymer regions. The F1CDx variant calling pipeline imposes a filter based on MAF of ≥ 0.10 for indels in homopolymer regions to reduce the likelihood of calling false positives resulting from artifacts introduced by the technology. As such, the difference observed was due to varying filter thresholds between the two platforms. Additional analytical concordance for CDx associated variants is also summarized in Table 6. For *NTRK1/2/3* fusions two analyses were conducted. A primary analysis was focused on the concordance of *NTRK1/2/3* rearrangement detection by F1CDx and evNGS assay where a sample was considered to be positive by F1CDx if any *NTRK1/2/3* rearrangements were present, otherwise it was considered as negative. This analysis was not conducted in accordance with the *NTRK1/2/3* biomarker calling rule but rather to determine the analytical accuracy of *NTRK1/2/3* rearrangement detection as *NTRK1/2/3* fusions are a subset of rearrangements, and the methodology to detect *NTRK1/2/3* rearrangement (fusions and non- fusion rearrangements) is the same. The secondary analysis focused on the concordance of *NTRK1/2/3* rearrangement detection that is predicted to result in an *NTRK1/2/3* fusion event per the F1CDx biomarker rule. In the secondary analysis, a sample was considered F1CDx positive only if it met the *NTRK1/2/3* biomarker rule, otherwise it was considered as F1CDx negative. For additional clinical concordance results for the CDx-associated variants, refer to the Summary of Clinical Studies in Section 12.

Table 6. Concordance summary for short variants inclusive of both substitutions and indels and CDx claims.

	F1CDx+ /evNGS+	F1CDx- /evNGS+	F1CDx+ /evNGS-	F1CDx- /evNGS-	PPA [95% CI]**	NPA [95% CI]**
All short variants¹	1282	73	375	284218	94.6% [93.3%-95.8%]	99.9% [99.9%-99.9%]
Substitutions¹	1111	39	334	242540	96.6% [95.4%-97.6%]	99.9% [99.8%-99.9%]
Indels¹	171	34	41	41678	83.4% [77.6%-88.2%]	99.9% [99.9%-99.9%]
<i>PIK3CA</i> substitutions in Breast Cancer	53	0	0	48	100.00% [93.3%-100.0%]	100.00% [92.6%-100.0%]
<i>FGFR2</i> fusions²	25	2	1	130	87.08% [61.40%,98.30%]	99.59% [92.87%,100.00%]
<i>MET</i> exon 14 SNVs and indels	49	0	1	118	100.0% [92.8%-100.0%]	99.27% [95.4%-100.0%]
<i>HRR</i> gene[#] substitutions	35	1	1	8243	97.22% [85.47%, 99.93%]	99.99% [99.93%, 100.00%]
<i>HRR</i> gene[#] indels	75	6	2	17627	92.59% [84.57%, 97.23%]	99.99% [99.96%, 100.00%]
<i>HRR</i> gene[#] rearrangements	10	1	5	1824	90.91% [58.72%, 99.77]	99.73% [99.36%, 99.91%]
<i>HRR</i> gene[#] copy number alterations	20	1	3	1356	95.24% [76.18%, 99.88]	99.78% [99.36%, 99.95%]

	F1CDx+ /evNGS+	F1CDx- /evNGS+	F1CDx+ /evNGS-	F1CDx- /evNGS-	PPA [95% CI]**	NPA [95% CI]**
<i>NTRK1, NTRK2, NTRK3</i> fusions	78 _{3, 4}	0 _{3, 4}	18 _{3, 4}	492 _{3, 4}	90.00% [75.00%, 100%] ^{3, 6}	99.92% [99.92%, 99.97%] ^{3, 6}
	16 _{3, 5}	2 _{3, 5}	0 _{3, 5}	20 _{3, 5}		
	64 _{7, 8}	10 _{7, 8}	4 _{7, 8}	510 _{7, 8}	54.08% [37.94%, 71.37%] ^{7, *}	99.98% [99.96%, 100.00%] ^{7, *}
	15 _{7, 9}	3 _{7, 9}	0 _{7, 9}	20 _{7, 9}		
<i>ROS1</i> fusions	79	8	2	84	90.8% [82.7%, 95.9%]	97.7% [91.9%, 99.7%]
<i>RET</i> fusions¹⁰	146	0	7	254	100% [97.44%, 100%]	97.32% [94.57%, 98.69%]
<i>AKT1, PIK3CA, and PTEN</i> alterations	144	6	9	13529	96.00% [91.55%, 98.15%] ¹⁰	99.93% [99.87%, 99.97%] ¹⁰
<i>BRAF</i> V600 mutations and <i>BRAF</i> fusions	93	3	3	102	96.88% [91.21%, 98.93%] ¹⁰	97.14% [91.93%, 99.02%] ¹⁰
<i>FANCA</i> alterations	38	2	5	103	95.00% [83.5%, 98.62%] ¹⁰	95.37% [89.62%, 98.01%] ¹⁰

¹The PPA and NPA were calculated without adjusting for the distribution of samples enrolled using the FoundationOne Laboratory Developed Test (F1 LDT), therefore these estimates may be biased upward.

²PPA and NPA were adjusted using a prevalence of 9.6% to account for sampling differential.

³Primary analysis: a sample was considered as positive if an *NTRK1/2/3* rearrangement was detected, otherwise it was considered as negative.

⁴Subset 1: samples where F1CDx served as the selection assay. Adjusted PPA and NPA based on an estimated prevalence of 0.32% in the intended use population to account for sampling differences were 100.00% [95%CI: 95.31%, 100.00%] and 99.94% [95%CI: 99.91%, 99.96%] respectively based on the primary analysis.

⁵Subset 2: clinical trial samples where local clinical trial assays (LCTAs) served as the selection assay. PPA and NPA were 88.89% [95%CI: 67.20%, 96.90%] and 100.00% [95%CI: 83.89%, 100%] respectively based on the primary analysis.

⁶ The weighted PPA and NPA are shown for the primary analysis. Bootstrap confidence intervals from 10000 simulations were used here instead of exact.

⁷Secondary analysis: a sample was considered F1CDx positive only if it met the *NTRK1/2/3* biomarker rule, otherwise it was considered as F1CDx negative.

⁸ Subset 1: samples where F1CDx served as the selection assay. Adjusted PPA and NPA based on an estimated prevalence of 0.32% in the intended use population to account for sampling differences were 13.58% [95%CI: 8.66%, 25.25%] and 99.98% [95%CI: 99.96%, 100.00%] respectively based on the secondary analysis.

⁹Subset 2: clinical trial samples where local clinical trial assays (LCTAs) served as the selection assay. PPA and NPA were 83.33% [95%CI: 60.78%, 94.16%] and 100.00% [95%CI: 83.89%, 100%] respectively based on the secondary analysis.

¹⁰ Unadjusted PPA and NPA shown along with their corresponding two-sided 95% Wilson score CIs.

* The weighted PPA and NPA are shown for the secondary analysis. Bootstrap confidence intervals from 10000 simulations were used here instead of exact.

** 95% 2-sided exact CIs were calculated, unless otherwise notated.

#HRR gene panel: *BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D* and *RAD54L*

The analysis for concordance of TMB-High (≥ 10 mutations per megabase) detection was performed using a CLIA validated whole exome sequencing (WES) assay. 218 samples were evaluated, of which 89 were not pre-screened by F1CDx (Set A) and 129 were pre-screened by F1CDx (Set B). Concordance results between F1CDx and WES for TMB calling are summarized in **Table 7** below.

Table 7. Concordance summary for TMB-High.

	F1CDx+ /evWES+	F1CDx- /evWES+	F1CDx+ /evWES-	F1CDx- /evWES-	PPA [95% CI]	NPA [95% CI]
TMB ≥ 10 mutations per megabase Set A	28	7	4	50	80.00% [62.50%,90.62%]	92.59% [82.62%,98.04%]
TMB ≥ 10 mutations per megabase Set B¹	23	1	17	88	92.31% [65.74%,100.0%]	90.84% [87.76%,93.99%]

¹PPA and NPA were adjusted using the prevalence of TMB—High estimated at 19%.

The overall PPA and NPA were calculated based on a weighted average of the results (Set A and Set B) in the TMB concordance analysis. Overall PPA was 87.28% (95% CI [64.42%, 96.17%]) and overall NPA was 91.56% (95% CI [85.66%, 95.64%]).

To determine a patient's MSI status, F1CDx employs a fraction-based (FB) MSI algorithm to categorize a tumor specimen as MSI-High (MSI-H) or microsatellite stable (MSS). The FB-MSI algorithm calculates the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score) based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. Two FB-MSI score thresholds are applied to classify a tumor specimen as having MSI-H or MSS status. MSI-H status is reported for patients with solid tumors whose samples have FB-MSI scores ≥ 0.0124 while MSS status is reported for patients with solid tumors whose samples have FB-MSI scores ≤ 0.0041 . Patients with solid tumors whose samples have FB-MSI scores >0.0041 and <0.0124 , an MSI "Cannot be Determined" result is reported.

To demonstrate the analytical accuracy of the MSI calling for the tumor profiling MSI indication, an analysis to assess concordance of MSI calling was performed using a PCR-based comparator assay. The study included 186 FFPE tumor specimens representing pan-tumor indications, of which 86 were selected with the PCR-based comparator assay, while 100 were selected with F1CDx. Of the 186 FFPE tumor specimens, 159 were evaluable with valid MSI results from both F1CDx and the comparator assay. Of the 86 samples selected with the PCR comparator assay, 24 failed to provide evaluable or valid F1CDx results due to QC failures, i.e., a 28% failure rate was observed primarily due to contamination as these samples were procured externally. Of the 100 samples selected with F1CDx, 3 failed to provide evaluable or valid F1CDx results, i.e., a 3% failure rate was observed.

The PCR-based assay-selected subset contained 62 samples and the F1CDx assay-select subset contained 97 samples. Because F1CDx employs two MSI thresholds and provides the following three outcomes based on MSI scores: MSI-H for samples with FB-MSI scores of ≥ 0.0124 , MSI-Cannot be determined for samples with FB-MSI scores >0.0041 and <0.0124 , and MSS for samples with FB-MSI scores of ≤ 0.0041 , two sets of analyses were conducted.

- For the first concordance analysis, to represent the commercial setting, samples with F1CDx MSI scores ≥ 0.0124 were treated as MSI-H/positive in the concordance analysis. Samples with F1CDx MSI scores <0.0124 and ≤ 0.0041 were treated as non-MSI-H or negative results. Samples with F1CDx MSI scores ≤ 0.0041 were treated as non-MSI-H or negative results.
- For the second concordance analysis, different from the commercial setting, samples with F1CDx MSI scores >0.0041 (this also includes samples with MSI scores of >0.0041 and <0.0124) were treated as positive results in the concordance analysis. Samples with F1CDx MSI scores ≤ 0.0041 were treated as negative results.

Since the PCR comparator assay provides three outcomes, MSI-H, MSI-Low and MSS, both MSI-Low and MSS were considered negative results for the analyses, while MSI-H was considered positive.

Concordance results between F1CDx and PCR for MSI-H and MSS calling within the combined datasets. i.e.,

samples selected with the PCR comparator assay and F1CDx assay were calculated. PPA and NPA between F1CDx and PCR for MSI-H and MSS calling within the combined datasets, i.e., samples selected with the PCR comparator assay and F1CDx assay are calculated by determining the proportion of comparator positive and negative samples that F1CDx is able to call concordantly. PPA and NPA were calculated using the observed, unadjusted data from the sample subset enrolled with the F1CDx assay; therefore, results may be biased due to how samples were selected.

The combined PPA and NPA using the ≥ 0.0124 threshold for MSI-H calling was 98.46% (95% CI [91.79% - 99.73%]) and 96.81% (95% CI [91.03% - 98.91%]) respectively. The combined PPA and NPA using the >0.0041 threshold for MSI-H calling was 100.00% (94.42%, 100.00%) and 87.23% (79.00%, 92.64%) respectively. The results demonstrate that while the PPA for MSI-H calling ranges from 98.46% to 100.00% using both thresholds, the range of NPA results is wide, from 87.23%-96.81%. The low NPA when using the >0.0041 threshold is driven by the proportion of samples with MSI-Cannot be determined status for MSI cases with MSI >0.0041 and <0.0124 (n=10). Of the 10 samples with MSI-Cannot be Determined status due to MSI scores >0.0041 and <0.0124 , 1 was MSI-High, 7 were MSS, while the remaining 2 samples had an MSI-Low status per the PCR based comparator.

While the concordance using both thresholds was high for samples from colorectal cancer (CRC) patients for the combined data sets, both PPA and NPA were 100.00%, concordance was lower for other disease ontologies (non-CRC). For non-CRC patient samples, the observed combined PPA and NPA using the ≥ 0.0124 threshold for MSI-H calling was 98.04% and 97.53% respectively, while the observed combined PPA and NPA using the >0.0041 threshold for MSI-H calling was 100.00% and 87.65% respectively. Although the number of samples from patients with uterus endometrial adenocarcinoma that had valid F1CDx results was low, 8 out of 19, the observed combined PPA and NPA using the ≥ 0.0124 threshold for MSI-H calling was 100% and 66.67% respectively, while the observed combined PPA and NPA using the >0.0041 threshold for MSI-H calling was 100.00% and 33.33%.

To demonstrate the analytical accuracy of the MSI calling for the tumor profiling MSI indication, a second evaluation of the concordance between the MSI classification (MSI-High (MSI-H)/deficient mismatch repair (dMMR) vs non-MSI-H/proficient mismatch repair (pMMR)) determined by the FB-MSI caller and mismatch repair (MMR) immunohistochemistry (IHC) assays was performed through a retrospective chart review of a randomly selected set of 134 colorectal cancer (CRC) and 52 uterus endometrial cancer patients from the FMI clinical commercial database. Overall, a total of 178 samples (including 128 CRC and 50 uterus endometrial cases) passed the F1CDx QC assessment, i.e., provided evaluable or valid F1CDx results and were used as the analysis dataset.

As for the concordance study using the PCR based comparator, two sets of concordance results were conducted described above.

The IHC assays provides two outcomes, dMMR and pMMR. dMMR are considered positive results and pMMR are considered negative results for the analyses.

The PPA and NPA for the overall sample set were 85.19% and 100.00%, respectively. Point estimates and 95% two-sided CI for PPA and NPA for the overall sample set were PPA 85.19% (95%CI [67.52, 94.08%]) and NPA 100.00% (95% CI [97.52%, 100.00%]) when using the ≥ 0.0124 threshold and PPA 88.89% (95% CI [71.94%, 96.15%]) and NPA 93.38% (95% CI [88.24%, 96.36%]) when using the >0.0041 threshold. Point estimates and 95% two-sided CI for PPA and NPA for the CRC cases were PPA 78.57% (95% CI [52.41%, 92.43%]) and NPA 100.00% (95% CI [96.74%, 100.00%]) when using the ≥ 0.0124 threshold and PPA 78.57% (95% CI [52.41%, 92.43%]) and NPA 95.61% (95% CI [90.14%, 98.11%]) when using the >0.0041 threshold. In totality, the evaluation passed the acceptance criteria of PPA and NPA $\geq 85\%$.

Point estimates and 95% two-sided CI for PPA and NPA for the endometrial cancer cases were 92.31% (95% CI [66.69%, 98.63%]) and 100.00% (95% CI [90.59%, 100.00%]) when using the ≥ 0.0124 threshold and PPA 100.00% (95% CI [77.19%, 100.00%]) and NPA 86.49% (95% CI [72.02%, 94.08%]) when using the >0.0041 threshold.

MSI-Cannot be determined status for MSI cases with MSI >0.0041 and <0.0124 was observed in 11 samples. Of the 11 samples, 1 (9%) was dMMR while the remaining 10, (91%) had pMMR status.

An additional accuracy study was conducted to demonstrate the accuracy of MSI-H calling to support the CDx indication as an aid in identifying MSI-H status in patients with solid tumors. The additional analysis to assess concordance of MSI-H calling was performed using a PCR-based comparator assay. The study design included evaluation of a test set of 161 commercially procured samples representing different tumor types to support a solid tumor indication, including samples from 7 major organ systems, as well as 56 screen failure samples from Merck's clinical trial study KEYNOTE-158. After sample processing and screening externally at the vendor and internally at FMI, a total of 111 samples failed to yield an evaluable or valid F1CDx result, while one (1) sample that underwent F1CDx sample processing was not evaluable by the PCR assay due to poor amplification.

In total, 105 samples across multiple disease indications with valid F1CDx and PCR-based MSI statuses were evaluated within the concordance analysis. MSI assessment was dichotomized to MSI-H or non- MSI-H for both F1CDx and the PCR assay results. Samples with F1CDx MSI scores ≥ 0.0124 were treated as MSI-H/positive in the concordance analysis. Samples with F1CDx FB- MSI scores <0.0124 were treated as non-MSI-H or negative results. The PCR assay includes MSI-H, MSI-L, and MSS, which was further dichotomized into MSI-H or positive and non-MSI-H (MSI-L and MSS) or negative in the concordance analysis.

Among the 105 samples, 98 were PCR-enrolled and seven (7) were F1CDx-enrolled. Because concordance in the F1CDx-enrolled set was 100%, a prevalence adjustment does not change estimates of PPA or NPA for the dataset. As such, the analysis was simplified, and the two (2) datasets (PCR- enrolled and F1CDx-enrolled) were combined directly. Point estimates for PPA and NPA were calculated directly, along with 95% two-sided Wilson Score confidence intervals (CIs).

The combined PPA was 100.00% with 2-sided 95% CI of [87.54% - 100.00%], see **Table 8**. The combined NPA was 97.44% with 2-sided 95% CI of [91.12% - 99.29%], see Table 8. Two (2) samples, both from endometrial cancer patients, exhibited discordant MSI status results between the assays. Both discordant samples were PCR-enrolled and exhibited F1CDx MSI-H results (FB-MSI score of 0.0216 and 0.0192) and PCR non-MSI-H results (MSS).

Table 8. Concordance Results MSI Detection Using PCR-based Comparator Assay

	F1CDx+/ PCR+	F1CDx- /PCR +	F1CDx+ /PCR -	F1CDx- /PCR -	PPA (95% CI)	NPA (95% CI)
Combined data sets (PCR and F1CDx enrolled)	27	0	2	76	100.00% (87.54% - 100.00%)	97.44% (91.12% - 99.29%)

For CRC patients in the combined data sets, for samples that yielded evaluable results (21 out of 53, 39.6%), PPA was 100% (10/10) and NPA was 100.00% (11/11) using the ≥ 0.0124 threshold for MSI-H calling. For non-CRC patient samples with evaluable results, the observed PPA and NPA in the combined data sets using the ≥ 0.0124 threshold for MSI-H calling were 100.00% (17/17) and 97.01% (63/65).

For the samples from patients with uterus endometrial adenocarcinoma that had evaluable F1CDx results (25 out of 58, 43.10%) the observed PPA and NPA in the combined data sets using the ≥ 0.0124 threshold for MSI-H calling were 100% (9/9) and 87.50% (14/16) respectively.

There were two (2) samples, both from patients with thyroid carcinoma, with MSI-Cannot be Determined status due to FB MSI scores >0.0041 and <0.0124 ; both were MSS per the PCR-based comparator.

11.2 Concordance – Comparison to FoundationOne®

To support the use of retrospective data generated using the FoundationOne® (F1 LDT), a concordance study was conducted with FoundationOne®CDx (F1CDx). This study evaluated a test set of 165 specimens. PPA and NPA between the F1CDx and F1 LDT, using the F1 LDT assay as the reference method, was calculated for all alterations, as well as for alterations binned by type: short variants, copy number alterations (CNAs) and rearrangements. A total of 2,325 variants, including 2,026 short variants, 266 CNAs and 33 rearrangements were included in the study. The study results are summarized in **Table 9** below.

Table 9. Summary of inter-laboratory concordance comparing F1CDx to the F1 LDT.

	F1CDx+/F1 LDT+	F1CDx-/F1 LDT+	F1CDx+/F1 LDT-	F1CDx-/F1 LDT-	PPA	NPA
All variants	2246	33	46	322890	98.6%	99.99%
All short variants	1984	19	23	299099	99.1%	99.99%
Substitutions	1692	10	19	254854	99.4%	99.99%
Indels	292	9	4	44245	97.0%	99.99%
All CNA	230	14	22	19204	94.3%	99.9%
Amplifications	157	10	12	14671	94.0%	99.9%
Losses	73	4	10	4533	94.8%	99.8%
Rearrangements	32	0	1	4587	100.0%	99.98%

11.3 Tissue Comparability

A large-scale retrospective analysis was conducted, using 80,715 specimens from 43 tissue types, in order to establish the comparability of assay performance across tumor tissue types. The goal of the study was to establish that assay performance after DNA extraction is independent of the tissue type from which the DNA was extracted. The retrospective analysis of data included specimens assayed using the FoundationOne (F1 LDT) assay. DNA extraction, and post-DNA extraction data were assessed for comparability of performance across tissue types. The dataset for analysis consisted of routine clinical samples analyzed using F1 LDT from March 25, 2015 to March 13, 2017.

Thirty-nine of the 43 tissue types had $\geq 90\%$ of specimens passing DNA extraction QC. Specimen DNA extraction pass rates for the remaining four tissue types, lung, pancreas, pelvis and prostate, were 89.6%, 89%, 89%, and 79.7%, respectively. Each of these four tissue types have characteristically small biopsies and may also be more likely to require macro-dissection.

Of specimens entering the assay at Library Construction (LC), 39 of 43 tissue types had $\geq 90\%$ of specimens resulting in a successful patient report being issued. The four tissue types below 90% include pancreatobiliary, appendix, pericardium, and prostate, and had pass rates of 83%, 88%, 79%, and 84%, respectively. For these four tissue types, the most frequent cause of failure was low tumor purity with no alterations detected. The mean LC yields across tissue types were 7,050 ng to 8,643 ng compared to the minimum required 545 ng. The percent of specimens passing the LC QC for each tissue type ranged from 98%-100%. After Hybrid Capture (HC), the mean yields across tissue types ranged from 434 ng to 576 ng, well above the minimum requirement of 140 ng. The percent of specimens passing HC across tissue types ranged from 97%-100%. The average median exon coverage assessed across tissue types ranged from 702X-793X, with percent of specimens passing QC for median coverage across tissue types ranging from 96%-100%. Uniformity of coverage was assessed by calculating the average percent of targets with $>100\text{X}$ coverage across tissue types, and ranged from 99.0%-99.8%. The percentage of specimens passing this QC metric ranged from 98%-100%. The average sequencing

error rate, assessed across tissue types, is 0.0028-0.0031, well below the required error rate (0.01) for assay acceptance. The pass rate for all tissue types was 100% for error rate. Performance data for this study is summarized in **Table 10** below.

Table 10. Summary of post-DNA extraction analysis

QC Metric Name	F1CDx QC Specification	Mean QC Performance Across Tissue Types	QC Pass Rate Across Tissue Types	Tissue types with $\geq 90\%$ QC Pass Rate
Overall report Pass/Qualified rate	Pass rate: $\geq 90\%$ specimens	N/A	79%-98%	39/43 (90.6%)
LC Yield	≥ 545 ng	7050–8643 ng	98-100%	43/43 (100%)
Library Yield after HC	≥ 140 ng	434-576 ng	97-100%	43/43 (100%)
Median Exon Coverage	$\geq 250X$	702-793X	96-100%	43/43 (100%)
Percent of target $>100X$ coverage	$\geq 95\%$ target at $\geq 100X$ coverage	99.0%-99.8% targets	98%-100%	43/43 (100%)
Sequencing error rate	$<1\%$	0.0028-0.0031	100%	43/43 (100%)
Noisy copy number data	N/A*	N/A	93.8-100%	43/43 (100%)

*for information only, not a specification

11.4 Analytical Specificity

11.4.1 Interfering Substances

The robustness of the FoundationOne®CDx (F1CDx) assay process was assessed while evaluating human formalin-fixed paraffin-embedded (FFPE) samples in the presence of exogenous and endogenous interfering substances. Five FFPE specimens representing five tumor types (ovary, lung, colorectal, breast and melanoma) including representative variant types (substitution, indel, amplification, homozygous deletion and rearrangement) were assessed in duplicate (**Table 11**). An additional 54 short alterations (substitutions and indels) were assessed. The addition of interfering substances including melanin (endogenous), ethanol (exogenous), proteinase K (exogenous), and molecular index barcodes (MIB) (exogenous) was evaluated to determine if they were impactful to F1CDx, and the results were compared to the control (no interferents) condition.

Table 11. Summary of tumor types and variant types included in study

Tumor Type	Gene (and variant as relevant)	Variant type
CRC	<i>FGFR1</i>	Rearrangement
	<i>BCL2L1</i>	Amplification
	<i>AXIN1</i> c.1058G>A (R353H)	Substitution
	<i>SOX9</i> c.768_769insGG (R257fs*23)	Insertion
Breast cancer	<i>ERBB2</i>	Amplification
	<i>AKT1</i>	Amplification
	<i>CCND1</i>	Amplification
Lung cancer	<i>CDKN2A</i>	Homozygous Deletion
	<i>CDKN2B</i>	Homozygous Deletion
	<i>EGFR</i>	Amplification
Ovarian cancer	<i>BRCA1</i> c.5263_5264insC (Q1756fs*74)	Insertion
	<i>ERCC4</i> c.2395C>T	Substitution
	<i>TP53</i> c.779_779delC (S261fs*84)	Deletion
Melanoma	<i>BRAF</i> c.1799T>A (V600E)	Substitution
	<i>TP53</i> c. 856G>A (E286K)	Substitution
	<i>IGF1R</i>	Amplification

Interfering substances included melanin, ethanol, proteinase K, and molecular index barcodes, as noted in **Table 12** below. Each of the five FFPE specimens were tested in either two or four replicates each, resulting in a total

of 170 data points across the five specimens (10 without interferent, 80 for evaluation of melanin, ethanol and proteinase K and 80 for molecular index barcodes) assessed in this study.

Table 12. Interfering substance evaluated

Substances	Level	# Samples	# Replicates/Sample
No Interferent	–	5	2
Melanin	0.025 µg/mL	5	2
Melanin	0.05 µg/mL	5	2
Melanin	0.1 µg/mL	5	2
Melanin	0.2 µg/mL	5	2
Proteinase K	0.04 mg/mL	5	2
Proteinase K	0.08 mg/mL	5	2
Ethanol	5%	5	2
Ethanol	2.5%	5	2
MIB	0	5	4
MIB	5%	5	4
MIB	15%	5	4
MIB	30%	5	4

Substances were considered as non-interfering if, when compared to no interferent, the DNA yield is sufficient to meet the standard processing requirements of DNA isolation (≥ 55 ng), if the quality was sufficient to create products per the specification of library construction (≥ 545 ng) and hybrid capture (≥ 140 ng), and the sample success rate (fraction of samples that met all process requirements and specifications), across all replicates in aggregate, is $\geq 90\%$. Sequence analysis was assessed as percent agreement for each sample and calculated as the number of replicates with the correct alteration call reported per the total number of replicates processed. Percent agreement (fraction of correct calls) was computed across all replicates. The acceptance for concordance required a minimum of 90% of correct calls within each treatment category.

All samples tested at all interfering substance levels met all process requirements and specifications; achieving the acceptance criterion of $\geq 90\%$, indicating that the sample quality was not impacted by the interfering substances at the levels evaluated. The concordance of variants for the melanin, proteinase K and MIB evaluations was 100%, and was 95.3% for the ethanol evaluation, each meeting the acceptance criterion of $\geq 90\%$, indicating that the performance was not affected by the tested interferents. In addition to the variants selected to represent specific alteration types summarized in Table 11, samples included in the study harbored 54 additional short alterations (substitutions and indels) and were 100% concordant across all replicates for each variant.

See Summary of Safety and Effectiveness Data for P160018 for additional interference studies, wherein the interference of necrotic tissue, triglycerides, hemoglobin, and xylene, in addition to ethanol, proteinase K, and MIBs, was evaluated in ovarian tissue and assessed *BRCA1/2* alterations.

An additional study was performed to assess the impact of endogenous and exogenous contaminants including melanin, ethanol, proteinase K, and MIB, on TMB-H (≥ 10 mutations per megabase) and MSI calling as a qualitative biomarker. The analysis included 19 retrospective samples from 3 previous studies and all acceptance criteria were met.

To supplement the previous additional study performed to assess the impact of interfering substances, an exploratory analysis was conducted to further evaluate the effect of endogenous (melanin, hemoglobin, and triglycerides) and exogenous (proteinase K, ethanol, MIB and xylene) interfering substances on MSI calling. All samples spiked with each interfering substance had their MSI calling performance compared to control replicates which had no interfering substances. The results demonstrated 100% agreement of MSI calling between the test and control replicates. Because agreement was 100%, there is no evidence to suggest that interfering substances tested in the exploratory analysis had an adverse effect on MSI calling.

11.4.1.1 Necrosis

An evaluation of necrosis and F1CDx MSI calling performance was conducted to determine whether necrotic tissue in solid tumors interfered with F1CDx MSI calling.

Evaluation of 39 samples with a valid MSI status (sample set included FB-MSI scores ranging from 0- 0.0776 and % necrosis ranging from 0-70%), as determined by both F1CDx and Promega MSI Analysis System v1.2 assays, demonstrated that the levels of necrosis present in these samples did not interfere with MSI calling. The positive percent agreement (PPA) with 95% 2- sided score CI was calculated to be 100.00% (79.61%, 100.00%) and the negative percent agreement (NPA) was calculated to 95.83% with 95% 2-sided score CI (79.76%, 99.26%). MSI concordance was evaluated for 25 samples with necrotic tissue and 14 samples without necrotic tissue. Within the necrosis-absent samples, the PPA was 100% (note: CI was not calculated due to small sample size) and the NPA was 91.67% (64.61%, 98.51%). Within the necrosis-present samples, the PPA was 100.00% (77.19%, 100.00%) and the NPA was 100.00% (75.75%, 100.00%). Comparable concordance was observed between the two subgroups in terms of PPA and NPA. In conclusion, necrosis was not found to interfere with the performance of the MSI calling of the F1CDx assay in this study when % necrosis is $\leq 70\%$. However, as samples above 70% necrosis were not evaluated as part of MSI calling performance, it is possible that there may be different performance in MSI biomarker QC failure when high % necrosis (i.e., above 70%) is present in tumor tissue.

11.4.2 In silico Analysis – Hybrid Capture Bait Specificity

Bait specificity was addressed through an assessment of coverage at the base level for targeted regions included in F1CDx. Lack of bait specificity and/or insufficient bait inclusion would result in regions of diminished high quality mapped reads due to the capture of off-target content. This analysis showed that all regions that may harbor alterations associated with companion diagnostic claims consistently have high quality (MQS ≥ 30), deep coverage $\geq 250X$. When assessing the entire gene set, 99.45% of individual bases in targeted coding regions ± 2 bp of flanking intronic splice site are covered with $\geq 100X$ coverage, and 91.45% of individual bases within targeted introns platform-wide had $\geq 100X$ coverage.

11.4.3 Carryover/Cross-contamination

No carryover or cross-contamination was observed when alternating positive and negative samples for *BRCA1* and *BRCA2* variants, assessed in a checker-board pattern (see Summary of Safety and Effectiveness Data for P160018). In addition, data from plates with high-level confirmed *ERBB2* amplifications, *EGFR* T790M alterations or *ALK* fusions were examined for cross-contamination in adjacent wells containing confirmed negative samples. No contamination was observed.

11.5 Precision

Reproducibility of alterations associated with CDx claims was evaluated. Reproducibility of inter-run replicates (run on different plates under different conditions) was assessed and compared across multiple study factors including reagent lots, sequencers, and plates (in the case of single-site studies), or reagent lots, LC start days, and sites (in the case of site-to-site precision studies) in a factorial design. FMI performed single-site and site-to-site precision studies with the objective of evaluating reproducibility of the F1CDx assay with challenging samples and alterations near the LoD across many tumor types. The reproducibility, and the 95% two-sided Wilson score CI, for single gene CDx alterations are shown in **Table 13**. Most single gene CDx alterations shown in the table were specified in the analytical validation protocol as being a target for the analysis. A few additional alterations were assessed for reproducibility if they met the CDx biomarker definition. The results demonstrate that the F1CDx assay has robust reproducibility in calling single gene CDx alterations both within a single site and across multiple sites.

FMI also performed studies for reagent lot-to-lot reproducibility and instrument-to-instrument reproducibility. Refer to SSED P170019 for reagent lot-to-lot reproducibility and instrument-to-instrument reproducibility

assessments. (https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf)

Table 13. Reproducibility for single gene CDx biomarkers

CDx Biomarker	Tumor Type	Variant*	Fold LoD[†]	Reproducibility [95% Two-Sided Score CI (%)]
AKT1 E17K	Breast cancer	49G>A / E17K [†]	1.27x	100 [85.69, 100]
		49G>A / E17K [§]	1.54x	100 [86.20, 100]
		49G>A / E17K [§]	1.74x	100 [86.20, 100]
		49G>A / E17K [†]	0.22x	50.00 [30.72, 69.28]
ERBB2 (HER2) amplification	Breast cancer	Amplification [†]	2.60x	100 [90.11, 100]
		Amplification [†]	2.04x	100 [90.11, 100]
		Amplification [†]	1.92x	100 [89.95, 100]
		Amplification [§]	1.42x	100 [86.20, 100]
		Amplification [§]	0.63x	100 [86.20, 100]
PTEN Alterations	Breast cancer	388C>T / R130X [†]	1.39x	100 [85.13, 100]
		370T>C / C124R [†]	1.35x	100 [83.89, 100]
		389G>A / R130Q [†]	1.24x	100 [85.69, 100]
		370T>A / C124S [†]	1.34x	100 [85.69, 100]
		77_78insTGAC / Y27fs*18 [†]	1.23x	100 [85.69, 100]
		PTEN-PTEN [§]	Reads: 1.12x	100 [86.20, 100]
		PTEN-N/A [§]	Reads: 0.95x	100 [86.20, 100]
		PTEN-N/A [§]	Reads: 0.98x	95.83 [79.76, 99.26]
		Loss [†]	1.06x	100 [86.20, 100]
		Loss [†]	1.23x	100 [86.20, 100]
		Loss [†]	1.19x	100 [85.69, 100]
PIK3CA SNVs	Breast cancer	3140A>G / H1047R [§]	1.04x	100 [86.20, 100]
		1624G>A / E542K [§]	2.62x	100 [86.20, 100]
		3140A>G / H1047R [†]	0.15x	52.8 [37.00, 68.00] [#]
		1633G>A / E545K [†]	0.98x	100 [90.36, 100]
		3140A>T / H1047L [†]	0.86x	100 [85.69, 100]
		3127A>G / M1043V [†]	1.01x	100 [86.20, 100]
		1633G>A / E545K [†]	1.05x	100 [85.13, 100]
		1624G>A / E542K [†]	0.43x	86.36 [66.67, 95.25]
		1624G>A / E542K [†]	0.39x	95.45 [78.20, 99.19]
		1636C>A / Q546K [†]	0.14x	63.64 [42.95, 80.27]
		1624G>A / E542K [†]	0.88x	100 [86.20, 100]
		3129G>A / M1043I [†]	0.93x	100 [86.20, 100]
		1035T>A / N345K [†]	1.00x	100 [85.13, 100]
		3127A>G / M1043V [†]	0.96x	100 [85.69, 100]

CDx Biomarker	Tumor Type	Variant*	Fold LoD†	Reproducibility [95% Two-Sided Score CI (%)]
		1633G>A / E545K [§]	1.51x	100 [86.20,100]
		1636C>G / Q546E [§]	1.88x	100 [86.20,100]
		1633G>A / E545K	3.08x	100 [86.20, 100]
		1258T>C / C420R	3.33x	100 [85.13, 100]
		1633G>C / E545Q	6.86x	100 [86.20, 100]
FGFR2 fusions	Cholangiocarcinoma	FGFR2-CCDC6 [†]	Reads: 4.16x TP: 7.41x	100 [90.11, 100]
		FGFR2-BICC1 [†]	Reads: 2.52x TP: 4.42x	100 [89.57, 100]
		FGFR2-BICC1 [†]	3.37x	100 [86.20, 100]
		FGFR2-TFCP2 [†]	3.47x	95.45 [78.20, 99.19]
		FGFR2-N/A [†]	2.37x	100 [86.20, 100]
KRAS: Codons 12/13 substitution	Colorectal cancer	38G>A / G13D [†]	6.83x	100 [90.36, 100]
		35G>A / G12D [†]	14.83x	100 [90.36, 100]
		34G>T / G12C [†]	10.52x	100 [90.36, 100]
		35G>T / G12V [†]	0.92x	94.3 [81.39, 98.42]
		34G>C / G12R [†]	1.88x	100 [90.36, 100]
		35G>A / G12D [§]	1.03x	87.5 [69.00, 95.66]
		35G>A / G12D [§]	3.01x	100 [86.20, 100]
		37G>T / G13C [§]	0.96x	90.00 [69.90, 97.21]
		38G>A / G13D [§]	2.73x	100 [86.20, 100]
KRAS wild-type: absence of mutations in exon 2, 3, and 4	Colorectal cancer	N/A [§]	N/A	100 [86.20, 100]
KRAS wild-type: absence of mutations in codons 12 and 13	Colorectal cancer	N/A [§]	N/A	100 [85.69, 100]
BRAF V600 and BRAF fusions	Low-grade glioma	BRAF 1799T>A/ V600E [§]	0.97x	100 [86.20, 100]
	Low-grade glioma	BRAF 1799T>A/ V600E [§]	0.78x	100 [86.20, 100]
	Low-grade glioma	BRAF-CDC42SE2 fusion [§]	Reads: 1.31x	100 [86.20, 100]
	Low-grade glioma	BRAF-KIAA1549 fusion [§]	Reads: 1.23x	100 [86.20, 100]
ALK rearrangements	NSCLC	ALK-EML4 [†]	Reads: 8.21x TP: 10.35x	100 [90.36, 100]
		ALK-EML4 [†]	Reads: 19.68x TP: 12.58x	100 [90.36, 100]
		ALK-EML4 [†]	Reads: 5.48x TP: 25.04x	100 [90.36, 100]
		ALK-EML4 [†]	Reads: 0.40x	100 [88.30, 100]
		ALK-EML4 [†]	Reads: 1.98x	100 [90.36, 100]

CDx Biomarker	Tumor Type	Variant*	Fold LoD†	Reproducibility [95% Two-Sided Score CI (%)]
		ALK-EML4 [§]	5.71x	100 [86.20, 100]
		ALK-EML4 [§]	7.62x	100 [86.20, 100]
BRAF V600E and V600K	NSCLC	1799T>A / V600E [§]	0.14x	25.0 [12.00, 44.90]
		1799T>A / V600E [§]	2.25x	100 [86.20, 100]
BRAF V600E and V600K	Melanoma	1799T>A / V600E [†]	19.10x	100 [90.36, 100]
		1798GT>AA / V600K [†]	30.35x	100 [90.11, 100]
		1799T>A / V600E [†]	1.20x	100 [90.11, 100]
		1799T>A / V600E [†]	3.10x	100 [90.36, 100]
		1799T>A / V600E [§]	2.14x	100 [86.20, 100]
		1799_1800TG>AA / V600E [§]	0.95x	75.0 [55.10, 88.00]
		1798_1799GT>AA / V600K [§]	4.38x	100 [86.20, 100]
		1798_1799GT>AA / V600K [§]	2.11x	100 [86.20, 100]
EGFR: Exon 19 deletion	NSCLC	2253_2276delATCTCCGAAAG CCAACAAGGAAAT / S752_L759del [†]	4.84x	100 [90.36, 100]
		2235_2249delGGAATTAAGAG AAGC / E746_A750del [†]	7.51x	100 [90.11, 100]
		2236_2246delGAATTAAGAGA / E746fs*13 [†]	3.76x	100 [90.11, 100]
		2236_2250 del / E746_A750 del [†]	0.97x	100 [90.36, 100]
		2235_2249 del / E746_A750 del [†]	2.58x	100 [90.11, 100]
		2235_2249delGGAATTAAGAG AAGC / E746_A750del [§]	0.83x	100 [86.20, 100]
		2235_2249delGGAATTAAGAG AAGC / E746_A750del [§]	2.34x	100 [86.20, 100]
EGFR: Exon 21 L858R	NSCLC	2573T>G / L858R [†]	8.71x	100 [89.85, 100]
		2573T>G / L858R [†]	11.83x	100 [90.11, 100]
		2573T>G / L858R [†]	0.90x	97.2 [85.83, 99.51]
		2573T>G / L858R [†]	1.49x	100 [90.36, 100]
		2573T>G / L858R [§]	1.17x	100 [85.69, 100]
		2573T>G / L858R [§]	2.24x	100 [86.20, 100]
EGFR: Exon 20 T790M	NSCLC	2369C>T / T790M [†]	2.88x	100 [90.36, 100]
		2369C>T / T790M [†]	7.72x	100 [90.36, 100]
		2369C>T / T790M [§]	0.73x	87.5 [69.00, 95.66]
		2369C>T / T790M [§]	2.62x	100 [86.20, 100]
MET: SNVs and indels lead to exon 14 skipping	NSCLC	2888-10_2911del34 / splice site 2888- 10_2911del34 [†]	1.34x	100 [86.20, 100]
		2888-37_2888-30delCGTCTTTA / splice site 2888- 37_2888-30delCGTCTTTA [†]	0.79x	95.83 [79.76, 99.26]
		2888-18_2888-5delCTTTCTCTGTTT / splice site 2888- 18_2888-5delCTTTCTCTGTTT [†]	4.09x	100 [85.69, 100]

CDx Biomarker	Tumor Type	Variant*	Fold LoD†	Reproducibility [95% Two-Sided Score CI (%)]
		3028G>A / D1010N‡	0.91x	95.83 [79.76, 100]
		3028+2 T>C / splice site 3028+2T>C‡	1.22x	100 [86.20, 100]
		2999_3028+4del34 / splice site 2999_3028+4del34‡	0.87x	100 [86.20, 100]
		3028+1 G>A / splice site 3028+1G>A‡	2.79x	100 [86.20, 100]
		3028_3028+2delGGT / splice site 3028_3028+2delGGT‡	1.61x	100 [85.69, 100]
ROS1 fusions	NSCLC	ROS1-CD74‡	Reads: 2.64x TP: 2.33x	100 [90.36, 100]
		ROS1-CD74‡	Reads: 3.57x TP: 4.13x	100 [90.36, 100]
NTRK1/2/3 fusions	Solid tumors	NTRK1-TPM3‡	Reads: 0.93x TP: 1.42x	100 [86.20, 100]
		NTRK1-LMNA‡	Reads: 1.69x TP: 1.50x	100 [85.89, 100]
		NTRK2-DSTYK‡	Reads: 1.45x TP: 3.06x	100 [85.18, 100]
		NTRK3-ETV6‡	Reads: 0.58x TP: 3.28x	95.80 [79.76, 99.90]
		NTRK3-ETV6‡	Reads: 2.68x TP: 6.57x	100 [90.36, 100]
		NTRK3-ETV6‡	Reads: 2.42x TP: 3.28x	100 [90.36, 100]
		NTRK3-ETV6‡	Reads: 10.86x TP: 5.64x	100 [85.89, 100]
RET fusions	Solid tumors	CCDC6-RET§	Reads: 1.37x	100 [86.2, 100]
		CCDC6-RET§	Reads: 2.09x	100 [85.1, 100]
		CCDC6-RET§	Reads: 2.14x	100 [85.7, 100]
		CCDC6-RET§	Reads: 1.90x	100 [86.2, 100]
		ERC1-RET§	Reads: 1.50x	100 [85.7, 100]
		KIF5B-RET§	Reads: 1.76x	100 [85.7, 100]
		KIF5B-RET§	Reads: 2.18x	100 [86.2, 100]
		KIF5B-RET§	Reads: 1.48x	100 [86.2, 100]
		NCOA4-RET§	Reads: 2.41x	95.5 [78.2, 99.2]
		NCOA4-RET§	Reads: 1.53x	100 [86.2, 100]
		NCOA4-RET§	Reads: 2.49x	100 [86.2, 100]
		NCOA4-RET§	Reads: 2.45x	100 [86.2, 100]
		PRPF19-RET§	Reads: 1.41x	95.8 [79.8, 99.3]
		TRIM24-RET§	Reads: 2.10x	100 [86.2, 100]

*CDS effect/protein effect for short variants; gene-partner gene for rearrangements; copy number subtype for copy number alterations.

†The Fold LoD is the observed average measurement (%VAF for subs/indels, %TP for copy number alterations, and reads/%TP for RE) across all valid replicates of the variant within the sample divided by the LoD for the variant. LoD was determined based on hit rate approach, which is a conservative approach that overestimates LoD. The column represents the level evaluated for the sample in relationship to the LoD for the variant.

‡Inter-run reproducibility for the samples were evaluated in an intermediate precision study conducted in Cambridge, MA. The factors evaluated in the study included 3 sequencers, 2-3 reagent lots, and/or 2 plates, each with 2-4 replicates.

§Inter-run reproducibility for the samples were evaluated in a site-to-site precision study conducted in Cambridge, MA and

Morrisville, NC. The factors evaluated in the study included 2 sites, 2 reagent lots, and 3 LC start dates, each with 2 replicates.

The breast sample with H1047R alteration has a VAF of 1%, which is below the LoD of 4.9% VAF.

Reproducibility was assessed for TMB status and fraction-based MSI (FB-MSI) status in multiple studies. The reproducibility for complex biomarkers (MSI and TMB) from those studies is shown in **Table 14**. For TMB-H status determination, the inclusion criteria for assessment of reproducibility are TMB ≥ 10 mut/Mb. For MSI status, samples were classified as MSI-H (≥ 0.0124) or non-MSI-H (<0.0124). The reproducibility results for TMB status and MSI status in F1CDx assay are robust both within a single site and across multiple sites.

For TMB determination, 13 samples met the inclusion criteria (TMB ≥ 10) for assessment of repeatability and reproducibility. Twelve of 13 samples (92.3%) met the $\leq 20\%$ Coefficient of Variation (CV) requirements; one sample fell just outside this requirement with a repeatability CV of 21% and reproducibility CV of 23%. The putative source of variability was determined to be low depth of coverage for this sample.

To evaluate the performance of MSI detection using the fraction FB-MSI caller, a prospectively designed retrospective analysis (Single site precision study 3 in **Table 14**) was performed using a set of 7 MSI-H samples and 59 non-MSI-H samples from eight tumor types. FFPE-derived DNA samples were selected from banked Foundation Medicine DNA samples. Each sample was tested in two or three replicates, in two runs, with three sequencers, and two or three reagent lots in a factorial design. A total of 36 replicates per sample was processed. Data analysis was performed for each sample separately. According to their MSI scores, samples were classified as MSI-H (≥ 0.0124) or non-MSI-H (<0.0124). An evaluation of within-laboratory (intermediate) precision for MSI status was performed by evaluation of reproducibility and repeatability estimated as the percent agreement for each sample. Samples or replicates with missing MSI results due to QC failure were excluded from the analysis. In total, there were 65 evaluable samples for this study, 7 MSI-H samples and 58 non-MSI-H samples. The 7 MSI-H samples had MSI scores ranging from 0.0226 to 0.0682 and 58 non-MSI-H samples had MSI scores ranging from 0.0043 to 0.0001. The agreement for reproducibility and repeatability was 100% for the 65 evaluable samples. For 64 of 65 samples the lower bound of the two-sided 95% score CI ranged from 89.57% to 90.36% for reproducibility and from 74.12% to 82.41% for repeatability. One sample with an average MSI score of 0.0009 had 7 evaluable replicates and agreement for reproducibility (7/7) was 100%; the lower bound of the two-sided 95% score CI was 64.57%. For the same sample the repeatability was 100%; the lower bound of the two-sided 95% score CI was 34.24%.

The same set of sample results were also analyzed using the 0.0041 threshold; samples were classified as MSS (≥ 0.0041) or non-MSS (>0.0041). An evaluation of intermediate precision, reproducibility, and repeatability for calling MSS vs non-MSS was performed. In total precision of MSI calling was evaluable in 56 MSS samples and 9 non-MSS samples. The agreement for reproducibility and repeatability ranged from 94.44% to 100% for the 64 of 65 evaluable samples. For 63 of 65 samples with reproducibility and repeatability ranging from 94.44% to 100% the lower bound of the two-sided 95% score CI ranged from 81.86% to 90.11% for reproducibility and from 67.20% to 82.41% for repeatability. One sample had 29 of 36 replicates failing to meet F1CDx QC metrics for MSI. For this sample, with an average MSI score of 0.000914, the agreement for reproducibility (7/7) was 100%, the lower bound of the two-sided 95% score CI was 64.57%. For the sample the repeatability was 100%; the lower bound of the two-sided 95% score CI was 34.24%. Finally, one sample had an average MSI score of 0.0043 and was close to the threshold of 0.0041. The agreement for reproducibility for this sample was 54.29% (19/35) and the lower bound of the two-sided 95% score CI was 38.19%. The agreement for repeatability for this sample was 0%.

A second precision study (Single site precision study 2 in **Table 14**) was conducted to evaluate intra-run repeatability and reproducibility for MSI calling by the F1CDx assay in tumors derived from 7 major organ systems (i.e., gastrointestinal, hepato-pancreatobiliary, urinary, endocrine, skin, thoracic, and reproductive)

to support pan-tumor testing. This study was comprised of 44 MSI-H and 2 non-MSI samples. FFPE-derived DNA samples were selected from banked Foundation Medicine DNA samples. The study examined reagent lots and instruments as factors in inter-run reproducibility by assessing samples with two replicates in each of two separate runs, using two reagent lots, and three sequencers. According to their MSI scores, samples were classified as MSI-H (≥ 0.0124) or non-MSI-H (<0.0124). Of the 46 samples, 42 samples had agreement for reproducibility ranging from 90.48% to 100.00%, with the lower bound the two-sided 95% score CI ranging from 71.09% to 86.20%. For four (4) samples with MSI scores close to the 0.0124 cut-off, ranging from 0.0116 to 0.0133, agreement for reproducibility ranged from 52.56% to 82.61%, with the lower bound of the two-sided 95% score CI ranging from 36.81% to 62.86%. Of the 46 samples, 39 samples had agreement for repeatability ranging from 91.67% to 100.00%, with the lower bound of the two-sided 95% score CI ranging from 64.61% to 74.74%. For six (6) samples agreement for repeatability ranged from 54.55% to 83.83%, with the lower bound the two-sided 95% score CI ranging from 28.01% to 55.20%. The observed MSI scores of these six samples were close to the cut-off of 0.0124, ranged from 0.0116 to 0.0154, thus explaining the disagreement of MSI status results near the threshold. The repeatability value of the 7th sample could not be calculated because 21 of 24 replicates were removed from the analysis due to failures in F1CDx laboratory process QC or MSI QC rules.

In order to provide for a more robust assessment of the impact of sequencing reagent lots on the within-laboratory (intermediate) precision of MSI calling by F1CDx, a supplemental evaluation was conducted using the 44 MSI-H samples and 2 non-MSI-H sample described in the second intermediate precision study above representing 7 major organ systems with a total of three (3) sequencing reagent lots. MSI within-laboratory precision and repeatability were assessed by testing each of the 46 samples with two (2) replicates, per each of two (2) separate runs (plates), using three (3) sequencing reagent lots, and three (3) HiSeq 4000 sequencers using a factorial design with a total of 36 sample replicates across the paired reagent lot/sequencer combination.

Since data from the previous study were used to support the precision assessment by comparing three (3) lots of reagents, processing failures noted in previous study were integrated into this validation study. Samples with less than 36 replicates could be evaluated, however, any sample that resulted in sequencing data for ≤ 12 evaluable replicates (e.g., wherein ≥ 24 replicates failed during processing) was not evaluated for repeatability or reproducibility. In total 1656 sample replicates were evaluated in the study. Of the 1656 sample replicates, 1518 replicates were successfully sequenced, and provided F1CDx evaluable results. Among the 46 samples, one lung adenocarcinoma sample was excluded from the analysis as all sample replicates failed LC or HC QC leaving no evaluable replicates for evaluation. Therefore, 45 of 46 samples provided F1CDx evaluable replicates that were considered in the data analysis.

According to their MSI scores, samples were classified as MSI-H (≥ 0.0124) or non-MSI-H (< 0.0124). Of the 45 samples, 41 samples had agreement for within-laboratory precision ranging from 91.18% to 100.00%, with the lower bound of the two-sided 95% score CI ranging from 77.04% to 90.36%. For 4 samples with MSI scores close to the 0.0124 cut-off, ranging from 0.0115 to 0.0138, agreement for within-laboratory precision ranged from 61.29% to 88.89%, with the lower bound of the two-sided 95% score CI ranging from 43.82% to 74.69%. Of the 45 samples, 39 samples had agreement for repeatability ranging from 92.86% to 100%, with the lower bound of the two-sided 95% score CI ranging from 68.53% to 80.64%. For 6 samples, agreement for repeatability ranged from 61.54% to 81.25%, with the lower bound the two-sided 95% score CI ranging from 35.52% to 56.99%. The observed MSI scores of these six samples were close to the cut-off of 0.0124, ranging from 0.0115 to 0.0157, thus explaining the disagreement of MSI status results near the threshold.

Refer to the Summary of Safety and Effectiveness for P170019/S029 for summary tables.

Together the results of these studies demonstrate that while the within-laboratory precision is high for samples well above and well below the two MSI score thresholds that are applied to classify a tumor specimen as having MSI-H or MSS status, there may be imprecision as shown by reproducibility and

repeatability results for samples near the two thresholds for MSI calling.

Table 14. Aggregated reproducibility for complex biomarkers (TMB and MSI)

	CDx Biomarker	Tumor Type	Number of Unique Samples	Biomarker Status	Reproducibility [95% Two-Sided Score CIs] (%)
Single Site precision study 1*	TMB	Solid tumors	17	TMB $\geq$ 10	97.33 [95.71, 98.35]
Single Site precision study 2*	TMB	Solid tumors	46	TMB $\geq$ 10	99.72 [99.18, 99.90]
Site-to-site precision study 1†	TMB	Solid tumors	46	TMB $\geq$ 10	99.53 [98.91, 99.80]
Single Site precision study 2*	MSI	Solid tumors	46	MSI-H	97.01 [95.81, 97.87]
Single Site precision study 3*	MSI	Solid tumors	65	MSI-H	100 [99.83, 100]
Site-to-site precision study 1†	MSI	Solid tumors	46	MSI-H	99.16 [98.41, 99.56]

*Inter-run reproducibility for the samples were evaluated in an intermediate precision study conducted in Cambridge, MA. The factors evaluated in the study included 3 sequencers, 2-3 reagent lots, and/or 2 plates, each with 2-4 replicates.

† Inter-run reproducibility for the samples were evaluated in a site-to-site precision study conducted in Cambridge, MA and Morrisville, NC. The factors evaluated in the study included 2 sites, 2 reagent lots, and 3 LC start dates, each with 2 replicates.

Reproducibility was also assessed for HRR gene CDx panels in prostate cancer. The aggregated results by variant type from the HRR single site precision study 1 are summarized in **Table 15**. The aggregated results by variant type from the HRR site-to-site precision study 2 for additional *HRR* genes are summarized in **Table 16**.

Table 15. Reproducibility for HRR gene panel variants

Variant Type	# of Variants	# of Detected Replicates	# of Total Replicates	Reproducibility* [95% Two-Sided Exact CIs] (%)
Substitution	10	226	238	95.0 [91.4, 97.4]
Indel	26	597	610	97.9 [96.4, 98.9]
RE	15	305	347	87.9 [83.4, 91.1]
Homozygous Deletion	11	242	259	93.4 [89.7, 96.1]
Total	62	1370	1454	94.2 [92.9, 95.4]

*Inter-run reproducibility for the samples were evaluated in an intermediate precision study conducted in Cambridge, MA (HRR single site precision study 1)

Table 16. Reproducibility for HRR gene panel (*ATR*, *FANCA*, *MLH1*, *MRE11A*, *NBN*) variants

Variant Type#	# of Variants	# of Detected Replicates	# of Total Replicates	Reproducibility* [95% Two-Sided Score CIs] (%)
Substitution	2	48	48	100.0 [92.59, 100.00]
Insertion	2	48	48	100.0 [92.59, 100.00]
Deletion	1	24	24	100.0 [92.59, 100.00]
RE	7	177	190	93.16 [88.65, 95.96]
Homozygous Deletion	2	48	48	100.0 [92.59, 100.00]
Total	14	345	358	96.37 [93.89, 97.87]

*Inter-run reproducibility for the samples were evaluated in a site-to-site precision study conducted in Cambridge, MA and Morrisville, NC (HRR site-to-site precision study 2).

One targeted variant is an indel with 100% reproducibility and is excluded from the aggregated categories above (i.e. not grouped into insertion or deletion variant types).

A single site precision study was also conducted to assess reproducibility of *FANCA* alterations in prostate

cancer. The results for the *FANCA* single site precision study are summarized in **Table 17**.

Table 17. Reproducibility for *FANCA* alterations in prostate cancer

Variant	Fold LoD [†]	Reproducibility *[95% Two-Sided Score CIs] (%)
<i>FANCA</i> Loss	0.80x	100.00 [83.89, 100.00]
<i>FANCA</i> _PRKACA	1.22x	100.00 [85.69, 100.00]
<i>FANCA</i> _ZNF778	0.75x	87.50 [69.00, 95.66]
<i>FANCA</i> _2730_2731delCT	1.63x	100.00 [85.13, 100.00]

* Inter-run reproducibility for the samples were evaluated in an intermediate precision study conducted in Cambridge, MA.

† The Fold LoD is the observed average measurement (VAF% for substitutions/indels, TP% for copy number alterations, and reads for RE) across all valid replicates of the variant within the sample divided by the median platform LoD for the variant.

The platform-level reproducibility was evaluated. The sample set selection for platform precision validation can be found in **Table 18**. Similarly, the platform-level reproducibility showed high overall agreement across alteration bins and high sample-level reproducibility as summarized in **Table 19** and

Table 20, and the reproducibility of negative calls ranges from 99.66% [99.58%, 99.73%] to 100.00 [99.98%, 100.00%]. The platform study included a total of 443 substitutions, 188 indels, 55 copy number amplifications, 13 copy number losses, and 18 rearrangements in the variant set across the samples, and 18 rearrangements in the variant set across the samples.

Table 18. Sample set selection for platform precision validation

Alteration Type	Number of Unique Samples	Alteration Size	Genomic Context
Substitution	3	-	-
Short Insertion	2	1-2bp	Homopolymer Repeats
Short Insertion	2	1-2bp	Dinucleotide Repeats
Short Insertion	2	3-5bp	-
Short Insertion	2	>5bp	-
Short Deletion	2	1-2bp	Homopolymer Repeats
Short Deletion	2	1-2bp	Dinucleotide Repeats
Short Deletion	2	3-5bp	-
Short Deletion	2	>5bp	-
Amplification	3	-	-
Homozygous Deletion	3	-	-
Rearrangement	3	-	-

Note: Two samples with *PIK3CA* alterations (E545K and H1047R) were represented in both the CDx and platform validation.

Table 19. Platform reproducibility by variant type

Variant Type	# of Variants	# of Detected Replicates	# of Total Replicates	Reproducibility [95% Two-Sided Exact CIs] (%)
Substitutions	443	439,649	439,899	99.94 [99.94, 99.95]
Indels	188	186,319	186,684	99.80 [99.78, 99.82]
Rearrangements	18	17,851	17,874	99.87 [99.81, 99.92]
CNAs	68	67,300	67,524	99.67 [99.62, 99.71]

Variant Type	# of Variants	# of Detected Replicates	# of Total Replicates	Reproducibility [95% Two-Sided Exact CIs] (%)
All Variants	717	711,119	711,981	99.88 [99.87, 99.89]

Table 20. Platform reproducibility across variants by sample

Variant Type	Reproducibility [95% Two-Sided Exact CIs] (%)
Substitution/Rearrangement/CNA	100.00 [99.40, 100.00]
Substitution/Indel/CNA	99.37 [98.38, 99.83]
Substitution/Indel	100.00 [99.10, 100.00]
Substitution/Indel/CNA	97.84 [96.89, 98.56]
Substitution/Indel	99.81 [98.94, 100.00]
Substitution/Indel	99.60 [97.81, 99.99]
Substitution/Indel/CNA	98.33 [97.11, 99.14]
Substitution/Indel	100.00 [99.83, 100.00]
Substitution/Indel/CNA	100.00 [99.32, 100.00]
Substitution/Indel/Rearrangement	96.46 [94.14, 98.05]
Substitution/CNA	98.67 [97.27, 99.46]
Substitution/Indel/Rearrangement/CNA	96.27 [95.39, 97.02]
Substitution/Indel/Rearrangement	98.23 [97.48, 98.80]
Substitution/Indel/CNA	98.32 [97.57, 98.89]
Substitution/Indel	99.30 [98.90, 99.58]
Substitution/Indel/Rearrangement/CNA	85.42 [82.27, 88.20]
Substitution/Indel/Rearrangement	97.75 [96.42, 98.68]
Substitution/Indel/Rearrangement	95.30 [92.97, 97.03]
Substitution/Indel/Rearrangement/CNA	100.00 [98.31, 100.00]
Substitution/Indel/Rearrangement/CNA	100.00 [99.25, 100.00]
Substitution/CNA	96.83 [94.90, 98.17]
Substitution/Indel/Rearrangement/CNA	95.97 [94.06, 97.40]
Substitution/Indel/CNA	100.00 [99.42, 100.00]
Substitution/Indel/Rearrangement/CNA	100.00 [99.30, 100.00]
Substitution/Rearrangement	100.00 [99.05, 100.00]
Substitution/CNA	96.99 [95.39, 98.15]
Substitution/Indel/Rearrangement/CNA	100.00 [98.95, 100.00]
Substitution/Indel/Rearrangement/CNA	99.80 [99.29, 99.98]

11.6 Analytical Sensitivity: Limit of Detection (LoD) and Limit of Blank (LoB)

11.6.1 Limit of Blank (LoB)

A Limit of Blank (LoB) of zero was confirmed through the assessment of alterations within the blank (i.e., biomarker-negative) samples, with a percentage of false positive results less than 5% (type I error risk $\alpha=0.05$). LoB results for single gene CDx variants, HRR gene panel CDx variants, and complex biomarkers (TMB and MSI) are presented in

Table 21, Table 22, and **Table 23,** respectively. All CDx variants were determined to have a LoB of 0, based on the false positive rate not exceeding 5%.

Table 21. False positive rate of single gene CDx biomarkers

CDx Biomarker	Tumor Type	Number of Replicates with Positive Calls/Number of Total Sample Replicates	False Positive Rate (%)
<i>AKT1</i> E17K	Breast cancer	0/60*	0
<i>ERBB2</i> (HER2) amplification	Breast cancer	0/4	0
<i>PIK3CA</i> SNVs	Breast cancer	0/60*	0
<i>PTEN</i> alterations	Breast cancer	0/60*	0
<i>FGFR2</i> rearrangements	Cholangiocarcinoma	0/56*	0
<i>BRAF</i> mutations and <i>BRAF</i> fusions	Low-grade glioma	0/60*	0
<i>BRAF</i> V600E and V600K	Melanoma	0/4	0
<i>ALK</i> rearrangements	NSCLC	0/4	0
<i>EGFR</i> Exon 19 Deletion	NSCLC	0/4	0
<i>EGFR</i> Exon 21 L858R	NSCLC	0/4	0
<i>EGFR</i> Exon 20 T790M	NSCLC	0/4	0
<i>RET</i> fusions	NSCLC	0/58*	0
<i>ROS1</i> fusion	NSCLC	0/60*	0
<i>NTRK 1/2/3</i> fusions	Solid tumors	0/63*	0
<i>RET</i> fusions	Solid tumors	0/126*	0
<i>RET</i> fusions	TC	0/64*	0

* The sample size evaluated for the study follows the CLSI guideline EP17-A2.

Table 22. False positive rate of HRR gene panel CDx biomarkers

CDx Biomarker	Tumor Type	Number of Replicates with Positive Calls/Number of Total Sample Replicates	False Positive Rate (%)
Homologous Recombination Repair (HRR) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>BARD1</i> , <i>BRIP1</i> , <i>CDK12</i> , <i>CHEK1</i> , <i>CHEK2</i> , <i>FANCL</i> , <i>PALB2</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RAD54L</i>) alterations	Prostate cancer	0/69*	0
HRR gene (<i>ATR</i> , <i>FANCA</i> , <i>MLH1</i> , <i>MRE11A</i> , <i>NBN</i>) alterations	Prostate cancer	0/60*	0

* The sample size evaluated for the study follows the CLSI guideline EP17-A2.

Table 23. False positive rate of complex biomarkers (TMB and MSI)

CDx Biomarker	Tumor Type	Number of Replicates with Positive Calls/Number of Total Sample Replicates	False Positive Rate (%)
TMB	Solid tumors	0/59*	0
MSI-high	Solid tumors	0/135*	0

* The sample size evaluated for the study follows the CLSI guideline EP17-A2.

The LoB was also assessed for 335 unique tumor profiling variants within 19 samples, each with 4 replicates, which resulted in a total of 75 valid sample replicates after lab processing. The false positive rate of tumor profiling variants by variant type and overall are presented in **Table 24**. None of the variants were detected and thus the LoB was confirmed as zero.

Table 24. False positive rate of tumor profiling variants by variant type

Variant Type	Number of Unique Variants	False Positive Rate (%)
Substitutions	242	0
Indels	71	0
Rearrangements	5	0
Copy Number Alterations	17	0
Total	335	0

11.6.2 Limit of Detection

The Limit of Detection (LoD) of alterations assessed by FoundationOne®CDx (F1CDx) was evaluated in part per CLSI EP12-A2 by following the guidance on methodologies for the empirical LoD calculation based on hit rates and the model based LoD. The LoD for short variants, including substitutions and indels, is based on variant allele frequency (VAF). The LoD for copy number alterations is based on computational tumor purity. The LoD for rearrangements is based on chimeric reads and computational tumor purity. Computational tumor purity is calculated by fitting the observed log-ratio and minor allele frequency data with statistical models that predict a genome-wide copy number profile, tumor ploidy, and tumor purity (i.e., computational tumor purity). The log-ratio profile is obtained by normalizing aligned tumor sequence reads by dividing read depth by that of a process-matched normal control, followed by a GC-content bias correction using Loess regression. The minor allele frequency profile is obtained from the heterozygous genome-wide SNPs. For LoD determination, biomarker-positive DNA is diluted with biomarker-negative DNA. A SNP-adjusted tumor purity for each diluted replicate was determined using the baseline computational tumor purity of the biomarker-positive DNA and a computationally determined titration ratio calculated through a regression of SNP allele frequencies. SNP-adjusted tumor purity allows for a more accurate determination of tumor purity in scenarios where computational tumor purity modeling may break down (e.g., when multiple DNA sources are mixed and/or the presence of low tumor purity).

The LoD was determined using the conservative hit rate approach and probit model approach. LoD by hit rate was defined as the mean measurement value (i.e., VAF, chimeric reads, or SNP adjusted tumor purity) at the lowest dilution level tested with at least 95% detection across replicates. The hit rate was computed as the number of replicates with positive variant calls per the total number of replicates tested at each dilution level. The maximum or median of LoD for single gene CDx biomarkers, complex biomarkers (TMB and MSI) and gene panel CDx biomarkers are presented in **Table 25**, **Table 26**, and **Table 27**, respectively.

Table 25. LoD estimation for single gene CDx biomarkers

CDx Biomarker	Tumor Type	LoD by Hit Rate Method	LoD by Probit Method
<i>AKT1</i> E17K [†] , §§	Breast cancer	6.13%	Not calculated
<i>ERBB2</i> (HER2) amplification*, #, §§	Breast cancer	25.3%	Not calculated
<i>PIK3CA</i> SNV*, §§	Breast cancer	4.91%	Not calculated

CDx Biomarker	Tumor Type	LoD by Hit Rate Method	LoD by Probit Method
<i>PTEN</i> SNV ^{§, †}	Breast cancer	5.72%	Not calculated
<i>PTEN</i> indels ^{§, †}	Breast cancer	5.67%	Not calculated
<i>PTEN</i> rearrangements [†]	Breast cancer	Reads: 20.45	Not calculated
<i>PTEN</i> homozygous deletions ^{§, ¶}	Breast cancer	35.25%	42.28%
<i>FGFR2</i> fusion*, ^{††}	Cholangiocarcinoma	Reads: 10.75 TP: 5.31%	Not calculated
<i>KRAS</i> Codons 12/13 substitution*, ^{§§}	Colorectal cancer	2.3%	Not calculated
<i>BRAF</i> V600 mutations [§]	Low-grade glioma	2.49%	Not calculated
<i>BRAF</i> fusions [†]	Low-grade glioma	Reads: 7.53	Not calculated
<i>ALK</i> rearrangements*, ^{§§}	NSCLC	Reads: 15.5 TP: 2.6%	Not calculated
<i>EGFR</i> Exon 19 deletion*, ^{§§}	NSCLC	5.1%	Not calculated
<i>EGFR</i> Exon 20 T790M*, ^{§§}	NSCLC	2.5%	Not calculated
<i>EGFR</i> Exon 21 L858R*, ^{§§}	NSCLC	2.4%	Not calculated
<i>MET</i> Exon 14 SNVs*, ^{§§}	NSCLC	2.9%	Not calculated
<i>MET</i> Exon 14 insertion and deletion*, ^{§§}	NSCLC	5.7%	Not calculated
<i>ROS1</i> fusion*, ^{††}	NSCLC	Reads:11.85 TP: 5.79%	Not calculated
<i>BRAF</i> V600E and V600K*, ^{§§}	Melanoma	2.0%	Not calculated
<i>BRCA</i> 1/2 Alteration in non-repetitive or homopolymer < 4 bp*, ^{**}	Ovarian cancer	N/A	5.9%
<i>BRCA</i> 1/2 Deletion in 8 bp homopolymer*, ^{**}	Ovarian cancer	N/A	15.3%
<i>NTRK1</i> rearrangements*, ^{††}	Solid tumors	Reads: 24.55 TP: 12.1%	Not calculated
<i>NTRK2</i> rearrangements*, ^{††}	Solid tumors	Reads: 24.16 TP: 11.5%	Not calculated
<i>NTRK3</i> rearrangements*, ^{††}	Solid tumors	Reads: 14.65 TP: 6.1%	Not calculated
<i>RET</i> fusions ^{†, ††}	Solid tumors	Reads: 8.75	Not calculated

* The LoD is reported as the maximum LoD among all unique samples or only one unique sample was tested.

† The LoD is reported as the median LoD among all unique samples, or only one unique sample was tested.

§ The LoD is determined via the confirmation of LoD. Platform LoD was used for the targeted dilution level.

† LoD for *PTEN* SNVs and indels was not directly established with biomarker positive samples, but an LoD of approximately 5% based on aggregated data analysis of LoD for SNVs from the original PMA was confirmed through a precision study using samples with alterations at or near 5% VAF and with at least 95% hit rate (inter-run reproducibility)

¶ LoD of 35.25% for *PTEN* homozygous deletions was confirmed through a precision study with at least 95% hit rate (reproducibility).

The number of copy number amplifications for the sample evaluated is 6 at the indicated tumor fraction.

** The evaluation of LoD followed the CLSI guideline on titration with five dilution levels and 20 replicates at each level.

†† The evaluation of LoD followed the CLSI guideline on titration with five dilution levels and 20 replicates at each level except

for the highest level.

§§ The evaluation of LoD followed the CLSI guideline on titration with five dilution levels but did not follow the CLSI guideline of having 20 replicates at each level.

Table 26. LoD estimation for complex biomarkers (TMB and MSI)

CDx Biomarker	Tumor Type	LoD by Hit Rate Method	LoD by Probit Method
TMB ≥ 10 mutations per megabase §	Solid tumors	TP: 28.16% *	Not calculated
MSI-H §	Solid tumors	TP: 9.76% (TP: 8.25%-15.67%) †	Not calculated

* The LoD is reported as the maximum LoD among all unique samples or only one unique sample was tested.

† The LoD is reported as the median (range) of LoD among all unique samples.

§ The evaluation of LoD followed the CLSI guideline on titration with five dilution levels and 20 replicates at each level except for the highest level.

Table 27. LoD estimation for *HRR* gene panel CDx biomarkers

CDx Biomarker	Variant Type	Tumor Type	LoD by Hit Rate Method*	LoD by Probit Method
<i>HRR</i> gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>BARD1</i> , <i>BRIP1</i> , <i>CDK12</i> , <i>CHEK1</i> , <i>CHEK2</i> , <i>FANCL</i> , <i>PALB2</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RAD54L</i>)	Base substitutions [†]	Prostate Cancer	6.33%	Not calculated
	Indels [†]	Prostate Cancer	12.74%	Not calculated
	<i>HRR</i> (HD) §	Prostate Cancer	23.9%	Not calculated
	RE §	Prostate Cancer	Reads: 39.3 TP: 20.1%	Not Calculated
<i>HRR</i> gene (<i>ATR</i> , <i>FANCA</i> , <i>MLH1</i> , <i>MRE11A</i> , <i>NBN</i>)	Base substitutions [#]	Prostate Cancer	9.76%	Not calculated
	Indels [#]	Prostate Cancer	15.79%	Not calculated
	HD [#]	Prostate Cancer	63.30%	Not calculated
	RE [§]	Prostate Cancer	Reads: 36.79	Reads: 23.15

*The LoD is reported as the maximum LoD among all unique samples or only one unique sample was tested.

† The evaluation of LoD did not follow the CLSI guideline on titration with five dilution levels and 20 replicates at each level.

§ The evaluation of LoD followed the CLSI guideline on titration with five dilution levels and 20 replicates at each level except for the highest level.

The LoD is determined via the confirmation of LoD. Platform LoD was used for the targeted dilution level.

For the F1CDx tumor profiling LoD assessment, the minimum and maximum were summarized by variant type. LoD calculations for the platform variants were based on the hit rate approach for variants with less than three levels with hit rate between 10% and 90% and probit approach for variants with at least three levels with hit rate between 10% and 90%. CDx variants and non-CDx variants with an average hit rate of 100% were excluded from the summary. The LoD estimation for tumor profiling variants by variant type are presented in **Table 28**.

Table 28. LoD estimation* for tumor profiling variants by variant type

Variant Type	Number of Variants	Minimum LoD	Maximum LoD
Short Variants	224	1.83%	20.41%
Substitutions	187	1.83%	11.78%
Indels	37	4.47%	20.41%
Rearrangements	3	Reads: 16.85 TP: 9.16%	Reads: 22.38 TP: 14.94%
Copy Number Alterations	18	9.58%	33.36%

*The evaluation of LoD followed the CLSI guideline on titration with five dilution levels but did not follow the CLSI guideline of having 20 replicates at each level.

The LoD estimation for tumor profiling variants by variant subtype and genomic context are presented in **Table 29**. For base substitutions, alterations classified as “known” are defined as those that are listed in the Catalog of Somatic Mutations in Cancer (COSMIC). Alterations classified as “other” include truncating events in tumor suppressor genes (splice, frameshift and nonsense) as well as variants that appear in hotspot locations but do not have a specific COSMIC association or are considered variants of unknown significance (VUS) due to lack of reported evidence and conclusive change in function. Note that the indels were grouped together (other than homopolymer repeat context) as they are similar in LoD characteristics. The indels ranged from 1 bp up to 42 bp insertions and deletions up to 276 bp. Indels at homopolymer repeat context had higher LoD, with a dependency on the length of the repeat context.

Table 29. LoD estimation* for tumor profiling variants by variant subtype by genomic context

Genomic Context	Number of Variants	Minimum LoD	Maximum LoD
Base Substitutions: known	21	1.8%	7.9%
Base Substitutions: other	166	5.9%	11.8%
Indels at non-homopolymer context, including insertions up to 42bp and deletions up to 276bp: known	3	4.5%	6.5%
Indels at non-homopolymer context, including insertions up to 42bp and deletions up to 276bp: other	17	6.0%	10.2%
Indels at homopolymer context: 5 bp repeat	8	10.0%	12.2%
Indels at homopolymer context: 6 bp repeat	2	13.6%	13.7%
Indels at homopolymer context: 7 bp repeat	4	16.3%	20.4%
Indels at homopolymer context: 8 bp repeat	3	17.0%	20.0%
Copy Number Alterations: Amplifications (CN >10)	8	9.6%	18.5%
Copy Number Alterations: Amplifications ($6 \leq \text{CN} \leq 10$)	7	19.5%	58.3%
Copy Number Alterations: Homozygous Deletions	3	33.4%	33.4%
Rearrangements (tumor purity based)	3	9.2%	14.9%
Rearrangements (reads based)	3	16.85	22.38

*The evaluation of LoD followed the CLSI guideline on titration with five dilution levels but did not follow the CLSI guideline of having 20 replicates at each level.

11.7 Stability

11.7.1 Reagent Stability

The claimed reagent stability is up to 12 months for reagents stored between 4°C and -20°C.

11.7.2 DNA Stability

The claimed DNA stability is up to 3 years for DNA samples stored at -20°C.

11.7.3 FFPE Sample Stability

The FFPE Slide Stability Study is an ongoing study with data summarized for T₀, T₁ (30 days), and T₂ (6 months). This study evaluated the stability of FFPE tumor tissue prepared as slides prior to DNA extraction for use within the FoundationOne®CDx (F1CDx) assay. Five tumor samples including ovarian, lung, colorectal cancer, melanoma and breast cancer that contained a variety of DNA alterations, as described in **Table 30** below. The five samples were selected to include specific alteration types that were reflective of the CDx alterations, but were found to contain additional alterations as well (13 CNAs, one rearrangement, 53 base substitutions and five indels; refer to **Table 31**). To assess stability of pre-cut FFPE tissue for genomic alterations, the agreement between results from the defined time points for each sample were calculated by comparing the alteration call reported at each follow-up time point to the alteration call at baseline (T₀). Alterations at the 30-day time point and the 6-month time point are in 100% agreement with the day 0 baseline results (T₀). The FFPE slides are considered stable for at least 6 months. Further assessment at months 12 and 15 will evaluate stability of FFPE slides beyond 6 months.

Table 30. Stability results at baseline, 30 days and 6 months.

Tissue	Baseline Call (T ₀)		Percent Agreement to T ₀	Percent Agreement to T ₀
	Gene	Variant Effect	30 days (T ₁)	6 months (T ₂)
Ovarian	BRCA1	c.1340_1341insG, p.H448fs*8	100% (2/2)	100% (2/2)
Lung	KRAS	c.34G>T, p.G12C	100% (2/2)	100% (2/2)
CRC	PIK3CA	c.3139C>T, p.H1047Y	100% (2/2)	100% (2/2)
CRC	PIK3CA	c.1258T>C, p.C420R	100% (2/2)	100% (2/2)
Melanoma	CDKN2A	Homozygous Deletion	100% (2/2)	100% (2/2)
Melanoma	CDKN2B	Homozygous Deletion	100% (2/2)	100% (2/2)
Breast	ERBB2	Amplification	100% (1/1)	100% (2/2)

Table 31. Percent agreement for each variant type

Variant type	Number of variants	30 days (T ₁) Percent Agreement (# agreement/total)	95% 2-sided CI LB, UB*	6 months (T ₂) Percent Agreement (# agreement/total)	95% 2-sided CI LB, UB*
Copy Number	13	100% (23/23)	85.2%, 100.0%	100% (26/26)	86.8%, 100.0%
Rearrangement	1	100% (2/2)	15.8%, 100.0%	100% (2/2)	15.8%, 100.0%
Substitution	53	100% (98/98)	96.3%, 100.0%	100% (106/106)	96.6%, 100.0%
Insertion/Deletion	5	100% (7/7)	59.0%, 100.0%	100% (10/10)	69.2%, 100.0%

*LB: lower bound; UB: upper bound

11.8 Reagent Lot Interchangeability

Identical reagents with the same specifications are used following the same protocols for both the FoundationFocus CDx_{BRCA} assay and FoundationOne®CDx. For reagent lot interchangeability performance data, see the Summary of Safety and Effectiveness Data for P160018.

11.9 General Lab Equipment and Reagent Evaluation

11.9.1 DNA Amplification

Identical reagents and equipment with the same specifications are used following the same protocols for both the FoundationFocus CDx_{BRCA} Assay and FoundationOne®CDx. For DNA amplification performance data, see the Summary of Safety and Effectiveness Data for P160018.

11.9.2 DNA Extraction

The performance of DNA extraction from FFPE tumor specimens was evaluated. The DNA extraction procedure for the FoundationOne®CDx (F1CDx) assay was assessed by testing FFPE specimens including two samples per tissue type for ten different tumor tissue types including lung, breast, ovarian, melanoma, colorectal, brain, hepatic, pancreatic, thyroid, and bladder with different representative types of alterations. Samples were run in duplicate for a total of 240 extractions, employing two different KingFisher Flex Magnetic Particle Processors (120 extractions per processor) and comparing across three extraction reagent lots (80 extractions per reagent lot). Average DNA yield was calculated across twelve (12) replicates for each sample. All average DNA yields were significantly above the minimum requirement of 55 ng, with the minimum being 758.3 ng. Only one sample aliquot of the 240 replicates failed the DNA yield specification, and the success rates based on the reagent lot and the equipment were 98.8% (79/80) and 99.2% (119/120), respectively, passing the acceptance criteria ($\geq 90\%$). Concordance of all genomic alterations detected was also analyzed for all variants across 12 replicates for each sample. **Table 32** provides a summary of concordance across replicates. A study with an additional ten samples will be completed post-market.

Table 32. Summary of concordance across replicates of DNA extraction study

Group	N _{concordance}	N _{total}	Concordance	95% CI
Substitutions (All MAF)	2700	2969	90.9%	[89.9% 91.9%]
Substitutions (MAF > 10%)	1631	1637	99.6%	[99.2% 99.9%]
Substitutions (All MAF, excluding hypermutated sample)*	1663	1685	98.7%	[98% 99.1%]
Indel (All)	465	476	97.7%	[95.9% 98.8%]
Copy Number: Amplification	307	314	97.8%	[95.4% 99%]
Copy Number: Loss	132	144	91.7%	[85.9% 95.3%]
Rearrangement	84	90	93.3%	[85.9% 97.2%]

*One sample included in the study was hypermutated, harboring many alterations near LoD and exhibited evidence of external contamination. Concordance of substitutions was 80.8% for this sample.

A DNA extraction study was performed to evaluate the FoundationOne®CDx (F1CDx) assay DNA extraction procedure with respect to TMB-H (≥ 10 mutations per megabase) calling. The analysis included 35 retrospective samples and all acceptance criteria were met.

11.9.2.1 CoExtraction Validation

A concordance study was performed to evaluate the variant calling concordance between samples with the existing F1CDx DNA extraction method (DNAx, baseline, 1 replicate) and the new extraction method (CoEx, test, 1 replicate). A total of 127 FFPE tumor specimens from 12 different tissue types were included in the study. **Table 33** below provides a summary of the concordance study results. The tumor profiling variants analyzed in this study included all reportable, non-CDx variants detected in this study.

Table 33. Concordance of targeted variants and biomarkers – CoExtraction

	Variant/Biomarker Type	PPA (95%CI)	NPA (95% CI)
Targeted CDx Variants and	Indels (short variants)	88.24 (15/17) (65.66, 96.71)	100 (196/196) (98.08, 100)

	Variant/Biomarker Type	PPA (95%CI)	NPA (95% CI)
Biomarkers	Substitutions (short variants)	100 (46/46) (92.29, 100)	98.98 (487/492) (97.64, 99.57)
	Rearrangements	100 (8/8)	100 (24/24) (86.2, 100)
	Amplifications (copy number alterations)	100 (6/6)	100 (8/8)
	Homozygous deletions (copy number alterations)	100 (1/1)	100 (13/13) (77.19, 100)
	TMB High	92.86 (26/28) (77.35, 98.02)	100 (71/71) (94.87, 100)
	MSI High	100 (11/11) (74.12, 100)	100 (89/89) (95.86, 100)
	All	96.58 (113/117) (91.54, 98.66)	99.44 (888/893) (98.7, 99.76)
Tumor Profiling Variants	Indels (short variants)	94.69 (357/377) (91.95, 96.54)	99.9957 (422896/422914) (99.9933, 99.9973)
	Substitutions (short variants)	96.07 (1685/1754) (95.05, 96.88)	99.9962 (2314383/2314472) (99.9953, 99.9969)
	Rearrangements	90.91 (40/44) (78.84, 96.41)	99.9955 (66628/66631) (99.9868, 99.9985)
	All	95.72 (2082/2175) (94.79, 96.50)	99.9961 (2803907/2804017) (99.9953, 99.9967)

A precision study was performed to assess the reproducibility and repeatability of the CoExtraction method in the F1CDx assay. The study included 47 unique FFPE tumor samples. First, six (6) curls were cut from each source block. The curls were processed with the CoExtraction method, using a combination of two unique CoExtraction reagent lots and two unique CoExtraction instrument lines. Second, the extracted DNA from each curl was subdivided into four (4) DNA sub-aliquots, for a total of 24 total replicates per source block entering precision testing (6 curl extractions x 4 extracted DNA subaliquots each = 24 total).

72 total targeted variants and biomarkers were analyzed, including 36 short variants, 8 rearrangements, 7 copy number alterations, 9 TMB, and 5 MSI, and data analysis was performed for each variant and biomarker separately. An evaluation of within-laboratory precision was performed by evaluation of reproducibility and repeatability estimated as the percent agreement for each variant and biomarker.

The agreement for reproducibility and repeatability of short variants was 100% for the 36 variants; the lower bound of the two-sided 95% CI ranged from 84.54% to 86.20% for reproducibility and from 70.90% to 75.75% for repeatability. The agreement for reproducibility and repeatability of rearrangements was 100% for the 8 variants; the lower bound of the two-sided 95% CI ranged from 85.69% to 86.2% for reproducibility and from 74.12% to 75.75% for repeatability. The agreement for reproducibility and repeatability of copy number alterations was 100% for the 7 variants; the lower bound of the two-sided 95% CI ranged from 85.69% to 86.2% for reproducibility and from 74.12% to 75.75% for repeatability.

The agreement for reproducibility and repeatability of TMB was 100% for 7 of 9 samples; the lower bound of the two-sided 95% CI for these 7 samples ranged from 83.18% to 86.2% for reproducibility and from 67.56% to 75.75% for repeatability. For 1 TMB sample, the agreement for reproducibility and repeatability was 95.5% and 90.0% with the lower bound of the two-sided 95% CI being 78.2% and 59.58%, respectively. There was 1 TMB sample that did not meet acceptance criteria and had an agreement for reproducibility and repeatability of 16.7% and 66.7% with the lower bound of the two-sided 95% CI being 6.68% and 39.06%, respectively. A discordance investigation revealed that this was a borderline case near the calling threshold where reproducibility is expected

to be most challenging.

The agreement for reproducibility and repeatability of MSI was 100% for 4 of the 5 samples; the lower bound of the two-sided 95% CI ranged from 84.54% to 86.2% for reproducibility and from 72.25% to 75.75% for repeatability. One MSI sample had an agreement for reproducibility and repeatability of 95.7% and 90.9% with the lower bound of the two-sided 95% CI being 79.01% and 62.26%, respectively.

11.9.3 Validation of Migration from F1CDx HiSeq 4000 to F1CDx NovaSeq 6000

Analytical validation studies were performed to support the transition of the F1CDx assay from the Illumina HiSeq 4000 sequencing (HiSeq) platform to the Illumina NovaSeq 6000 (NovaSeq) platform. The three studies performed (Migration, Precision and Guard Banding) are detailed below in Section 11.9.3.1 – 11.9.3.3.

11.9.3.1 F1CDx NovaSeq 6000 Migration Study.

A total of 204 variant-positive and 30 variant-negative samples were processed (variant-negative samples were defined as samples that did not have any known or likely somatic variants). In total 234 unique DNA samples were evaluated. Each variant-positive sample contained at least one pre-specified targeted variant, which included CDx and clinically significant variant. In addition, samples with TMB $\geq$ 10 mutations per megabase or MSI-H status were evaluated in the migration study. Two replicates of each unique sample were processed, one on NovaSeq configuration and one on the HiSeq configuration.

Pass rates for all samples at library construction, hybridization capture, and pipeline QC steps were calculated. The overall pass rates for HiSeq workflow and NovaSeq workflow were 96.15% and 98.72% respectively.

The overall PPA and NPA of all DNA samples extracted with either the DNAX or CoEx methods, across all targeted CDx variants, and by variant and complex biomarker types were calculated and reported in **Table 34**. The concordance analysis was also stratified by variant and complex biomarker type (substitutions, deletions, insertions, copy-number amplifications, copy-number losses, TMB, and MSI), and by HiSeq sample replicates LoD level (overall, $\geq 1xLoD$, and $<1xLoD$). Overall, the targeted CDx variant PPA/NPA analysis results demonstrated high concordance in targeted CDx variant calling between the HiSeq and NovaSeq F1CDx workflows.

Table 34. Overall Targeted CDx Variant PPA and NPA

Variant Type	PPA (%)			NPA (%)
	Overall	$\geq LoD$	$< LoD$	
CNA	100.00 (29/29) [88.30, 100.00]	100.00 (29/29) [88.30, 100.00]	NA [#]	100.00 (462/462) [99.18, 100.00]
amplification	100.00 (11/11) [74.12, 100.00]	100.00 (11/11) [74.12, 100.00]	NA [#]	100.00 (18/18) [82.41, 100.00]
loss	100.00 (18/18) [82.41, 100.00]	100.00 (18/18) [82.41, 100.00]	NA [#]	100.00 (444/444) [99.14, 100.00]
RE	100.00 (55/55) [93.47, 100.00]	100.00 (53/53) [93.24, 100.00]	100.00 (2/2) *	99.96 (4755/4757) [99.85, 99.99]
SV	100.00 (70/70) [94.80, 100.00]	100.00 (67/67) [94.58, 100.00]	100.00 (3/3) *	100.00 (2860/2860) [99.87, 100.00]
substitution	100.00 (43/43) [91.80, 100.00]	100.00 (41/41) [91.43, 100.00]	100.00 (2/2) *	100.00 (1157/1157) [99.67, 100.00]
insertion	100.00 (9/9) [70.09, 100.00]	100.00 (9/9) [70.09, 100.00]	NA [#]	100.00 (616/616) [99.38, 100.00]
deletion	100.00 (18/18) [82.41, 100.00]	100.00 (17/17) [81.57, 100.00]	100.00 (1/1) *	100.00 (1087/1087) [99.65, 100.00]
TMB ^{&}	100.00 (30/30) [88.65, 100.00]	100.00 (20/20) [83.89, 100.00]	100.00 (9/9) *	98.79 (163/165) [95.69, 99.67]

MSI ^{&}	100.00 (14/14) [78.47, 100.00]	100.00 (13/13) [77.19, 100.00]	NA [#]	100.00 (170/170) [97.79, 100.00]
Overall	100.00 (210/210) [98.20, 100.00]	100.00 (193/193) [98.05, 100.00]	100.00 (15/15) [79.61, 100.00]	99.96 (8416/8420) [99.88, 99.98]

[#] No below LoD targeted CDx variants/ No targeted CDx variants in CoEx samples for subcategory of variant types, and PPA was not calculated.

[&] One of the MSI-H sample and one of the TMB-H sample did not pass computational purity QC metrics and tumor purity was not available to be compared to LoD.

^{*}95% CIs were not provided for outcome with less than 10 sample replicate pairs.

The overall PPA and NPA of all DNA samples extracted with either the DNAX or CoEx methods, for all tumor profiling variants were calculated and reported in **Table 35**. The concordance analysis was also stratified by variant (substitutions, deletions, insertions, copy-number amplifications, copy-number losses), and by HiSeq sample replicates LoD level (overall, $\geq 1xLoD$, and $<1xLoD$). For copy number amplification reported as Category 2-3 under the tumor profiling, a new copy number amplification filtering threshold (Copy number (CN)/ploidy ratio of ≥ 3) was implemented for F1CDx when using the NovaSeq instrument to make copy number amplification calls. For copy number losses enhancements in loss detection were also implemented. The results presented in Table **Table 35** for copy number amplifications evaluate the concordance between the F1CDx using HiSeq and NovaSeq when applying the new copy number amplification filtering threshold (CN/ploidy ratio of ≥ 3) to both versions of the F1CDx test. Further, the results presented in **Table 35** show the concordance between the F1CDx using HiSeq and NovaSeq when applying the new copy number loss enhancements for both version of the F1CDx test. The results in **Table 35** demonstrate high concordance between the HiSeq and NovaSeq assays in calling tumor profiling variants for substitutions, insertions, deletions, copy number amplification, and copy number losses.

Due to the change in the threshold for copy number amplification in F1CDx when run using the NovaSeq, which is estimated to result in reporting as negative for approximately 56% to 70% of copy number amplifications currently categorized as equivocal with the HiSeq 4000, particularly for samples with modeled ploidy of triploid or greater, FMI will conduct additional post-market study(ies). These studies aim to confirm the accuracy of copy number amplification calling for tumor profiling variants reported under Categories 2-3 for F1CDx using the NovaSeq system. FMI will also evaluate the accuracy of copy number loss calling in the post-market setting to confirm the accuracy of copy number loss detection by F1CDx when using the NovaSeq system.

Table 35. Tumor profiling variant concordance: Overall PPA and NPA

Variant Type	PPA (%)			NPA (%)
	Overall	$\geq LoD$	$<LoD$	
CNA	92.43 (232/251) [#] [88.48, 95.10]	96.37 (186/193) [#] [92.70, 98.23]	78.95 (45/57) [#] [66.71, 87.53]	99.97 (25277/25285) [99.94, 99.98]
amplification	93.75 (120/128) [#] [88.15, 96.80]	93.88 (92/98) [#] [87.28, 97.16]	93.10 (27/29) [#] [78.04, 98.09]	99.97 (18011/18016) [99.94, 99.99]
loss	91.06 (112/123) [84.69, 94.93]	98.95 (94/95) [94.28, 99.81]	64.29 (18/28) [45.83, 79.29]	99.96 (7266/7269) [99.88, 99.99]
RE	95.74 (135/141) [91.03, 98.04]	96.27 (129/134) [91.56, 98.40]	85.71 (6/7) [48.69, 97.43]	99.94 (25379/25395) [99.90, 99.96]
SV	97.75 (740/757) [96.43, 98.59]	99.67 (611/613) [98.82, 99.91]	89.58 (129/144) [83.52, 93.59]	99.97 (144126/144171) [99.96, 99.98]
deletion	97.13 (473/487) [95.23, 98.28]	100.00 (409/409) [99.07, 100.00]	82.05 (64/78) [72.10, 89.00]	99.97 (92219/92249) [99.95, 99.98]
insertion	98.48 (65/66) [91.90, 99.73]	98.08 (51/52) [89.88, 99.66]	100.00 (14/14) [78.47, 100.00]	99.97 (13594/13598) [99.92, 99.99]

substitution	99.02 (202/204) [96.50, 99.73]	99.34 (151/152) [96.37, 99.88]	98.08 (51/52) [89.88, 99.66]	99.97 (38313/38324) [99.95, 99.98]
Overall	96.34 (1107/1149) # [95.10, 97.28]	98.51 (926/940) # [97.52, 99.11]	86.54 (180/208) # [81.23, 90.52]	99.96 (194782/194851) [99.96, 99.97]

ERBB2_amplification in a single NSCLC sources sample was not grouped to $\geq$ LoD/ $<$ LoD category due

to missing tumor purity for the HiSeq replicate of the sample (sample replicate failed computational tumor purity QC and no TP output in pipeline).

*95% CIs were not provided for outcome with less than 10 sample replicate pairs.

11.9.3.2 Inter-Site Precision Study with F1CDx NovaSeq 6000

Samples with variant allele frequencies (VAF) for short variants, tumor purities (TP) for copy number alterations, and supporting reads for rearrangements at 1-1.5x LoD and 2-3x LoD were evaluated, for inter- run reproducibility and intra-run repeatability. For inter-run reproducibility, different sites, reagent lots, and sequencers were utilized for sample processing. This site-to-site precision study evaluated variant calling agreement among the Cambridge (CAM) and Research Triangle Park (RTP) sites with the F1CDx NovaSeq configuration.

Three primary areas of evaluation were performed to assess the precision of the updated F1CDx assay NovaSeq configuration. These areas focused on: 1) reproducibility of targeted CDx variants, 2) reproducibility of tumor profiling variants, and 3) reproducibility of TMB, and MSI status. The results herein demonstrate that the NovaSeq configuration is robust with regard to the reproducibility and repeatability of calling genomic alterations and biomarkers.

A total of 47 samples were selected to represent targeted alterations for testing in this study. Each sample was tested with the updated F1CDx NovaSeq configuration. In total, 1128 sample replicates were evaluated per study design.

To evaluate reproducibility for targeted CDx variants, the positive reproducibility (fraction of positive calls) of DNA samples extracted with either the DNAX or CoEx methods, across all valid replicates for each source sample were computed and the 95% 2-sided Wilson's score CIs were calculated and reported in **Table 36**. There were a total of 1121 sample replicates with passed or qualified QC status and included in the analysis.

Table 36. Overall Reproducibility for Targeted CDx Variants

Variant Type	Positive Reproducibility			Negative Reproducibility
	Overall	$\geq$ LoD	$<$ LoD	
CNA	96.86 (278/287) [94.15, 98.34]	96.86 (278/287) [94.15, 98.34]	NA*	100.00 (1713/1713) [99.78, 100.00]
amplification	100 (120/120) [96.90, 100.00]	100 (120/120) [96.90, 100.00]	NA*	100.00 (96/96) [96.15, 100.00]
loss	94.61 (158/167) [90.08, 97.14]	94.61 (158/167) [90.08, 97.14]	NA*	100.00 (1617/1617) [99.76, 100.00]
RE	99.75 (402/403) [98.61, 99.96]	99.74 (380/381) [98.53, 99.95]	100 (22/22) [85.13, 100.00]	100.00 (10422/10422) [99.96, 100.00]
SV	100 (288/288) [98.68, 100.00]	100 (288/288) [98.68, 100.00]	NA*	100.00 (3076/3076) [99.88, 100.00]
substitution	100 (216/216) [98.25, 100.00]	100 (216/216) [98.25, 100.00]	NA*	100.00 (2029/2029) [99.81, 100.00]
insertion	100 (24/24) [86.20, 100.00]	100 (24/24) [86.20, 100.00]	NA*	100.00 (404/404) [99.06, 100.00]
deletion	100 (48/48) [92.59, 100.00]	100 (48/48) [92.59, 100.00]	NA*	100.00 (643/643) [99.41, 100.00]
Overall	98.98 (968/978) [98.13, 99.44]	98.95 (946/956) [98.09, 99.43]	100 (22/22) [85.13, 100.00]	100.00 (15211/15211) [99.97, 100.00]

Note. * No below LoD targeted CDx variants/ No targeted CDx variants in CoEx samples for subcategory of variant types, and reproducibility was not calculated.

Positive reproducibility for tumor profiling variants was evaluated for all variants that are positive in at least one sample using DNA samples extracted with either the DNAX or CoEx methods and reported in **Table 37**. The set of tumor profiling variants in this analysis includes both targeted CDx and non- targeted tumor profiling variants. The ground truth for targeted variants was set to be positive. Ground truth for non-targeted variants was determined by the majority call across all valid replicates in a source sample.

Table 37. Overall Positive Reproducibility for Tumor Profiling Variants

Variant Type	Positive Reproducibility		
	Overall	≥ LoD	<LoD
CNA	97.88 (1431/1462) # [97.01, 98.50]	99.32 (1309/1318) # [98.71, 99.64]	83.33 (40/48) # [70.42, 91.30]
amplification	98.87 (878/888) # [97.94, 99.39]	100 (792/792) # [99.52, 100.00]	95.83 (23/24) # [79.76, 99.26]
loss	96.34 (553/574) # [94.47, 97.59]	98.29 (517/526) # [96.78, 99.10]	70.83 (17/24) # [50.83, 85.09]
RE	97.74 (953/975) [96.61, 98.51]	98.6 (916/929) [97.62, 99.18]	80.43 (37/46) [66.83, 89.35]
SV	99.09 (4127/4165) [98.75, 99.33]	99.97 (3684/3685) [99.85, 100.00]	92.29 (443/480) [89.56, 94.36]
substitution	98.76 (2790/2825) [98.28, 99.11]	100 (2513/2513) [99.85, 100.00]	88.78 (277/312) [84.80, 91.82]
insertion	100 (312/312) [98.78, 100.00]	100 (288/288) [98.68, 100.00]	100 (24/24) [86.20, 100.00]
deletion	99.71 (1025/1028) [99.15, 99.90]	99.89 (883/884) [99.36, 99.98]	98.61 (142/144) [95.08, 99.62]
Overall	98.62 (6511/6602) # [98.31, 98.88]	99.61 (5909/5932) # [99.42, 99.74]	90.59 (520/574) # [87.93, 92.72]

Note. * No below LoD tumor profiling variants in CoEx samples for subcategory of variant types, and reproducibility was not calculated.

Sample failed computational purity QC and no tumor purity output from pipeline, the LoD category of copy number alterations in those three samples were unknown and their reproducibility did not count into the ≥/< LoD reproducibility.

For complex biomarkers, positive reproducibility was 100.00 for TMB and MSI. Negative reproducibility was 99.62 for TMB and 100.00 for MSI.

In summary, the reproducibility in variant calling with the F1CDx NovaSeq configuration supports the migration of F1CDx from the HiSeq to NovaSeq. However, given the change in the copy number amplification filtering threshold (CN/ploidy ratio of ≥ 3 threshold) for F1CDx when using the NovaSeq platform, additional precision and LoD studies will also be evaluated in the post-market setting to confirm the safety and effectiveness of the device for copy number amplification calling under Categories 2-3 of the tumor profiling indication.

11.9.3.3 Guard Banding/Robustness for DNA Input with F1CDx NovaSeq 6000

The impact of DNA input variation on the performance of the F1CDx assay on the NovaSeq platform was evaluated and reported in Table **Table 38**. This guard banding study assessed impact at each of the three process steps in the workflow, LC, HC, and sequencing. The guard banding levels were determined upon the established DNA input requirements for the assay and included the established lower and upper limits, 50% and 80% of the lower limit, 120% and 150% of the upper limit. For each of the three guard banding tests, LC, HC and sequencing, seven (7) DNA samples with two replicates were required for testing.

Table 38. Sample Processing Pass Rate at Guard Bands

Guard Band	DNA Input Level	Pass Rate % (#)	Pass Rate 95% CI %
Library Construction (LC)	25 ng	100.00 (14/14)	[78.47, 100.00]
	40 ng	100.00 (14/14)	[78.47, 100.00]
	50 ng*	92.86 (13/14)	[68.53, 98.73]
	1000 ng*	100.00 (14/14)	[78.47, 100.00]
	1200 ng	100.00 (14/14)	[78.47, 100.00]
	1500 ng	100.00 (14/14)	[78.47, 100.00]
Hybrid Capture (HC)	175 ng	78.57 (11/14)	[52.41, 92.43]
	280 ng	100.00 (14/14)	[78.47, 100.00]
	350 ng*	100.00 (14/14)	[78.47, 100.00]
	2000 ng*	100.00 (14/14)	[78.47, 100.00]
	2400 ng	100.00 (14/14)	[78.47, 100.00]
	3000 ng	100.00 (14/14)	[78.47, 100.00]
Sequencing	0.5 nM	100.00 (14/14)	[78.47, 100.00]
	0.8 nM	100.00 (14/14)	[78.47, 100.00]
	1.0 nM*	100.00 (14/14)	[78.47, 100.00]
	1.2 nM	100.00 (14/14)	[78.47, 100.00]
	1.5 nM	100.00 (14/14)	[78.47, 100.00]

Note. *Specified normal input range

An evaluation of complex biomarker status was performed for each replicate at each stage and input level. The biomarker status for those samples at each stage and input level were all positive, generating a 100% positive rate.

In summary, each of the three (3) guard banding processes evaluated herein demonstrated reliable and robust performance at normal process DNA input levels. Decreased performance may be observed at DNA input levels outside of the specified inputs, e.g., low pass rates of 78.57% are observed at DNA input levels for hybrid capture that are 50% lower than the minimum specified input for the F1CDx test.

11.10 Guard banding/Robustness

Guard banding studies were performed to evaluate the impact of process variation with regard to the measurement of DNA concentration at various stages of the process. Guard bands were evaluated relative to observed and measured process variability for Library Construction (LC), Hybrid Capture (HC), and Sequencing. Each of the three guard banding experiments demonstrated reliable and robust performance at all DNA input levels evaluated.

A total of 255 samples were processed; ninety (90) to assess DNA input into LC, ninety (90) to assess DNA input into HC, and seventy-five (75) to assess DNA input into sequencing. For LC input, five samples were run in triplicate over six different DNA input levels representing -20% and -50% from the lower limit (50 ng) to +20% and +50% from the upper limit (1000 ng) needed for LC (n=90). Five samples were run in triplicate over six DNA input levels representing -25% and -50% from the lower limit (0.5 µg) to +25% and +50% from the upper limit (2.0 µg) for HC input. The third component of the guard banding study evaluated the captured DNA input into the sequencing reaction. Five samples were run in triplicate over five different DNA input levels representing ±10% and ±20% from the required amount needed for sequencing (1.75 nM; n=75). Concordance of detected alterations was calculated for each condition across successful replicates. Results from this study support the robustness of the FoundationOne®CDx (F1CDx) process. The study design and results are shown below in **Table 39, Table 40, Table 41, and Table 42.**

Table 39. Summary of the success rate per process and per input level, and concordance of substitutions (SUB) among successful replicates

Process	Input Level	# of Sample Failures	Variant Type	# of Concordant Successes	# of Variant Comparisons	Success Rate (95% CI) (Number of Concordant comparisons)
LC	25 ng	1/15	SUB	184	184	100.0% (98.0%, 100.0%)
LC	40 ng	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
LC	50 ng	0/15	SUB	191	192	99.5% (97.1%, 100%)
LC	1000ng	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
LC	1200 ng	0/15	SUB	191	192	99.5% (97.1%, 100%)
LC	1500 ng	0/15	SUB	190	192	99.0% (96.3%, 99.9%)
HC	0.25 µg	15/15	SUB	0	0	NA* (no samples sequenced)
HC	0.375 µg	12/15	SUB	30	30	100.0% (88.4%, 100.0%)
HC	0.5 µg	1/15	SUB	166	166	100.0% (97.8%, 100.0%)
HC	2.0 µg	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
HC	2.5 µg	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
HC	3.0 µg	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
Seq	1.4 nM	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
Seq	1.575 nM	1/15	SUB	180	180	100.0% (98.0%, 100.0%)
Seq	1.75 nM	1/15	SUB	184	184	100.0% (98.0%, 100.0%)
Seq	1.925 nM	0/15	SUB	192	192	100.0% (98.1%, 100.0%)
Seq	2.1 nM	0/15	SUB	192	192	100.0% (98.1%, 100.0%)

* All samples failed at the input level of 0.25 µg and as a result, there is no data available to present for that level.

Table 40. Summary of the success rate per process and per input level, and concordance of insertions and deletions (INDEL) among successful replicates

Process	Input Level	# of sample failures	Variant Type	# of concordant successes	# of variant comparisons	Success Rate (95% CI) (Number of Concordant comparisons)
LC	25 ng	1/15	INDEL	17	17	100.0% (80.5%, 100.0%)
LC	40 ng	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
LC	50 ng	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
LC	1000ng	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
LC	1200 ng	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
LC	1500 ng	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
HC	0.25 µg	15/15	INDEL	0	0	NA* (no samples sequenced)
HC	0.375 µg	12/15	INDEL	4	4	100.0% (39.8%, 100.0%)
HC	0.5 µg	1/15	INDEL	18	18	100.0% (81.5%, 100.0%)
HC	2.0 µg	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
HC	2.5 µg	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
HC	3.0 µg	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
Seq	1.4 nM	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
Seq	1.575 nM	1/15	INDEL	16	16	100.0% (79.4%, 100.0%)

Seq	1.75 nM	1/15	INDEL	17	17	100.0% (80.5%, 100.0%)
Seq	1.925 nM	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)
Seq	2.1 nM	0/15	INDEL	18	18	100.0% (81.5%, 100.0%)

* All samples failed at the input level of 0.25 µg and as a result, there is no data available to present for that level.

Table 41. Summary of the success rate per process and per input level, and concordance of rearrangements (RE) among successful replicates

Process	Input Level	# of sample failures	Variant Type	# of concordant successes	# of variant comparisons	Success Rate (95% CI) (Number of Concordant comparisons)
LC	25 ng	1/15	RE	6	6	100.0% (54.1%, 100.0%)
LC	40 ng	0/15	RE	6	6	100.0% (54.1%, 100.0%)
LC	50 ng	0/15	RE	6	6	100.0% (54.1%, 100.0%)
LC	1000ng	0/15	RE	6	6	100.0% (54.1%, 100.0%)
LC	1200 ng	0/15	RE	6	6	100.0% (54.1%, 100.0%)
LC	1500 ng	0/15	RE	6	6	100.0% (54.1%, 100.0%)
HC	0.25 µg	15/15	RE	0	0	NA* (no samples sequenced)
HC	0.375 µg	12/15	RE	2	2	100.0% (15.8%, 100.0%)
HC	0.5 µg	1/15	RE	6	6	100.0% (54.1%, 100.0%)
HC	2.0 µg	0/15	RE	6	6	100.0% (54.1%, 100.0%)
HC	2.5 µg	0/15	RE	6	6	100.0% (54.1%, 100.0%)
HC	3.0 µg	0/15	RE	6	6	100.0% (54.1%, 100.0%)
Seq	1.4 nM	0/15	RE	8	9	88.9% (51.8%, 99.7%)
Seq	1.575 nM	1/15	RE	9	9	100.0% (66.4%, 100.0%)
Seq	1.75 nM	1/15	RE	8	8	100.0% (63.1%, 100.0%)
Seq	1.925 nM	0/15	RE	8	9	88.9% (51.8%, 99.7%)
Seq	2.1 nM	0/15	RE	7	9	77.8% (40.0%, 97.2%)

* All samples failed at the input level of 0.25 µg and as a result, there is no data available to present for that level.

Table 42. Summary of the success rate per process and per input level, and concordance of copy number alterations (CN) among successful replicates

Process	Input Level	# of sample failures	Variant Type	# of concordant successes	# of variant comparisons	Success Rate (95% CI) (Number of Concordant comparisons)
LC	25 ng	1/15	CN	128	128	100.0% (97.2%, 100.0%)
LC	40 ng	0/15	CN	132	132	100.0% (97.2%, 100.0%)
LC	50 ng	0/15	CN	132	132	100.0% (97.2%, 100.0%)
LC	1000ng	0/15	CN	132	132	100.0% (97.2%, 100.0%)
LC	1200 ng	0/15	CN	132	132	100.0% (97.2%, 100.0%)
LC	1500 ng	0/15	CN	132	132	100.0% (97.2%, 100.0%)
HC	0.25 µg	15/15	CN	0	0	NA* (no samples sequenced)
HC	0.375 µg	12/15	CN	13	14	92.9% (66.1%, 99.8%)
HC	0.5 µg	1/15	CN	107	108	99.0% (95.0 %, 100.0%)
HC	2.0 µg	0/15	CN	129	132	97.7% (93.5%, 99.5%)

HC	2.5 µg	0/15	CN	129	132	97.7% (93.5%, 99.5%)
HC	3.0 µg	0/15	CN	130	132	98.5% (94.6%, 99.8%)
Seq	1.4 nM	0/15	CN	131	132	99.2% (95.9%, 100.0%)
Seq	1.575 nM	1/15	CN	122	128	95.3% (90.1%, 98.3%)
Seq	1.75 nM	1/15	CN	128	128	100.0% (97.2%, 100.0%)
Seq	1.925 nM	0/15	CN	130	132	98.5% (94.6%, 99.8%)
Seq	2.1 nM	0/15	CN	131	132	99.2% (95.9%, 100.0%)

* All samples failed at the input level of 0.25 µg and as a result, there is no data available to present for that level.

12 Clinical Studies

Several CDx claims described in sections 12.1–12.7 and summarized in section 12.8 were based on a non-inferiority (NI) statistical testing approach using the enrichment design presented in the paper by Li (2016)¹, when the concordance study sample is not a random sample from the companion diagnostic FoundationOne®CDx (F1CDx) intended use population and a reference standard is not available.

To assess clinical concordance, F1CDx was compared to an FDA-approved CDx (CCD). All studies based on NI passed the acceptance criteria specified in each study protocol. Clinical concordance studies, with the exception of *ALK* and *EGFR* T790M, used randomly selected samples from FMI's clinical archives (initially tested with FoundationOne) and were subject to pre-screening bias. Therefore, the concordance results may be over- or underestimated and the failure rate may be underestimated.

Additional CDx claims are described in section 12.9–12.23 including:

- For the CDx indication to identify *PIK3CA* alterations in breast cancer patients intended to be treated with alpelisib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from the patients screened for enrollment into the study CBYL719C2301 (SOLAR-1).
- For the CDx indication to identify *BRCA1* and *BRCA2* in ovarian patients intended to be treated with olaparib, the effectiveness was demonstrated using specimens from the patients screened for enrollment into study D0818C00001 (SOLO1).
- For the CDx indication to identify *FGFR2* fusions and select rearrangements in cholangiocarcinoma (CCA) patients to determine eligibility for treatment with pemigatinib, the effectiveness of F1CDx was demonstrated through a clinical bridging study using specimens from the patients screened for enrollment into the INCB 54828-202 (FIGHT-202) trial.
- For the indication to identify SNVs and indels that lead to *MET* exon 14 skipping in NSCLC patients to determine eligibility for treatment with capmatinib, the effectiveness of the F1CDx was demonstrated through a clinical bridging study using specimens from the patients screened for enrollment into the CINC280A2201 (GEOMETRY-mono 1) trial.
- For the CDx indication to identify mutations in homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC) patients to determine eligibility for treatment with olaparib, the effectiveness of the F1CDx assay was demonstrated based on the results from the PROfound trial.
- For the CDx indication to identify solid cancer patients with TMB-H (defined as ≥ 10 mutations per megabase) tumors to determine eligibility for treatment with pembrolizumab, the effectiveness of the F1CDx assay was demonstrated through a prospectively-planned retrospective analysis of clinical specimens from the patients enrolled in the KEYNOTE-158 clinical trial.
- For the CDx indication to identify *NTRK1*, *NTRK2*, or *NTRK3* fusions in patients with solid tumors that are intended to be treated with larotrectinib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from patients enrolled in the LOXO-TRK-14001 (Bayer 20288, NCT02122913), -15002 (Bayer 20289, NAVIGATE, NCT02576431), and -15003 (Bayer 20290, SCOUT, NCT02637687) clinical trials.
- For the CDx indication to identify *NTRK1*, *NTRK2*, or *NTRK3* fusions in patients with solid tumors that are

intended to be treated with entrectinib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from patients enrolled in the ALKA-372-001 (ALKA), RXDX-101-01 (STARTRK-1), and RXDX-101-02 (STARTRK-2) clinical trials.

- For the CDx indication to identify *ROS1* fusions in patients with NSCLC that are intended to be treated with entrectinib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from patients enrolled in the ALKA-372-001 (ALKA), RXDX-101-01 (STARTRK-1), and RXDX-101-02 (STARTRK-2) clinical trials.
- For the CDx indication to identify *BRCA1*, *BRCA2* alterations in prostate cancer patients that are intended to be treated with niraparib + abiraterone acetate, the effectiveness of the F1CDx assay was demonstrated using specimens from the patients screened for enrollment into the MAGNITUDE clinical study.
- For the CDx indication to identify *RET* fusions in patients with solid tumors that are intended to be treated with selpercatinib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from patients enrolled in the LIBRETTO-001 clinical study.
- For the CDx indication to identify *BRAF* V600E alterations in patients with NSCLC that are intended to be treated with encorafenib in combination with binimetinib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from patients enrolled in the PHAROS (ARRAY-818-202) clinical study.
- For the CDx indication to identify *AKT1*, *PIK3CA*, or *PTEN* alterations in breast cancer patients that are intended to be treated with capivasertib in combination with fulvestrant, the effectiveness of the F1CDx assay was demonstrated based on the results from the CAPItello-291 clinical trial.
- For the CDx indication to identify *BRCA1*, *BRCA2* alterations in prostate cancer patients that are intended to be treated with LYNPARZA[®] (olaparib) in combination with abiraterone, the effectiveness of the F1CDx assay was demonstrated based on the results from the D081SC00001 (PROpel) clinical trial.
- For the CDx indication to identify *BRAF* V600 mutations and *BRAF* fusions in pediatric low-grade glioma patients that are intended to be treated with tovorafenib, the effectiveness of the F1CDx assay was demonstrated through the clinical bridging study using specimens from patients enrolled in the FIREFLY-1 clinical study.
- For the CDx indication to identify HRR gene alterations in mCRPC patients to determine eligibility for treatment with talazoparib in combination with enzalutamide, the effectiveness of the F1CDx assay was demonstrated based on the results from the TALAPRO-2 clinical trial.
- For the CDx indication to identify *PIK3CA* mutations in breast cancer patients that are intended to be treated with ITOVEBI[™] (inavolisib) in combination with palbociclib and fulvestrant, the effectiveness of the F1CDx assay was demonstrated based on the results from the INAVO120 clinical trial.

12.1 FoundationOne[®]CDx Concordance Study for EGFR Exon19del/L858R

Clinical validity of FoundationOne[®]CDx (F1CDx) as a companion diagnostic used for identifying patients with advanced NSCLC who may be eligible for treatment with Gilotrif[®] (afatinib), Iressa[®] (gefitinib), or Tarceva[®] (erlotinib) was established by retrospectively testing 282 samples from NSCLC patients. The *EGFR* diagnostic results from the F1CDx assay were compared against those obtained from the approved **cobas**[®] *EGFR* Mutation Test v2 (Roche Molecular Systems, referred to as **cobas**[®] *EGFR* v2 below). Samples were tested using **cobas**[®] *EGFR* v2 (CCD1) with an approximately equal number of mutation positive and negative samples, followed by testing with F1CDx and a second, replicate testing of **cobas**[®] *EGFR* v2 (CCD2). NSCLC tumor samples used for this study were not obtained from a clinical trial and had limited demographic data available. For this study age and gender data were available and were found to be similar to the pivotal study EURTAC.

Two separate concordance analyses were performed: one with samples with complete records only (N = 267), and the other with all the 282 samples, where missing data were handled by multiple imputation. Data from concordance testing are summarized in **Table 43** below.

Table 43. Concordance Table with CCD1, CCD2 and F1CDx results with eligible samples

	CCD1+				CCD1-			
	CCD2+	CCD2-	CCD2 missing	Total	CCD2+	CCD2-	CCD2 missing	Total
F1CDx+	106	0	0	106	1	1*	0	2
F1CDx-	2**	1	0	3	3	153	0	156
F1CDx Missing	3	0	0	3	1	9	2	12
Total	111	1	0	112	5	163	2	170

* QRF006212 was the only sample where both replicates of the **cobas**® EGFR v2 assay reported negative results but F1CDx reported positive for L858R with AF 33%. Upon further review, F1CDx identified a second somatic mutation in-cis (on same allele) as that of L858R with identical AF only 17bp downstream: *EGFR* A864P. Therefore, it is suspected that this second mutation interfered with the allele-specific PCR primers of **cobas**® EGFR v2, and thus L858R went undetected.

** QRF005867 was reported as positive for both replicates of **cobas**® EGFR v2 for exon19 deletion, but negative by F1CDx. F1CDx detected the exon19 deletion, but incorrectly annotated the variant as 2 frameshift mutations. This would have been corrected by manual curation review, which was not part of this concordance study. QRF005883 was also reported as positive for both replicates of **cobas**® EGFR v2 for exon19 deletion, but negative by F1CDx. F1CDx identified an 18bp exon 19 insertion event, with protein effect K745_E746insIPVAIK. As **cobas**® EGFR v2 is not designed to detect insertion events at exon 19, it is likely an error by **cobas**® EGFR v2.

Fifteen (15) samples were assigned as missing data for F1CDx, two of which also had missing results for CCD2. Missing data was caused by process failures or samples not meeting assay specifications.

By defining the reference standard as the consensus calls between CCD1 and CCD2, F1CDx achieved a PPA of 98.1% (106/108) (95% CI [93.5%, 99.8%]) and NPA of 99.4% (153/154) (95% CI [96.4%, 100.0%]). These data are summarized in **Table 44**.

Table 44. Summary of concordance data using agreement between CCD1 and CCD2 as the reference

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDX+	106	1
F1CDX-	2	153

The mutations detected by the **cobas**® EGFR v2 include all the mutations detected by *therascreen*® EGFR RGQ PCR Kit (QIAGEN), as well as a few additional exon19 deletions/L858R variants. Several concordance studies comparing the **cobas**® EGFR v2 and *therascreen*® EGFR RGQ PCR Kit have been reported in the literature^{7,8,9}, supporting that these two assays are concordant.

Additionally, a post-market concordance study will be completed comparing F1CDx to the *therascreen*® EGFR RGQ PCR Kit.

In addition, based on results of the FLAURA (NCT02296125) study, an additional therapeutic product, osimertinib, was approved on April 18, 2018, for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA approved test. The companion diagnostic for this indication included the **cobas**® EGFR Mutation Test v2 (Roche Molecular Systems) whose claims were expanded, to include Tagrisso® (osimertinib) for the same *EGFR* exon 19 deletions and *EGFR* exon 21 L858R alterations as approved in the F1CDx PMA (P170019) on November 30, 2017. Consequently, Tagrisso® (osimertinib) was added to the F1CDx label for *EGFR* exon 19 deletions and *EGFR* exon 21 L858R alterations in NSCLC patients.

12.2 FoundationOne®CDx Concordance Study for EGFR T790M

The study established the clinical validity of the FoundationOne®CDx (F1CDx) as a companion diagnostic device used for identifying NSCLC patients harboring *EGFR* T790M that may be eligible for treatment with Tagrisso® (osimertinib). The patient samples and corresponding demographic information were obtained from

AstraZeneca in connection with the clinical studies entitled AURA (NCT01802632), AURA2 (NCT02094261) and AURA3 (NCT02151981). The *EGFR* T790M diagnostic results from the F1CDx assay were compared against the consensus calls between the original T790M testing used in the AURA, AURA2 and AURA3 studies and a separate run of the FDA approved **cobas**® *EGFR* v2 (Roche Molecular Systems; designated as comparator companion diagnostic, CCD), using an NI approach.

Two separate concordance analyses were performed: one included samples with complete records only (N = 227), and the second analysis was with all the 312 samples, where missing data was handled by multiple imputation. A summary of concordance is presented in **Table 45**.

Table 45. Concordance table with CCD1, CCD2 and F1CDX results with eligible samples

	CCD1+				CCD1-			
	CCD2+	CCD2-	CCD2 missing	Total	CCD2+	CCD2-	CCD2 missing	Total
F1CDx+	87	19	1	107	8	15	0	23
F1CDx-	1	4	0	5	0	93	2	95
F1CDx Missing	21	4	8	33	1	37	11	49
Total	109	27	9	145	9	145	13	167

Eighty-two samples were assigned as missing data for F1CDx, which consisted of 78 samples with no sequencing results from F1CDx and four samples with QC status as "Fail" after curation. CCD2 had 22 samples with missing data in total, in which 19 samples also had missing values in F1CDx.

The concordance analysis above shows that for the results of PPA, F1CDx is more concordant with both CCD1 and CCD2 than CCD1 is with CCD2; the opposite is true for NPA results. See the Venn Diagram below for the T790M-positive calls (**Figure 1**).




Figure 1. Venn Diagram for EGFR T790M-positive samples

A difference in detection sensitivity between CCD1 and CCD2 was observed, with CCD1 appearing to be more sensitive than CCD2. This could be attributed to the fact that CCD1 was run 2-3 years ago using freshly biopsied tissue, while CCD2 testing was recently performed using DNA extracted from archival FFPE sections. **Figure 2** below illustrates the relationship between allele frequency and detection by F1CDx, CCD1 and CCD2. The results demonstrated that F1CDx detects mutations at allele frequency lower than 5% which are not detected by the **cobas**® v2 assay. The clinical performance in this subset of the patient population (patients with an *EGFR* T790M mutation detected with an allele fraction <5%) and has not been established.




Figure 2. Distribution of MAF in F1CDx+ (FCD) samples

By defining the reference standard as the consensus calls between CCD1 and CCD2, F1CDx achieved a PPA of 98.9% (87/88) (95% CI [93.8%, 100.0%]) and NPA of 86.1% (93/108) (95% CI [78.1%, 92.0%]) as summarized in **Table 46** below.

Table 46. Summary of concordance data using agreement between CCD1 and CCD2 as the reference

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDx+	87	15
F1CDx-	1	93

12.3 FoundationOne®CDx Concordance Study for ERBB2 (HER2)

Clinical validity of FoundationOne®CDx (F1CDx) as a companion diagnostic device used to identify patients eligible for treatment with approved HER2-directed therapies including Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), and Perjeta® (pertuzumab) was established. A study was performed using 317 pre-screened retrospective samples obtained from patients with advanced breast cancer. The failure rate for pre-screening is not known; however, the sample set is enriched for samples with HER2+ samples with ratio between 2 and 3 representing 27% of samples compared to the expected range of 8-10% reported in literature^{10,11}. The *ERBB2* amplification positive results from the F1CDx assay were compared against those obtained from the approved HER2 FISH PharmDx® Kit (Dako Denmark A/S). The samples used for this study were not obtained from a clinical trial and had limited demographic data available. For this study age and ethnicity data were available. Age data were compared to the Danish Study for the Danish Breast Cancer Group clinical trial 89-D in 1990 and was found to have a similar distribution, though the mean age was higher for the concordance samples.


Concordance data are summarized in **Table 47** below.

Table 47. Concordance Table with CCD1, CCD2 and F1CDx results with eligible samples

	CCD1+			CCD1-		
	CCD2+	CCD2-	Total	CCD2+	CCD2-	Total
F1CDx+	101	2	103	3	3	6
F1CDx-	12	10	22	6	180	186
Total	113	12	125	9	183	192

The prevalence of the *ERBB2*/HER2 amplification mutation in the intended use (IU) population is based on the ASCO guideline and is estimated to be 17.5%. To assess the impact of prevalence for the main results of this study, a sensitivity analysis was performed using the lower and upper bound of the prevalence guideline of 15% and 20%. The sensitivity analysis also showed that there was no impact on the study conclusion. The distribution of age is similar to the IU population for all samples tested. However, there was missing demographic data from the sample population. For missing data analysis using multiple imputation, the results show that based on the missing at random (MAR) assumption, the invalid test results did not affect the conclusion of this study.

The Venn diagrams for samples tested positive or negative for *ERBB2*/HER2-amplification mutation in all three assays (F1CDx, CCD1 and CCD2) are presented in **Figure 3**.

**Figure 3. Venn Diagrams for ERBB2-amplification positive (left panel) and negative (right panel) samples**

These two Venn diagrams illustrate concordance among F1CDx, CCD1 and CCD2. For the F1CDx+ samples, concordance of F1CDx with CCD1 or CCD2 was better than concordance between the same platform tests CCD1 and CCD2; for the F1CDx- samples, F1CDx was more consistent in calling negative alterations than either CCD1 or CCD2.

Using the consensus calls between CCD1 and CCD2 as the reference standard, i.e., limiting analysis to only the samples in which CCD1 and CCD2 are in agreement, the results are shown in **Table 48** below:

Table 48. Summary of concordance data using agreement between CCD1 and CCD2 as the reference

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDx+	101	3
F1CDx-	12	180

Based on these results, PPA is 89.4% (101/113) (95% CI [82.2%, 94.4%]) and NPA is 98.4% (180/183) (95% CI [95.3%, 99.7%]).

12.4 FoundationOne®CDx Concordance Study for ALK

Clinical validity of FoundationOne®CDx (F1CDx) as a companion diagnostic device used to identify non- small cell lung cancer (NSCLC) patients eligible for treatment with approved *ALK*-directed therapies including Alecensa® (alectinib), XALKori® (crizotinib), or Zykadia® (ceritinib) was established. The study was performed

using 175 tumor samples from patients with histologically-confirmed NSCLC including enrolled patients as well as screen failures from the clinical trial NCT02075840, Roche study number BO28984 (also known as the ALEX study), which is a randomized, active controlled, multicenter Phase III open-label study designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naïve *ALK* rearrangement positive advanced NSCLC. The *ALK* diagnostic results from the F1CDx panel were compared against those obtained from the FDA approved Ventana *ALK* (D5F3) CDx Assay ("Ventana IHC", Ventana Medical Systems, Inc.) and Vysis *ALK* Break- Apart FISH Probe Kit ("Vysis FISH", Abbott Molecular). The Vysis FISH assay results used were obtained from the ALEX study. In this concordance study, the majority of the samples were from the IU population of the clinical trial NCT02075840. The concordance results are summarized in **Table 49** below.

Table 49. Concordance table with CCD1, CCD2 and F1CDx results with eligible samples

	CCD1 +			CCD1 -		
	CCD2 +	CCD2 -	Total	CCD2 +	CCD2 -	Total
F1CDx +	78	1	79	3	0	3
F1CDx -	6*	7	13	5	75	80
Total	84	8	92	8	75	83

*Two samples harbored *ALK* rearrangements that were detected by F1CDx but were classified as negative based on the study protocol.

The Venn diagrams for samples tested positive or negative for *ALK*-rearrangement mutation in all three assays (F1CDx, CCD1 and CCD2) are shown in **Figure 4**.




Figure 4. Venn Diagrams for *ALK*-rearrangement positive (left panel) and negative (right panel) samples

These two Venn diagrams illustrate concordance among F1CDx, CCD1 and CCD2. A number of samples with discordant results between CCD1 and CCD2 were observed. This is expected because Vysis FISH Assay (CCD2) is a technology that probes at the DNA level while Ventana *ALK* IHC assay examines protein expression. When samples that were discordant between CCD1 and CCD2 were excluded, the concordance between F1CDx+ with CCD1+ and CCD2+ samples was superior to concordance between CCD1+ and CCD2+ samples. For the F1CDx- samples, F1CDx was more consistent in calling negative alterations than either CCD1 or CCD2.

Using the consensus calls between CCD1 and CCD2 as the reference standard, i.e. limiting analysis to only the samples in which CCD1 and CCD2 are in agreement, the results are shown in **Table 50** below:

Table 50. Summary of concordance data using agreement between CCD1 and CCD2 as the reference

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDx+	78	0

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDx-	6*	75

*Two samples harbored *ALK* rearrangements that were detected by F1CDx but were classified as negative based on the study protocol.

Based on these results, PPA is 92.9% (78/84) (95% CI [85.1%, 97.3%]) and NPA is 100% (75/75) (95%CI [95.2%, 100.0%]).

In addition, based on results of the ALTA-1L (NCT02737501) study, an additional therapeutic product, Alunbrig (brigatinib), was approved on May 22, 2020 for the treatment of patients with metastatic NSCLC whose tumors harbor *ALK* rearrangements, as detected by an FDA approved test. The companion diagnostic for this indication included Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit whose claims were expanded to include Alunbrig (brigatinib) for the same *ALK* rearrangements, as approved in the F1CDx PMA (P170019) on November 30, 2017. Subsequently, Alunbrig (brigatinib) was added on the F1CDx label for *ALK* rearrangements in NSCLC patients.

12.5 FoundationOne®CDx Concordance Study for KRAS

Clinical validity of FoundationOne®CDx (F1CDx) as a companion diagnostic device used to identify colorectal cancer patients that may not benefit from certain *EGFR* inhibitor treatments, including Erbitux® (cetuximab) or Vectibix® (panitumumab), due to alterations in *KRAS* was established. The study was performed using 342 retrospective samples obtained from patients with advanced front-line or later-line colorectal cancer (CRC). Samples used in this study underwent pre-screening using the FoundationOne laboratory developed test (F1 LDT) or prescreening by an external vendor to enrich for positive samples. The prescreen failure rate using the F1 LDT was 3.7% and is unknown for the external vendor. The *KRAS* diagnostic results from the F1CDx assay were compared against those obtained from the approved *therascreen*® *KRAS* RGQ PCR Kit (QIAGEN). The samples used for this study were not obtained from a clinical trial and had limited demographic data available. For this study age, gender and ethnicity data were available. Age and gender characteristics were found to be similar between the F1CDx concordance study and the pivotal studies, with the percentage of male samples in the concordance study being slightly lower compared to the pivotal studies (CRYSTAL and PRIME). Concordance data are summarized in **Table 51** below.

Table 51. Concordance Table with CCD1, CCD2 and F1CDx results with eligible samples

	CCD1+				CCD1-			
	CCD2+	CCD2-	CCD2 missing	Total	CCD2+	CCD2-	CCD2 missing	Total
F1CDx+	173	0	2	175	0	0	0	0
F1CDx-	0	2	0	2	1	154	7	162
F1CDx Missing	0	0	0	0	0	3	0	3
Total	173	2	2	177	1	157	7	165

Twelve (12) samples are assigned as missing data, including 3 samples with missing data in F1CDx and 9 samples with missing data in CCD2.

The prevalence of the *KRAS* mutation in the IU population is based on the CRYSTAL study for cetuximab (35.6%) and PRIME study for panitumumab (40%). The key statistics of PPA and NPA between F1CDx and the two replicates of the *therascreen*® *KRAS* assay (CCD1 and CCD2) were estimated based on the result in **Table 54**. Multiple imputation was used to impute the missing data and showed that missing data did not impact study conclusions. The summary statistics of age and sex were highly similar to the estimates from the pivotal trial CRYSTAL (for cetuximab) and PRIME (for panitumumab) studies.

By defining the reference standard as the consensus calls between CCD1 and CCD2, F1CDx achieved a PPA of 100% (173/173) (95% CI [97.9%, 100.0%]) and NPA of 100% (154/154) (95% CI [97.6%, 100.0%]).

Table 52. Summary of concordance data using agreement between CCD1 and CCD2 as the reference

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDx+	173	0
F1CDx-	0	154

12.6 FoundationOne®CDx Concordance Study for BRAF

Clinical validity of the FoundationOne®CDx (F1CDx) as a companion diagnostic device used to identify melanoma patients that may be eligible for treatment with approved *BRAF*-directed therapies was established. The study was performed using 305 retrospective samples obtained from patients with advanced melanoma. 157 samples used in this study underwent pre-screening using the FoundationOne laboratory developed test (F1 LDT) and 27 were prescreened by an external vendor to enrich for positive samples. The prescreen failure rate using the F1 LDT was 3.7% and is unknown for the external vendor. The *BRAF* diagnostic results from the F1CDx assay were compared against those obtained from the approved **cobas**® 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc; referred to as the **cobas**® BRAF assay below). These samples were not obtained from a clinical trial and had demographic data limited to age and gender. The distributions of age and gender to the intended use population (BRIM- 3 trial) was found to be comparable.

Concordance analysis showed that the upper bounds of 95% one-sided Confidence Interval (CI) were below 20% for all four NI hypothesis tests. Thus, it can be concluded with 95% confidence that the differences of results between F1CDx and **cobas**® BRAF assays are less than 20%, the non-inferiority (NI) margin. Concordance results are summarized in **Table 53** below.

Table 53. Concordance Table with CCD1, CCD2 and F1CDx results with eligible samples

	CCD1+			CCD1-		
	CCD2+	CCD2-	Total	CCD2+	CCD2-	Total
F1CDx+	166	0	166	3	14	17
F1CDx-	1	0	1	0	121	121
Total	167	0	167	3	135	138

Because the **cobas**® BRAF assay has lower sensitivity for detection of dinucleotide mutations, a separate analysis was conducted that included only eligible samples without dinucleotide mutations. A total of 273 (=305-32) samples were available for this analysis. The concordance results are summarized in **Table 54**.

Table 54. Concordance Table with CCD1, CCD2 and F1CDx results with eligible samples excluding samples with dinucleotide mutations detected by F1CDx

	CCD1+			CCD1-		
	CCD2+	CCD2-	Total	CCD2+	CCD2-	Total
F1CDx+	149	0	149	1	1*	2
F1CDx-	1**	0	1	0	121	121
Total	150	0	150	1	122	123

*QRF006472 was the only sample where both replicates of the **cobas**® BRAF assay reported negative results but F1CDx reported positive. The Allele Frequency of this sample was 3.45% with the computational tumor purity of 10%. According to Table 4 of the **cobas**® BRAF assay insert, the **cobas**® BRAF assay can correctly detect all *BRAF* V600E mutant specimens that have a minimum % mutant DNA above 5% and when the minimum tumor content is at least 15%. Thus, the discordance can be explained by F1CDx's high sensitivity in the lower % mutant DNA and low tumor purity condition.

QRF006374 was the only sample where both replicates of the **cobas® BRAF assay reported positive results but F1CDx reported negative. A mutation was recorded in the line data (Appendix 7) having protein effect V600_K601>E, which is a non-frameshift deletion of 3 nucleotides with CDS effect 1799_1801delTGA. This more complex mutation does result in V600E, but because of annotation differences to the canonical V600E, it was called negative by F1CDx.

PPA and NPA were calculated by defining the reference standard as the consensus calls between CCD1 and CCD2. The observed performance of **cobas**® BRAF assay has lower sensitivity for detection of dinucleotide V600 alterations (including V600K) than the single nucleotide V600E 1799T>A alteration, particularly at allele frequency below 40% detected by F1CDx, therefore, the data presented will include PPA/NPA results both with both alterations as the study was designed, as well as for V600E only in **Table 55**. A study using the THxID™ BRAF kit (bioMérieux) was conducted using 29 samples with BRAF V600 dinucleotide mutation detected by F1CDx and 29 negative samples to provide a better evaluation of V600 dinucleotide concordance. Out of the 51 samples with valid results from the THxID™ BRAF kit (**Table 56**), there was only one discordant result (F1CDx-/THxID+), achieving a PPA of 96.3% (26/27) (95% CI [81.0%, 99.9%]) and NPA of 100% (24/24) (95% CI [85.8%, 100.0%]).

Table 55. PPA and NPA for BRAF V600 detection with cobas® BRAF

	PPA	NPA
All V600 alterations	99.4% (166/167)	89.6% (121/135)
Single nucleotide V600E (1799T>A)	99.3% (149/150)	99.2% (121/122)

Table 56. Concordance of BRAF dinucleotide samples with THxID™ BRAF kit

Dinucleotide Samples	THxID+	THxID-	Total
F1CDx+	26	0	26
F1CDx-	1	24	25
Total	27	24	51

To support the expansion of F1CDx to identify patients with rare BRAF V600 mutation-positive unresectable or metastatic melanoma, who may benefit from treatment with atezolizumab (Tecentriq®) in combination with cobimetinib and vemurafenib, the accuracy of detection of the rare V600 mutations in the clinical trial was evaluated. A total of 7 BRAF V600D or V600R subjects were identified in the IMspire150 clinical trial through central confirmatory testing at FMI, including 5 specimens with V600R and 2 with V600D mutations. Limited data was available to confirm the V600D results. Additional real-world data was provided from melanoma samples with rare variants. While the ability to distinguish between rare V600 mutations could not be completely resolved given the lack of available clinical trial specimens, the data support the detection capability of rare BRAF V600 alterations by F1CDx.

12.7 FoundationOne®CDx Concordance Study for KRAS/NRAS

A post-market commitment for F1CDx was performed to provide additional evidence to support the clinical validity of F1CDx in identifying colorectal cancer (CRC) patients eligible for treatment with Vectibix® (panitumumab) as follow-on companion diagnostic (FCD) device, by demonstrating concordance between F1CDx and the Praxis Extended RAS Panel (Praxis test) in detecting KRAS and NRAS mutations. The study was conducted via retrospective analysis of clinical samples obtained from CRC patients. This study included 99 KRAS/NRAS mutation-positive and 96 KRAS/NRAS with valid test results mutation-negative (WT) CRC samples identified by the Praxis test. The samples used for testing in this study were external to the samples used in the original pivotal study for the FDA approval of the Praxis test (as shown in Table 37).

Patient samples were intended to reflect the intended use (IU) population of CRC patients eligible for treatment with panitumumab. Gender information was used for demographic analysis. The distribution of the gender characteristics was similar to the panitumumab pivotal trial population. The similarity of the gender distribution demonstrated that the selected test samples were representative of the IU population. In addition, comparisons of patient and disease-related characteristics were made between the samples used in the study and the IU population used for the Praxis test approval in the RAS mutation-negative (wild-type) CRC patients, to ensure the screened population was representative of the IU population.

CRC samples were screened using the Praxis test (CCD1) with an approximately equal number of KRAS/NRAS

mutation positive and negative (wild-type (WT)) samples, followed by testing with F1CDx (FCD) and a second, replicate testing of the Praxis test (CCD2). After testing was complete (CCD1, CCD2, and FCD), the variant calls were evaluated based on the agreement between both the F1CDx and the Praxis test results and the agreement between the two replicates of the Praxis test results. Concordance analysis results are summarized in **Table 57** below.

Table 57. Concordance Table with CCD1, CCD2 and F1CDx results with eligible samples

	CCD1+				CCD1-			
	CCD2+	CCD2-	Invalid CCD2	Total	CCD2+	CCD2-	Invalid CCD2	Total
FCD+	99	0	3	102	0	1	0	1
FCD-	0	0	0	0	0	95	1	96
Invalid FCD	2	0	0	2	0	21	0	21
Total	101	0	3	104	0	117	1	118

Thirty-five (35) samples are assigned as invalid data, including 23 samples with missing data in FCD, 8 samples with missing data in CCD1 and 4 samples with missing data in CCD2.

The key statistics of PPA and NPA between F1CDx and the two replicates of the Praxis test (CCD1 and CCD2) were estimated based on the result in **Table 58**. Multiple imputation was used to impute the missing data and showed that missing data did not impact study conclusions. F1CDx achieved a PPA of 100% (99/99) (95% CI [96.26%, 100%]) and NPA of 98.96% (95/96) (95% CI [96.88%, 100%]).

Table 58. Summary of concordance data using agreement between CCD1 and CCD2 as the reference

	CCD1+/CCD2+	CCD1-/CCD2-
F1CDx+	99	1
F1CDx-	0	95

The data demonstrated that the concordance between F1CDx (as the FCD) and Praxis (as CCD1/CCD2) was non-inferior to the concordance between Praxis replicates CCD1 and CCD2. The upper bounds of the corresponding one-sided 95% CI met the acceptance criteria with a NI margin less than 10%.

12.8 Summary of Clinical Concordance Studies

A summary of clinical concordance study results is included in **Table 59** below. The reference standard used to calculate positive percent agreement (PPA) and negative percent agreement (NPA) below is defined as the consensus calls between the two comparator methods or comparator runs. Agreement calculations solely using consensus calls may overestimate the performance of FoundationOne®CDx (F1CDx).

Table 59. Summary of PPA and NPA for CDx concordance studies

Biomarker	PPA	NPA	Comparator Method
EGFR exon 19 deletions and L858R	98.1% (106/108)	99.4% (153/154)	cobas® EGFR Mutation Test v2
EGFR T790M	98.9% (87/88)	86.1% (93/108)	cobas® EGFR Mutation Test v1 cobas® EGFR Mutation Test v2
ALK rearrangements	92.9% (78/84)	100% (75/75)	Ventana ALK (D5F3) CDx Assay Vysis ALK Break-Apart FISH Probe Kit
KRAS	100% (173/173)	100% (154/154)	therascreen® KRAS RGQ PCR Kit
KRAS and NRAS	100% (99/99)	98.96% (95/96)	Praxis Extended RAS Panel
ERBB2(HER2) Amplifications	89.4% (101/113)	98.4% (180/183)	Dako HER2 FISH PharmDx® Kit

Biomarker	PPA	NPA	Comparator Method
<i>BRAF</i> V600	99.4% (166/167)	89.6% (121/135) ¹	cobas ® 4800 <i>BRAF</i> V600 Mutation Test
<i>BRAF</i> V600E	99.3% (149/150)	99.2% (121/122)	cobas ® 4800 <i>BRAF</i> V600 Mutation Test
<i>BRAF</i> V600 dinucleotide ²	96.3% (26/27)	100% (24/24)	THxID™ <i>BRAF</i> kit

¹ Sensitivity of dinucleotide detection of *BRAF* V600K and V600E was found to be significantly reduced in **cobas**® *BRAF* test, in particular for samples in which F1CDx detected the dinucleotides to be of lower than 40% MAF, leading to low NPA values.

² A study using the THxID™ *BRAF* kit (bioMérieux) was conducted with samples with *BRAF* V600 dinucleotide mutation detected by F1CDx and *BRAF* V600 negative samples to provide a better evaluation of V600 dinucleotide concordance.

12.9 Clinical evaluation of *BRCA1/2* classification for treating ovarian cancer patients with olaparib

12.9.1 Summary of the Clinical Study – Olaparib D0818C00001 (SOLO1)

The clinical performance of F1CDx for *BRCA1/2* classification was established based on available tumor analysis using the F1CDx in the clinical study D0818C00001 (SOLO1). SOLO1 was a Phase III, randomized, double-blind, placebo-controlled, multicenter trial, that compared the efficacy of Lynparza® (olaparib) with placebo in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer with *BRCA* mutation (documented mutation in *BRCA1* or *BRCA2*) following first-line platinum-based chemotherapy. A total of 391 patients were randomized (2:1) to receive Lynparza tablets 300 mg orally twice daily (n=260) or placebo (n=131). Patients were required to have a documented mutation in *BRCA1* or *BRCA2* that were known or predicted to be a loss of function mutation.

Treatment was continued for up to 2 years or until disease progression or unacceptable toxicity; however, patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider could derive further benefit from continuous treatment, could be treated beyond 2 years. Randomization was stratified by response to first-line platinum-based chemotherapy (complete or partial response). The major efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

The study was designed to recruit *BRCAm* patients, i.e., germline or somatic *BRCAm* (*gBRCAm* or *sBRCAm*). At the time of study initiation, a health authority approved tumor diagnostic test was not available. Patients known to have *BRCA* mutation/s (*gBRCA*, i.e., blood or *tBRCA*, i.e., tumor) prior to randomization could enter the study based on this result provided that all such testing had been undertaken in appropriately accredited laboratories (i.e., testing done for research use only [RUO] was not acceptable). In addition, the patients must have consented to provide blood samples for a confirmatory *gBRCA* test post randomization using a blood-based germline *BRCA* test. However, patients could enter the study if they were known to have a tumor *BRCAm* (*tBRCAm*) based on a local, clinically validated test. Tumor tissue was requested for all randomized patients and where possible, retrospectively tested prior to database lock with the F1CDx assay. Since few patients underwent tumor testing during the SOLO1 recruitment period, the patients recruited were predominantly *gBRCAm* as determined by local results or a *gBRCA* clinical trial assay (CTA); however, there were 2 patients with *sBRCAm* tumors. Based on strong biological rationale, it is predicted that patients with a *BRCA* mutation that is somatic in origin will derive a similar clinical efficacy benefit to those with a mutation that is germline in origin.

12.9.2 Accountability of the PMA Cohort

Out of the 391 patients randomized in SOLO1, 368 (94.1%) had an available tumor sample for testing. Of these, 335 (85.6%) patients had a valid tumor tissue F1CDx result. Out of the 335 with a valid tumor tissue F1CDx result, 313 patients were confirmed to carry a deleterious mutation in either *BRCA1* or *BRCA2* by F1CDx. The PMA cohort represented 80.1% of the full analysis set (FAS) in SOLO1. Of the 22 patients that were not confirmed to carry a deleterious mutation by F1CDx, 12 were not confirmed to have a deleterious mutation by F1CDx in their tumor tissue due to differences in the variant classification criteria used by F1CDx compared to the *gBRCA* CTA. The remaining 10 patients that were not confirmed to carry deleterious *BRCA1/2* mutations in their tumor tissue had genomic rearrangements that consisted of large-scale genomic deletions (affecting at least one whole exon), or large-scale genomic insertions including exon duplications. These patients represented 10 out of a total of 20

randomized patients in SOLO1 that had genomic rearrangements in *BRCA1/2* detected by the *gBRCA* CTA.

12.9.3 Efficacy Evaluation

The primary efficacy endpoint was investigator assessed PFS evaluated according to RECIST, version 1.1. SOLO1 met the primary endpoint demonstrating a statistically significant improvement in investigator- assessed PFS for olaparib compared to placebo. Results from a blinded independent review were consistent.

The effectiveness of the F1CDx test was based on a subset of 313 ovarian cancer patients whose tumor tissue was confirmed to carry deleterious *tBRCAm* status. **Table 60** presents a summary of key efficacy outcome variables for patients whose tissue was confirmed to have *tBRCAm* status by F1CDx. PFS in the confirmed F1CDx *tBRCAm* patients was consistent with the results of the FAS, namely that SOLO1 met the primary endpoint, demonstrating a substantial improvement in PFS for olaparib compared with placebo. The sensitivity analysis of PFS to assess possible ascertainment bias using blinded independent centralized review (BICR) in the F1CDx confirmed *tBRCAm* patient subset was consistent with the BICR-assessed PFS analysis in the FAS and confirmed its robustness. Overall, the primary efficacy outcome in the F1CDx *tBRCAm* subset were consistent with the FAS.

Table 60. Summary of key efficacy outcome variables in the FAS and in the F1CDx *tBRCAm* subset

	FAS n=391		F1CDx <i>tBRCAm</i> n=313	
	Olaparib (n=260)	Placebo (n=131)	Olaparib (n=206)	Placebo (n=107)
PFS by Investigator Assessment				
Number of events/total number of patients (%)	102/260 (39)	96/131 (73)	80/206 (39)	81/107 (76)
Median PFS (months) ^a	Not reached	13.8	Not reached	11.9
HR (95% CI) ^b	0.30 (0.23-0.41)		0.28 (0.20-0.38)	
p-value (2-sided) ^c	p<0.0001		p<0.0001	

^a PFS is defined as the time from randomization until data of RECIST progression or death.

^b Hazard ratio from a Cox proportional hazards model including response to previous platinum chemotherapy (complete response versus partial response) as a covariate.

^c The p-value is derived from a stratified log-rank test.

12.10 FoundationOne®CDx Clinical Bridging Study for PIK3CA

The safety and effectiveness of FoundationOne®CDx (F1CDx) for detecting *PIK3CA* alterations in breast cancer patients who may benefit from treatment with alpelisib was demonstrated in a retrospective analysis of specimens from patients enrolled in SOLAR-1. SOLAR-1 is the pivotal Phase III, randomized, double-blind, placebo-controlled study of alpelisib in combination with fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced breast cancer whose disease had progressed or recurred on or after an aromatase inhibitor based treatment (with or without CDK4/6 combination) (SOLAR-1, NCT2437318).

A bridging study was conducted to assess the clinical efficacy of F1CDx in identifying *PIK3CA* alteration positive patients for treatment with alpelisib in combination with fulvestrant and the concordance between *PIK3CA* status (mutant or non-mutant) tested with the clinical trial enrollment assays (referred to as clinical trial assay [CTA1] and [CTA2]) and the F1CDx in the intent-to-test population. F1CDx was used to retrospectively test the stored patient samples from SOLAR-1 with sufficient residual tumor material (N = 415 of the total 572 enrolled patients). Samples from 296 patients enrolled with the CTA1 (119 *PIK3CA* alteration positive patients and 177 *PIK3CA* alteration negative patients), and 119 patients enrolled with the CTA2 (115 *PIK3CA* alteration positive patients and 4 *PIK3CA* alteration negative patients), were retrospectively tested with F1CDx.

12.10.1 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.10.2 Effectiveness Results

12.10.2.1 Concordance Analysis

The concordance between F1CDx and the two enrollment assays (CTA1 and CTA2) was assessed. The point estimates of PPA, NPA and OPA for F1CDx compared to the CTAs are provided in **Table 61** and **Table 62** below.

Table 61. Agreement between CDx and CTA1 based on the CTA1 results (Primary analysis set, CTA1-enrolled)

Measure of agreement	Without invalid CDx results		With invalid CDx results	
	Percent agreement (N)	95% CI (1)	Percent agreement (N)	95% CI (1)
PPA	93.8% (106/113)	(87.7%, 97.5%)	93.0% (106/114)	(86.6%, 96.9%)
NPA	98.8% (159/161)	(95.6%, 99.8%)	95.8% (159/166)	(91.5%, 98.3%)
OPA	96.7% (265/274)	(93.9%, 98.5%)	94.6% (265/280)	(91.3%, 97.0%)

(1) The 95% CI calculated using the Clopper-Pearson Exact method.

- Samples not tested are excluded from the analysis.

- Samples tested on deviation are excluded from the analysis.

Table 62. Agreement between CDx and CTA2 based on the CTA2 results (Concordance analysis set for CTA2)

Measure of Agreement	Without invalid CDx results		With invalid CDx results	
	Percent Agreement (N)	95% CI (1)	Percent Agreement (N)	95% CI (1)
PPA	91.6% (197/215)	(87.1%, 95.0%)	90.4% (197/218)	(85.7%, 93.9%)
NPA	98.8% (162/164)	(95.7%, 99.9%)	97.0% (162/167)	(93.2%, 99.0%)
OPA	94.7% (359/379)	(92.0%, 96.7%)	93.2% (359/385)	(90.3%, 95.5%)


(1) The 95% CI calculated using the Clopper-Pearson Exact method.

- Samples not tested are excluded from the analysis.

- Samples tested on deviation are excluded from the analysis.

12.10.2.2 Clinical Efficacy Results in the SOLAR-1 Mutant Cohort

The SOLAR-1 clinical trial met its primary objective demonstrating a statistically significant improvement in PFS by investigator assessment in patients with *PIK3CA* alteration positive tumors. Supportive analysis included PFS based on blinded independent review committee (BIRC). Alpelisib in combination with fulvestrant demonstrated an estimated 35% risk reduction of disease progression or death compared to the placebo plus fulvestrant arm (HR = 0.65; 95% CI: 0.50, 0.85; p = 0.00065) in the *PIK3CA* alteration cohort. The median PFS was prolonged by a clinically relevant 5.3 months, from 5.7 months in the placebo plus fulvestrant arm to 11.0 months in the alpelisib plus fulvestrant arm (**Figure 5**).



Stratified Logrank test and stratified Cox model using strata defined by (i) prior CDK 4/6 inhibitor use. (ii) presence of liver and/or lung metastases.

Figure 5. Kaplan-Meier plot of progression free survival by treatment in the mutant patients randomized in the original SOLAR-1 trial (Primary analysis set)

12.10.2.3 Clinical Efficacy Results in the CDx-Positive Population

Efficacy analyses were performed for patients determined to be CDx-positive (*PIK3CA* alteration detected by F1CDx) and compared to the efficacy results in the SOLAR-1 *PIK3CA* mutant cohort. The clinical efficacy in the CDx-positive population was estimated by pooling the hazard ratios calculated for 1) the CTA1-enrolled patients that were CDx-positive and 2) the CTA2-enrolled patients that were CDx-positive.

Table 63 and **Table 64** show the efficacy results in the CTA1-enrolled CDx-positive patients (HR = 0.52, 95% CI: 0.29, 0.93) and the results in the CTA2-enrolled (CTA2+, CDx+) patients (HR = 0.35, 95% CI: 0.16, 0.77), respectively.

For the sensitivity analysis to c for the clinical efficacy of alpelisib in combination with fulvestrant for the *PIK3CA* CDx-positive population, the hazard ratio estimates ranged from 0.43 to 0.44. The upper bounds of the 95% confidence intervals for the corresponding hazard ratios were all below 1.0. Sensitivity analysis against the missing CDx results demonstrated the robustness of the efficacy analysis.

Table 63. Clinical efficacy on progression free survival in the CTA1-enrolled CDx-positive patients (Primary analysis set, CTA1-enrolled)

Progression free survival (months)	Alpelisib 300mg qd + Fulv N=56	Placebo qd + Fulv N=52	HR(95% CI)
			Alpelisib 300mg qd + Fulv / Placebo qd + Fulv (1)
No of events (%)	41 (73.2)	41 (78.8)	0.52 (0.29, 0.93)

Progression free survival (months)	Alpelisib 300mg qd + Fulv N=56	Placebo qd + Fulv N=52	HR(95% CI) Alpelisib 300mg qd + Fulv / Placebo qd + Fulv (1)
PD (%)	39 (69.6)	41 (78.8)	
Death (%)	2 (3.6)	0	
No of censored (%)	15 (26.8)	11 (21.2)	
Median (95% CI) (2)	11.2 (8.3, 18.5)	5.5 (1.9, 10.9)	

(1) Hazard ratio (HR) estimated using Cox regression model. The model is adjusted by the identified baseline clinical covariates, as well as the covariates that are imbalanced between treatment and control. The model is stratified by the two stratification factors: presence of lung and/or liver metastases, previous treatment with any CDK4/6 inhibitor.

CI: Wald Confidence Interval.

(2) The 95% CI calculated from PROC LIFETEST output using the method of Brookmeyer and Crowley (1982).

-CDx results obtained on deviation are treated as missing.

Table 64. Clinical efficacy on progression free survival in the CTA2-enrolled (CTA2+, CDx+) patients (Primary analysis set, CTA2-enrolled)

Progression free survival (months)	Alpelisib 300mg qd + Fulv N=42	Placebo qd + Fulv N=48	HR(95% CI) Alpelisib 300mg qd + Fulv / Placebo qd + Fulv (1)
No of events (%)	19 (45.2)	36 (75.0)	0.35 (0.16, 0.77)
PD (%)	18 (42.9)	31 (64.6)	
Death (%)	1 (2.4)	5 (10.4)	
No of censored (%)	23 (54.8)	12 (25.0)	
Median (95% CI) (2)	10.9 (5.6, NE)	4.2 (2.1, 7.4)	

(1) Hazard ratio (HR) estimated using Cox regression model. The model is adjusted by the identified baseline clinical covariates, as well as the covariates that are imbalanced between treatment and control. The model is stratified by the two stratification factors: presence of lung and/or liver metastases, previous treatment with any CDK4/6 inhibitor.

CI: Wald Confidence Interval.

(2) The 95% CI calculated from PROC LIFETEST output using the method of Brookmeyer and Crowley (1982).

-CDx results obtained on deviation are treated as missing.

12.10.2.4 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying breast cancer patients with *PIK3CA* alterations who may be eligible for treatment with alpelisib.

12.11 Clinical evaluation of FGFR2 rearrangement detection for treating Cholangiocarcinoma (CCA) patients with pemigatinib

The clinical performance of F1CDx for detecting *FGFR2* fusions and rearrangements in CCA patients who may benefit from treatment with pemigatinib was established with clinical data generated from the Incyte trial INCB 54828-202, and a clinical bridging study to establish concordance between the confirmatory clinical trial assay (CTA) and the F1CDx assay.

12.11.1 Summary of the Clinical Study – INCB 54828-202 (FIGHT-202)

Study INCB 54828-202 is a prospective, multicenter, open-label, Phase II study in participants with previously treated, advanced/metastatic or surgically unresectable cholangiocarcinoma, including participants with *FGFR2*-rearranged cholangiocarcinoma. The primary endpoint of Study INCB 54828-202 was the objective response rate (ORR) in participants with *FGFR2*-rearranged cholangiocarcinoma to determine whether treatment with pemigatinib is safe and effective. Participants in Study INCB 54828-202 were assigned to cohorts for statistical analysis based on tumor *FGF/FGFR* status as determined by the FMI F1 CTA: Cohort A included

participants with *FGFR2* fusions and select rearrangements in cholangiocarcinoma, and Cohorts B and C included participants with other cholangiocarcinoma molecular subtypes. Eligible participants received pemigatinib on a 2-weeks-on/1-week-off schedule at a starting dose of 13.5 mg once a day. Treatment continued until documented disease progression or unacceptable toxicity.

In the trial, a patient whose tumor harbors an *FGFR2* rearrangement containing an intact kinase domain was defined as eligible under the following conditions:

- *FGFR2* rearrangements with a literature-derived known partner gene regardless of strand or frame,
- *FGFR2* rearrangements in the same 5' to 3' orientation and in frame with a novel partner gene,
- *FGFR2* rearrangements with one breakpoint in the hotspot region (intron 17-exon 18) and the other breakpoint in an intergenic region or within another gene. This rule excludes 3' duplications of only exon 18,
- Intragenic duplication of the kinase domain (exon 9-17)

12.11.2 Accountability of the PMA Cohorts

A total of 146 participants with previously treated, advanced/metastatic or surgically-unresectable cholangiocarcinoma were enrolled in Study INCB 54828-202. Based on tumor sample testing from the FMI F1 CTA, 145 participants were included in the efficacy evaluable population after one participant was not able to be confirmed by the F1 CTA. The 145 participants were assigned to one of the following cohorts for statistical analyses:

- Cohort A: 107 participants with *FGFR2* fusions/rearranged cholangiocarcinoma
- Cohort B: 20 participants with other *FGF/FGFR* alterations
- Cohort C: 18 participants with tumors negative for *FGF/FGFR* alterations

The efficacy of PEMAZYRE was determined in cohort A (107) patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least 1 prior therapy and who had an *FGFR2* gene fusion or non-fusion rearrangement, as determined by the clinical trial assay. Qualifying in-frame fusions and other rearrangements were predicted to have a breakpoint within intron 17/exon 18 of the *FGFR2* gene leaving the *FGFR2* kinase domain intact.

12.11.3 Efficacy Evaluation

12.11.3.1 Clinical efficacy results in Intent to Treat population

The major efficacy outcome measures were overall response rate (ORR) and duration of response (DoR) as determined by an independent review committee (IRC) according to RECIST v1.1. The results of this study are shown in **Table 65** below.

Table 65. Efficacy results in FIGHT-202 trial

Efficacy Parameter	PEMAZYRE N = 107
ORR (95% CI)	36% (27, 45)
Complete response	2.8%
Partial response	33%

12.11.3.2 Summary of the Clinical Bridging Study

Following testing by the F1 CTA, residual DNA for patients in INCB 54828-202 was banked to support the clinical bridging study testing with the F1CDx assay. The safety and effectiveness of F1CDx for detecting *FGFR2* rearrangements in CCA patients who may benefit from treatment with pemigatinib was demonstrated in a

retrospective analysis of residual DNA from patients enrolled in the INCB 54828-202 trial. Residual DNA was available for 108 patients screened with the CTA (80 in Cohort A, 14 in Cohort B, 10 in Cohort C, and 4 screen failures). in addition to 73 *FGFR2* rearrangement-negative specimens for a total of 181 positive and negative F1CDx evaluable samples included in the analysis. A bridging study was conducted to assess the clinical efficacy of F1CDx in identifying *FGFR2* rearrangement positive patients for treatment with pemigatinib and the concordance between *FGFR2* rearrangement status (mutant and non-mutant) tested with the CTA and F1CDx in the efficacy evaluable population. Of the evaluable specimens in cohort A (n=80), the most common finding was *FGFR2-BICC1* [27% (22/80)] in the evaluable set. Patients also had rearrangements without an identifiable partner gene. All of the biomarker positive cases in the F1CDx *FGFR2* CCA Clinical Bridging Study had breakpoints in the *FGFR2* hotspot region, intron 17 – exon 18 (**Figure 6**).

Clinical efficacy results in the CDx-positive population

Clinical utility of F1CDx was evaluated by estimation of clinical efficacy in the *FGFR2* rearranged, CTA- enrolled population based on the primary objective of ORR per central review per RECIST v1.1 criteria. Sensitivity analysis, using the multiple imputation method, was performed to evaluate the robustness of the clinical efficacy estimate against the 27 missing CDx results from Cohort A and 14 missing results from cohort B and C combined. The ORR for the F1CDx *FGFR2*-rearrangement-positive population estimated by the bridging study was 37.50% and aligns with the ORR for the CTA *FGFR2*-rearrangement- positive population, which was 35.51% (**Table 66**). Sensitivity analysis, using the multiple imputation method, was performed to evaluate the robustness of the clinical efficacy estimate against the 27 missing CDx results from the efficacy evaluable population (Cohort A). The distribution of *FGFR2* fusions in the trial that were available for bridging is shown in **Figure 6** below.

Table 66. Summary of ORR in different subpopulations for completed data

Population	CTA+	CTA+ and F1CDx+	CTA+ and F1CDx-
n	107	80	0
ORR	35.51%	37.50%	N/A
95% 2-sided exact CIs	[26.50%,45.35%]	[26.92%,49.04%]	N/A

Note: Given the NPA=1, the efficacy of F1CDx *FGFR2* rearrangement positives can be estimated from the (CTA+, F1CDx+) group.




Figure 6. Distribution of FGFR2 fusions and rearrangements in Cohort A in support of efficacy

12.11.3.3 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.11.3.4 Clinical Concordance

Patients with valid F1CDx results together with FMI archived samples were used to demonstrate concordance of F1CDx to the CTA. Retrospective testing with F1CDx yielded 181 CDx-evaluable results used for further analysis (84 positive and 97 negative). Agreement between F1CDx and the CTA was demonstrated. The PPA, NPA, OPA, adjusted PPV, and adjusted NPV all exhibited 100% agreement between the F1CDx assay and the F1 CTA.

12.11.3.5 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying CCA patients with *FGFR2* fusions and rearrangements who may be eligible for treatment with pemigatinib.

12.12 Clinical evaluation of MET exon 14 classification for treating NSCLC patients with capmatinib

The clinical performance of F1CDx for detecting SNVs and indels that lead to *MET* exon 14 skipping in NSCLC patients who may benefit from treatment with capmatinib was established with clinical data generated from the Novartis trial CINC280A2201 (GEOMETRY-mono 1), and a clinical bridging study to establish concordance between the enrollment clinical trial assay (CTA) and the F1CDx assay.

12.12.1 Summary of the Clinical Study – CINC280A2201 (GEOMETRY-mono 1)

GEOMETRY-mono 1 is a prospectively designed, multicenter, open-label, single arm Phase II study of oral cMET inhibitor (capmatinib) in adult patients with *EGFR* wild-type (wt), advanced NSCLC. The primary objective was to assess overall response rate (ORR) by a BIRC assessment to determine whether treatment with capmatinib is effective. Patients have been enrolled into multiple cohorts of the study, out of which the bridging study was focused on the fully-enrolled *MET* exon 14 deletion positive Cohorts 4 and 5b. Cohort 4 only enrolled pretreated (second and third line) *MET* exon 14 deleted patients, and Cohort 5b only enrolled treatment-naïve *MET* exon 14 deleted patients. Patients were screened for enrollment into Cohorts 4 and 5b for *MET* exon 14 deletion status using a *MET* exon 14 deletion reverse- transcriptase PCR (RT-PCR) CTA. After initial patient screening, clinical samples were stored for retrospective testing. GEOMETRY-mono 1 is an ongoing trial that was initiated on June 11, 2015 with first patient first visit (FPFV). Patients receive 400 mg of capmatinib orally twice daily in tablet form. Dose adjustments for capmatinib are permitted for safety concerns. Efficacy is evaluated every six weeks from the first day of treatment until RECIST 1.1 disease progression.

12.12.2 Summary of the Clinical Bridging Study

The safety and effectiveness of F1CDx for detecting SNVs and indels that lead to *MET* exon 14 skipping in NSCLC patients who may benefit from treatment with capmatinib was demonstrated in a retrospective analysis of samples from patients enrolled in the GEOMETRY-mono 1 trial. A bridging study was conducted to assess the clinical efficacy of F1CDx in identifying patients positive for SNVs and indels that lead to *MET* exon 14 skipping for treatment with capmatinib and the concordance between *MET* exon 14 deletion status tested with the CTA and F1CDx in the intent-to-test population. Retrospective testing with F1CDx was done for patients from Cohorts 4 and 5b, and a random selection of *MET* exon 14 deletion negative patients. The retrospective testing population consisted of 204 patients (78 *MET* exon 14 deletion positive patients, and 126 *MET* exon 14 deletion negative patient samples), originally tested by the *MET* exon 14 CTA for patient selection.

12.12.3 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.12.4 Accountability of the PMA Cohorts

A total of 3036 patients were screened for trial eligibility from 152 investigational sites across 25 countries. 2551

patients within the original 3036 were screened for *MET* exon 14 deletion by the CTA. Within that screened population, 2295 patients produced valid positive and negative CTA results. As of April 15, 2019, a total of 334 patients had been enrolled into all available cohorts. Of the patients whose samples produced valid CTA results, 97 were enrolled into Cohorts 4 and 5b of the GEOMETRY-mono 1 trial, with 69 and 28 patients respectively. *MET* exon 14 deletion negative patients were not enrolled in the GEOMETRY-mono 1 trial. Available samples from *MET* exon 14 deletion negative patients were evaluated for the bridging study, including 130 randomly selected CTA-negative patients. Out of the 130 CTA- negative samples, 93 were randomly assigned to Cohort 4 and 37 to Cohort 5b. Of the 227 positive and negative samples (97 positive and 130 negative), retrospective testing with F1CDx was performed for 204 CTA-tested patient samples that met the F1CDx sample testing criteria (78 positive and 126 negative). The F1CDx testing yielded 198 CDx-evaluable results and six (6) invalid results for the CDx and CTA concordance analysis.

Sensitivity analyses were conducted with all 227 samples to determine the impact of missing F1CDx results on concordance and efficacy results, which included 19 positive patient samples not tested due to failing to meet the F1CDx minimum tissue sample requirements, laboratory error and/or not meeting quality control metrics.

12.12.5 Clinical Concordance

The primary concordance analysis was conducted on 204 samples (78 positive and 126 negative). Agreement between F1CDx and the CTA was demonstrated. The point estimates of PPA, NPA and OPA between F1CDx and the CTA, shown in **Table 67**, were calculated with and without invalid CDx results, using the CTA results as reference for the CTA-enrolled patients.

Table 67. Agreement between F1CDx and CTA based on CTA results in combined cohorts by F1CDx sample requirements

	Measure of agreement	Without CDx "Invalid"		With CDx "Invalid"	
		Percent agreement % (n/N)	95% CI (1)	Percent agreement % (n/N)	95% CI (1)
Cohort 4 and Cohort 5b	PPA	98.6 (72/ 73)	(92.6, 100)	92.3 (72/ 78)	(84.0, 97.1)
	NPA	100 (125/125)	(97.1, 100)	99.2 (125/126)	(95.7, 100)
	OPA	99.5 (197/198)	(97.2, 100)	96.6 (197/204)	(93.1, 98.6)

N: The total number of patients. It is the denominator for percentage (%) calculation.

n: Number of patients with agreement between CTA and CDx.

(1) The 95% CI calculated using Clopper-Pearson method

12.12.6 Efficacy Evaluation

GEOMETRY- mono 1 clinical efficacy results

The GEOMETRY-mono 1 clinical trial met the primary objective, demonstrating a high ORR as assessed by BIRC. Treatment with capmatinib was considered efficacious in both Cohort 4 (second and third line) and Cohort 5b (treatment-naïve) as demonstrated by an ORR per BIRC of 40.6% (95% CI: 28.9, 53.1) and of 67.9% (95% CI: 47.6, 84.1), respectively (**Table 68** below). Robustness of the data was further confirmed by the supportive analysis of ORR by Investigator assessment, ORR for the PFS and for key subgroups.

Table 68. Treatment-naïve and previously treated MET-skipping positive locally advanced or metastatic NSCLC - efficacy results in patients treated with capmatinib in GEOMETRY-mono 1

Efficacy Parameter	Previously Treated (Cohort 4) N = 69	Treatment-Naïve by (Cohort 5b) N = 28
Overall Response Rate^a, % (95% CI)^b	40.6 (28.9, 53.1)	67.9 (47.6, 84.1)
Complete Response (CR), n (%)	0	3.6%
Partial Response (PR), n (%)	40.6%	64.3%

^a Determined by RECIST v1.1.

^b Clopper and Pearson exact binomial 95% CI.

Clinical efficacy results in the CDx-positive population

Clinical utility of F1CDx was evaluated by estimation of clinical efficacy in the CTA-enrolled *MET* exon 14 deletion positive patient population, as assessed by the primary objective of ORR by BIRC. Baseline demographic and disease characteristics were compared between the CDx evaluable and CDx unevaluable within all enrolled CTA-positive patients in Cohorts 4 and 5b. Clinical efficacy of capmatinib in patients with SNVs and indels that lead to *MET* exon 14 skipping with valid CDx results and after imputing missing CDx results were similar between the CDx-positive and CTA-positive patient groups in the GEOMETRY-mono 1 trial. **Table 69** shows the efficacy results in CTA enrolled CDx-positive patients, while detailed efficacy results are available in Tables 16 and 17 of the SSED.

Table 69. Summary of clinical efficacy results by test method and sample set

Test Method	Cohort 4 ORR with 95% CI	Cohort 5b ORR with 95% CI
F1CDx	44.2% (30.6 – 58.7%)	70% (45.7 – 88.1 %)
CTA	40.6% (28.9 – 53.1%)	67.9% (47.6 – 84.1%)

12.12.7 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying NSCLC patients with SNVs and indels that lead to *MET* exon 14 skipping who may be eligible for treatment with capmatinib.

12.13 Clinical evaluation of HRR gene alterations for treating prostate cancer patients with olaparib

The clinical performance of F1CDx for determination of the mutation status of the HRR gene panel was established based on confirmed FMI F1CDx subgroup results, which were derived from tumor analysis results using the CLIA HRR CTA in the clinical study D081DC00007 (PROfound).

Study Design

PROfound was a Phase III, randomised, open-label, multicentre trial to assess the efficacy and safety of olaparib monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) that have qualifying homologous recombination repair (HRR) gene mutations that were predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function) who have failed prior treatment with a new hormonal agent (NHA).

Patients were randomised in a 2:1 ratio to the treatments as specified below:

- Olaparib tablets orally 300 mg bd
- Investigators choice of NHA with either enzalutamide 160 mg orally once daily (od) or abiraterone acetate 1000 mg orally qd with prednisone 5 mg orally bd (prednisolone was permitted for use instead of prednisone, if necessary)

Eligible patients were those with HRRm mCRPC, who had progressed following prior treatment with an NHA. All patients must have had a qualifying HRR mutation assessed via the FMI CLIA HRR CTA to be randomised. Qualifying HRR gene mutations were *BRCA1*, *BRCA2* and *ATM* for Cohort A, and *BARD1*, *BRIP1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *PPP2R2A*, *RAD51B*, *RAD51C*, *RAD51D* and *RAD54L* for Cohort B.

Note: Although patients with *PPP2R2A* gene mutations were enrolled in the trial, Lynparza is not indicated for the treatment of patients with this gene mutation because of lack of response, and a numerical decrement in both rPFS and OS compared to enzalutamide or abiraterone.

Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

Efficacy Evaluation

PROfound met its primary objective, demonstrating a statistically significant improvement in rPFS as assessed by BICR with olaparib 300 mg bd compared with investigators choice of NHA in Cohort A. Specifically, the PROfound efficacy data with olaparib demonstrated:

- A statistically significant improvement in rPFS as assessed by BICR with olaparib 300 mg bd compared with investigators choice of NHA in Cohort A, with a 66% reduction in the risk of BICR-confirmed radiological disease progression or death and a prolongation of median progression free interval of 3.8 months with olaparib vs investigators choice of NHA. The rPFS outcome in the confirmed FMI F1CDx subgroup (HR 0.33 [95% CI 0.24, 0.46]) was consistent with the Full Analysis Set (FAS) (HR 0.34 [95% CI 0.25, 0.47]).

Table 70. Summary of analysis of rPFS based on BICR (Cohort A)

Analysis group:	Full Analysis Set		Confirmed FMI F1CDx Subgroup	
	Olaparib 300 mg bd (N=162)	Investigators choice of NHA (N=83)	Olaparib 300 mg bd (N=157)	Investigators choice of NHA (N=83)
n (%) of events ^a	106 (65)	68 (82)	101 (64)	68 (82)
Treatment effect				
Median rPFS (95% CI) [months]	7.4 (6.24, 9.33)	3.6 (1.91, 3.71)	7.4 (6.87, 9.33)	3.6 (1.91, 3.71)
HR (95% CI) ^b	0.34 (0.25, 0.47)		0.33 (0.24, 0.46)	
2-sided p-value ^c	<0.0001		<0.0001	

^a Progression, as assessed by BICR, was defined by RECIST 1.1 and/or PCWG-3 or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anticancer therapy prior to progression.

^b The HR and CI were calculated using a Cox proportional hazards model adjusted for the variables selected in the primary pooling strategy (prior taxane use and measurable disease in Cohort A). The Efron approach was used for handling ties. An HR <1 favours olaparib 300 mg bd.

^c The analysis was performed using the log-rank test stratified by the variables selected in the primary pooling strategy (prior taxane use and measurable disease in Cohort A) using the Breslow method for handling ties.

bd twice daily; BICR blinded independent central review; CI confidence interval; FAS full analysis set; HR hazard ratio; NHA new hormonal agent; PCWG-3 Prostate Cancer Working Group 3; RECIST Response Evaluation Criteria in Solid Tumours; rPFS radiological progression-free survival.

- There was a statistically significant improvement in confirmed radiological ORR by BICR for patients in Cohort A with measurable disease at baseline in the olaparib arm compared with the investigators' choice of NHA arm. The efficacy in the confirmed FMI F1CDx subgroup showed a similar performance as compared to the Full Analysis Set.

Table 71. Confirmed radiological objective response rate, logistic regression based on BICR (EFR; Cohort A)

Analysis group	Treatment group	N	Number (%) of patients with response ^a	Comparison between groups
				2-sided p-value ^b
Full Analysis Set	Olaparib 300 mg bd	84	28 (33.3)	<0.0001
	Investigators choice of NHA	43	1 (2.3)	
Confirmed FMI F1CDx Subgroup	Olaparib 300 mg bd	84	27 (33.8)	<0.0001
	Investigators choice of NHA	43	1 (2.3)	

^a Radiological objective response rate determined based on BICR assessed RECIST 1.1 and bone scan data (using all scans regardless of whether they were scheduled or not) in patients with measurable disease. Response required confirmation. Radiological objective response rate compared using logistic regression (PROC GENMOD) adjusting for previous taxane use as a covariate.

^b Where the number of patients with a response was ≥ 5 , a 1-sided p-value was calculated based on twice the change in log-likelihood resulting from the addition of the treatment factor to the model that contains the specified covariates. Where the number of patients with a response was < 5 , the 2-sided p-value was calculated based on the mid p-value modification of the Fisher's exact test.

- There was a statistically significant improvement in rPFS as assessed by BICR for olaparib-treated patients compared with investigators choice of NHA-treated patients in Cohort A+B, with a 51% reduction in the risk of radiological disease progression or death and a prolongation of median progression-free interval of 2.3 months with olaparib vs investigators choice of NHA (HR=0.49; 95% CI 0.38, 0.63; $p < 0.0001$; median rPFS 5.8 months vs 3.5 months, respectively, for FAS and confirmed FMI F1CDx subgroup).

Table 72. Summary of analysis of rPFS based on BICR (Cohort A+B)

Analysis group:	Full Analysis Set		Confirmed FMI F1CDx Subgroup	
	Olaparib 300 mg bd (N=256)	Investigators choice of NHA (N=131)	Olaparib 300 mg bd (N=248)	Investigators choice of NHA (N=128)
n (%) of events ^a	180 (70.3)	99 (75.6)	172 (69.4)	96 (75.0)
Treatment effect				
Median rPFS (95% CI) [months]	5.8 (5.52, 7.36)	3.5 (2.20, 3.65)	6.2 (5.52, 7.36)	3.5 (2.10, 3.65)
HR (95% CI) ^b	0.49 (0.38, 0.63)		0.49 (0.38, 0.63)	
2-sided p-value ^c	< 0.0001		< 0.0001	

^a Progression, as assessed by BICR, was defined by RECIST 1.1 and/or PCWG-3 or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anticancer therapy prior to progression.

^b The HR and CI were calculated using a Cox proportional hazards model adjusted for the variables selected in the primary pooling strategy (prior taxane use and measurable disease in Cohort A+B). The Efron approach was used for handling ties. An HR < 1 favours olaparib 300 mg bd.

^c The analysis was performed using the log-rank test stratified by the variables selected in the primary pooling strategy (prior taxane use and measurable disease in Cohort A+B) using the Breslow method for handling ties.

bd twice daily; BICR blinded independent central review; CI confidence interval; FAS full analysis set; HR hazard ratio; NHA new hormonal agent; PCWG-3 Prostate Cancer Working Group 3; RECIST Response Evaluation Criteria in Solid Tumours; rPFS radiological progression-free survival.

- In Cohort A, the interim OS data indicate a trend for OS benefit in olaparib -treated patients compared with investigators choice of NHA-treated patients, with a median OS improvement of 3.4 months in the olaparib-arm vs the investigators choice of NHA arm (HR=0.64; 95% CI 0.43, 0.97; $p = 0.0173$; median OS 18.5 months vs 15.1 months, respectively).
- The olaparib safety and tolerability profile in this study was consistent with that observed in previous studies of olaparib.

12.14 Clinical Evaluation of pembrolizumab in TMB-H solid tumors

Summary of the Clinical Study – KEYNOTE-158

The clinical performance of F1CDx for detecting TMB-H (defined as TMB ≥ 10 mutations per megabase) and the efficacy of KEYTRUDA (pembrolizumab) were investigated in a prospectively-planned retrospective analysis of 10 cohorts (A through J) of patients with various previously treated unresectable or metastatic solid tumors with high tumor mutational burden (TMB) who were enrolled in a multicenter, non-randomized, open-label trial, KEYNOTE-158 (NCT02628067). The trial excluded patients who previously received an anti-PD-1 or other immune-modulating monoclonal antibody, or who had an autoimmune disease, or a medical condition that required immunosuppression. Patients received KEYTRUDA 200 mg intravenously every 3 weeks until

unacceptable toxicity or documented disease progression. Assessment of tumor status was performed every 9 weeks for the first 12 months and every 12 weeks thereafter.

The statistical analysis plan pre-specified ≥ 10 and ≥ 13 mutations per megabase using F1CDx as cutpoints to assess TMB. Testing of TMB was blinded with respect to clinical outcomes. The major efficacy outcome measures were ORR and DoR in the patients who have received at least one dose of KEYTRUDA as assessed by BICR according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

In KEYNOTE-158, 1,050 patients (Cohorts A through J) were included in the efficacy analysis population. TMB was analysed in the therapeutic efficacy (TE) subset of 790 patients with sufficient tissue for testing based on testing requirements for the investigational F1CDx assay. Of the 790 patients, 102 (13%) had tumors identified as TMB-H (defined as a TMB ≥ 10 mutations per megabase). Among the 102 TMB-H patients, the study population characteristics were: median age of 61 years (range: 27 to 80), 34% age 65 or older; 34% male; 81% White; and 41% ECOG PS of 0 and 58% ECOG PS of 1. TMB was also analysed in the device validation (DV) population of 719 patients using the final F1CDx assay. Of the 719 patients, 91 (13%) had tumor identified as TMB-H (≥ 10 mutations per megabase) and the study population characteristics were: median age of 60 years (range: 27 to 80), 35% age 65 or older; 34% male; 81% White; and 41% ECOG PS of 0 and 58% ECOG PS of 1.

Efficacy results for the therapeutic efficacy (TE) (n=102) and device validation (DV) (n=91) populations are summarized in **Table 73**.

Table 73. Efficacy results for patients with TMB-H (≥ 10 mut/Mb) cancer in KEYNOTE-158

Endpoint	KEYTRUDA 200 mg every 3 weeks	
	Therapeutic Efficacy Population n=102*	Device Validation Population n=91*
Objective Response Rate		
ORR (95% CI)	29% (21, 39)	33% (24, 44)
Complete response rate	4%	4%
Partial response rate	25%	29%
Duration of Response		
Median in months (range)	NR (2.2+, 34.8+) [†]	NR (2.2+, 34.8+) [†]
% with duration ≥ 6 months	87%	87%
% with duration ≥ 12 months	57%	57%
% with duration ≥ 24 months	50%	50%

* Median follow-up time of 11.1 months for TE population, and 13.4 months for DV population.

[†] Based on patients (n=30) with a response by independent review

+ Denotes ongoing NR = not reached

ORR was assessed by tumor type, and the results were similar in the TE and DV populations. Efficacy results per tumor type are shown for the TE and DV populations in **Table 74** and **Table 75**, respectively. ORR was generally higher in the TMB-H population for most tumor types than in the non-TMB-H population.

Table 74. Summary of best objective response per tumor type in TE population

Tumor Type*	TMB ≥10 mut/Mb				TMB <10 mut/Mb				ORR Ratio [†] TMB ≥10 mut/Mb vs. TMB <10 mut/Mb
	N	n	%	95% CI [†]	N	n	%	95% CI [†]	
Overall	102	30	29	(21, 39)	688	43	6	(5, 8)	4.7
Anal	14	1	7	(0.2, 34)	75	8	11	(5, 20)	0.7
Neuroendocrine	5	2	40	(5, 85)	82	1	1	(0, 7)	32.8
Endometrial	15	7	47	(21, 73)	67	4	6	(2, 15)	7.8
Cervical	16	5	31	(11, 59)	59	7	12	(5, 23)	2.6
Vulvar	12	2	17	(2, 48)	59	2	3	(0, 12)	4.9
Small Cell Lung	34	10	29	(15, 47)	42	4	10	(3, 23)	3.1
Mesothelioma	1	0	0	(0, 98)	84	9	11	(5, 19)	0.0
Thyroid	2	2	100	(16, 100)	78	3	4	(1, 11)	26.0
Salivary	3	1	33	(1, 91)	79	3	4	(1, 11)	8.8

* No TMB-H patients were identified in the cholangiocarcinoma cohort
[†] Based on binomial exact confidence interval method.
[†] ORR ratios were calculated prior to rounding the objective response values shown in this table

Table 75. Summary of best objective response per tumor type in DV population.

Tumor Type	TMB ≥10 mut/Mb				TMB <10 mut/Mb				ORR Ratio TMB ≥10 mut/Mb vs. TMB <10 mut/Mb
	N	n	%	95% CI [†]	N	n	%	95% CI [†]	
Overall	91	30	33	(24, 44)	628	41	7	(5, 9)	5.0
Anal	14	1	7	(0.2, 34)	73	8	11	(5, 20)	0.7
Neuroendocrine	5	2	40	(5, 85)	73	1	1	(0, 7)	29.2
Endometrial	15	7	47	(21, 73)	64	3	5	(1, 13)	10.0
Cervical	15	5	33	(12, 62)	52	6	12	(4, 23)	2.9
Vulvar	10	2	20	(3, 56)	52	2	4	(0.5, 13)	5.2
Small Cell Lung	26	10	38	(20, 59)	30	4	13	(4, 31)	2.9
Mesothelioma	1	0	0	(0, 98)	80	9	11	(5, 20)	0.0
Thyroid	2	2	100	(16, 100)	75	3	4	(1, 11)	25.0
Salivary	3	1	33	(1, 91)	74	3	4	(1, 11)	8.2

* No TMB-H patients were identified in the cholangiocarcinoma cohort
[†] Based on binomial exact confidence interval method.
[†] ORR ratios were calculated prior to rounding the objective response values shown in this table

The KEYNOTE-158 results indicate that pembrolizumab monotherapy provides clinically meaningful ORR and DoR in previously treated participants with TMB-H solid tumors across cancer types who have no satisfactory alternative treatment options.

12.15 Clinical evaluation of VITRAKVI (larotrectinib) in patients with solid tumors with NTRK1, NTRK2, NTRK3 fusions

Summary of Clinical Studies

The clinical validity of FoundationOne®CDx (F1CDx) for detecting *NTRK1*, *NTRK2*, or *NTRK3* fusions in patients with solid tumors who may benefit from treatment with larotrectinib was demonstrated in a clinical bridging study that consisted of the retrospective analysis of specimens from patients enrolled in the LOXO-TRK-14001 (Bayer 20288, NCT02122913), -15002 (Bayer 20289, NAVIGATE, NCT02576431), and -15003 (Bayer 20290, SCOUT,

NCT02637687) clinical trials (referred to as 14001, 15002, and 15003, respectively) supplemented with *NTRK* fusion negative samples from the FMI clinical archive. Study 14001 is an on-going, multicenter, open-label, Phase 1 dose escalation study in adult patients with advanced solid tumors (all comers) unselected for *NTRK* gene fusion cancer. Following the dose escalation portion of the study, a dose expansion was initiated for patients with documented TRK fusion cancer and for patients who the Investigator believed might benefit from a highly selective TRK inhibitor. Study 15002 is an on-going multi-center, open-label, Phase 2 “basket” study in patients age 12 and older with recurrent advanced solid tumors with a documented *NTRK* gene fusion as assessed by an outside laboratory. Finally, Study 15003 is an on-going multi-center, open-label, Phase 1/2 study in pediatric patients aged from birth to 21 years with advanced solid or primary central nervous system (CNS) tumors.

NTRK fusion status to determine patient eligibility for enrollment was performed using local clinical trial assay (LCTAs) that included DNA next generation sequencing (NGS), RNA NGS, fluorescent in situ hybridization (FISH), and reverse transcriptase- polymerase chain reaction (RT-PCR) methods. The majority of 105 clinical trial patients with known *NTRK* fusion status enrolled into the trials had been tested with NGS methods (92%); 51% of the 105 patients had been tested with DNA NGS methods and 41% with RNA NGS methods. Of the 105 clinical trial patients, 78 patients were *NTRK* fusion positive and 27 were *NTRK* fusion negative. The assessment of efficacy of larotrectinib was based on the first 55 patients with solid tumors with an *NTRK* gene fusion enrolled across the three clinical trials. The primary endpoint was overall response rate (ORR) according to independent review committee assessment using RECIST v1.1 criteria. The ORR of the 55 patient set was 75%, 95% CI: [61%, 85%].

Accountability of the PMA Cohort

Of the 78 *NTRK* fusion positive patients and 27 *NTRK* fusion negative patients enrolled in 14001, 15002, and 15003, 45 patients and 24 patients, respectively, had samples available for testing with F1CDx for a total of 69 samples. Of the 69 samples, 67 samples had valid results and were used to support the clinical concordance analysis. Two (2) samples had invalid results due to failing F1CDx input criteria or low tumor purity. Of the 55 *NTRK* fusion positive patients in the efficacy set, 32 had samples available testing with F1CDx. F1CDx testing yielded 31 valid results to support the F1CDx efficacy analysis. One sample was invalid due to failing F1CDx input criteria.

In addition to clinical trial samples, 206 supplemental *NTRK* fusion negative samples as determined by the DNA NGS FoundationOne LDT were provided from the FMI clinical archive to support the clinical concordance study. Of these 206 samples that were re-tested on F1CDx, 203 samples had valid results.

FoundationOne®CDx Clinical Bridging Study for *NTRK*

A clinical bridging study was conducted to assess the clinical effectiveness of F1CDx in identifying *NTRK1*, *NTRK2*, or *NTRK3* fusion positive patients for treatment with larotrectinib, and to assess the concordance between *NTRK* fusion positive samples tested with the LCTAs and F1CDx. F1CDx was used to retrospectively test the available patient samples from studies 14001, 15002, and 15003 (N = 69) and the supplemental *NTRK* fusion negative samples (N = 206).

Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks. Refer to Drugs@FDA for complete safety information on VITRAKVI® (larotrectinib)

Effectiveness Results

Concordance Analysis

The concordance analysis between the F1CDx and the LCTAs using the clinical trial samples and supplemental negatives is shown in **Table 76**.

Table 76. Concordance between the F1CDx and LCTA methods for detection of NTRK gene fusions based on the LCTA results (all patients tested by CDx)

Measurement of Agreement	Excluding CDx invalid results		Including CDx invalid results	
	% Agreement (N)	95% CI ^(a)	% Agreement (N)	95% CI ^(a)
Positive percent agreement	84.1% (37/44)	69.9% -93.4%	82.2% (37/45)	67.9% -92.0%
Negative percent agreement	100.0% (226/226)	98.4% -100.0%	98.3% (226/230)	95.6% -99.5%
Overall percent agreement	97.4% (263/270)	94.7% -99.0%	95.6% (263/275)	92.5% -97.7%

Abbreviations: CDx = Companion Diagnostic; CI = Confidence Interval; LCTA= Local Clinical Trial Assay; NTRK = Neurotrophic Tyrosine Kinase.

The LCTA inferred *NTRK3* gene fusions were considered fusion positive.

^a The 95% CI was calculated using the Clopper-Pearson exact method.

A sensitivity analysis against the 34 missing CDx results was conducted to assess the robustness of the agreement analysis. Missing CDx results for the LCTA fusion positive patients were imputed using a logistic regression model including 10 covariates (race, ethnicity, age group, stage of disease at initial diagnosis, prior cancer systemic treatments, prior cancer related surgery, ECOG performance status, *NTRK* fusion gene, LCTA method sample substrate, and binary clinical response to larotrectinib). Agreement estimates, including the imputed values, were PPA= 78.3%, 95% CI [64.4%, 89.9%] and NPA=100% (**Table 77**). The method of calculation for the 95% confidence interval accounted for both within and between imputation variance.

Table 77. Concordance between the CDx and LCTA methods for detection of NTRK gene fusions including imputed values in LCTA fusion positive patients with missing CDx results

Measure of Agreement	% Agreement	95% CI ^(a)
PPA	78.3%	64.4%, 89.9%
NPA	100.0%	100.0%, 100.0%
OPA	94.4%	90.5%, 97.4%

^a The 95% CI was calculated based on multiple imputation (MI) Boot pooled sample method.

The F1CDx assay showed high concordance with the DNA NGS LCTA methods with PPA = 95%, 95% CI [75%, 100%] and NPA = 100%, 95% CI [98%, 100%] (**Table 78**).

Table 78. Concordance between the CDx and DNA NGS LCTA methods for detection of NTRK gene fusions based on LCTA results and excluding invalid results

Measure of Agreement	% Agreement (N)	95% CI ^(a)
PPA	95.0% (19/20)	75.1%, 99.9%
NPA	100.0% (221/221)	98.3%, 100.0%
OPA	99.6% (240/241)	97.7%, 100.0%

^a The 95% CI was calculated based on Clopper-Pearson exact method.

However, the positive concordance of F1CDx with RNA NGS methods was lower (PPA = 70%, 95% CI [46%, 88%]) (**Table 79**).

Table 79. Concordance between the CDx and RNA NGS LCTA methods for detection of NTRK gene fusions based on LCTA results and excluding invalid results

Measure of Agreement	% Agreement (N)	95% CI ^(a)
PPA	70.0% (14/20)	45.7%, 88.1%
NPA	100.0% (4/4)	39.8%, 100.0%
OPA	75.0% (18/24)	53.3%, 90.2%

^a The 95% CI was calculated based on Clopper-Pearson exact method.

F1CDx was concordant with FISH and RT-PCR based on testing of 5 samples (**Table 80**). Due to the low sample counts, agreement measures were not calculated.

Table 80. Contingency table comparing NTRK fusion detection results between the CDx and the FISH and RT-PCR LCTA methods (all patients tested by CDx)

F1CDx result by test method	LCTA positive	LCTA negative
FISH		
CDx Positive	3	0
CDx Negative	0	1
Total	3	1
RT-PCR		
CDx Positive	1	0
CDx Negative	0	0
Total	1	0

FISH = Fluorescence in Situ Hybridization; RT-PCR = Reverse Transcriptase-Polymerase Chain Reaction.

A total of 7 of the 275 samples tested with the F1CDx assay showed discordant results between F1CDx and the LCTAs. All 7 discordant results were *NTRK* fusion positive by the LCTA and fusion negative by F1CDx. Of the seven (7) discordant results, six (6) had been tested with an RNA NGS LCTA method and one (1) with an DNA NGS LCTA method.

The discordances between the RNA NGS LCTA methods and F1CDx can be explained by to differences in technology used to detect *NTRK1/2/3* fusions, as well as an expected degree of measurement error by the LCTAs and F1CDx. *NTRK* often presents complex genomic rearrangement events with a variety of breakpoints spanning multiple introns. This complexity of rearrangement events presents certain limitations for targeted DNA sequencing. F1CDx was designed to focus on hotspot introns that are repeatedly described in the literature, which means rare and complex breakpoints may not be captured by F1CDx baiting. The DX1 bait-set used by the F1CDx assay includes the coding regions of *NTRK1*, *NTRK2*, and *NTRK3* and select introns from these genes, however no introns within *NTRK3* are baited and the *NTRK1* intron 8, and *NTRK2* intron 12 are not fully baited. While the most common fusion partner of *NTRK3*, *ETV6*, has several introns baited which allows for detection *ETV6-NTRK3* fusions, *EVT6* intron 5 is also not fully baited. A portion of fusion events between these two genes are likely being undetected as a result of DX1 also not baiting intron 4 of *ETV6*.

Of the seven (7) discordant patients, four (4) patients had complete or partial response, supporting that these four (4) samples were most likely true positives. Investigation findings concluded that F1CDx did not detect the fusion events in six (6) of the discordances for one of two reasons: 1) F1CDx does not bait the intron where the breakpoint occurred, or 2) the rearrangement event was too complex to be fully baited by F1CDx, and therefore the full picture of the event was not captured. The remaining one (1) discordant case could have been explained by time of sample collection and testing, since the sample tested by F1CDx was from a sample collected at a different timepoint than used for the LCTA test.

Clinical Efficacy Results

Clinical effectiveness of F1CDx was evaluated by estimation of clinical efficacy in the F1CDx-positive, LCTA-positive population. Clinical outcome was assessed by independent review committee using RECIST 1.1 criteria. Efficacy of larotrectinib in the F1CDx positive, LCTA-positive population was 77% (95% CI: [56%, 91%]) overall response rate (see **Table 81**). This is comparable to the efficacy for the NDA filing, where larotrectinib demonstrated an estimated 75% (95% CI: [61%, 85%]) overall response rate in the NDA efficacy population. Of the 26 F1CDx-positive patients in the efficacy set, six (6) (23%) patients had achieved a complete response and 14 (54%) had received a partial response with larotrectinib therapy (see **Table 81**).

Table 81. Primary efficacy results: the best overall response and overall response rate for NTRK fusion positive patients by LCTA and CDx results in the efficacy analysis set

Clinical outcome	LCTA fusion positive (N=55)	CDx fusion positive and LCTA fusion positive (N=26)	CDx fusion Negative and LCTA fusion positive (N=5)	CDx fusion Results missing and LCTA fusion positive (N=24)
ORR% (95% CI^(a))	75% (61%, 85%)	77% (56%, 91%)	80% (28%, 99%)	71% (49%, 87%)
Complete response	12 (22%)	6 (23%)	2 (40%)	4 (17%)
Partial response	29 (53%) ^b	14 (54%)	2 (40%)	13 (54%) ^b
Duration of Response^(c)	N=41	N=20	N=4	N=17
Range (months)	1.6, 33.2	1.6, 20.3	3.7, 23.6	2.7, 33.2
% with duration ≥ 6 months	73.2%	80.0%	50.0%	70.6%
% with duration ≥ 9 months	63.4%	65.0%	50.0%	64.7%
% with duration ≥ 12 months	39.0%	25.0%	50.0%	52.9%

^a The 95% confidence interval was calculated using the Clopper-Pearson exact method.

^b Includes one pediatric patient with unresectable infantile fibrosarcoma who underwent resection following partial response and who remained disease-free at data cutoff.

^c Includes patients with ongoing response after data cutoff.

Twenty-four (24) patients have missing CDx results (i.e., 43.6% of the PAS population have missing results). Sensitivity analysis against the 24 missing CDx results was conducted to assess the robustness of the clinical efficacy analysis for the F1CDx positive patients. Missing CDx results for the LCTA fusion positive patients in the efficacy set were imputed 100 times using a logistic regression model including 9 covariates based on the missing at random (MAR) assumption. Covariates identified included covariates imbalanced between the CDx evaluable and CDx non- evaluable sets, covariates associated with the F1CDx results and covariates associated with patient clinical response to larotrectinib. 9 covariates were used in the imputation model for the efficacy sensitivity analysis: race, ethnicity, age group, gender, stage of disease at initial diagnosis, ECOG performance status, *NTRK* fusion gene, LCTA method sample substrate, and binary clinical response to larotrectinib. Clinical efficacy, including the imputed CDx results, was ORR=74%, 95% CI [59%, 89%] (**Table 82**) and was similar to the results of the primary efficacy analysis (ORR=77%, 95% CI [56%, 91%]) **Table 81**). However, it should be noted that the clinical effectiveness of F1CDx to identify patients with solid tumors with *NTRK1*, *NTRK2* or *NTRK3* fusions who may benefit from larotrectinib treatment is based on ~56% of the efficacy population.

Table 82. Sensitivity analysis for overall response rate by CDx result for NTRK fusion positive patients including imputed values for missing CDx results in the efficacy analysis set

Clinical Outcome	CDx fusion positive and LCTA fusion positive	CDx fusion negative and LCTA fusion positive
ORR% (95% CI^(a))	74% (59% - 89%)	78% (46% - 100%)

^a The 95% confidence interval was calculated based on MI Boot pooled sample method.

Sensitivity analysis was performed to estimate ORR in the total F1CDx positive population including the F1CDx positive, LCTA positive and the F1CDx positive, LCTA negative subpopulations. To assess the potential impact of the F1CDx positive, LCTA negative portion of the F1CDx positive intended use population on clinical effectiveness, 206 *NTRK* negative samples by the FoundationOne LDT were selected from the FMI clinical archive along with 24 *NTRK* negative clinical trial samples available for testing were used to obtain a NPA that

was representative for the LCTAs used to enroll patients in the larotrectinib trials. Since the estimated NPA (PPV) is 100%, the ORR for the F1CDx positive population is the same as the ORR for the F1CDx positive and LCTA positive population. However, the NPA estimate between F1CDx and LCTA is subject to uncertainty and could be biased given that the majority of the *NTRK* fusion negative patients, in both the full population and those whose samples were available for testing with F1CDx had been tested using DNA NGS methods (>70%). FoundationOne LDT was the most commonly used DNA based NGS method that was used for *NTRK* fusion status determination for patients in the larotrectinib clinical trials. The same assay was also used to select the supplemental negative samples in the clinical bridging study as the representative LCTA. Therefore, the estimated NPA could be subject to bias.

Sensitivity analysis to determine the minimum PPV that will lead to an ORR of 30% at the lower bound of the two-sided 95% confidence interval for the CDx positive population was performed. This analysis was conducted to determine the NPA corresponding to this tipping point PPV by assuming fixed prevalence of *NTRK* fusion (0.32%)¹² and PPA (84%) observed from the concordance analysis to demonstrate the robustness of the study results.

For each value of *c* (the scaling factor for the assumed ORR (LCTA negative/F1CDx positive)), the tipping point PPV that led to an ORR of the F1CDx positive population with the lower bound of the two-sided 95% confidence interval at 30% was determined. When *c* is greater than or equal to 0.85,

indicating the ORR in the LCTA negative/F1CDx positive population is close to the ORR in the LCTA positive/F1CDx positive population, the two-sided 95% lower confidence limit (LCL) of ORR is always greater than 30% so there is no tipping point of PPV. At all values of PPV (and NPA), the two-sided 95% LCL is > 30%. At *c* values between 0 and 0.8, a tipping point PPV ranges from 99.5% to 88.6% and NPA ranges from 100% to 99.97%.

Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying solid tumor patients harboring *NTRK1*, *NTRK2*, or *NTRK3* fusions that may be treated with VITRAKVI® larotrectinib.

12.15.1 Post-Approval Study (PAS) to Support the Clinical Effectiveness of F1CDx for Treatment with VITRAKVI (larotrectinib)

An additional study was conducted post approval to evaluate the clinical effectiveness of F1CDx. The post approval study (PAS) retrospectively tested patient samples from 17 patients with solid tumors with *NTRK1/2/3* fusions enrolled based on local tests in the LOXO-TRK-15002 (NAVIGATE) and LOXO-TRK-15003 (SCOUT) clinical studies evaluating the efficacy of larotrectinib.

All 17 patient samples passed the F1CDx QC criteria and therefore had F1CDx evaluable results. Of the 17 patients, 11 had an *NTRK1/2/3* fusion detected by F1CDx while the remaining 6 were *NTRK1/2/3* fusion negative. Eight (8) of 17 cases evaluated in the clinical PAS were pediatric cases from patients that were less than 18 years of age. Of the 6 out of 17 patients with *NTRK1/2/3* fusions that were missed by F1CDx in the PAS, i.e., had *NTRK1/2/3* gene fusions detected by local tests but had an F1CDx negative (-) status, 4 were pediatric cases, with ages less than 18 years of age. Two (2) of these patients had infantile fibrosarcoma (IFS) and 2 had soft tissue sarcoma.

The ORR observed for the local test positive and F1CDx-positive population (n=11) was 63.6% (7/11), 95% two-sided score CI: 30.8%, 89.1%. This is similar to the ORR observed for the PAS-positive population, n=17, which was 64.7% (11/17), 95% two-sided score CI: 38.3%, 85.8%.

Although the small sample size of the PAS was small, the similar ORR observed in the PAS *NTRK1/2/3* fusion positive population by F1CDx compared to the ORR in the local testing fusion positive population confirms clinical effectiveness of F1CDx. However, F1CDx was not able to detect 35.3% (6/17) of *NTRK1/2/3* fusions in

rare cancers that have a high prevalence of *NTRK1/2/3* fusions; therefore additional clinical investigation for *NTRK1/2/3* fusions determined to be negative by F1CDx is recommended for cancers with high *NTRK1/2/3* fusion rates (e.g., soft tissue infantile fibrosarcoma, kidney mesoblastic nephroma, salivary gland secretory carcinoma (MASC), breast secretory carcinoma) such that patients may not forgo a potentially effective therapy.

12.16 Clinical Evaluation of KEYTRUDA (pembrolizumab) in patients with MSI-H solid tumors

A clinical bridging study using 444 patient samples from KEYNOTE-158 Cohort K (n=321) and KEYNOTE-164 (n=123) was conducted to establish the clinical validity of the F1CDx as a CDx for pembrolizumab in MSI-H solid tumors. KEYNOTE-158 is an ongoing multicenter, global, open-label trial of KEYTRUDA in patients with multiple types of advanced (unresectable and/or metastatic) cancers who have failed prior therapy. All patients enrolled in this study had a histologically or cytologically documented, advanced solid tumor that was incurable and for which prior standard first-line treatment had failed. Patients had progressed on or were intolerant to therapies that are known to provide clinical benefit. All patients received pembrolizumab 200 mg Q3W. All patients enrolled in this study had a histologically or cytologically documented, advanced solid tumor that was incurable and for which prior standard first-line treatment had failed. Patients had progressed on or were intolerant to therapies that are known to provide clinical benefit. All patients received pembrolizumab 200 mg Q3W. KEYNOTE-158 Cohort K enrolled patients with unresectable or metastatic MSI-H/dMMR solid tumors (except CRC). KEYNOTE-164 is a multicenter, multicohort, single arm, open-label trial designed to evaluate the efficacy of pembrolizumab in previously treated patients with unresectable or metastatic MSI-H/dMMR CRC tumors. Local IHC or PCR assays were primarily used to enroll KEYNOTE-158 Cohort K and KEYNOTE-164 participants. All participants received pembrolizumab 200 mg Q3W.

Primary objectives of KEYNOTE-158 Cohort K and KEYNOTE-164 were to evaluate ORR per RECIST 1.1 (assessed by central imaging) to pembrolizumab. Secondary objectives included assessment of DOR, PFS and OS in the pembrolizumab treated participants. The data cut-off date for the clinical efficacy analyses for KEYNOTE-158 was October 05, 2020 and September 09, 2019 for KEYNOTE 164.

Samples from KEYNOTE-158 Cohorts A-J patients (patients in rare tumor non-CRC cohorts who had failed prior therapy and tumor bank samples were additionally tested with F1CDx to determine the NPA of the F1CDx vs. CTA. Sample accounting is included in **Table 83**.

Table 83. F1CDx Sample Accounting Across Cohorts

STUDY	F1CDx Tested	F1CDx Evaluable
All	1664	1189
KN158 Cohort K	168	104
KN158 Cohort A to J	1006	716
KN164	81	62
Tumor Bank	409	307

Together 28.47% of samples, 473 out of 1664, failed to provide F1CDx valid results. Of these 473, 132 did not provide F1CDx valid results due to MSI QC failures.

Concordance Analysis

Table 84 shows concordance between the CTA and F1CDx evaluable samples across solid tumors. There were 15 CTA non-evaluable samples (14 from KEYNOTE-158 Cohort A-J and 1 tumor bank) out of 1189 F1CDx evaluable samples and these samples were therefore excluded from the concordance analyses, leaving 1,174 for the analyses.

Table 84. Concordance between CTA and F1CDx

Tumor Type	N	CTA+ F1CDx+	CTA+ F1CDx-	CTA- F1CDx+	CTA- F1CDx-	PPA % (95% CI)	NPA % (95% CI)	OPA % (95% CI)
All	1174	134	58	7	975	69.8 (63.0, 75.8)	99.3 (98.5, 99.7)	94.5 (93.0, 95.6)
Colorectal	151	60	13	0	78	82.2 (71.9, 89.3)	100.0 (95.3, 100.0)	91.4 (85.8, 94.9)
Endometrial	101	28	4	5	64	87.5 (71.9, 95.0)	92.8 (84.1, 96.9)	91.1 (83.9, 95.2)
Gastric	66	11	3	0	52	78.6 (52.4, 92.4)	100.0 (93.1, 100.0)	95.5 (87.5, 98.4)
Ovarian	10	7	3	0	0	70.0 (39.7, 89.2)	NA	70.0 (39.7, 89.2)
Others	846	28	35	2	781	44.4 (32.8, 56.7)	99.7 (99.1, 99.9)	95.6 (94.0, 96.8)

CTA-Positive includes samples from KEYNOTE-158 Cohorts A-K and Tumor Bank

CTA-Negative includes sample from KEYNOTE-158 Cohorts A-J and Tumor Bank

Demographic Characteristics

For the clinical device bridging study, baseline characteristics were compared between the CTA positive, F1CDx evaluable and F1CDx non-evaluable populations.

As noted above, the CTA-positive population consists of 444 patients, 321 from KEYNOTE-158 Cohort K and 123 from KEYNOTE-164. Among these 444 patients, the baseline characteristics were: median age of 59 years, 36% ≥ 65 years of age; 46% male; 78% White, 13% Asian, and 4% Black; and 44% had an ECOG PS of 0 and 56% had an ECOG PS of 1. Ninety-three percent (93%) of patients had metastatic disease. Sixty-two percent (62%) of patients received 2 or more prior lines of therapy.

Clinical Efficacy Results

The clinical validity of F1CDx for the detection of MSI-H status in patients with solid tumors was based on estimation of clinical efficacy in the F1CDx-positive, CTA-positive population. The major efficacy outcome measure was ORR per RECIST 1.1 (assessed by central imaging). ORR for the CTA positive, F1CDx positive/CTA positive, F1CDx negative/CTA positive, and F1CDx missing/CTA positive are presented in **Table 85**.

Table 85. Efficacy Results in KEYNOTE-164 and KEYNOTE-158 Cohort K Combined

	CTA positive (N=444)	F1CDx positive and CTA positive (N=107)	F1CDx negative and CTA positive (N=58)	F1CDx result missing and CTA positive (N=279)
Clinical outcome				
ORR% (95% CI^(a))	31.8% (27.4, 36.3)	43.0% (33.5, 52.9)	12.1% (5.0, 23.3)	31.5% (26.1, 37.3)
Complete response	38 (8.6%)	13 (12.1%)	2 (3.4%)	23 (8.2%)
Partial response	103 (23.2%) ^b	33 (30.8%)	5 (8.6%)	65 (23.3%)
Duration of Response	N=141	N=46	N=7	N=88
Median in months (range)	NR (2.1+ - 51.1+)	NR (3.7+ - 46.2+)	15.1 (6.1+ - 32.2+)	NR (2.1+ - 51.1+)
% with duration ≥ 6	129 (95.6)	43 (95.6)	7 (100.0)	79 (95.2)

	CTA positive (N=444)	F1CDx positive and CTA positive (N=107)	F1CDx negative and CTA positive (N=58)	F1CDx result missing and CTA positive (N=279)
Clinical outcome				
months				
% with duration $\geq$ 12 months	104 (90.1)	36 (88.6)	4 (83.3)	64 (91.4)

(a) Based on binomial exact confidence interval method.

Database Cutoff Date:

KEYNOTE 164: September 09, 2019,

KEYNOTE 158: October 05, 2020

The ORR in the CTA-positive population was 31.8% (141/444), (95% CI: 27.4, 36.3). There were 53 CTA-positive participants who also had F1CDx results with partial or complete responses.

Among them 86.8% (46/53) were positive by F1CDx (95% CI: 74.7, 94.5). There were 112 CTA-positive participants who also had F1CDx results with no responses. Among the 112 CTA positive patients who did not respond to KEYTRUDA, only 54.5% (61/112) were positive by F1CDx (95% CI: 44.8, 63.9). Taken together, F1CDx has a higher percent of positive results among participants with responses than among participants without responses [difference between 86.8% (46/53) and 54.5% (61/112) was 32.3% with 95% CI: (17.6, 44.6)].

The ORR in F1CDx-positive/CTA-positive participants was 43.0% (46/107), (95% CI: 33.5, 52.9).

The ORR in F1CDx-negative/CTA-positive participants was 12.1% (7/58), (95% CI: 5.0, 23.3). The ORR in F1CDx-positive/CTA-positive participants was higher than the ORR in F1CDx-negative/CTA-positive participants [difference between 43.0% (46/107) and 12.1% (7/58) was 30.9% with 95% CI: (16.7, 42.8)].

The similarity of the ORR for the CTA-positive population (n=444) overall (31.8%, 95% CI: 27.4, 36.3) and for those missing a valid F1CDx result (n=279; 31.5%, 95% CI: 26.1, 37.3) suggests no overt imbalance in efficacy effect of pembrolizumab between patients on whom the F1CDx was or was not obtained.

Sensitivity Analysis

Sensitivity analyses with regard to missing values were conducted to evaluate the robustness of the ORR estimates in consideration of the subjects with missing/invalid CDx results and the missing F1CDx-positive, CTA-negative population that was not enrolled and evaluated by KEYNOTE-158 Cohort K and KEYNOTE-164 clinical studies.

To evaluate the impact of missing/invalid F1CDx results, the distribution of patients for baseline covariates, disease characteristics, tumor organ system, and tumor types was compared among the CTA-positive population, the F1CDx-evaluable/CTA-positive subpopulation, and F1CDx-missing CTA-positive subpopulation. A multiple imputation method was utilized to account for patients with missing or non-evaluable F1CDx MSI tumor status (n=279). The imputation model included the clinical outcome and covariates that are considered predictive of missingness of the F1CDx tumor status and showing some predictive value of the F1CDx tumor status.

The clinical efficacy (ORR) for the F1CDx-positive subjects in the device intended use population was estimated under different assumed scenarios based on observed and imputed F1CDx results.

For the F1CDx-positive, CTA-negative population that was not enrolled and evaluated by KEYNOTE-158 Cohort K and KEYNOTE-164 clinical studies, bridging equations that involved an ORR attenuation factor that ranges from 0 (assume full attenuation of the efficacy in CTA-negative/F1CDx-positive) to 1 (assume no attenuation of the efficacy in CTA-negative/F1CDx-positive compared to the observed ORR in F1CDx-positive patients in the efficacy population) were used for the clinical efficacy analysis in this missing population.

Sensitivity analysis considering the NPA and assuming different CTA positivity rates in the F1CDx intended use

population, which ranged 2-5%, were investigated to assess influence on the efficacy estimated for the intended use, i.e., F1CDx positive subjects. These sensitivity analyses demonstrated the robustness of the clinical efficacy estimate from the primary analysis.

Subgroup Analyses

Response to KEYTRUDA for the CTA positive, F1CDx-positive/CTA-positive, F1CDx- negative/CTA-positive and F1CDx-missing/CTA-positive the F1CDx patients was analyzed by primary tumor type. Within the F1CDx positive patients for the efficacy set, 13 tumor types were represented.

Response rates by tumor types are included in **Table 86**.

Table 86. ORR Estimates per tumor type in Subpopulations by F1CDx Status

Tumor Type	Responder (n) / Subpopulation (N), ORR% (95% CI)			
	CTA-Positive (N=444)	F1CDx-Positive and CTA-Positive (N=107)	F1CDx-Negative and CTA-Positive (N=58)	F1CDx-result missing and CTA-Positive (N=279)
CRC	42/123, 34.1% (25.8, 43.2)	19/48, 39.6% (25.8, 54.7)	1/13, 7.7% (0.2, 36.0)	22/62, 35.5% (23.7, 48.7)
Non-CRC	99/321, 30.8% (25.8, 36.2)	27/59, 45.8% (32.7, 59.2)	6/45, 13.3% (5.1, 26.8)	66/217, 30.4% (24.4, 37.0)
Endometrial	33/68, 48.5% (36.2, 61.0)	5/17, 29.4% (10.3, 56.0)	3/4, 75.0% (19.4, 99.4)	25/47, 53.2% (38.1, 67.9)
Gastric	13/42, 31.0% (17.6, 47.1)	6/11, 54.5% (23.4, 83.3)	0/3, 0.0% (0.0, 70.8)	7/28, 25.0% (10.7, 44.9)
Ovarian	8/24, 33.3% (15.6, 55.3)	5/7, 71.4% (29.0, 96.3)	0/3, 0.0% (0.0, 70.8)	3/14, 21.4% (4.7, 50.8)
Small Intestine	12/25, 48.0% (27.8, 68.7)	3/9, 33.3% (7.5, 70.1)	NA	9/16, 56.3% (29.9, 80.2)
Cholangio carcinoma	9/22, 40.9% (20.7, 63.6)	3/4, 75.0% (19.4, 99.4)	1/3, 33.3% (0.8, 90.6)	5/15, 33.3% (11.8, 61.6)
Breast	1/11, 9.1% (0.2, 41.3)	1/1, 100.0% (2.5, 100)	0/1, 0.0% (0.0, 97.5)	0/9, 0.0% (0.0, 33.6)
Pancreatic	4/22, 18.2% (5.2, 40.3)	2/2, 100.0% (15.8, 100.0)	0/2, 0.0% (0.0, 84.2)	2/18, 11.1% (1.4, 34.7)
Brain	1/17, 5.9% (0.1, 28.7)	NA	1/2, 50.0% (1.3, 98.7)	0/15, 0.0% (0.0, 21.8)
Sarcoma	3/14, 21.4% (4.7, 50.8)	NA	0/7, 0.0% (0.0, 41.0)	3/7, 42.9% (9.9, 81.6)
Neuroendocrine	2/12, 16.7% (2.1, 48.4)	NA	0/6, 0.0% (0.0, 45.9)	2/6, 33.3% (4.3, 77.7)
Other	13/64, 20.3% (11.3, 32.2)	2/8, 25.0% (3.2, 65.1)	1/14, 7.1% (0.2, 33.9)	10/42, 23.8% (12.1, 39.5)

Database Cutoff Date:

KEYNOTE 164: September 9, 2019,

KEYNOTE 158: October 5, 2020

In the two (2) tumor types with the highest MSI-H prevalence across solid tumors, the ORR in F1CDx-positive/CTA-positive subpopulation CRC (n=48) and endometrial cancer (n=17) were 39.6% (95% CI: 25.8, 54.7) and 29.4% (95% CI: 10.3, 56.0) respectively. For non-CRC tumors combined, the ORR in F1CDx-positive/CTA-positive subpopulation (n=59) was 45.8% (95% CI: 32.7, 59.2).

While the point estimate for ORR in endometrial cancer patients with F1CDx-positive/CTA- positive status is lower than the point estimate for CTA positive patients, efficacy data from KEYNOTE 158 Cohort D, which enrolled endometrial cancer patients provides additional efficacy data for the F1CDx positive endometrial cancer population. There were 17 KEYNOTE-158 Cohort D patients that were determined to be F1CDx MSI-H; Seven out of the 17 F1CDx MSI-H (positive) patients were responders, and thus the ORR in these 17 F1CDx-positive patients was 41.2% (95% CI: 18.4, 67.1).

Effectiveness Conclusions

The data from the analytical validation and clinical device bridging studies support the reasonable assurance of safety and effectiveness of the F1CDx assay when used in accordance with the indications for use as an aid in identifying MSI-H status in patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options who may benefit from treatment with KEYTRUDA. Data from the KEYNOTE-158 and KEYNOTE 164 trials with data cut-off dates of October 05, 2020 and September 09, 2019, respectively, demonstrate that patients who had MSI-H status received benefit from treatment with KEYTRUDA and support the addition of the proposed CDx indication to F1CDx.

Safety Conclusions

The F1CDx assay is an *in vitro* diagnostic test, which involves testing of DNA extracted from FFPE tumor tissue. The assay can be performed using DNA extracted from existing (archival) tissue samples routinely collected as part of the diagnosis and patient care. The risks of the device are assessed based on data collected in the clinical study conducted to support PMA approval as described above. Risks of the F1CDx assay are associated with failure of the device to perform as expected or failure to correctly interpret test results and, subsequently, inappropriate patient management decisions in cancer treatment.

Patients with false positive results may undergo treatment with KEYTRUDA without clinical benefit and may experience adverse reactions associated with KEYTRUDA therapy. Patients with false negative results may not be considered for treatment with KEYTRUDA.

There is also a risk of delayed results, which may lead to delay of treatment with KEYTRUDA when patients receive an MSI "Cannot be Determined" result by the F1CDx assay. Patients with MSI "Cannot be Determined" result due an FB-MSI score >0.0041 and <0.0124 , should be re- tested with a validated orthogonal (alternative) method as these MSI scores represent a range of scores with low reliability. The likelihood of a patient receiving this result is 3.29% within solid tumors. Patients with an MSI- "Cannot Be Determined" result due to a post-sequencing quality control (QC) failure should consider re-testing with FoundationOneCDx or a validated orthogonal (alternative) method, if clinically appropriate. The likelihood of a patient receiving an invalid result for MSI status which takes into account samples failing to meet QC criteria defined within pathology review, DNA extraction, Library Construction, and Hybrid Capture, genomic analysis and MSI QC specific criteria is approximately 21.5% to 28.5% within solid tumors as observed in within the F1CDx clinical commercial testing and device clinical bridging study.

Refer to Drugs@FDA for complete safety information on pembrolizumab (KEYTRUDA).

12.16.1 Post-Approval Study to Support the Clinical Effectiveness of F1CDx for the Treatment with KEYTRUDA

An additional post approval study was conducted to evaluate the clinical effectiveness of F1CDx by retrospectively testing 41 patient samples from patients with non-CRC solid tumors with MSI- H/dMMR status as determined by CTAs enrolled and treated with KEYTRUDA in Keynote 158 cohort K. Of these 41 patient samples, 31 patients had F1CDx results that passed QC criteria, i.e., yielded evaluable/valid results with F1CDx. Of the 31 patients with F1CDx evaluable results, 21 were confirmed by F1CDx as MSI-H. The remaining 10 patients did not have MSI-H status confirmed by F1CDx; 8 patients had MSS status and 2 had MSI-cannot be determined status due to MSI scores being >0.0041 but <0.0124 . The ORR in the 21 patients with confirmed MSI-H by F1CDx was 42.9%; 95% CI: 21.8, 66.0. The ORR in the 10 patients that did not have MSI-H status confirmed by F1CDx

was 30%; 95% CI: 6.7, 65.2. The ORR in the F1CDx non-evaluable population, i.e., had invalid results by F1CDx, was 10%; 95%CI:0.3, 44.5. The results of the post approval study further confirmed the clinical effectiveness for F1CDx to identify patients with solid tumors with MSI-H status that may benefit from KEYTRUDA therapy.

12.17 Clinical Evaluation of ROZLYTREK (entrectinib) in Solid Tumor Patients with NTRK Fusions

The clinical effectiveness of F1CDx for detecting *NTRK1*, *NTRK2*, *NTRK3* (NTRK) fusions in solid tumors of patients who may benefit from treatment with entrectinib was demonstrated in a retrospective analysis of specimens from patients enrolled in clinical trials ALKA-372-001 (ALKA), RXDX-101-01 (STARTRK-1), and RXDX-101-02 (STARTRK-2).

12.17.1 Summary of the Clinical Studies

ALKA was a phase 1 dose escalation study of entrectinib in adult patients with advanced metastatic solid tumors. STARTRK-1 was a phase 1, multicenter, open-label study of entrectinib in adult patients with locally advanced or metastatic cancer confirmed to be positive for *NTRK1*, *NTRK2*, *NTRK3*, or NSCLC patients harboring *ROS1* fusions. STARTRK-2 is an open-label, multicenter basket study of entrectinib for the treatment of patients with solid tumors that harbor *NTRK1*, *NTRK2*, *NTRK3*, or NSCLC patients *ROS1* rearrangements.

12.17.2 Accountability of the PMA Cohort

A total of 330 unique samples were evaluated, including 52 clinical trial samples and 278 procured samples. Initially, the clinical bridging study included 54 NTRK efficacy evaluable patient samples, as well as 20 additional NTRK patients who were enrolled between Dec 1, 2017 and Apr 30, 2018.

Ultimately, 41 NTRK efficacy evaluable patient samples and 11 additional NTRK patients who were enrolled between Dec 1, 2017 and Apr 30, 2018 had sufficient material to support clinical bridging.

12.17.3 Summary of the Clinical Bridging Study

The bridging study was conducted to assess: 1) concordance between the local clinical trial assays (CTAs) and F1CDx ; and 2) estimate the overall response rate (ORR) in the efficacy population (CTA- positive population) for entrectinib treatment among clinical study participants whose tumor samples met the biomarker criteria, as determined by retrospective testing with the F1CDx.

12.17.4 Clinical Concordance

A total of 265 samples were evaluated in the concordance evaluation between F1CDx and the CTAs which included a wide range of assays, including RNA-based assays. The concordance analysis population consisted of the F1CDx-evaluable samples.

Concordance was evaluated using the results of PPA and NPA. The PPA and NPA, presented in **Table 87**, were established as 63.6%% (CI 46.6-77.8%) and 100.00% (CI 98.4-100.00%), respectively.

Table 87. Concordance for NTRK Fusions between F1CDx and the CTAs

		CTAs		
		Detected	Not Detected	Total
F1CDx	Detected	21	0	21
	Not Detected	12	232	244
	Total	33	232	265
Agreement Statistics with CTAs as comparator		PPA _{CTAs} 63.6% [46.6%, 77.8%]*	NPA _{CTAs} 100.00% [98.4%, 100.0%]*	

* Confidence intervals calculated using the Wilson score method

12.17.5 Efficacy Evaluation

12.17.5.1 Clinical efficacy results in the CDx-positive population for solid tumor patients with NTRK1, 2, 3 fusions treated with entrectinib

The clinical efficacy of entrectinib in the pivotal clinical trial was measured in Overall Response Rate (ORR) with either confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR). Only clinical samples with clinical outcome data were used in this analysis.

The ORR for all 74 samples of this study (CTA+) population was 62.2% (46/74) with Exact 2-sided 95% CI [50.1, 73.2]. Seventeen (17) patients (17/21) were CTA+ and exhibited F1CDx *NTRK*-positive results. The ORR for this population was 81.0% with Exact 2-sided 95% CI [58.1, 94.6]. Eleven (11) patients were CTA+ but F1CDx *NTRK*-negative. The ORR for this population was 36.4% (4/11) with Exact 2-sided 95% CI [10.9, 69.2]. Forty-two (42) patients were CTA+ but without a F1CDx *NTRK* result. The ORR for this population was 59.5% (25/42) with Exact 2-sided 95% CI [43.3, 74.4], as summarized in **Table 88**.

Table 88. Efficacy by NTRK Status in Biomarker Subgroups

Clinical outcome	CTA positive population (N=74)	F1CDx positive and CTA positive (N=21)	F1CDx negative and CTA positive (N=11)	F1CDx result missing and CTA positive (N=42)
ORR% [95% CI*]	62.2% [50.1, 73.2]	81.0 [58.1, 94.6]	36.4 [10.9, 69.2]	59.5 [43.3, 74.4]
Complete response	5 (6.8%)	3 (14.3%)	0 (0%)	2 (4.8%)
Partial response	41 (55.4%)	14 (66.7%)	4 (36.4%)	23 (54.8%)
Number of responders	N=46	N=17	N=4	N=25
Duration of Response				
Median in months (range)	7.4 (1.4-26.0)	9.2 (1.9-22.1)	11.1 (1.4-26.0)	7.1 (2.8-25.9)
% with duration ≥ 6 months	54.3% (25/46)	52.9% (9/17)	75% (3/4)	52% (13/25)
% with duration ≥ 9 months	43.5% (20/46)	52.9% (9/17)	75% (3/4)	32% (8/25)
% with duration ≥ 12 months	30.4% (14/46)	35.3% (6/17)	50% (2/4)	24% (6/25)

*Exact 2-sided 95% CI reported

12.17.5.2 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.17.5.3 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying solid tumor patients with *NTRK1*, 2, or 3 fusions who may be eligible for treatment with entrectinib.

12.17.6 Post-Approval Study (PAS) to Support the Clinical Effectiveness of F1CDx for the Treatment with ROZLYTREK (entrectinib)

A post approval study (PAS) was conducted to confirm the clinical effectiveness of F1CDx as a CDx device for identification of patients with solid tumors with *NTRK1/2/3* fusions who may benefit from treatment with entrectinib. The post approval study consisted of a partial clinical bridging that utilized patient samples from the ALKA, STARTRK-1, STARTRK-2 and TAPISTRY clinical trials which enrolled patients with solid tumors with *NTRK1/2/3* fusions identified via the local enrollment test and the F1CDx assay. The PAS population consisted

of 168 patients with solid tumors with *NTRK1/2/3* fusions enrolled in the STARTRK-2 and TAPISTRY; 141 patients were enrolled based on local tests and 27 based on F1CDx results. Of the 141 patients with local *NTRK1/2/3* fusion-positive status, 45 were evaluable by F1CDx. Of the 45 patients with samples that had valid F1CDx results and had *NTRK1/2/3* fusion positive status per local tests, 23 were F1CDx positive, while 22 were F1CDx negative, yielding a PPA of 51.11% [95% two-sided score CI: 37.00%, 65.04%]. Based on the PAS group, PPA for *NTRK1* is 71.43% (10/14) and the PPA for *NTRK3* is 39.29% (11/28). There was one patient with *NTRK2* fusion-positive status per a local test; this patient was negative for *NTRK1/2/3* fusions by F1CDx. Therefore, the low PPA is primarily driven by a low detection rate for *NTRK3* fusion by F1CDx, which does not fully cover the *NTRK3* gene and common fusion partners.

Since samples from screen negative patients in the PAS population were not available for retesting with F1CDx, the NPA was re-estimated based on the re-analysis of concordance data for the negative samples evaluated in the sPMA cohort. The NPA observed in the reanalysis in the PAS was 99.57% (231/232), where the NPA from the original sPMA analysis was 100% (232/232) as shown in Table 81 above. The difference in the NPA was due to an update to curation procedures for rearrangements leading to classification of one additional rearrangement in one sample as biomarker positive.

The ORR observed for the local test positive and F1CDx-positive population and F1CDx positive enrolled population was 65.22% [95% two-sided score CI: 44.89%, 81.19%] and 66.67 [95% two-sided score CI: 47.82%, 81.36%] which is similar to the ORR observed for the PAS-positive population, which was 63.10% [95% two-sided score CI: [55.58%, 70.02%]. The ORR estimated for the F1CDx-positive population via the partial bridging study ranged from 46.36% to 65.45% under different assumptions on the unobserved clinical efficacy for CTA-negative and F1CDx-positive patients from the clinical trial, with corresponding 95% two-sided empirical CIs: [39.98%, 53.66%] and [59.09%, 71.82%].

The results from the PAS confirm the clinical effectiveness of F1CDx as a CDx device for identifying solid tumor patients with *NTRK* fusions who may benefit from treatment with entrectinib.

12.18 Clinical Evaluation of ROZLYTREK (entrectinib) in NSCLC Patients with ROS1 Fusions

The clinical effectiveness of F1CDx for detecting *ROS1* fusions in NSCLC patients who may benefit from treatment with entrectinib was demonstrated in a retrospective analysis of specimens from patients enrolled in clinical trials ALKA-372-001 (ALKA), RXDX-101-01 (STARTRK-1), and RXDX-101-02 (STARTRK-2).

12.18.1 Summary of the Clinical Studies

ALKA was a phase 1 dose escalation study of entrectinib in adult patients with advanced metastatic solid tumors. STARTRK-1 was a phase 1, multicenter, open-label study of entrectinib in adult patients with locally advanced or metastatic cancer confirmed to be positive for *NTRK1*, *NTRK2*, *NTRK3*, or NSCLC patients harboring *ROS1* fusions. STARTRK-2 is an open-label, multicenter basket study of entrectinib for the treatment of patients with solid tumors that harbor *NTRK1*, *NTRK2*, *NTRK3*, or NSCLC patients *ROS1* rearrangements.

12.18.2 Accountability of the PMA Cohort

A total of 395 unique samples were evaluated, including 85 clinical trial samples and 310 procured samples. Initially, the clinical bridging study included 51 *ROS1* NSCLC efficacy evaluable samples, as well as 41 additional *ROS1*-positive, *ROS1* inhibitor-naïve NSCLC patients with measurable disease who had insufficient follow-up (<12 months) at time of the NDA submission and an additional 67 *ROS1* NSCLC patients who were enrolled prior to October 31, 2018. In total, clinical outcome data from 159 patients enrolled before October 31, 2018 based on the May 1, 2019 clinical data cutoff date were planned for use in the bridging analysis. Ultimately 85 of these clinical trial samples were available to support the clinical bridging analysis; 16 *ROS1* NSCLC efficacy evaluable samples, 21 additional *ROS1*-positive, *ROS1* inhibitor-naïve NSCLC patients with measurable disease who had

insufficient follow-up (<12 months) at time of the NDA submission and an additional 48 ROS1 NSCLC patients who were enrolled prior to October 31, 2018.

12.18.3 Summary of the Clinical Bridging Study

The clinical efficacy analysis was performed by analyzing the concordance between F1CDx and the enrollment CTAs, followed by the imputation of the missing F1CDx result to then determine the clinical outcome of the ROS1-rearrangement positive population identified with F1CDx.

The ROS1 clinical efficacy population (n=51) consisted of nine (9) patients from ALKA, seven (7) from STARTRK-1, and 35 patients from STARTRK-2. ROS1 positivity was determined by NGS in 71% and by FISH in 29% of the study patient population. Fifty-five percent (55%) had central laboratory confirmation of ROS1 positivity using the study clinical trial assay (CTA). The ORR of the ROS1-positive NDA population was 78%. The 95% Confidence Interval (CI) was [65%, 89%].

12.18.4 Clinical Concordance

A total of 291 samples were evaluated in the concordance evaluation between F1CDx and the CTAs which included a wide range of assays, including RNA-based assays. The concordance analysis population consisted of the F1CDx-evaluable samples.

Concordance was evaluated using the results of PPA and NPA. The PPA and NPA, presented in **Table 89**, were established as 73.9% (95% CI 59.7-84.4%) and 99.2% (95% CI 97.1-99.8%), respectively.

Table 89. Concordance for ROS1 Fusions between F1CDx and the CTAs

		CTAs		
		Detected	Not Detected	Total
F1CDx	Detected	34	2	36
	Not Detected	12	243	255
	Total	46	245	291
Agreement Statistics with CTAs as comparator		PPA _{CTAs} 73.9% [59.7%, 84.4%]	NPA _{CTAs} 99.2% [97.1%, 99.8%]	

* Confidence intervals calculated using the Wilson score method

12.18.5 Efficacy Evaluation

12.18.5.1 Clinical efficacy results in the CDx-positive population for NSCLC patients with ROS1 fusions treated with entrectinib

The clinical efficacy of entrectinib in the pivotal clinical trial was measured in Overall Response Rate (ORR) with either confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR). Only clinical samples with clinical outcome data were used in this analysis.

The ORR in the CTA-positive population was 67.3% (107/159), (95% CI: 59.4, 74.5). Thirty-four (34) patients (34/46) were CTA+ and exhibited F1CDx ROS1-positive results. The ORR for this population was 64.7% (22/34) with Exact 2-sided 95% CI [46.5, 80.3]. Twelve (12) patients were CTA+ but F1CDx ROS1-negative. The ORR for this population was 58.3% (7/12) with the Exact 2-sided 95% CI [27.7, 84.8].

One-hundred thirteen (113) patients were CTA+ but without a F1CDx ROS1 result. The ORR for this population was 69.0% (78/113) with Exact 2-sided 95% CI [59.6, 77.4], as summarized in **Table 90**.

Table 90. Efficacy by ROS1 Status in Biomarker Subgroups

Clinical outcome	CTA positive population (N=159)	F1CDx positive and CTA positive (N=34)	F1CDx negative and CTA positive (N=12)	F1CDx result missing and CTA positive (N=113)
ORR% [95% CI*]	67.3% [59.4, 74.5]	64.7 [46.5, 80.3]	58.3 [27.7, 84.8]	69.0 [59.6, 77.4]

Clinical outcome	CTA positive population (N=159)	F1CDx positive and CTA positive (N=34)	F1CDx negative and CTA positive (N=12)	F1CDx result missing and CTA positive (N=113)
Complete response	14 (8.8%)	3 (8.8%)	0 (0%)	11 (9.7%)
Partial response	93 (58.5%)	19 (55.9%)	7 (58.3%)	67 (59.3%)
Number of responders	N=107	N=22	N=7	N=78
Duration of Response				
Median in months (range)	9.5 (1.8-42.3)	10.1 (1.9-24.6)	9.5 (3.5-24.6)	9.5 (1.8-42.3)
% with duration ≥ 9 months	61.7% (66/107)	72.7% (16/22)	57.1% (4/7)	59.0% (46/78)
% with duration ≥ 12 months	41.1% (44/107)	36.4% (8/22)	42.9% (3/7)	42.3% (33/78)
% with duration ≥ 18 months	19.6% (21/107)	4.5% (1/22)	14.3% (1/7)	24.4% (19/78)

***Exact 2-sided 95% CI reported**

12.18.5.2 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.18.6 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying NSCLC patients with *ROS1* fusions who may be eligible for treatment with entrectinib.

12.19 Clinical Evaluation of AKEEGA® (niraparib + abiraterone acetate) in metastatic castration resistant prostate (mCRPC) Patients with BRCA1, BRCA2 Alterations

The clinical performance of F1CDx for detection of *BRCA1*, *BRCA2* alterations in mCRPC patients who may benefit from AKEEGA was established with clinical data generated from F1CDx in the clinical study 64091742PCR3001 (hereafter referred to as MAGNITUDE).

12.19.1 Summary of the Clinical Study – 64091742PCR3001 (MAGNITUDE, PCR3001)

The MAGNITUDE trial is a Phase 3, randomized, double-blinded, placebo-controlled, multicenter study of niraparib in combination with abiraterone acetate (AA) and prednisone versus abiraterone acetate and prednisone (AAP) for treatment of subjects with metastatic prostate cancer. Participants in study PCR3001 were assigned to cohorts based on HRR alteration status as determined by tissue and plasma assays. During the prescreening phase, subjects were required to submit both blood and tumor (archival or recently collected) samples for determination of HRR gene alteration status. A total of 423 patients were screened and enrolled into Cohort 1. Within the enrolled Cohort 1 population, 229 patients with *BRCA1* and *BRCA2* alterations detected by the tissue and/or plasma assays comprised the analysis set for for this study. The primary efficacy endpoint was radiographic progression-free survival (rPFS) as assessed by the blinded independent central review (BICR) committee.

The assessment of efficacy was conducted using the *BRCA* subgroup from Cohort 1 of the MAGNITUDE study that consists of subjects who were enrolled in Cohort 1 with *BRCA1* and *BRCA2* alterations.

12.19.2 Accountability of the PMA Cohort

Of the 423 HRR+ patients enrolled in Cohort 1, 229 patients with *BRCA1* and *BRCA2* alterations were detected by at least one assay (either tissue, plasma, or both), which comprised the *BRCA* subgroup. Of the 229 *BRCA* subgroup samples, 179 produced F1CDx-evaluable results. Within this subgroup, 161 patients were *BRCA1* or *BRCA2* alteration positive by F1CDx and 18 were *BRCA1* and *BRCA2* alteration negative by F1CDx. The remaining

50 patients did not have a valid F1CDx result.

12.19.3 Efficacy Evaluation

The clinical efficacy for each subgroup (i.e., F1CDx *BRCA*+, F1CDx *BRCA*-, F1CDx invalid results, and not tested with F1CDx) within the analysis set was evaluated in terms of rPFS. The median rPFS was estimated with Kaplan-Meier estimates. The hazard ratio (HR) and log(HR) were calculated by both stratified and multivariate Cox regression for each subgroup. A sensitivity analysis was performed to evaluate the robustness of the clinical efficacy accounting for uncertainty due to missing data.

The estimated median rPFS for the F1CDx *BRCA*+ group was 18.43 months (95% CI: [16.13, NA]) for the treatment arm and 10.87 months (95% CI [8.31, 13.80]) for the control arm. The median rPFS for the F1CDx *BRCA*- group was 11.04 months in the treatment arm. Among the control arm, 2 radiographic progression events occurred out of 6 patients; the rPFS probability did not drop below 50% and the median rPFS could not be estimated. For the F1CDx invalid results group, the median rPFS was 14.98 months in the treatment arm compared to 16.43 months in the control arm. Within the not tested by F1CDx group, only 1 radiographic progression event was observed out of 9 patients in the treatment arm; the rPFS probability did not drop below 50% and thus the median rPFS could not be estimated. The median rPFS in the control arm was 8.34 months.

Table 91. BRCA Subgroup Efficacy Summary in the F1CDx BRCA+ and F1CDx BRCA- Populations

Population	No. of Patients		No. of Events		Median rPFS (months) [§]	
	Niraparib + AAP	Placebo + AAP	Niraparib + AAP	Placebo + AAP	Niraparib + AAP	Placebo + AAP
F1CDx <i>BRCA</i> +	76	85	30	51	18.43 [16.13, NA ^{§§}]	10.87 [8.31,13.80]
F1CDx <i>BRCA</i> -	12	6	9	2	11.04	NA ^{§§§}
F1CDx invalid results	17	18	5	10	14.98	16.43
Not tested by F1CDx	9	6	1	3	NA ^{§§§§}	8.34

[§] 95% CIs of the median rPFS were provided for group F1CDx *BRCA*+

^{§§} The 95% CI upper bound cannot be estimated because the upper bound of the confidence band for rPFS probability did not drop below 50%.

^{§§§} Two radiographic progression events occurred out of 6 patients. Due to the low frequency of the events (i.e., 2/6), the rPFS probability did not drop below 50% and thus the median could not be estimated. The rPFS of the two events were 4.57 months and 8.21 months.

^{§§§§} One radiographic progression event occurred out of nine patients at 2.00 months. Due to low frequency of the events (1/9), the rPFS probability did not drop below 50% and thus the median could not be estimated.

Stratified and multivariate Cox regression models were built. The primary model was a stratified Cox regression model with the planned treatment as the only covariate and two pre-specified strata in drug SAP including prior AAP use and past taxane-based chemo exposure. Gene mutation group based on enrolling assay (*BRCA1/2*+ vs others) was not used because all patients were *BRCA1/2*+

Table 92 presents the estimated HRs among different subgroups (F1CDx *BRCA*+, F1CDx *BRCA*-, F1CDx invalid results, and not tested with F1CDx). The HR by stratified Cox regression for the F1CDx *BRCA*+ group was 0.45 (95% CI: [0.28,0.71]), which suggested a 55% reduction in the risk of radiographic progression when using niraparib+AAP compared with placebo+AAP. The upper bound of the 95% CI is 0.71 and is less than 1 indicating superior clinical efficacy in the treatment arm compared to the control arm with statistical significance. The HR was 3.34 (95% CI: [0.33,33.79]) for the F1CDx *BRCA* group, 0.89 (95% CI: [0.27,2.93]) for the F1CDx invalid results group and 0.19 (95% CI: [0.02,2.07]) for the not tested with F1CDx group.

Table 92. Estimations of HR and log(HR) by Stratified Cox in the BRCA Subgroup Population

Population	HR between treatment and control arms	95% CI for HR between treatment and control arms
F1CDx <i>BRCA</i> +	0.45	[0.28,0.71]
F1CDx <i>BRCA</i> -	3.34	[0.33,33.79]
F1CDx invalid results	0.89	[0.27,2.93]
Not tested by F1CDx	0.19	[0.02,2.07]

12.19.4 Sensitivity Analysis – Impact of F1CDx Unevaluable Set (F1CDx invalid results + not tested by F1CDx)

A sensitivity analysis was performed to evaluate the robustness of the clinical efficacy estimated accounting for the F1CDx-unevaluable (F1CDx invalid results and not tested by F1CDx) results for enrolled patients from the analysis set.

The F1CDx unevaluable results were imputed using a multivariate logistic regression model based on the missing at random (MAR) assumption. The rPFS and HR were re-estimated for the F1CDx *BRCA*+ population based on imputed data with a bootstrapping multiple imputation method. The median rPFS was estimated to be 16.56 months (95% CI: [14.98, 21.95]) in the treatment arm and 10.87 months (95% CI: [8.31,13.67]) in the placebo arm, comparable to the primary efficacy results with 18.43 months for the treatment arm and 10.87 months for the placebo arm (Table 72). The HR was 0.44 (95% CI: [0.16,0.73]) by stratified Cox regression, which is comparable to the observed HR of 0.45 by stratified Cox regression. The robustness of the clinical efficacy analysis was demonstrated by accounting for the missingness of F1CDx testing results.

12.19.5 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.19.6 Conclusions

The data from this study supports reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying prostate cancer patients with *BRCA1*, *BRCA2* alterations who may benefit from treatment with AKEEGA (Niraparib + Abiraterone acetate).

12.20 Clinical Evaluation of RETEVMO (selpercatinib) in Solid Tumor Patients with RET Fusions

The clinical effectiveness of F1CDx for detecting *RET* fusions in patients with solid tumors who may benefit from treatment with selpercatinib was demonstrated in a retrospective analysis of specimens from patients enrolled in the LIBRETTO-001 clinical study.

12.20.1 Summary of the Clinical Trial- LIBRETTO-001

The LIBRETTO-001 clinical study is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors, including *RET* fusion-positive solid tumors (e.g., NSCLC, thyroid, pancreas, colorectal), *RET*-mutant medullary thyroid cancer (MTC), and other tumors with *RET* activation (e.g., mutations in other tumor types or other evidence of *RET* activation). This study included two parts: Phase 1 (dose escalation and dose expansion) and Phase 2 (dose expansion). The primary objective of the Phase 1 portion of the study was to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of selpercatinib. RP2D was determined to be 160 mg of selpercatinib orally twice daily (BID). The primary objective of Phase 2 was to assess the efficacy of selpercatinib. Efficacy was measured by the objective response rate (ORR) using RECIST 1.1, as appropriate for tumor type, as assessed by blinded independent review committee (BIRC).

Evidence of a *RET* gene alteration was not required for Phase 1 initially; once adequate pharmacokinetic (PK)

exposure was achieved, evidence of a *RET* gene alteration in tumor and/or blood was required. For participation in Phase 2, evidence of a *RET* gene alteration in tumor and/or blood is required. The *RET* alteration results were generated from laboratories with CLIA, ISO/IEC, CAP, or other similar certification. Enrollment into study cohorts is based on tumor type, type of *RET* alteration, and prior treatment.

Efficacy of selpercatinib for the FDA-approved NSCLC, thyroid cancer (TC), and tumor agnostic (TA) indications was established through the LIBRETTO-001 clinical study. The NSCLC NDA population was based on a total of 144 patients enrolled by June 17, 2019 who were enrolled in cohorts defined as “previously treated with platinum chemotherapy” (previously treated) and “treatment naïve”. For accelerated approval in the selpercatinib NDA, the ORRs and CIs using the exact CI method for NSCLC previously treated and treatment naïve patients were 64% (95% CI [54%, 73%]) and 85% (95% CI [70%, 94%]), respectively.

The TC NDA population was based on a total of 27 patients enrolled by June 17, 2019 who were enrolled in cohorts defined as “RAI-refractory and had received sorafenib, lenvatinib, or both” (previously treated) and “RAI-refractory and systemic therapy naïve” (systemic therapy naïve). The ORRs and CIs using the exact CI method for TC previously treated and systemic therapy naïve patients were 79% (95% CI [54%, 94%]) and 100% (95% CI [63%, 100%]), respectively. The TA sNDA population was based on a total of 41 patients. The TA indication was based on a population of 41 patients enrolled by March 24, 2021. The ORR and CI using the exact CI method for the TA patients was 44% (95% CI [28%, 60%]).

12.20.2 Accountability of the NDA and sNDA Cohorts

There were 175 patients from the LIBRETTO-001 clinical study with sufficient tissue samples available for testing with F1CDx. Of the 41 patients in the TA sNDA population, 21 had samples available. Of the 144 patients in the NSCLC NDA population, 52 had samples available, and 74 additional samples were also available from non-efficacy-evaluable patients for the concordance assessment. Finally, of the 27 patients in the TC NDA population, 21 had samples available, and 7 additional samples were also available from non-efficacy-evaluable patients for the concordance assessment. After sample processing, there were 15 TA sNDA samples, 87 NSCLC samples (35 NDA efficacy, 52 patients not evaluated for efficacy), and 26 TC samples (21 NDA efficacy, 5 patients not evaluated for efficacy) with valid F1CDx results. The pooled pan-tumor population (PPT) consisted of the combined TA sNDA population, the NSCLC NDA efficacy population, and the TC NDA efficacy population, which yielded a total of 71 samples with valid F1CDx test results. The PPT population combined selpercatinib efficacy populations and included patients with different cancer types for the solid tumor indication. Separate efficacy analyses were also conducted on each of the NSCLC NDA, TC NDA, and TA sNDA populations alone, and separate concordance analyses were conducted on the NSCLC and TC populations alone for additional supporting data.

In addition to the clinical study samples, 311 samples (100 pan-tumor, 107 NSCLC, and 104 TC) from FMI's clinical archives were processed by F1CDx for the *RET* fusion-negative (CTA-) population. There were six F1CDx sample failures and 305 samples with valid F1CDx results; 138 samples (98 solid tumor, 20 NSCLC, and 20 TC) with valid F1CDx results were used in the PPT concordance analysis.

12.20.3 Summary of the Clinical Bridging Study

A clinical bridging study was conducted to assess the clinical effectiveness of F1CDx in identifying *RET* fusion positive patients for treatment with selpercatinib, and to assess the concordance in detecting *RET* fusions between the CTAs and F1CDx. F1CDx was used to retrospectively test the available patient samples from the LIBRETTO-001 clinical study (N = 175) and the supplemental *RET* fusion negative samples (N = 311).

12.20.4 Clinical Concordance

A total of 71 *RET* fusion-positive and 138 fusion-negative samples with valid F1CDx results in the PPT population were evaluated in the concordance assessment between F1CDx and the CTAs in LIBRETTO-001. A contingency table with the concordance results is provided in **Table 93**.

Table 93. PPT contingency table comparing RET fusions between the CTAs and F1CDx

		CTA		
		Detected (+)	Not Detected (-)	Total
F1CDx	Detected (+)	64	0	64
	Not Detected (-)	7	138	145
	Unevaluable [†]	141	2	143
	Total	212	140	352
Agreement statistics excluding unevaluable [†] results [2-sided 95% CI]*		PPA 90.1% [81.0%, 95.1%]	NPA 100% [97.3%, 100%]	
Percent unevaluable [†]		66.5%	1.4%	

[†]F1CDx-unevaluable CTA+ patients include those who did not have a sample tested by F1CDx or those whose sample failed F1CDx testing. The percent F1CDx-invalid for the CTA+ patients was 24.5% (23 out of the 94 patients tested by F1CDx). F1CDx-unevaluable CTA- patients only include those whose sample failed F1CDx testing (1.4%; 2 out of the 140 patients tested by F1CDx).

*Two-sided 95% CI is calculated by the Wilson-Score Method.

Concordance was evaluated using PPA and NPA. The PPA and NPA, presented in **Table 93**, were established as 90.1% (95% CI [81.0%, 95.1%]) and 100% (95% CI [97.3%, 100%]), respectively, after excluding invalid results.

The PPT concordance results, as well as the supporting concordance results from the NSCLC, TA and TC populations, are summarized in **Table 94**.

Table 94. Summary of concordance results for population groups in the clinical bridging study

Tumor Type	PPA% (N F1CDx+ CTA+ / N CTA+) [95% CI]*	NPA% (N F1CDx- CTA- / N CTA-) [95% CI]*
PPT	90.1 (64/71) [81.0, 95.1]	100 (138/138) [97.3, 100]
TA	86.7 (13/15) [62.1, 96.3]	100 (98/98) [96.2, 100]
NSCLC	92.0 (80/87) [84.3, 96.0]	100 (107/107) [96.5, 100]
TC	88.5 (23/26) [71.0, 96.0]	100 (100/100) [96.3, 100]

*Wilson score method was used to calculate the 2-sided 95% CI.

12.20.5 Efficacy Evaluation

The clinical validity of F1CDx for the detection of *RET* fusions in patients with solid tumors was based on estimation of clinical efficacy (ORR) in the F1CDx-positive population and subgroups of the CTA+ population by F1CDx status. The major efficacy outcome measure was ORR using RECIST 1.1 as assessed by BIRC.

The ORR in the CTA-positive population was 66.5% (141/212), (2-sided 95% Wilson score CI [59.9%, 72.5%]). The F1CDx+|CTA+ population consisted of 64 patients with valid F1CDx test results. The ORR for the F1CDx+|CTA+ patients was 75.0% (48/64) (2-sided 95% Wilson score CI [63.2%, 84.0%]). Seven (7) patients were CTA+ but *RET* fusion-negative by F1CDx, and the ORR for this population was 57.1% (4/7). One-hundred forty-one (141) patients were CTA+ but without a valid F1CDx *RET* fusion result. The ORR for this population was 63.1% (89/141) (2-sided 95% Wilson score CI [54.9%, 70.6%]). The ORR for each subpopulation in the PPT population is presented in **Table 95**.

Table 95. PPT efficacy in the bridging study subpopulations

	CTA+	F1CDx+ CTA+	F1CDx- CTA+	F1CDx unevaluable CTA+
# Total	212	64	7	141
# Responders (CR or PR)	141	48	4	89
ORR (%)	66.5	75.0	57.1	63.1
Two-sided 95% CI (%)	[59.9, 72.5]	[63.2, 84.0]	N/A*	[54.9, 70.6]

*The CI is not provided for sample sizes ≤10.

**Wilson score method was used to calculate the 2-sided 95% CI.

The ORR estimated for the F1CDx-positive population was 75.0% (2-sided 95% CI [64.4%, 85.6%]) using the Wald's method to calculate the CI.

The PPT efficacy results, as well as the supporting efficacy analysis results from the TA, NSCLC, and TC populations, are summarized in **Table 96**.

Table 96. Summary of efficacy results for population groups in the clinical bridging study

Tumor Type (N)		Responder (n) / Subpopulation (N), ORR% [95% CI] ¹				ORR% [95% CI] ²
		CTA+	F1CDx+ CTA+	F1CDx- CTA+	F1CDx Unevaluable CTA+	CDx+
PPT (212)		141/212 66.5% [59.9, 72.5]	48/64 75.0% [63.2, 84.0]	4/7 57.1% [N/A*]	89/141 63.1% [54.9, 70.6]	75.0% [64.4, 85.6]
TA (41)		18/41 43.9% [29.9, 59.0]	8/13 61.5% [35.5, 82.3]	0/2 0% [N/A*]	10/26 38.5% [22.4, 57.5]	61.5% [35.1, 88.0]
NSCLC	Prior-treated (105)	67/105 63.8% [54.3, 72.4]	19/26 73.1% [53.9, 86.3]	1/1 100% [N/A*]	47/78 60.3% [49.2, 70.4]	73.1% [56.0, 90.1]
	Treatment-naïve (39)	33/39 84.6% [70.3, 92.8]	5/7 71.4% [N/A*]	1/1 100% [N/A*]	27/31 87.1% [71.1, 94.9]	71.4% [38.0, 100]
TC	Prior-treated (19)	15/19 78.9% [56.7, 91.5]	9/11 81.8% [52.3, 94.9]	1/2 50.0% [N/A*]	5/6 83.3% [N/A*]	81.8% [59.0, 100]
	Treatment-naïve (8)	8/8 100% [N/A*]	7/7 100% [N/A*]	1/1 100% [N/A*]	0 N/A [N/A]	100% [N/A**]

¹Wilson score method was used to calculate 95% CI. For the CTA+ population, please refer to the drug label for the ORR CI for CTA+ calculated using the Exact method.

²Wald's method was used to calculate the 95% CI.

*The CI is not provided for sample sizes ≤10.

**The variance to estimate the CI is inestimable using normal approximation methods because the ORR was 100%.

12.20.6 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.20.7 Conclusions

The concordance and efficacy assessments conducted on the PPT population support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying patients with solid

tumors with *RET* fusions who may be eligible for treatment with selpercatinib.

12.21 Clinical Evaluation of Braftovi® (encorafenib) in combination with Mektovi® (binimetinib) in NSCLC Patients with BRAF V600E Alterations

The clinical effectiveness of F1CDx for detecting *BRAF* V600E alterations in patients with NSCLC who may benefit from treatment with encorafenib in combination with binimetinib was established through a clinical bridging study in which samples from patients enrolled in the PHAROS (ARRAY-818-202) clinical trial were retrospectively tested by F1CDx.

12.21.1 Summary of the Clinical Studies

The PHAROS Clinical Trial is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability, and efficacy of encorafenib given in combination with binimetinib in patients with *BRAF* V600E-mutant metastatic NSCLC. The study evaluated the efficacy and safety of encorafenib + binimetinib in treatment-naïve and previously treated NSCLC patients with *BRAF* V600E alterations as measured by objective response rate (ORR).

The clinical trial population included 59 treatment-naïve patients, and 39 previously treated patients with the locally confirmed *BRAF* V600E mutation using PCR- or NGS-based local laboratory assay with either tumor tissue or ctDNA from blood.

12.21.2 Accountability of the PMA Cohort

A total of 198 samples including clinical trial samples and FMI banked samples were included in the clinical bridging study. Of the 198 samples, 98 were biomarker-positive samples by the enrolling assays used in the PHAROS clinical trial. Fifty-nine of the 98 samples were from treatment-naïve patients, and the remaining 39 samples were from the previously treated patients enrolled in the PHAROS clinical trial. Of the 98 patients that had *BRAF* V600E status, six (6) were enrolled with the F1CDx assay and therefore were excluded from the concordance analysis. Of the remaining 92 patients, three (3) patient samples did not meet the minimum incoming sample acceptance criteria, while an additional one (1) patient sample did not have any material remaining for testing with F1CDx and were thus included in the F1CDx- unevaluable set. Therefore, a total of 88 CTA+ samples were included for F1CDx testing. Ten of the 88 CTA+ samples were not processed due to insufficient DNA mass after post DNA extraction. Of the 78 CTA+ samples that were processed, 1 failed at the hybrid capture (HC) QC metrics and four samples that failed post-sequencing QC metrics. Therefore, 73 CTA+ samples yielded valid F1CDx results.

In addition to the 98 biomarker-positive samples, there were one hundred (100) biomarker-negative samples that were randomly selected from a previous validation study for analysis.

12.21.3 Summary of the Clinical Bridging Study

The clinical bridging study was conducted to assess: 1) concordance between the local CTAs and F1CDx, and 2) to estimate the objective response rate (ORR) in the efficacy population (CTA-positive population) for encorafenib and binimetinib treatment among clinical study participants whose tumor samples were *BRAF* V600E positive, as determined by retrospective testing with the F1CDx.

12.21.4 Clinical Concordance

To assess concordance between the local CTAs and F1CDx, a total of 88 CTA+ samples and 100 CTA- samples were evaluated. Of the 88 CTA+ samples, 73 samples yielded valid F1CDx results. Concordance was evaluated by calculating PPA and NPA for samples with valid F1CDx results. The PPA and NPA, presented in **Table 97**, were established as 93.15% (95% CI 84.95-97.04%) and 100.00% (95% CI 96.30-100.00%), respectively.

Table 97. Concordance between F1CDx and the CTAs for BRAF V600E

		CTAs		
		Detected	Not Detected	Total
F1CDx	Detected	68	0	68
	Not Detected	5	100	105
	Total	73	100	173
Agreement Statistics with CTAs as comparator		PPA _{CTAs} 93.15% [84.95%, 97.04%]	NPA _{CTAs} 100.00% [96.30%, 100.00%]	

* Confidence intervals calculated using the Wilson 2-sided 95% CI

12.21.5 Efficacy Evaluation

12.21.5.1 Clinical efficacy results in the CDx-positive population for NSCLC patients with BRAF V600E alterations treated with encorafenib in combination with binimetinib

The clinical validity of F1CDx was demonstrated by assessing clinical efficacy in the F1CDx *BRAF* V600E positive population based on the ORR. The ORR is defined as the proportion of patients with objective response of either complete response (CR) or partial response (PR) based on RECIST 1.1 as determined by independent radiology review (IRR), and duration of response (DoR) as assessed by independent review committee (IRC). The ORR was calculated for each sub-population by F1CDx *BRAF* V600E mutation status. The efficacy results for treatment-naïve patients and for previously treated patients are presented in **Table 98** and **Table 99** respectively.

For the Fifty-nine (59) treatment-naïve patients that were enrolled into the study, the ORR was 74.6% (44/59), (Exact 2-sided 95% CI: 61.6%, 85.0%). Two of the 59 patients were enrolled by F1CDx and were *BRAF* V600E-positive in which one of them was a drug responder with an ORR of 50% (1/2). Forty-one (41) patients were CTA+ and exhibited F1CDx *BRAF* V600E-positive results. The ORR for this population was 82.9% (34/41) with Exact 2-sided 95% CI [67.9%, 92.8%]. Five (5) patients were CTA+ but F1CDx *BRAF* V600E-negative. The ORR for this population was 40% (2/5). 11 patients were CTA+ but without a F1CDx *BRAF* V600E result. The ORR for this population was 63.6% (7/11) with Exact 2-sided 95% CI [30.8%, 89.1%], as summarized in **Table 98**.

Table 98. Efficacy by BRAF V600E status in Biomarker Subgroups for treatment-naïve patients

Clinical outcome	CTA positive or F1CDx enrolled [‡] (N=59)	F1CDx positive and CTA positive (N=41)	F1CDx negative and CTA positive (N=5)	F1CDx result missing and CTA positive (N=11)	F1CDx enrolled (N=2)
ORR% [95% CI*]	74.6 [61.6, 85.0]	82.9 [67.9, 92.8]	40.0 [N/A [§]]	63.6 [30.8, 89.1]	50.0 [N/A [§]]
Complete response	9 (15.3%)	8 (19.5%)	0 (0%)	0 (0%)	1 (50.0%)
Partial response	35 (59.3%)	26 (63.4%)	2 (40.0%)	7 (63.6%)	0 (0%)
Number of responders	N=44	N=34	N=2	N=7	N=1
Duration of Response					
Median in months (range)	N/A [§] (1.4, 29.5)	N/A [§] (1.9, 29.5)	4.2 (4.2, 29.0)	N/A [§] (1.4, 26.0)	N/A [§] (14.7, 14.7)
% with duration ≥6 months	75.0% (33/44)	79.4% (27/34)	50.0% (1/2)	57.1% (4/7)	100% (1/1)
% with duration ≥12 months	59.1% (26/44)	61.8% (21/34)	50.0% (1/2)	42.9% (3/7)	100% (1/1)

*Exact 2-sided 95% CI reported

[‡]59 enrolled trial patients include 57 patients enrolled by CTA and two (2) patients enrolled by F1CDx

[§]CI's are presented when sample size is >10

[§]Median DoR could not be calculated as the response rate had not yet fallen to 50%

For the Thirty-nine (39) previously treated patients that were enrolled into the study, the ORR was 46.2% (18/39), (Exact 2-sided 95% CI: 30.1%, 62.8%). Four of the 39 patients were enrolled by F1CDx and were *BRAF* V600E-positive in which two of them were drug responders with an ORR of 50% (2/4). Twenty-seven (27) patients were CTA+ and exhibited F1CDx *BRAF* V600E-positive results. The ORR for this population was 51.9% (14/27) with Exact 2-sided 95% CI [31.9%, 71.3%]. Eight (8) patients were CTA+ but without a F1CDx *BRAF* V600E result. The ORR for this population was 25% (2/8) as summarized in **Table 99**.

Table 99. Efficacy by *BRAF* V600E status in Biomarker Subgroups for previously treated patients

Clinical outcome	CTA positive or F1CDx enrolled [✓] (N=39)	F1CDx positive and CTA positive (N=27)	F1CDx negative and CTA positive (N=0)	F1CDx result missing and CTA positive (N=8)	F1CDx enrolled (N=4)
ORR% [95% CI*]	46.2 [30.1, 62.8]	51.9 [31.9, 71.3]	N/A ^x [N/A ^x]	25.0 [N/A [✓]]	50.0 [N/A [✓]]
Complete response	4 (10.3%)	2 (7.4%)	0 (N/A ^x)	1 (12.5%)	1 (25.0%)
Partial response	14 (35.9%)	12 (44.4%)	0 (N/A ^x)	1 (12.5%)	1 (25.0%)
Number of responders	N=18	N=14	N=0	N=2	N=2
Duration of Response					
Median in months (range)	16.7 (1.9, 28.7)	N/A ^g (1.9, 28.7)	N/A ^x (N/A ^x)	16.7 (12.1, 16.7)	4.4 (4.4, 11.1)
% with duration ≥6 months	66.7% (12/18)	64.3% (9/14)	N/A ^x (0/0)	100% (2/2)	50.0% (1/2)
% with duration ≥12 months	33.3% (6/18)	28.6% (4/14)	N/A ^x (0/0)	100% (2/2)	0% (0/2)

*Exact 2-sided 95% CI reported

✓39 enrolled trial patients include 35 patients enrolled by CTA and four (4) patients enrolled by F1CDx

✓CIs are presented when sample size is >10

^gMedian DoR could not be calculated as the response rate had not yet fallen to 50%

^xValue was not presented as there were no responders in this subgroup

The drug efficacy (ORR) for the F1CDx+ population was also calculated for the treatment-naïve and previously treated cohorts separately by the partial bridging method via multiple imputation in which the number of CDx+|CTA- patients was estimated and the clinical outcome of F1CDx+|CTA- were imputed.

The estimated ORR for the treatment-naïve cohort F1CDx+ patients ranged from 79.81% to 81.41%. The previously treated cohort F1CDx+ ranged from 49.85% to 51.45%.

To evaluate the robustness of the estimated clinical efficacy against the missing F1CDx *BRAF* V600E results, a sensitivity analysis employed the multiple imputation method to impute the missing F1CDx results. The concordance analysis between the CTAs and F1CDx, and the clinical efficacy for F1CDx *BRAF* V600E positive patients were calculated by accounting for the imputed data.

The clinical efficacy of the F1CDx+ population was then estimated on the imputed datasets. The partial bridging method was applied with 200 imputations to the 200 imputed datasets from the sensitivity analysis. For the treatment-naïve cohort, the median F1CDx+ efficacy ranged from 79.47% to 81.48%. For the previously treated cohort, the median F1CDx+ efficacy ranged from

45.00% to 46.40%. The sensitivity analysis demonstrated the study conclusions were robust to missing F1CDx *BRAF* V600E results.

12.21.5.2 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.21.6 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying NSCLC patients with *BRAF* V600E alterations who may be eligible for treatment with encorafenib in combination with binimetinib.

12.22 Clinical evaluation of TRUQAP™ (capivasertib) in combination with Faslodex (fulvestrant) in breast cancer patients with *PIK3CA*/*AKT1*/*PTEN* alterations

The clinical effectiveness of F1CDx for detecting *PIK3CA*/*AKT1*/*PTEN* alterations in breast cancer patients who may benefit from treatment with capivasertib in combination with fulvestrant was demonstrated in a retrospective analysis of tumor tissue specimens from patients enrolled in the CAPItello-291 clinical study.

12.22.1 Summary of the Clinical Study- CAPItello-291

The CAPItello-291 study is a Phase III, double-blind, placebo-controlled, parallel-group, randomized, multicenter study assessing the efficacy and safety of capivasertib in combination with fulvestrant versus placebo in combination with fulvestrant as treatment for locally advanced (inoperable) or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR-positive/HER2-negative) breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

Patients were randomized into CAPItello-291 irrespective of their tumor's *PIK3CA*/*AKT1*/*PTEN* alteration status. Patients that fulfilled key eligibility criteria, and consented to enroll in the study, were randomized into CAPItello-291 in a 1:1 ratio to receive either capivasertib + fulvestrant, or placebo + fulvestrant. Patients continued to receive study treatment until disease progression or unacceptable toxicity occurs, or if the patient requested to stop the study treatment. The dual primary endpoints of the trial were progression-free survival (PFS) in the Overall Population and PFS in the *PIK3CA*/*AKT1*/*PTEN*-Altered subgroup. Patients outside mainland China with an *PIK3CA*/*AKT1*/*PTEN*-altered tumor were identified post randomization by F1CDx central testing of tumor tissue collected prior to randomization based on a prespecified list of molecular alterations.

12.22.2 Accountability of the PMA Cohort

Of the 901 patients initially screened for the CAPItello-291 study, 193 were screen failures and were not randomized. The remaining 708 patients were randomized at a 1:1 ratio into the capivasertib + fulvestrant (n=355) and placebo + fulvestrant (n=353) arms of the trial. Ultimately, eight patient samples originating from China were not tested with F1CDx and 14 patients had no sample available for testing, leaving 686 patient samples tested by F1CDx. Of the 686 patient samples sent for F1CDx testing, 92 patients provided a sample that either failed to meet the input requirements (pre-analytical failure) or failed to meet the QC metrics required by the assay during processing (post-analytical failure) resulting in 594 patients with valid F1CDx results. Out of the 289 patients with *PIK3CA*/*AKT1*/*PTEN*-altered status in CAPItello-291, 287 were determined to be *PIK3CA*/*AKT1*/*PTEN*-altered by F1CDx, which comprised the F1CDx-Altered population. Two (2) altered patients from China were not tested with F1CDx.

12.22.3 Efficacy Evaluation of F1CDx

The CAPItello-291 study demonstrated that treatment with capivasertib + fulvestrant resulted in a clinically meaningful and statistically significant improvement in Investigator-assessed progression-free survival (PFS) by RECIST v1.1 compared with placebo + fulvestrant in the *PIK3CA*/*AKT1*/*PTEN*-altered population.

As presented in **Table 100**, the median PFS in the F1CDx-*PIK3CA*/*AKT1*/*PTEN* Altered Population treated with capivasertib + fulvestrant was 7.3 months [95% CI: 5.5-9.1] versus 3.1 months [95% CI: 2.0-3.7] in the placebo + fulvestrant cohort. In the F1CDx *PIK3CA*/*AKT1*/*PTEN* Altered Population, a 51% reduction in the risk of progression in favor of capivasertib + fulvestrant was observed (HR: 0.49; 95% CI: 0.38-0.64; p<0.001). These results are comparable to those observed in the overall *PIK3CA*/*AKT1*/*PTEN* Altered population which consisted

of 289 patients, 287 which had F1CDx results as shown in **Table 100**.

Table 100. Progression-free Survival Based on Investigator Assessments, per RECIST v1.1 for F1CDx PIK3CA/AKT1/PTEN Altered Population

	F1CDx PIK3CA/AKT1/PTEN Altered		PIK3CA/AKT1/PTEN Altered Overall ^a	
	Capivasertib + fulvestrant (N=153)	Placebo + fulvestrant (N=134)	Capivasertib + fulvestrant (N=155)	Placebo + fulvestrant (N=134)
Investigator-assessed Progression Free Survival (PFS)				
Total number of patients with events, n (%)	119 (77.8)	115 (85.8)	121 (78.1)	115 (85.8)
Median PFS (95% CI) * [months]	7.3(5.5-9.1)	3.1(2.0-3.7)	7.3 (5.5-9.0)	3.1 (2.0-3.7)
Hazard ratio (95% CI) *	0.49(0.38-0.64)		0.50 (0.38-0.65)	
2-sided p- value	<0.001		<0.001	
Investigator-assessed Objective Response Rate (ORR)				
Patients with measurable disease	Capivasertib= 130 Placebo= 124		Capivasertib= 132 Placebo= 124	
ORR% (95% CI)	Capivasertib= 28.5 (20.9, 37.0) Placebo= 9.7 (5.1, 16.3)		Capivasertib= 28.8 (21.2, 37.3) Placebo= 9.7 (5.1, 16.3)	
Complete response rate	Capivasertib= 3 (3.2%) Placebo= 0		Capivasertib= 3 (3.2%) Placebo= 0	

* 95% CI were calculated using the Exact Method

Unadjusted ORR (95% CI) is an exact binomial confidence interval

^a The Altered Overall population contains 2 additional patient samples that were tested using an alternative testing method. The results were used in the drug efficacy results but not were tested by F1CDx.

These data establish that there is statistically significant, improved PFS in F1CDx PIK3CA/AKT1/PTEN Altered patients treated with capivasertib + fulvestrant (n=153) versus those treated with placebo + fulvestrant (n=134) with a PFS HR of 0.49 (95% CI: 0.38-0.64; p<0.001). Patients without AKT1/PIK3CA/PTEN-Altered status did not derive a statistically meaningful benefit from capivasertib + fulvestrant when compared to placebo + fulvestrant.

12.22.4 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.22.5 Conclusions

The efficacy assessment conducted on the F1CDx- PIK3CA/AKT1/PTEN Altered population support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying breast cancer patients with PIK3CA/ AKT1/PTEN alterations who may be eligible for treatment with capivasertib in combination with fulvestrant.

12.23 Clinical evaluation of LYNPARZA® (olaparib) in combination with abiraterone in mCRPC Patients with BRCA1, BRCA2 Alterations

The clinical performance of FoundationOne CDx in detecting BRCA1 and BRCA2 alterations (BRCA1/2) in patients with metastatic castration-resistant prostate cancer who may benefit from LYNPARZA® (olaparib) in combination with abiraterone was established with clinical data generated from FoundationOne CDx in the clinical study D081SC00001 (hereafter referred to as PROpel).

12.23.1 Summary of the Clinical Study – D081SC00001 (PROpel)

The PROpel trial was a randomized, double-blind, placebo-controlled, multicenter study of olaparib plus

abiraterone relative to placebo plus abiraterone as first line therapy in men with mCRPC. Patients were randomized 1:1 to receive either olaparib plus abiraterone or placebo plus abiraterone. All patients received either prednisone or prednisolone 5 mg twice daily, and a GnRH analog or prior bilateral orchiectomy. Enrollment into the PROpel trial followed an all-comer approach. Genomic testing was conducted after patient randomization and before the primary analysis of the study.

The major efficacy outcome measure of the PROpel study was investigator-assessed radiographic progression free survival (rPFS). Overall survival (OS) was an additional efficacy outcome measure. *BRCA1/2* mutation (*BRCAm*) status was assessed after randomization and before the primary analyses by both NGS-based tumor tissue (FoundationOne CDx) and ctDNA (FoundationOne Liquid CDx) tests.

12.23.2 Tissue to Liquid concordance

A total of 1103 patients were enrolled in PROpel. Of these, 796 patients were randomized in PROpel while 307 patients were not randomized. Of the 796 randomized patients, tumor tissue samples were available for 782 patients (98.2%; 782/796) to enable FoundationOneCDx testing, and ctDNA samples were available for 794 patients (99.7%; 794/796) to enable FoundationOne Liquid CDx testing.

The concordance between FoundationOne CDx (as reference) and FoundationOne Liquid CDx was evaluated by calculation of the positive percent agreement (PPA), negative percent agreement (NPA), positive predictive value (PPV) and negative predictive value (NPV) in the 491 patients randomized in PROpel with valid results for both FoundationOne CDx and FoundationOne Liquid CDx tests (**Table 101**).

Table 101 Concordance between FoundationOne CDx and FoundationOne Liquid CDx *BRCAm* status in PROpel

		FoundationOne CDx tissue test		
		<i>BRCAm</i>	Non- <i>BRCAm</i>	Total
FoundationOne Liquid CDx ctDNA test	<i>BRCAm</i> ^a	34	18	52
	Non- <i>BRCAm</i> ^b	12	427	439
	Total	46	445	491
		PPA % (95% CI)		
		73.9 (59.7, 84.4)		
		NPA % (95% CI)		
		96.0 (93.7, 97.4)		
		PPV % (95% CI)		
		65.4 (51.8, 76.8)		
		NPV % (95% CI)		
		97.3 (95.3, 98.4)		

Note: The reference is the tumor tissue test (FoundationOne CDx).

^a Defined as any deleterious or suspected deleterious *BRCA1/2* gene mutation detected.

^b Defined as no deleterious or suspected deleterious *BRCA1/2* gene mutation detected. Test failed/samples are not included in concordance analysis.

PPA = Positive Percentage Agreement, NPA = Negative Percentage Agreement, PPV = Positive Predictive Value, NPV = Negative Predicted Value. The 95% confidence interval (CI) for PPA, NPA, PPV and NPV is calculated using the Wilson method.

12.23.3 Efficacy Evaluation

The clinical validity of FoundationOne CDx was demonstrated by assessing clinical efficacy in the *BRCA1/2*

positive population based on rPFS and OS. Of the 796 randomized patients in PROpel, 85 had *BRCAM* determined by either a positive ctDNA test or a tumor tissue test. The clinical efficacy was evaluated in terms of rPFS by investigator assessment and OS. The HR was calculated using a Cox proportional hazards model.

A statistically significant improvement in rPFS for Lynparza/abiraterone compared to placebo/abiraterone was observed in the intention to treat (ITT) population. In an exploratory analysis in the subgroup of 711 patients without an identified *BRCAM*, the rPFS hazard ratio was 0.77 (95% CI: 0.63, 0.96) and the OS hazard ratio was 0.92 (95% CI: 0.74, 1.14), indicating that the improvement in the ITT population was primarily attributed to the results seen in the subgroup of patients with *BRCAM*.

In the analysis of *BRCAM* patients as determined by FoundationOne CDx, the rPFS hazard ratio was 0.31 (95% CI [0.13, 0.68]) and the OS hazard ratio was 0.30 (95% CI [0.12, 0.67]). The magnitude of treatment effect was also numerically greater in comparison to the non-*BRCAM* subgroup (rPFS HR=0.78; 95% CI [0.60, 1.00] and OS HR=1.06; 95% CI [0.81, 1.37]).

Table 102 summarizes the efficacy results in the 85 patients in PROpel with *BRCAM* as determined by either a positive FoundationOne CDx test and/or a positive FoundationOne Liquid CDx test (the total *BRCAM* population) and in the 50 patients with *BRCAM* as determined by FoundationOne CDx.

Table 102. Efficacy analyses in PROpel

	Total <i>BRCAM</i> population (n=85)		F1CDx+ <i>BRCAM</i> population (n=50)	
	Lynparza/abiraterone N = 47	Placebo/abiraterone N = 38	Lynparza/abiraterone N = 26	Placebo/abiraterone N = 24
Radiological Progression-Free Survival (rPFS) ^a				
Events, n (%)	14 (30)	28 (74)	9 (35)	18 (75)
Median (95% CI), months	NR (NR, NR)	8 (6, 15)	NR (NR, NR)	10 (6, 18)
Hazard ratio (95% CI) ^b	0.24 (0.12, 0.45)		0.31 (0.13, 0.68)	
Overall Survival (OS)				
Events, n (%)	13 (28)	25 (66)	8 (31)	17 (71)
Median (95% CI), months	NR (NR, NR)	23 (18, 34)	NR (NR, NR)	20 (16, 34)
Hazard ratio (95% CI) ^b	0.30 (0.15, 0.59)		0.30 (0.12, 0.67)	

NR: Not reached

^aInvestigator-assessed

^bCalculated using an unstratified univariable Cox proportional hazards model

12.23.4 Sensitivity Analysis – Impact of F1CDx Unevaluable Set (FoundationOneCDx invalid results + not tested by FoundationOneCDx)

A sensitivity analysis was performed to assess the robustness of the clinical efficacy estimated after accounting for the F1CDx-unevaluable (failed FoundationOne CDx testing or not tested by FoundationOne CDx) results. Following imputation, the HR estimated for rPFS based on the Cox proportional hazards model using the complete dataset was 0.34 (95% CI: [0.16, 0.71]) and the HR estimated for OS based on the Cox proportional hazards model following imputation was 0.34 (95% CI: [0.16, 0.71]) in the *BRCAM* subgroup of patients as determined by FoundationOne CDx testing. Comparable results were seen with those from the observed dataset,

which demonstrated the efficacy results were robust after accounting for the missing FoundationOne CDx results.

12.23.5 Safety Analysis

The FoundationOne CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.23.6 Conclusions

The data from this study demonstrated the clinical validity of using the FoundationOne CDx assay to identify patients with metastatic castration-resistant prostate cancer with *BRCA1/2* alterations for the treatment with LYNPARZA[®] (olaparib) in combination with abiraterone.

12.24 Clinical evaluation of OJEMDA[™] (tovorafenib) in pediatric low-grade glioma patients with BRAF V600 mutations and BRAF fusions

The clinical effectiveness of F1CDx for detecting BRAF V600 mutations and BRAF fusions in pediatric low-grade glioma (pLGG) patients who may benefit from treatment with tovorafenib was demonstrated in a retrospective analysis of tumor tissue specimens from patients enrolled in the FIREFLY-1 (FF-1) clinical trial.

12.24.1 Summary of the Clinical Study – FIREFLY-1

The FF-1 study is a Phase II, multi-center, non-randomized, open-label trial assessing the efficacy, safety and pharmacokinetics of tovorafenib in pediatric patients aged 6 months to ≤ 25 years with relapsed or refractory LGGs or advanced solid tumors harboring a known activating *RAF* alteration, including *BRAF* V600 mutations and *BRAF* fusions.

Patient eligibility for the FF-1 trial was determined from existing documented evidence of *BRAF* alteration status from various testing platforms including IHC, fluorescence *in situ* hybridization (FISH), polymerase chain reaction (PCR) and/or sequencing (Sanger or NGS). Enrollment into one of 3 study arms was dependent on the presence of a *BRAF* or *RAF* alteration and tumor type (LGG vs. solid tumors). The primary analysis set for the NDA baseline imaging-evaluable population and for the CDx clinical validation studies includes patients enrolled in Arm 1 of the FF-1 trial only. Tovorafenib was granted accelerated approval by FDA for *BRAF* V600 mutation and *BRAF* fusion positive pLGG patients in April 2024 based on data from patients using the Response Assessment in Pediatric Neuro-Oncology (RAPNO)-LGG criteria in the FIREFLY-1 trial with *BRAF* V600 mutations and *BRAF* fusions.

12.24.2 Accountability of the PMA Cohort

A total of 197 patient samples were evaluated by F1CDx in the clinical bridging study: 77 *BRAF* V600 mutation positive or *BRAF* fusion positive (CTA+) samples from the FF-1 clinical trial and 120 *BRAF* V600 mutation negative or *BRAF* fusion negative (CTA-) samples (sourced from FMI sample archives and via commercial procurement). Among the 197 samples evaluated, 3 CTA+ samples did not have available material for F1CDx testing. Therefore, 194 samples, including clinical trial samples, samples from FMI sample archives and commercially procured samples were processed by F1CDx in this study. Of these 194 samples, 174 samples had valid F1CDx test results and 20 samples failed during pre- and post- sequencing processing steps.

Seventy-six (76) (including the one F1CDx-enrolled patient) out of 77 CTA+ patients were the basis of the approval of tovorafenib (RAPNO-LGG evaluable population).

12.24.3 Summary of the Clinical Bridging Study

The clinical bridging study was conducted to assess the clinical effectiveness of F1CDx in identifying *BRAF* V600 mutations and *BRAF* fusions in pLGG patients for treatment with tovorafenib and to assess the

concordance in detecting *BRAF* V600 mutations and *BRAF* fusions between the CTAs and F1CDx. F1CDx testing was performed retrospectively on the available patient samples from the FF-1 clinical study (N=77) and the CTA- samples (N=120).

12.24.4 Clinical Concordance

A concordance analysis between CTAs and F1CDx was performed with the 75 (excluding the one F1CDx-enrolled patient) RAPNO-LGG evaluable CTA-enrolled patients and 120 CTA- samples. A contingency table is provided below in **Table 103**.

Table 103. Contingency Table Comparing BRAF V600 Mutation or BRAF Fusion Between the CTA and F1CDx Based on RAPNO-LGG Evaluable Population

	CTA		
	CTA+	CTA-	Total
F1CDx+	41	2	43
F1CDx-	12	117	129
F1CDx-unevaluable	22	1	23
Total	75	120	195

PPA was established as 77.36% (95% two-sided score CI: [64.47%, 86.55%]) and NPA was 98.32% (95% two-sided score CI: [94.08%, 99.54%]). Prevalence adjusted PPV and NPV were calculated using 70.96% as the biomarker prevalence. The prevalence adjusted PPV was 99.12% (95% two-sided CI: [97.77%, 100.00%]) and the prevalence adjusted NPV was 63.99% (95% two-sided CI: [53.79%, 77.60%]).

Table 104. Concordance Results for BRAF V600 Mutation or BRAF fusion with F1CDx Relative to CTA Based on RAPNO-LGG Evaluable Population

Metric	Numerator	Denominator	Point Estimate (%)	95% Two-sided CI (%)	Method for CI
PPA	41	53	77.36	[64.47, 86.55]	Wilson Score
NPA	117	119	98.32	[94.08, 99.54]	Wilson Score
Adjusted PPV	N/A	N/A	99.12	[97.77, 100.00]	Bootstrap
Adjusted NPV	N/A	N/A	63.99	[53.79, 77.60]	Bootstrap

12.24.5 Efficacy Evaluation

The clinical validity of F1CDx for the detection of *BRAF* V600 mutations and *BRAF* fusions in pLGG patients for the CTA+ population was based on estimation of clinical efficacy in the F1CDx-positive population and subgroups of the CTA+ population stratified by F1CDx status. The efficacy endpoint was overall response rate (ORR) as assessed by IRC based on the RAPNO-LGG evaluable population. ORR was defined as the observed proportion of patients whose best overall response is confirmed complete response (CR) or partial response (PR) as determined by IRC and by the treating investigator. The point estimate ORR and 95% two-sided CI calculated using the Wilson-Score method, for each sub-population is presented in **Table 105**. An ORR of 52.00% (39/75, 95% two-sided score CI: [40.87%, 62.93%]) was observed for the 75 CTA-enrolled biomarker-positive subjects based on RAPNO-LGG criteria. Since the adjusted PPV was not 100%, the tipping point analysis under varied values of the tuning parameter (denoted as *c*) was performed to estimate the ORR for patients-identified as

biomarker positive by F1CDx (F1CDx+). The estimated F1CDx ORR ranged from 50.95% to 51.22% when c ranged from 0 to 1. The ORR and two-sided 95% CI for F1CDx+ population is presented in **Table 105**, **Table 106**, and **Table 107**. These results showed that the ORR for the F1CDx+ population is comparable to the ORR for the CTA+ population, which demonstrated clinical utility of F1CDx in identifying *BRAF* alterations V600 mutations and *BRAF* fusions in the RAPNO-LGG evaluable population who may benefit from the treatment of tovorafenib.

Table 105. Efficacy (ORR as determined by IRC using the RAPNO-LGG Criteria) based on all NDA Patients

Sub-population	No. of Patients	No. of Responders	ORR (%)	95% Two-sided Wilson Score CI (%)*
CTA+	75	39	52.00	[40.87, 62.93]
F1CDx+ CTA+	41	21	51.22	[36.48, 65.75]
F1CDx- CTA+	12	5	41.67	[19.33, 68.05]
F1CDx-evaluable CTA+	53	26	49.06	[36.12, 62.12]
F1CDx-unevaluable CTA+	22	13	59.09	[38.73, 76.74]
F1CDx-enrolled	1	0	0.00	N/A

*CIs are only reported if the sample size > 10.

Table 106. Efficacy (ORR as determined by IRC using the RAPNO-LGG Criteria) based on Patients Harboring BRAF Fusions

Sub-population	No. of Patients	No. of Responders	ORR (%)	95% Two-sided Wilson Score CI (%)*
CTA+	55	29	52.73	[39.79, 65.31]
F1CDx+ CTA+	28	14	50.00	[32.63, 67.37]
F1CDx- CTA+	9	3	33.33	N/A
F1CDx-evaluable CTA+	37	17	45.95	[31.04, 61.62]
F1CDx-unevaluable CTA+	18	12	66.67	[43.75, 83.72]
F1CDx-enrolled	1	0	0.00	N/A

*CIs are only reported if the sample size > 10.

Table 107. Efficacy (ORR as determined by IRC using the RAPNO-LGG Criteria) based on Patients Harboring BRAF Mutations

Sub-population	No. of Patients	No. of Responders	ORR (%)	95% Two-sided Wilson Score CI (%)*
CTA+	12	6	50.00	[25.38, 74.62]
F1CDx+ CTA+	9	5	55.56	N/A
F1CDx- CTA+	0	N/A	N/A	N/A
F1CDx-evaluable CTA+	9	5	55.56	N/A
F1CDx-unevaluable CTA+	3	1	33.33	N/A
F1CDx-enrolled	0	N/A	N/A	N/A

*CIs are only reported if the sample size > 10.

Table 108. Bridging study estimated drug efficacy (ORR as determined by IRC using the RAPNO-LGG evaluable population) for the F1CDx+ population based on observed data

c	Estimated ORR for F1CDx+ (%)	95% two-sided Wald CI (%)
0	50.95	[35.78, 66.13]
0.3	51.03	[35.86, 66.20]
0.5	51.09	[35.92, 66.26]
0.7	51.14	[35.97, 66.31]
1.0	51.22	[36.05, 66.39]

12.24.6 Sensitivity Analysis

A sensitivity analysis was conducted to assess the robustness of the concordance and the clinical efficacy results accounting for the patients with missing F1CDx status. The sensitivity analysis employed the multiple imputation method to impute missing F1CDx results and used the imputed and observed datasets to estimate the concordance and the ORR for F1CDx+ patients. The mean ORR estimated for the F1CDx+ population ranges from 51.46% to 51.73% when *c* ranges from 0 to 1, which is comparable to the efficacy estimates for F1CDx+ patients (ranges from 50.95% to 51.22% when *c* ranges from 0 to 1) in the observed data shown in **Table 106**. Overall, the sensitivity analysis results demonstrated the robustness of the concordance and the clinical efficacy results accounting for the missing F1CDx statuses.

12.24.7 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.24.8 Conclusions

The concordance and efficacy analysis conducted supports reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying *BRAF* V600 mutations and *BRAF* fusions in pLGG patients who may be eligible for treatment with tovorafenib.

12.25 Clinical evaluation of TEPMETKO® (tepotinib) in advanced or metastatic NSCLC patients with *MET* exon 14 skipping alterations

The clinical performance of F1CDx for detecting SNVs and indels that lead to *MET* exon 14 skipping alterations in patients with advanced or metastatic NSCLC (aNSCLC) who may benefit from treatment with tepotinib was established through a clinical bridging study with clinical data for patients from the VISION clinical study (NCT02864992).

12.25.1 Summary of the Clinical Study – NCT02864992 (VISION)

The VISION clinical trial is a single-arm, open-label, multicenter, non-randomized, multicohort study of *MET* inhibitor, TEPMETKO (tepotinib) in adult patients with advanced or metastatic NSCLC harboring *MET* exon 14 skipping alterations. Identification of *MET* exon 14 skipping alterations was prospectively determined using central laboratories employing either a next-generation sequencing-based or PCR-based clinical trial assay using tissue (66%) and/or plasma (57%) samples.

The VISION clinical trial consists of two parts. Part 1 included the pivotal Cohort A (*MET* exon 14 skipping alterations) and Cohort B (*MET* amplification, *MET* exon14 skipping-negative). Part 2 included Cohort C (confirmatory part for *MET* exon 14 skipping alterations). TEPMETKO was administered orally at 450 mg, once daily in 21-day cycles. Subjects were selected based on defined *MET* alterations or *MET* amplification identified

in tumor tissue and/or in circulating tumor DNA (ctDNA) derived from plasma. On February 3, 2021, the FDA granted accelerated approval to TEPMETKO® (tepotinib) for the treatment of adult patients with metastatic NSCLC harboring *MET* exon 14 skipping alterations and on February 15, 2024, the traditional approval was granted by the FDA.

12.25.2 Accountability of the PMA Cohorts

A total of 627 patient samples were evaluated by F1CDx based on DNA extracted from FFPE samples with F1CDx's standard extraction method (CoEx) or archived DNA extracts (exDNA) from the VISION clinical trial in the clinical bridging study consisting of: 342 *MET* exon 14 skipping alteration positive samples that tested positive for *MET* exon 14 skipping alteration by the CTAs (CTA+) from the VISION clinical trial (Cohort A and C) and 285 *MET* exon 14 skipping alteration negative patient samples that tested negative for *MET* exon 14 skipping alterations by the CTAs (CTA-) from the VISION clinical trial. Out of 627 patients, 170 did not have available CoEx (FFPE) or exDNA for F1CDx testing and 17 failed F1CDx testing, and thus, were F1CDx-unevaluable samples. The remaining 440 samples were evaluable by F1CDx.

Concordance between F1CDx results from matched CoEx and exDNA samples was evaluated in 299 patients with evaluable results for both sample types, demonstrating high concordance (positive percent agreement (PPA), negative percent agreement (NPA), positive predictive value (PPV), and negative predictive value (NPV)) ranging from 98.73% to 100%) with only one discordance observed. These results support the comparability of CoEx and exDNA samples; therefore, both sample types were included in the following analysis. Results from CoEx tissue samples were prioritized for analysis if both were available.

12.25.3 Summary of the Clinical Bridging Study

A clinical bridging study was conducted to assess the clinical effectiveness of F1CDx in identifying SNVs and indels that lead to *MET* exon 14 skipping alterations in patients with aNSCLC for treatment with tepotinib and the concordance in detecting *MET* exon 14 skipping alterations status between the CTAs and F1CDx. Retrospective testing with F1CDx was done for patients from cohorts A and C of the VISION clinical trial, and a random selection of *MET* exon 14 skipping-negative patients from VISION trial screen-fails. F1CDx testing was performed retrospectively on the available patient samples from the VISION clinical trial.

12.25.4 Clinical Concordance

A concordance analysis between CTAs and F1CDx was performed with 440 samples with valid F1CDx testing results. One patient, enrolled by F1CDx locally but not confirmed by central CTA, was excluded from the analysis. A contingency table is provided below in **Table 109**.

Table 109. Contingency Table Comparing METex14 Skipping Alteration Status between CTAs and F1CDx based on CoEx or exDNA Samples

	CTA		
	CTA+	CTA-	Total
F1CDx+	154	4	158
F1CDx-	12	270	282
F1CDx unevaluable	175	11	186
Total	341	285	626*

*One (1) patient enrolled by F1CDx locally but not confirmed by central CTA was excluded.

The PPA was established as 92.77% (95% two-sided score CI: [87.79%, 95.82%]) and the NPA was 98.54% (95% two-sided score CI: [96.31%, 99.43%]). Since patients were enrolled and initially tested by CTAs, the prevalence-adjusted PPV and NPV were calculated by adjusting for the prevalence of METex14 skipping alterations (3%) among the intended use (IU) population. The prevalence-adjusted PPV was estimated to be 66.28% (95% two-sided CI: [48.91%, 88.97%]) and the prevalence-adjusted NPV was 99.77% (95% two-sided CI: [99.66%, 99.89%]).

Table 110. Concordance Results between CTAs and F1CDx based on CoEx or exDNA Samples*

	Prevalence	Numerator	Denominator	Point Estimate (%)	95% Two-Sided CI (%)	Method for CI Calculation
PPA	N/A	154	166	92.77	[87.79, 95.82]	Wilson score
NPA	N/A	270	274	98.54	[96.31, 99.43]	Wilson score
Unadjusted PPV	N/A	154	158	97.47	[93.67, 99.01]	Wilson score
Unadjusted NPV	N/A	270	282	95.74	[92.71, 97.55]	Wilson score
Adjusted PPV	3%	N/A	N/A	66.28	[48.91, 88.97]	Bootstrapping
Adjusted NPV	3%	N/A	N/A	99.77	[99.66, 99.89]	Bootstrapping

*One (1) patient enrolled by F1CDx locally but not confirmed by central CTA was excluded.

12.25.5 Efficacy Evaluation

The clinical validity of F1CDx for the detection of *MET* exon 14 skipping alterations in patients with aNSCLC was demonstrated by assessing clinical efficacy in the F1CDx *MET*ex14 positive population based on response rate (ORR) as the primary efficacy endpoint. ORR is defined as the proportion of patients with best response of confirmed Complete Response (CR) or Partial Response (PR) as determined by Blinded independent review committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The clinical efficacy of tepotinib was assessed for treatment-naïve patients (1L) and previously treated patients (2L+) based on the NDA population (Cohort A and C). One patient locally enrolled by F1CDx but not confirmed by central CTA was excluded. Therefore, a total of 312 CTA+ patients were evaluated.

To evaluate the secondary efficacy endpoint, duration of response (DOR), the median DOR was calculated by the Kaplan-Meier method along with its two-sided 95% CI for all the patients.

The efficacy results are provided in **Table 111** and **Table 112**, for treatment-naïve patients (1L) and **Table 113** and **Table 114** for previously treated patients (2L+). The estimated ORR and the corresponding 95% CIs for the F1LCDx+/CTA+ population in the treatment-naïve cohort and previously treated cohort are 64.06% [51.82%, 74.71%] and 50.77% [38.92%, 62.54%], respectively (**Table 111** and **Table 113**). The efficacy estimates for the F1CDx+ population by treatment lines are provided in **Table 112** and **Table 114**. These results are comparable with the observed ORR for the CTA+ population in the respective cohort by treatment lines.

Table 111. Efficacy in Treatment-naïve Patients (1L) from NDA Population based on CoEx or exDNA Samples

	CTA+	F1CDx+ CTA+	F1CDx- CTA+	F1CDx evaluable CTA+	F1CDx unevaluable CTA+
# Total	164	64	6	70	94
# Responders (CR or PR)	94	41	0	41	53
ORR (%)	57.32	64.06	0.00	58.57	56.38
Two-sided 95% Score CI (%)	[49.66, 64.63]	[51.82, 74.71]	N/A*	[46.88, 69.37]	[46.30, 65.96]

*CI not reported due to the small sample size (e.g., <10)

Table 112. Bridging Study Estimated Efficacy (ORR) for 1L Patients in the F1CDx+ Population based on CoEx or exDNA Samples*

c	ORR (%)	Two-sided 95% CI (%)
0%	49.06	[31.43, 66.69]
30%	53.56	[39.66, 67.46]
50%	56.56	[44.82, 68.30]
70%	59.56	[49.52, 69.61]
100%	64.06	[55.11, 73.02]

* Estimated using concordance between F1CDx and CTA where the CTA+ set includes 1L patients from NDA and CTA- set includes all the CTA- patients.

Table 113. Efficacy in Previously Treated Patients (2L+) from NDA Population based on CoEx or exDNA Samples (by Excluding the F1CDx-locally enrolled Patient)*

	CTA+	F1CDx+ CTA+	F1CDx- CTA+	F1CDx evaluable CTA+	F1CDx unevaluable CTA+
# Total	148	65	3	68	80
# Responders (CR or PR)	67	33	2	35	32
ORR (%)	45.27	50.77	66.67	51.47	40.00
Two-sided 95% Score CI (%)	[37.47, 53.31]	[38.92, 62.54]	N/A*	[39.83, 62.95]	[29.96, 50.95]

*One (1) 2L+ patient enrolled by F1CDx locally but not confirmed by central CTA was excluded.

*CI not reported due to the small sample size (e.g., <10).

Table 114. Bridging Study Estimated Efficacy (ORR) for 2L+ Patients in the F1CDx+ Population based on CoEx or exDNA samples (by Excluding the F1CDx-locally enrolled Patient)*

c	ORR (%)	Two-sided 95% CI (%)
0%	40.60	[25.38, 55.82]
30%	43.65	[31.09, 56.21]
50%	45.68	[34.60, 56.77]
70%	47.72	[37.73, 57.70]
100%	50.77	[41.46, 60.08]

* Estimated using concordance between F1CDx and CTA where the CTA+ set includes 2L+ patients from NDA and CTA- set includes all the CTA- patients, with the F1CDx-locally enrolled 2L+ patient excluded.

12.25.6 Sensitivity Analysis

A sensitivity analysis was conducted to assess the robustness of the concordance and the clinical efficacy results accounting for the patients with missing F1CDx status. The sensitivity analysis employed the multiple imputation method to impute the missing F1CDx results and estimate the concordance and the ORR for F1CDx+ patients. Overall, comparable results were seen with those from the observed data, which demonstrated the robustness of the concordance and the clinical efficacy results accounting for the missing F1CDx statuses.

12.25.7 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.25.8 Conclusions

The data from this study support reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying SNVs and indels that lead to *MET* exon 14 skipping alterations in patients with aNSCLC who may be eligible for treatment with tepotinib.

12.26 Clinical evaluation of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) patients with HRR gene alterations

The clinical effectiveness of F1CDx for detecting *HRR* gene alterations in mCRPC patients who may benefit from treatment with talazoparib in combination with enzalutamide was demonstrated using clinical data generated from F1CDx in Part 2 of the TALAPRO-2 clinical study.

12.26.1 Summary of the Clinical Study – TALAPRO-2

The TALAPRO-2 clinical trial is an international, Phase 3, two-part study enrolling patients with mCRPC where no systemic cancer treatments have been initiated after documentation of CRPC, with the exception of androgen deprivation therapy and first-generation anti-androgen agents. Part 1 was open-label and non-randomized and evaluated the safety, tolerability, and pharmacokinetics (PK) of talazoparib in combination with enzalutamide. Part 2 was randomized, double-blinded, and placebo-controlled and evaluated the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide. Part 2 of the study included 2 cohorts and randomized patients 1:1 to talazoparib in combination with enzalutamide versus placebo in combination with enzalutamide. The major efficacy outcome measure of Part 2 was radiographic progression-free survival (rPFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Prostate Cancer Working Group (PCWG3) (bone) criteria, assessed by Blinded Independent Central Review (BICR). A secondary efficacy outcome measure was Overall Survival (OS).

The first cohort (Cohort 1) of Part 2 enrolled 805 mCRPC patients unselected for HRR status (referred to as an all-comers population). However, HRR deficiency assessment prior to randomization was required for stratification. After enrollment for Cohort 1 was closed, enrollment into the study continued but was restricted to patients with HRR deficiencies (Cohort 2). Cohort 2 enrolled 230 patients harboring HRR gene alterations that were likely to sensitize the patient's tumor to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition (HRR-deficient). Patients with alterations in at least one of the 12 HRR genes (*ATM*, *ATR*, *BRCA1*, *BRCA2*, *CDK12*, *CHEK2*, *FANCA*, *MLH1*, *MRE11A*, *NBN*, *PALB2*, or *RAD51C*) were identified prior to randomization

by central testing of tumor tissue (F1CDx) or circulating tumor DNA (ctDNA)-based next generation sequencing assays.

Of the 805 mCRPC patients enrolled into Cohort 1, 169 patients were HRR-deficient and thus, there were altogether 399 HRR-deficient patients including 230 patients from Cohort 2.

12.26.2 Accountability of the sPMA Cohort

The clinical validation study was based on the combined HRR-deficient populations in the TALAPRO-2 study which consisted of 399 HRR-deficient patients from Cohort 1 and Cohort 2. Of these 399 HRR-deficient patients, a total of 302 patients had valid results by F1CDx and 97 were not tested or did not have valid results by F1CDx. Out of the 302 HRR-deficient patients with F1CDx valid results, 247 were F1CDx+ and 55 were F1CDx-.

12.26.3 Efficacy Evaluation of F1CDx

The clinical validity of F1CDx was demonstrated by assessing clinical efficacy in the F1CDx HRR-deficient (HRRm) positive population based on rPFS.

The TALAPRO-2 study met its primary endpoint, as treatment with talazoparib in combination with enzalutamide resulted in a clinically meaningful and statistically significant improvement in rPFS in the intent-to-treat (ITT), HRRm population. Please refer to the TALZENNA USPI for Cohort 2 rPFS and OS results .

As presented in **Table 115**, the median rPFS in the F1CDx-HRR deficient population was non estimable (NE) (95% two-sided CI: [27.40, NE]) in the experimental treatment group and 13.80 months (95% two-sided CI: [10.97, 16.62]) in the placebo group as estimated by the Kaplan-Meier method [13]. The median rPFS may be unavailable because the probability of being event free did not fall below 50% in the Kaplan-Meier estimate¹³. The estimated HR based on stratified Cox regression models and the Breslow tie handling method¹⁵ was 0.30 (95% two-sided CI: [0.20, 0.46]) comparing the treatment group versus the placebo group. The results demonstrate improved rPFS and reduced risk of disease progression or death in patients who received treatment with talazoparib in combination with enzalutamide.

Table 115. Efficacy analyses in TALAPRO-2 in the ITT population and F1CDx+ HRRm Subjects

	ITT Total HRRm population (n=399)		F1CDx+ HRRm population (n=247)	
	Talazoparib/ enzalutamide N =200	Placebo/ enzalutamide N = 199	Talazoparib/ enzalutamide N = 132	Placebo/ enzalutamide N = 115
rPFS Events, n (%)	66 (33)	104 (52)	39 (30)	68 (59)
Median rPFS (95% CI), months	NE(21.9, NE)	13.8 (11.0, 16.7)	NE (27.40, NE)	13.8 (10.97, 16.62)
Hazard ratio (95% CI)	0.45 (0.33, 0.61) ^a		0.30 (0.20, 0.46) ^b	

NE: non estimable. Median rPFS and the associated CI bounds may be unavailable when the rPFS rate did not fall below 50% in the Kaplan-Meier estimate.

^a Estimated based on Cox proportional hazards model stratified by previous treatment.

^b Estimated based on a multivariate Cox proportional hazards model adjusting for disease localization and baseline pain score, and stratified by previous treatment.

A sensitivity analysis was performed to assess the robustness of the clinical efficacy estimated after accounting for the F1CDx-unevaluable (failed F1CDx testing or not tested by F1CDx) results. Following imputation, the HR estimated for rPFS based on the Cox proportional hazards model using the complete dataset was 0.37 (95% CI: [0.35, 0.40]) in the HRRm population as determined by F1CDx testing. Comparable results were seen with those from the observed dataset, which demonstrated the efficacy results were robust after accounting for the missing F1CDx results.

12.26.4 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.26.5 Conclusions

The efficacy analysis supports reasonable assurance of the safety and effectiveness of the F1CDx assay when used to aid clinicians in identifying mCRPC patients with *HRR* gene alterations who may be eligible for and benefit from treatment with talazoparib in combination with enzalutamide.

12.27 Clinical evaluation of ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant in breast cancer patients with *PIK3CA* alterations

The clinical validity of the FoundationOne CDx assay as a companion diagnostic device for identifying *PIK3CA* mutations in patients with locally advanced or metastatic breast cancer who may benefit from treatment with ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant was established using clinical data from the INAVO120 clinical trial.

12.27.1 Summary of the Clinical Study INAVO120

INAVO120 (WO41554/NCT04191499) is a Phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy of the triplet combination of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with *PIK3CA*-mutated, Hormone Receptor-Positive (HR+), HER2-negative (HER2-) locally advanced or metastatic breast cancer, who have not received prior systemic therapy for locally advanced or metastatic disease and whose disease progressed during or within 12 months of completing adjuvant endocrine therapy. *PIK3CA* mutation (*PIK3CA*m) status was prospectively determined in a central laboratory using the FoundationOne Liquid CDx assay on plasma-derived ctDNA or in local laboratories using various validated PCR or NGS assays on tumor tissue or plasma. All patients were required to provide both a freshly collected pre-treatment blood sample and a tumor tissue sample for central evaluation and determination of *PIK3CA*m status.

The major efficacy outcome measure was investigator (INV)-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Additional efficacy outcome measures included overall survival (OS), INV-assessed objective response rate (ORR), and INV-assessed duration of response (DOR).

In the NDA population, the median PFS (months) with 95% 2-sided CI for the inavolisib cohort was 15.0 [11.3, 20.5] months, and the median PFS for the placebo cohort was 7.3 [5.6, 9.3] months. The PFS hazard ratio (HR) for inavolisib in combination with palbociclib and fulvestrant vs. placebo in combination with palbociclib and fulvestrant and the associated 2-sided 95% CI was estimated as 0.43 [0.32, 0.59] (Turner et al, 2024).

12.27.2 Accountability of the sPMA Cohort

A total of 325 CTA+ patients were included in the NDA efficacy population for ITOVEBI™ (inavolisib) or placebo plus palbociclib and fulvestrant in the INAVO120 trial. Of these 325 patients, 43 were from China: they are considered as CTA evaluable and F1CDx unevaluable for the sensitivity analysis provided in Section 12.25.6. Of the remaining 282 patients (325 - 43), 38 were enrolled by local assays, leaving 244 (282-38) enrolled as F1LCDx+. For the 244 patients enrolled by F1LCDx, one patient was enrolled by a locally commissioned F1LCDx test. Of the 38 local test-enrolled patients, 34 have evaluable F1LCDx test results (9 F1LCDx- and 25 F1LCDx+) and 4 are prospective F1LCDx unevaluable (1 failure, 3 unavailable) leaving 269 (244 + 25) F1LCDx+ samples and 9 F1LCDx- samples. Of the 269 F1LCDx+ samples, 207/269 (77.0%) have evaluable confirmatory F1CDx status, including 71.0% (191/269) F1CDx+ patients and 5.9% (16/269) F1CDx- patients. The remaining 62/269 (23.0%) patients are F1CDx unevaluable. For the 9 F1LCDx- patients, 7 are F1CDx evaluable.

To support the concordance analysis of *PIK3CA* mutation(s) between the enrollment assays and F1CDx, 63 available screen failed patients from INAVO120 who are F1LCDx- with evaluable F1CDx results were included in the bridging study with an additional 54 F1LCDx- samples from the FMI archives. The additional 54 FMI archive negatives are breast cancer samples that were selected randomly according to F1LCDx negative status with blinded or no F1CDx status and sufficient matched materials for both F1LCDx and F1CDx testing.

Concordance was assessed between F1LCDx, the majority enrollment assay, and F1CDx, as well as between CTA and F1CDx. The concordance analyses assessing the agreement of identified *PIK3CA*m status were performed with a total of 331 subjects with valid F1CDx testing results for the concordance analysis between F1LCDx and F1CDx and 334 subjects for the concordance analysis between CTA and F1CDx, since 3 of 4 non-China F1LCDx unevaluable patients are F1CDx evaluable.

12.27.3 Summary of the Clinical Bridging Study

The clinical bridging study was conducted to assess 1) concordance between all assays used for enrollment (i.e., CTA) and F1CDx and 2) to estimate the drug efficacy in the F1CDx IU population

The CDx efficacy analysis population was represented by the patients from the NDA efficacy population (*PIK3CA* mutation positive, HR+, HER2-negative locally advanced or metastatic breast cancer patient) whose tumor tissue (FFPE) was positive for one or more study eligible *PIK3CA* mutations by F1CDx (i.e., F1CDx+), and assessed the clinical trial primary endpoint, PFS.

12.27.4 Concordance between F1CDx and F1LCDx assays based on INAVO120 trial data

The concordance analysis also assessed the agreement of identified *PIK3CA* mutation(s) status between the F1CDx and F1LCDx assays for patients with breast cancer and was performed with 331 subjects with valid F1CDx testing results from the INAVO120 F1LCDx evaluable population, tissue-matched screen fails, and an additional 54 F1LCDx- samples from the FMI archives used to further support concordance analysis.

Contingency **Table 116** **Table 116. Contingency Table Comparing *PIK3CA* Mutations between F1LCDx and F1CDx** summarizes the concordance analysis results and agreement assessments between F1CDx and F1LCDx (the primary CTA used for enrollment).

Table 116. Contingency Table Comparing PIK3CA Mutations between F1LCDx and F1CDx

		F1LCDx		
		F1LCDx+	F1LCDx-	Total
F1CDx	F1CDx+	191	21	212
	F1CDx-	16	103	119
	F1CDx <u>Unevaluable</u>	62	2	64
	Total	269	126	395
Agreement Statistics excluding unevaluable results [Two-sided 95% CI]*		PPA 92.27% [87.81%, 95.19%]	NPA 83.06% [75.49%, 88.65%]	

* Two-sided 95% CI is calculated by the Wilson-Score method for PPA and NPA

The prevalence-adjusted PPV and NPV were also calculated by adjusting for the prevalence of PIK3CA alteration(s) among the ITT population and are provided in **Table 117**. The prevalence of the biomarker is defined as the proportion of biomarker positive patients in the breast cancer population and is estimated as Prev = 40% based on literature (Stemke-Hale, 2008). The bootstrapping method was used to calculate the CI for adjusted PPV and NPV.

Table 117. Predictive Value Concordance Analysis Results for F1CDx PIK3CA Mutation Calling Relative to F1LCDx

Metric	Prevalence	Point Estimate (%)	95% Two-Sided CI (%)	Method for CI Calculation
Adjusted PPV	40%	78.41	[72.03, 85.17]	Bootstrapping
Adjusted NPV	40%	94.16	[91.47, 96.69]	Bootstrapping

12.27.5 Clinical Concordance

To assess concordance between the CTAs (local CTAs or F1LCDx) and F1CDx, a total of 325 CTA+ samples and 117 CTA- samples were evaluated. Of the 325 CTA+ samples, 217 samples yielded valid F1CDx results. Concordance was evaluated by calculating PPA and NPA for samples with valid F1CDx results. The PPA and NPA, presented in **Table 118**, were established as 92.63 with two-sided 95% CI [88.36%, 95.41%] and 88.03% with two-sided 95% CI [80.91%, 92.74%], respectively. HR estimates for the F1CDx+ population ranged from 0.39 with two-sided 95% CI [0.26, 0.57] to 0.41 [0.29, 0.59] when including all enrolled subjects as CTA+, varying c, and according to planned treatment. Further details on concordance and efficacy analysis considering all enrolled subjects as CTA+ are provided in **Table 118** to

Table 122 below.

Table 118. Contingency Table Comparing PIK3CA Status by F1CDx Assay and CTAs for the Analysis Set Including all Enrolled Subjects as CTA+

		CTA		
		CTA+	CTA-	Total
F1CDx	F1CDx+	201	14	215
	F1CDx-	16	103	119
	F1CDx <u>Unevaluable</u>	108	NA	108
	Total	325	117	442
Agreement Statistics excluding unevaluable results [Two-sided 95% CI]*		PPA 92.63% [88.36%, 95.41%]	NPA 88.03% [80.91%, 92.74%]	

* Two-sided 95% CI is calculated by the Wilson-Score method for PPA and NPA.

The prevalence-adjusted PPV and NPV were also calculated by adjusting for the prevalence of PIK3CA alteration(s) among the ITT population and are provided in **Table 119**. The prevalence of the biomarker is defined as the proportion of biomarker positive patients in the breast cancer population and is estimated as Prev = 40% based on literature (Stemke-Hale, 2008). The bootstrapping method was used to calculate the CI for adjusted PPV and NPV.

Table 119. Concordance Analysis Results Between CTAs and F1CDx Including all Enrolled Subjects as CTA+

Metric	Prevalence	Point Estimate (%)	95% Two-Sided CI [%]	Method for CI Calculation
Adjusted PPV	40%	83.77	[77.22, 90.21]	Bootstrapping
Adjusted NPV	40%	94.71	[92.27, 96.95]	Bootstrapping

12.27.6 Efficacy Evaluation

The efficacy endpoint, PFS, was analyzed for the PIK3CA mutation(s) positive population considering all enrolled subjects as CTA+ and according to F1CDx detection status or evaluability for the bridging study population.

For each treatment arm, Kaplan-Meier curves were used to estimate the time-to-event distributions. The 50th percentile of Kaplan-Meier estimates were used to estimate the median duration of PFS and are reported with a 2-sided 95% CI based on the Brookmeyer-Crowley method (Brookmeyer and Crowley, 1982) in **Table 120** according to planned treatment groups (TRT01P). The PFS hazard ratio (HR) for inavolisib in combination with palbociclib and fulvestrant vs. placebo in combination with palbociclib and fulvestrant and the associated two-sided 95% CI was estimated using a Cox proportional hazards model stratified by the randomization factors of the clinical trial with results presented in **Table 121**. **Table 122** shows the bridging study estimated HR for F1CDx+ IU population based on F1CDx evaluable data according to planned treatment.

Table 120. Efficacy in the Bridging Study Populations Including all Enrolled Subjects as CTA+*

Subgroup	# of Patients		# of Survival Events		Range of PFS (Months)		Median PFS (Months)		Median PFS (Months) 95% Two-sided CI	
	Inavo+ Palbo+ Fulv	Pbo+ Palbo+ Fulv	Inavo+ Palbo+ Fulv	Pbo+ Palbo+ Fulv	Inavo+ Palbo+ Fulv	Pbo+ Palbo+ Fulv	Inavo+ Palbo+ Fulv	Pbo+ Palbo+ Fulv	Inavo+ Palbo+ Fulv	Pbo+ Palbo+ Fulv
CTA+	161	164	82	113	[0, 37.6]	[0, 38.8]	15.0	7.4	[11.4, 21.0]	[5.8,9.3]
F1CDx+ & CTA+	109	92	56	60	[0, 37.6]	[0, 34.8]	17.2	7.3	[13.4, 25.8]	[5.9,11.1]
F1CDx Evaluable & CTA+	116	101	60	66	[0, 37.6]	[0, 38.8]	16.6	7.4	[11.6, 25.7]	[6.2,10.9]
F1CDx Unevaluable & CTA+	45	63	22	47	[0, 30.2]	[0, 35.5]	11.2	5.6	[8.5, 21]	[3.8,10.8]

*Efficacy is evaluated according to planned treatment indicator (TRT01P) group treated with inavolisib in combination with palbociclib and fulvestrant (Inavo+Palbo+Fulv) vs the control group treated with placebo in combination with palbociclib and fulvestrant (Pbo+Palbo+Fulv)

Table 121. Estimation of HR Including all Enrolled Subjects as CTA+

Subgroup	HR between Treatment and Control Arms	Two-sided 95% CI
CTA+	0.43	[0.32, 0.59]
F1CDx+ & CTA+	0.39	[0.26, 0.58]
F1CDx Evaluable & CTA+	0.44	[0.30, 0.64]
F1CDx Unevaluable & CTA+	0.49	[0.27, 0.88]

Table 122. Bridging Study Estimated HR for F1CDx+ Population for the IU Population Based on F1CDx Evaluable Data Including all Enrolled Subjects as CTA+

C	HR between Treatment and Control Arms	Two-sided 95% CI
0.0	0.41	[0.29, 0.59]
0.3	0.40	[0.28, 0.58]
0.5	0.40	[0.28, 0.58]
0.7	0.39	[0.27, 0.57]
1.0	0.39	[0.26, 0.57]

12.27.7 Sensitivity Analysis

A sensitivity analysis was conducted with all enrolled patients considered CTA+ to assess the robustness of the concordance and the clinical efficacy results when accounting for the patients with missing F1CDx status via multiple imputation method. The F1CDx unevaluable results were imputed using a multivariate logistic regression model. The imputation model included covariates that either are distributed unevenly between the F1CDx evaluable and F1CDx unevaluable patients, had significant association to clinical outcome, or were predictive of missingness of the F1CDx tumor status.

Following imputation, the clinical efficacy for the F1CDx+ population as well as the two-sided 95% CI were

evaluated. The estimated HR for the F1CDx+ population according to planned treatment was evaluated as ranging from 0.40 with two-sided 95% CI [0.28, 0.58] to 0.42 [0.31, 0.58] for constant c varied from 1.0 to 0.0 and the method for CI accounting for both within and between imputation variances. These imputed efficacy results are comparable to those from the primary efficacy analysis when bridging from CTA, which ranged from 0.39 with two-sided 95% CI [0.26, 0.57] to 0.41 [0.29, 0.59] as c varied from 1.0 to 0.0. The sensitivity analysis demonstrated that the clinical efficacy in F1CDx+ intended use population was robust to missing F1CDx testing results.

12.27.8 Safety Analysis

The F1CDx assay is not expected to directly cause actual or potential adverse effects, but test results may directly impact patient treatment risks.

12.27.9 Conclusions

The concordance and efficacy analysis conducted supports reasonable assurance of the effectiveness of the F1CDx assay when used to aid clinicians in identifying *PIK3CA* mutations in breast cancer patients who may be eligible for treatment with ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant.

13 CDx Classification Criteria

13.1 CDx classification criteria for ALECENSA® (alectinib), ALUNBRIG® (brigatinib), XALKORI® (crizotinib), or ZYKADIA® (ceritinib) for patients with NSCLC

Presence of an *ALK* rearrangement that meets one or more of the following conditions:

- *ALK* rearrangement with *EML4* as a partner gene
- *ALK* rearrangement with a breakpoint in intron 19, excluding internal inversions or duplications

13.2 CDx classification criteria for ERBITUX® (cetuximab) and VECTIBIX® (panitumumab) for patients with colorectal cancer

KRAS/*NRAS* wild-type (absence of mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)).

13.3 CDx classification criteria for AKEEGA® (niraparib + abiraterone acetate) or LYNPARZA® (olaparib) in combination with abiraterone for patients with prostate cancer, or for LYNPARZA® (olaparib) for patients with ovarian cancer

Presence of a *BRCA1* or *BRCA2* alteration listed in **Table 123**.

Table 123. Eligible *BRCA1* or *BRCA2* alterations

Gene (Transcript)	Variant type	Biomarker rules
<i>BRCA1</i> (NM_007294)	Short variant	- Any nonsense¹, frameshift, or splice site² variant - For <i>BRCA2</i>, truncating mutations must occur upstream of bases encoding amino acid 3326 - Any of the alterations³ listed in Table 124 or Table 125
	Copy number alteration	Homozygous deletion of one or more exons, regardless of transcript
	Rearrangement	Any rearrangement predicted to disrupt protein function, regardless of transcript

1 This rule excludes missense mutations in the start codon and short variant deletions spanning from upstream of the start codon (annotated as M1?), unless otherwise noted in the variant tables.

2 Defined as any splicing event that spans or occurs within ± 2 bases of the intron/exon junction.

3 *ATM* and *BRCA1/2* inactivating mutation lists may change over time as a result of periodic review of new evidence, in accordance with FDA-approved variant classification procedures.

Table 124. List of short variants in *BRCA1* NM_007294

M1I	C44Y	R1495M	R1699Q	R1753T	Y1853C
M1R	C47F	R1495T	R1699W	K1759N	C1787_G1788>SD
M1T	C47R	E1559K	L1705P	L1764P	splice site 212+3A>G
M1V	C47S	E1559Q	G1706E	I1766N	splice site 213-11T>G
M18K	C47Y	A1623G	G1706R	I1766S	splice site 213-12A>G
M18T	C61G	S1655F	A1708E	G1770V	splice site 302-3C>G
L22S	C61S	T1685A	V1714G	M1775K	splice site 4675+3A>T
C24R	C61Y	T1685I	S1715N	M1775R	splice site 4986+3G>C
I26N	C64G	H1686R	S1715R	L1780P	splice site 4986+5G>A
T37R	C64R	V1688del	W1718C	C1787S	splice site 4986+6T>C
T37K	C64W	M1689R	S1722F	G1788V	splice site 4986+6T>G
C39G	C64Y	T1691I	V1736A	P1812A	splice site 5074+3A>G
C39R	R71G	T1691K	V1736G	A1823T	splice site 5194-12G>A
C39W	R71K	D1692H	G1738E	V1833M	splice site 5406+4A>G
C39Y	R71M	D1692N	G1738R	W1837G	
H41R	R71T	D1692Y	D1739G	W1837C	
C44F	S770L	A1693del	D1739V	W1837R	
C44S	R1495K	C1697R	G1748D	V1838E	

Table 125. List of short variants in *BRCA2* NM_00059

M1I	V211L	W2626R	I2675V	G2748D	N3187K
M1R	Y600C	I2627F	L2686P	R2784W	splice site 316+4delA
M1T	K1530N	L2647P	L2688P	G2793R	splice site 316+5G>A
M1V	R2336H	L2653P	T2722K	Q2829R	splice site 8487+3A>G
D23N	R2336L	R2659G	T2722R	A2911E	splice site 8754+3G>C

D23Y	R2336P	R2659K	D2723A	E3002K	splice site 8754+4A>G
S142I	T2412I	R2659T	D2723G	R3052W	splice site 8754+5G>A
S142N	L2510P	Y2660D	D2723H	G3076V	splice site 8954-5A>G
V159M	R2602T	E2663K	D2723V	D3095E	
G173R	H2623R	E2663V	G2724W	D3095G	
V211I	W2626C	S2670L	Y2726C	N3124I	

13.4 CDx classification criteria for PIQRAY® (alpelisib) for patients with breast cancer

Presence of a *PIK3CA* alteration resulting in H1047R, E545K, E542K, C420R, E545A, E545D [1635G>T only], E545G, Q546E, Q546R, H1047L, or H1047Y.

13.5 CDx classification criteria for PEMAZYRE® (pemigatinib) for patients with cholangiocarcinoma

Presence of an *FGFR2* rearrangement that meets one or more of the following conditions:

- Any rearrangement involving *FGFR2* and a literature-derived known partner gene, regardless of strand or frame
- Any rearrangement involving *FGFR2* and a novel partner gene that is both in-frame and in-strand
- Any *FGFR2* rearrangement with one breakpoint in the hotspot region (intron 17-18) and the other breakpoint in an intergenic region or within another gene; this rule excludes 3' duplications of only exon 18
- Any intragenic duplication of the *FGFR2* kinase domain (exon 9-17)

13.6 CDx classification criteria for TABRECTA® (capmatinib) and TEPMETKO® (tepotinib) for patients with NSCLC

Presence of an exon 14 *MET* alteration that results in exon skipping, including:

- Intronic deletion ≥5 base pair at the 5' exonic boundary affecting positions -3 to -30
- Indel at the 5' exonic boundary affecting positions -1 or -2
- Base substitution or indel at the 3' exonic boundary affecting positions 0, +1, +2, or +3.
- Intronic insertion at the 5' exonic boundary affecting positions -3 to -24.
- Short variant deletion with CDS effect c.3026_3027delAA.

13.7 CDx classification criteria for LYNPARZA® (olaparib) for patients with prostate cancer

Presence of an HRR alteration listed in **Table 126**.

Table 126. Eligible HRR alterations

Gene (Transcript)	Variant type	Biomarker rules
<i>ATM</i> (NM_000051) <i>BARD1</i> (NM_000465) <i>BRCA1</i> (NM_007294) <i>BRCA2</i> (NM_000059)	Short variant	- Any nonsense¹, frameshift, or splice site² variant - For <i>BRCA2</i>, truncating mutations must occur upstream of bases encoding amino acid 3326 - For <i>FANCL</i>, truncating mutations must occur upstream of bases encoding amino acid 365

<i>BRIP1</i> (NM_032043) <i>CDK12</i> (NM_016507) <i>CHEK1</i> (NM_001274) <i>CHEK2</i> (NM_007194) <i>FANCL</i> (NM_018062) <i>PALB2</i> (NM_024675) <i>RAD51B</i> (NM_133509) <i>RAD51C</i> (NM_058216) <i>RAD51D</i> (NM_002878) <i>RAD54L</i> (NM_003579)		Any of the alterations³ listed in Table 124, Table 125, or Table 127
	Copy number alteration	Homozygous deletion of one or more exons, regardless of transcript
	Rearrangement	Any rearrangement predicted to disrupt protein function, regardless of transcript

1 This rule excludes missense mutations in the start codon and short variant deletions spanning from upstream of the start codon (annotated as M1?), unless otherwise noted in the variant tables.

2 Defined as any splicing event that spans or occurs within ± 2 bases of the intron/exon junction.

3 *ATM* and *BRCA1/2* inactivating mutation lists may change over time as a result of periodic review of new evidence, in accordance with FDA-approved variant classification procedures.

Table 127. List of short variants in ATM NM_000051

M1I	Y2470D	F2827C
M1L	A2524P	R2832C
M1T	R2547_S2549del	S2855_V2856>RI
P292L	A2622V	D2913Y
D2016G	D2625_A2626>EP	R3008C
R2032K	V2662D	R3008H
E2039K	D2708N	splice site 331+5G>A
A2067D	V2716A	splice site 8418+5_8418+8delGTGA
R2227C	G2765S	

13.8 CDx classification criteria for PIQRAY® (alpelisib) for patients with breast cancer

Presence of a *PIK3CA* alteration resulting in H1047R, E545K, E542K, C420R, E545A, E545D [1635G>T only], E545G, Q546E, Q546R, H1047L, or H1047Y.

13.9 CDx classification criteria for ROZLYTREK® (entrectinib) or VITRAKVI® (larotrectinib) for patients with solid tumors

Presence of an *NTRK1*, *NTRK2*, or *NTRK3* fusion that meets the following condition:

- In-strand rearrangement events that may lead to a *NTRK1*, *NTRK2*, or *NTRK3* RNA fusion with another protein-coding gene in which the *NTRK* kinase domain is not disrupted. This also includes rearrangement events that result in reciprocal fusions (*NTRK*-3' and 5'-*NTRK* events).

In this regard, out-of-strand events are considered as non-fusion rearrangements and are classified as CDx biomarker negative. Intragenic fusions in which genomic rearrangement events are wholly internal to the *NTRK1*, *NTRK2*, or *NTRK3* genes (i.e., *NTRK1*-*NTRK1*, *NTRK2*-*NTRK2*, *NTRK3*-*NTRK3* events) are also considered biomarker negative. Unidentified partners (encoded as N/A) or LINC non-coding partners are also considered

CDx biomarker negative.

13.10 CDx classification criteria for ROZLYTREK® (entrectinib) for patients with NSCLC

Presence of a *ROS1* fusion that meets the following condition:

- In-strand rearrangement events that may lead to a *ROS1* RNA fusion with another protein-coding gene in which the *ROS1* kinase domain is not disrupted. *ROS1* must be on the 3' end of the detected fusion.

In this regard, out-of-strand events are considered as non-fusion rearrangements and are classified as CDx biomarker negative. Intragenic fusions in which genomic rearrangement events are wholly internal to *ROS1* (i.e., *ROS1-ROS1* events) are also considered biomarker negative. Unidentified partners (encoded as N/A) or LINC non-coding partners are also considered CDx biomarker negative. *ROS1* fusions with novel partners are required to be in frame.

13.11 CDx classification criteria for RETEVMO® (selpercatinib) for patients with solid tumors

Presence of a *RET* fusion that involves another protein-coding gene and meets the following conditions:

- *RET* and the partner gene must be in the same 5'-3' orientation
- *RET* must be on the 3' end of the detected rearrangement
- The *RET* breakpoint must occur before the start of the kinase domain (amino acids 724-1016)

13.12 CDx classification criteria for TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant) for patients with breast cancer

Presence of any *AKT1*, *PIK3CA*, or *PTEN* alteration listed in **Table 128** **Error! Reference source not found..**

Table 128. Eligible *AKT1*, *PIK3CA*, or *PTEN* alterations

Gene (Transcript)	Variant type	Biomarker rules
<i>AKT1</i> (NM_001014431)	Short variant	Any short variant with protein effect E17K
<i>PIK3CA</i> (NM_006218)	Short variant	Any short variant with protein effect R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L, G1049R
<i>PTEN</i> (NM_000314)	Short variant	Any short variant with protein effect C124R, C124S, G129E, G129V, G129R, R130Q, R130G, R130L, R130P, C136R, C136Y, S170R, R173C
		Any nonsense ¹ , frameshift, or splice site ² alteration
	Copy number alteration	Homozygous deletion of one or more exons, regardless of transcript
	Rearrangement	Any inactivating rearrangement, regardless of transcript

¹ Missense mutations in the start codon and short variant deletions spanning from upstream of the start codon (annotated as M1?) are included in this category

² Defined as any splicing event that spans or occurs within ±2 bases of the intron/exon junction

13.13 CDx classification criteria for OJEMDA™ (tovorafenib) for patients with pediatric low-grade glioma

Presence of a *BRAF* alteration listed in **Table 129**

Table 129. Eligible *BRAF* alterations

Gene (Transcript)	Variant type	Biomarker description
<i>BRAF</i> (NM_004333)	Short variant	Any missense alteration resulting in V600X ¹
	Rearrangement	Any fusion event that involves <i>BRAF</i> and another protein-coding gene and meets all the following criteria: <i>BRAF</i> and the partner gene must be in the same 5'-3' orientation <i>BRAF</i> must be on the 3' end of the detected fusion - The <i>BRAF</i> breakpoint must occur after the autoinhibitory domain and before the kinase domain

¹ X refers to any single amino acid change resulting from a missense alteration.

13.14 CDx classification criteria for TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for patients with prostate cancer

Presence of an HRR alteration listed in **Table 130**

Table 130. Eligible HRR alterations

Gene (Transcript)	Variant type	Biomarker rules
<i>ATM</i> (NM_000051) <i>ATR</i> (NM_001184) <i>BRCA1</i> (NM_007294) <i>BRCA2</i> (NM_000059) <i>CDK12</i> (NM_016507) <i>CHEK2</i> (NM_007194) <i>FANCA</i> (NM_000135) <i>MLH1</i> (NM_000249) <i>MRE11A</i> (NM_005590) <i>NBN</i> (NM_002485) <i>PALB2</i> (NM_024675) <i>RAD51C</i> (NM_058216)	Short variant	- Any nonsense¹, frameshift, or splice site² variant - For <i>BRCA2</i>, truncating mutations must occur upstream of bases encoding amino acid 3326 - Any of the alterations³ listed in Table 124, Table 125, Table 127, or Table 131
	Copy number alteration	Homozygous deletion of one or more exons, regardless of transcript
	Rearrangement	Any rearrangement predicted to disrupt protein function, regardless of transcript

¹ This rule excludes missense mutations in the start codon and short variant deletions spanning from upstream of the start codon (annotated as M1?), unless otherwise noted in the variant tables.

² Defined as any splicing event that spans or occurs within ± 2 bases of the intron/exon junction.

³ *ATM* and *BRCA1/2* inactivating mutation lists may change over time as a result of periodic review of new evidence, in accordance with FDA-approved variant classification procedures.

Table 131. List of short variants in *CHEK2*, *FANCA*, *MLH1*, and *RAD51C*

Gene (Transcript)	Short variant
<i>CHEK2</i> (NM_007194)	R117G, G151S, K373E, A392V
<i>FANCA</i> (NM_000135)	F320L, F1263del
<i>MLH1</i> (NM_000249)	R265C
<i>RAD51C</i> (NM_058216)	L219S

13.15 CDx classification criteria for ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant for patients with breast cancer

Presence of a *PIK3CA* alteration listed in **Table 132**

Table 132. Eligible *PIK3CA* short variants

R88Q	N345D	E453G	E542V	Q546H	H1047L	G1049R
G106A	N345H	E453K	E545A	Q546K	H1047N	G1049S
G106D	N345I	E453Q	E545D	Q546L	H1047P	
G106R	N345K	E453V	E545G	Q546P	H1047Q	
G106S	N345S	E542A	E545K	Q546R	H1047R	
G106V	N345T	E542D	E545L	M1043I	H1047T	
K111N	N345Y	E542G	E545Q	M1043T	H1047Y	
K111R	C420R	E542K	E545R	M1043V	G1049A	
K111E	E453A	E542Q	E545V	H1047D	G1049C	
G118D	E453D	E542R	Q546E	H1047I	G1049D	

14 References

1. Li M. Statistical Methods for Clinical Validation of Follow-On Companion Diagnostic Devices via an External Concordance Study, *J Biopharm Stat* 26:6, 1067-107
2. Li H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 26, 589-595 (2010).
3. Li H., Handsaker B., Wysoker A., et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078-2079 (2009).
4. DePristo MA., Banks E., Poplin R., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 43, 491-498 (2011).
5. Forbes SA, Bindal N., Bamford S., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res* 39, D945-950 (2011).
6. Compeau PE., Pevzner PA., Tesler, G. How to apply de Bruijn graphs to genome assembly. *Nat Biotechnol* 29, 987-991 (2011).
7. Kimura H., Ohira T., Uchida O., et al. Analytical performance of the cobas *EGFR* mutation assay for Japanese non-small-cell lung cancer. *Lung Cancer* 83, 329-333 (2014).
8. Lopez-Rios F., Angulo B., Gomez B., et al. Comparison of molecular testing methods for the detection of *EGFR* mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. *J Clin Pathol* 66, 381-385 (2013).
9. Wong AT, To RM, Wong CL, et al. Evaluation of 2 Real-Time PCR Assays for In Vitro Diagnostic Use in

the Rapid and Multiplex Detection of *EGFR* Gene Mutations in NSCLC. *Diagn Mol Pathol* 22, 138- 43 (2013).

10. Press et al., HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical **Trials**, *J Clin Oncol* 34:3518-3528, 2016
11. Dowsett, M. et al, Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated with Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial, *J Clin Oncol* 27:2962-2969, 2009
12. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK Targeted Therapeutics. *JCO Precis Oncol*. 2018;2018:10.1200/PO.18.00183.
13. Turner NC, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. *NEJM*. 2024;391(17).
14. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 2008; 68; 6084-91.
15. R. Brookmeyer, and J. Crowley. "A Confidence Interval for the Median Survival Time." *Biometrics*, vol. 38, no. 1, pp.29–41, 1982. JSTOR, <https://doi.org/10.2307/2530286>.

PATIENT

DISEASE **Prostate acinar adenocarcinoma**
NAME
DATE OF BIRTH
SEX
MEDICAL RECORD #

PHYSICIAN

ORDERING PHYSICIAN
MEDICAL FACILITY
ADDITIONAL RECIPIENT
MEDICAL FACILITY ID
PATHOLOGIST

SPECIMEN

SPECIMEN SITE
SPECIMEN ID
SPECIMEN TYPE
DATE OF COLLECTION
SPECIMEN RECEIVED

FDA-Approved Content

Companion Diagnostic (CDx) Findings

A companion diagnostic provides essential information for the safe and effective use of a corresponding drug or biological product. This table contains therapies associated with FoundationOne®CDx's FDA-approved companion diagnostic indications.

GENOMIC FINDINGS
CDx-INDICATED THERAPIES

No Companion Diagnostic (CDx) alterations for FoundationOne®CDx were detected.

Tumor Profiling Results

FoundationOne®CDx is FDA-approved to provide tumor mutation profiling results for oncology patients with solid tumors.

GENOMIC FINDINGS & BIOMARKERS IDENTIFIED

Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See *professional services* section for additional information.

Microsatellite status MS-Stable §

Tumor Mutational Burden 2 Muts/Mb §

LYN amplification §

NF1 NF1(NM_001042492) deletion intron 2 - intron 26 §

PTEN loss §

§ Refer to appendix for limitation statements related to detection of any copy number alterations, gene rearrangements, BRCA1/2 alterations, MSI, or TMB results in this section.

Please refer to appendix for Explanation of Clinical Significance Classification and for variants of unknown significance (VUS).

ORDERED TEST #

APPENDIX

About FoundationOne®CDx

INTENDED USE

FoundationOne®CDx (F1CDx) is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.

TABLE 1: COMPANION DIAGNOSTIC INDICATIONS

TUMOR TYPE	BIOMARKER(S) DETECTED	THERAPY
Breast cancer	<i>AKT1</i> E17K; <i>PIK3CA</i> R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L and G1049R; and <i>PTEN</i> alterations	TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant)
	<i>ERBB2</i> (HER2) amplification	HERCEPTIN® (trastuzumab) KADCYLA® (ado-trastuzumab emtansine) PERJETA® (pertuzumab)
	<i>PIK3CA</i> mutations	ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant
	<i>PIK3CA</i> mutations (C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y)	PIQRAY® (alpelisib)
Cholangiocarcinoma	<i>FGFR2</i> fusions and select rearrangements	PEMAZYRE® (pemigatinib)
Colorectal cancer	<i>KRAS/NRAS</i> wild-type (absence of mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146))	ERBITUX® (cetuximab) VECTIBIX® (panitumumab)
	<i>BRAF</i> V600 mutation-positive	TECENTRIQ® (atezolizumab) in combination with COTELLIC® (cobimetinib) and ZELBORAF® (vemurafenib)
Melanoma	<i>BRAF</i> V600E	BRAF Inhibitor Approved by FDA*
	<i>BRAF</i> V600E and V600K	BRAF/MEK Inhibitor Combinations Approved by FDA* MEKINIST® (trametinib)
Non-small cell lung cancer (NSCLC)	<i>ALK</i> rearrangements	ALECENSA® (alectinib) ALUNBRIG® (brigatinib) XALKORI® (crizotinib) ZYKADIA® (ceritinib)
		BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
		TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)
		EGFR Tyrosine Kinase Inhibitors (TKI) Approved by FDA*
	<i>EGFR</i> exon 19 deletions and <i>EGFR</i> exon 21 L858R alterations	TAGRISSO® (osimertinib)
	<i>EGFR</i> exon 20 T790M alterations	TABRECTA® (capmatinib)
	<i>MET</i> single nucleotide variants (SNVs) and indels that lead to <i>MET</i> exon 14 skipping	TEPMETKO® (tepotinib)
	<i>ROS1</i> fusions	ROZLYTREK® (entrectinib)
Ovarian cancer	<i>BRCA1</i> , <i>BRCA2</i> alterations	LYNPARZA® (olaparib)

TABLE CONTINUED ON NEXT PAGE

© 2026 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Leah Commander, M.D. |
Lauren L. Ritterhouse Casariego, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Douglas A. Mata, M.D., M.P.H., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 400 Summer St., Boston, MA 02210 · CLIA: 22D2027531

ORDERED TEST #

APPENDIX
About FoundationOne®CDx
TABLE 1: COMPANION DIAGNOSTIC INDICATIONS CONTINUED

TUMOR TYPE	BIOMARKER(S) DETECTED	THERAPY
Pediatric low-grade glioma	<i>BRAF</i> V600 mutation-positive and <i>BRAF</i> fusions	OJEMDA™ (tovorafenib)
Prostate cancer	<i>BRCA1</i> , <i>BRCA2</i> alterations	AKEEGA® (niraparib + abiraterone acetate)
		LYNPARZA® (olaparib) in combination with abiraterone
	Homologous Recombination Repair (<i>HRR</i>) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>ATR</i> , <i>CDK12</i> , <i>CHEK2</i> , <i>FANCA</i> , <i>MLH1</i> , <i>MRE11A</i> , <i>NBN</i> , <i>PALB2</i> , <i>RAD51C</i>) alterations	TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide)
	Homologous Recombination Repair (<i>HRR</i>) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>BARD1</i> , <i>BRIP1</i> , <i>CDK12</i> , <i>CHEK1</i> , <i>CHEK2</i> , <i>FANCL</i> , <i>PALB2</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RAD54L</i>) alterations	LYNPARZA® (olaparib)
Solid Tumors	<i>MSI</i> -High	KEYTRUDA® (pembrolizumab)
	<i>NTRK1/2/3</i> fusions	ROZLYTREK® (entrectinib)
		VITRAKVI® (larotrectinib)
	<i>RET</i> fusions	RETEVMO® (selpercatinib)
	<i>TMB</i> ≥ 10 mutations per megabase	KEYTRUDA® (pembrolizumab)

*For the most current information about the therapeutic products in this group, go to: <https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm>

The median exon coverage for this sample is 2,240x

ORDERED TEST #

APPENDIX

About FoundationOne®CDx

TEST PRINCIPLE

FoundationOne®CDx (F1CDx) is performed exclusively at Foundation Medicine, Inc. owned and operated sites using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The assay employs CoExtraction, an automated DNA/RNA co-extraction methodology for DNA extraction from routine FFPE biopsy or surgical resection specimens; 50-1000 ng of DNA will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons (refer to Table 2 and Table 3 for the complete list of genes included in F1CDx). In total, the assay detects alterations in a total of 324 genes. Using the Illumina® NovaSeq 6000, hybrid capture-selected libraries are sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data is then processed using a customized analysis pipeline designed to detect all classes of genomic alterations, including base substitutions, indels, copy number alterations (amplifications and homozygous gene deletions), and select genomic rearrangements (e.g., gene fusions). Rearrangements in one of the targeted genes included in Table 3 may be reported along with their uniquely identified genomic partners, which can be any gene in the genome even if not explicitly targeted by the assay. Additionally, genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) are reported.

PERFORMANCE CHARACTERISTICS

Please refer to product label:
foundationmedicine.com/f1cdx

WARNINGS AND PRECAUTIONS

1. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
2. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
3. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an ERBB2 amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical

concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of ERBB2 copy number 4 in breast cancer is estimated to be approximately 2%. HER2 overexpression occurs in 18-20% of breast cancers (Owens et al. 2004 [PMID: 15140287]; Salmon et al. 1987 [PMID: 3798106]; Yaziji et al. 2004 [PMID: 15113815]). Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay.
4. Samples with <25% tumor may have decreased sensitivity for the detection of copy number alterations including *ERBB2*.
5. Clinical performance of Tagrisso® (osimertinib) in patients with an *EGFR* exon 20 T790M mutation detected with an allele fraction <5% is ongoing and has not been established.
6. Due to differences in variant calling between assays and technologies, the FoundationOne CDx assay may not identify and report approximately 16% (10/61) of copy number alterations and approximately 18% (3/17) of rearrangements.
7. Confirmatory testing using a clinically validated assay should be performed for all copy number alterations and rearrangements not associated with CDx claims noted in Table 1 of the Intended Use but used for clinical decision making.
8. For patients with solid tumors whose samples have MSI scores >0.0041 and <0.0124, an MSI "Cannot Be Determined" result is reported. Patients with this result should be retested with a validated orthogonal (alternative) method as these MSI scores represent a range of scores with low reliability. The likelihood of a patient receiving this result is ~3.29% within solid tumors.
9. Patients with solid tumors may also receive an MSI status reported as "Cannot Be Determined" due to a quality control (QC) failure. When all sample-level quality metrics are met, the rate of MSI "Cannot Be Determined" results due to a QC failure is 8.96%. Patients with this result should consider re-testing with FoundationOne CDx or an orthogonal (alternative) method, if clinically appropriate.
10. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
11. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community.
12. The test is intended to be performed on specific serial number-controlled instruments by Foundation Medicine, Inc.
13. Alterations in polyT homopolymer runs may not be reliably detected in BRCA1/2.
14. Certain large rearrangements in BRCA1/2 including large scale genomic deletions (affecting at least one whole exon), insertions or other deleterious genomic rearrangements including inversions or transversion events, may not be detected in an estimated 5% of ovarian cancer patients with BRCA1/2 mutations by F1CDx.
15. Certain potentially deleterious missense or small in-frame deletions in BRCA1/2 may not

ORDERED TEST

APPENDIX

About FoundationOne®CDx

- be reported under the “CDx associated findings” but may be reported in the “Other alterations and biomarkers identified” section in the patient report.
16. Alterations at allele frequencies below the established limit of detection may not be detected consistently.
 17. While the overall positive percent agreement between trial enrollment assays and F1CDx was 84% (37/44), thirty percent (30%) (6/20) of patients enrolled in the VITRAKVI clinical studies using RNA-based NGS detection were negative for *NTRK* fusions by F1CDx. Four of the six patients (4/6 or 60%) that were negative for *NTRK* fusions by F1CDx had a response to larotrectinib. Therefore, F1CDx may miss a subset of patients with solid tumors with *NTRK1/2/3* fusions who may derive benefit from VITRAKVI.
 18. *NTRK2* fusions per the F1CDx CDx biomarker rules for *NTRK1/2/3* fusions were not well-represented in analytical validation studies.
 19. While the overall positive percent agreement between trial enrollment assays and F1CDx was 63.6% (21/33), 52.4% (11/21) of patients enrolled in the ROZLYTREK clinical studies using RNA-based NGS detection were negative for *NTRK* fusions by F1CDx. 36.4% (4/11) of the patients enrolled using RNA-based NGS detection that were negative for *NTRK* fusions by F1CDx had a response to ROZLYTREK.
 20. While the overall positive percent agreement between trial enrollment assays and F1CDx was 73.9% (34/46), 30.3% (10/33) of patients enrolled in the ROZLYTREK clinical studies using RNA-based NGS detection were negative for *ROS1* fusions by F1CDx. 50% (5/10) of the patients enrolled using RNA-based NGS detection that were negative for *ROS1* fusions by F1CDx had a response to ROZLYTREK.
 21. Due to differences in technology, F1CDx, FISH, and IHC may identify slightly different populations when detecting *ALK* rearrangements. 6.5% of negatives by F1CDx may be positive by both IHC and FISH. See Section 3.4 of the device label for more information.
 22. Certain gene fusions, homozygous deletions and rearrangements including but not limited to *BRCA1*, *BRCA2*, *CDK12*, and indels in *PALB2* were not adequately represented in analytical validation studies and may not be detected consistently by F1CDx.
 23. Due to technological differences in detection, patients who are negative by F1CDx for *RET* fusions may derive benefit from RETEVMO when determined to be positive by other test methods.
 24. Rearrangement detection relies on the breakpoint of the targeted genes listed in Table 3. Rearrangements reported with genomic partners that consist of genes not targeted by the assay have not been validated by the assay.
 25. Additional clinical investigation for *NTRK1/2/3* fusions determined to be negative by F1CDx is recommended for cancers with high *NTRK1/2/3* fusion rates (e.g., soft tissue infantile fibrosarcoma, kidney mesoblastic nephroma, salivary gland secretory carcinoma (MASC), breast secretory carcinoma) such that patients may not forgo a potentially effective therapy.
 26. F1CDx may miss a subset of patients with solid tumors with *NTRK3* fusions due to the design of the test not fully covering the *NTRK3* gene and common fusion partners.
 27. This assay did not detect 24.3% (9/37) of *BRAF* fusions in the clinical validation study supporting this indication. Reduced sensitivity to detect *BRAF* fusions in the clinical validation samples was attributed to sub-optimal quality metrics, including low tumor purity, observed across the whole sample population. Physicians who receive a negative report for *BRAF* fusions for patients with pediatric low-grade glioma should consider following up with another test such that patients may not forgo a potentially effective therapy.
 28. The effect of hemoglobin interference has not been evaluated for the reporting of tumor mutational burden (TMB) with the FoundationOne®CDx assay.

ASSAY CONFIGURATION SPECIFIC TO THIS ISSUED REPORT

MR Suite Version (RG) 9.1.1
MR Reporting Config Version 88
Analysis Pipeline Version v3.45.1
Computational Biology Suite Version 7.3.1
Sequencer Type: NovaSeq 6000
Extraction Method: CoExtraction

ORDERED TEST #

APPENDIX

Genes assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

TABLE 2 | DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B or WTX)	
APC	AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX
AURKA	AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3-3A (H3F3A)
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11 (MRE11A)	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	NTRK3
P2RY8	PALB2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)
PDGFRA	PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1
PMS2	POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI
PRKN (PARK2)	PTCH1	PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51
RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10
REL	RET	RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO
SNCAIP	SOC3	SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3
STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)	TYRO3	TET2	TGFBR2
TIPARP	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3	U2AF1	VEGFA
VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703			

TABLE 3 | DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC**	TERT***	TPR552

**TERC is an NCRNA

***Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Tumor Mutational Burden (TMB)

PATIENT

DISEASE Breast carcinoma (NOS)
NAME
DATE OF BIRTH
SEX
MEDICAL RECORD #

PHYSICIAN

ORDERING PHYSICIAN
MEDICAL FACILITY
ADDITIONAL RECIPIENT
MEDICAL FACILITY ID
PATHOLOGIST

SPECIMEN

SPECIMEN SITE
SPECIMEN ID
SPECIMEN TYPE
DATE OF COLLECTION
SPECIMEN RECEIVED

FDA-Approved Content

Companion Diagnostic (CDx) Findings

A companion diagnostic provides essential information for the safe and effective use of a corresponding drug or biological product. This table contains therapies associated with FoundationOne®CDx's FDA-approved companion diagnostic indications.

GENOMIC FINDINGS
PIK3CA E542K

CDx-INDICATED THERAPIES

Itovebi™ (Inavolisib) in combination with palbociclib and fulvestrant
Piqray® (Alpelisib)
Truqap™ (Capivasertib) in combination with Faslodex® (Fulvestrant)

Tumor Profiling Results

FoundationOne®CDx is FDA-approved to provide tumor mutation profiling results for oncology patients with solid tumors.

GENOMIC FINDINGS & BIOMARKERS IDENTIFIED

Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See *professional services* section for additional information.

Microsatellite status MS-Stable §

Tumor Mutational Burden 2 Muts/Mb §

ATM R2032K

FGFR1 amplification §

MDM2 amplification §

NSD3 (WHSC1L1) amplification §

PIK3CA E542K

ZNF703 amplification §

§ Refer to appendix for limitation statements related to detection of any copy number alterations, gene rearrangements, BRCA1/2 alterations, MSI, or TMB results in this section.

Please refer to appendix for Explanation of Clinical Significance Classification and for variants of unknown significance (VUS).

PATIENT

DISEASE Colon adenocarcinoma (CRC)
NAME
DATE OF BIRTH
SEX
MEDICAL RECORD #

PHYSICIAN

ORDERING PHYSICIAN
MEDICAL FACILITY
ADDITIONAL RECIPIENT
MEDICAL FACILITY ID
PATHOLOGIST

SPECIMEN

SPECIMEN SITE
SPECIMEN ID
SPECIMEN TYPE
DATE OF COLLECTION
SPECIMEN RECEIVED

FDA-Approved Content

Companion Diagnostic (CDx) Findings

A companion diagnostic provides essential information for the safe and effective use of a corresponding drug or biological product. This table contains therapies associated with FoundationOne®CDx's FDA-approved companion diagnostic indications.

GENOMIC FINDINGS
KRAS/NRAS

absence of mutation at codons 12, 13, 59, 61, 117, 146 (wildtype)

CDx-INDICATED THERAPIES

Erbix® (Cetuximab)

Vectibix® (Panitumumab)

Tumor Profiling Results

FoundationOne®CDx is FDA-approved to provide tumor mutation profiling results for oncology patients with solid tumors.

GENOMIC FINDINGS & BIOMARKERS IDENTIFIED

Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See *professional services* section for additional information.

Microsatellite status MS-Stable §

Tumor Mutational Burden 5 Muts/Mb §

APC Q1367*

KMT2D (MLL2) R4484*

KRAS D33E ✖

RET G115S

TP53 Y220C

§ Refer to appendix for limitation statements related to detection of any copy number alterations, gene rearrangements, BRCA1/2 alterations, MSI, or TMB results in this section.

Please refer to appendix for Explanation of Clinical Significance Classification and for variants of unknown significance (VUS).


POTENTIAL RESISTANCE

While this patient has a CDx-positive finding, a co-occurring alteration identified may confer resistance to a therapy indicated above.

PATIENT

DISEASE **Prostate acinar adenocarcinoma**
NAME
DATE OF BIRTH
SEX
MEDICAL RECORD #

PHYSICIAN

ORDERING PHYSICIAN
MEDICAL FACILITY
ADDITIONAL RECIPIENT
MEDICAL FACILITY ID
PATHOLOGIST

SPECIMEN

SPECIMEN SITE
SPECIMEN ID
SPECIMEN TYPE
DATE OF COLLECTION
SPECIMEN RECEIVED

FDA-Approved Content

Companion Diagnostic (CDx) Findings

A companion diagnostic provides essential information for the safe and effective use of a corresponding drug or biological product. This table contains therapies associated with FoundationOne®CDx's FDA-approved companion diagnostic indications.

GENOMIC FINDINGS
ATM Q1839*

CDx-INDICATED THERAPIES

Lynparza® (Olaparib)
Talzena® (Talazoparib) in combination with Xtandi® (Enzalutamide)

Tumor Profiling Results

FoundationOne®CDx is FDA-approved to provide tumor mutation profiling results for oncology patients with solid tumors.

GENOMIC FINDINGS & BIOMARKERS IDENTIFIED

Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See *professional services* section for additional information.

Microsatellite status MS-Stable §

Tumor Mutational Burden 2 Muts/Mb §

ATM Q1839*

PTEN loss §

TMPRSS2 TMPRSS2(NM_005656)-ERG(NM_004449) fusion (T3; E4) §

§ Refer to appendix for limitation statements related to detection of any copy number alterations, gene rearrangements, BRCA1/2 alterations, MSI, or TMB results in this section.

Please refer to appendix for Explanation of Clinical Significance Classification and for variants of unknown significance (VUS).

ORDERED TEST #

APPENDIX

About FoundationOne®CDx

INTENDED USE

FoundationOne®CDx (F1CDx) is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.

TABLE 1: COMPANION DIAGNOSTIC INDICATIONS

TUMOR TYPE	BIOMARKER(S) DETECTED	THERAPY
Breast cancer	<i>AKT1</i> E17K; <i>PIK3CA</i> R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L and G1049R; and <i>PTEN</i> alterations	TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant)
	<i>ERBB2</i> (HER2) amplification	HERCEPTIN® (trastuzumab) KADCYLA® (ado-trastuzumab emtansine) PERJETA® (pertuzumab)
	<i>PIK3CA</i> mutations	ITOVEBI™ (inavolisib) in combination with palbociclib and fulvestrant
	<i>PIK3CA</i> mutations (C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y)	PIQRAY® (alpelisib)
Cholangiocarcinoma	<i>FGFR2</i> fusions and select rearrangements	PEMAZYRE® (pemigatinib)
Colorectal cancer	<i>KRAS/NRAS</i> wild-type (absence of mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146))	ERBITUX® (cetuximab) VECTIBIX® (panitumumab)
Melanoma	<i>BRAF</i> V600 mutation-positive	TECENTRIQ® (atezolizumab) in combination with COTELLIC® (cobimetinib) and ZELBORAF® (vemurafenib)
	<i>BRAF</i> V600E	BRAF Inhibitor Approved by FDA*
	<i>BRAF</i> V600E and V600K	BRAF/MEK Inhibitor Combinations Approved by FDA*
		MEKINIST® (trametinib)
Non-small cell lung cancer (NSCLC)	<i>ALK</i> rearrangements	ALECENSA® (alectinib) ALUNBRIG® (brigatinib) XALKORI® (crizotinib) ZYKADIA® (ceritinib)
	<i>BRAF</i> V600E	BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)
	<i>EGFR</i> exon 19 deletions and <i>EGFR</i> exon 21 L858R alterations	EGFR Tyrosine Kinase Inhibitors (TKI) Approved by FDA*
	<i>EGFR</i> exon 20 T790M alterations	TAGRISSO® (osimertinib)
	<i>MET</i> single nucleotide variants (SNVs) and indels that lead to <i>MET</i> exon 14 skipping	TABRECTA® (capmatinib) TEPMETKO® (tepotinib)
	<i>ROS1</i> fusions	ROZLYTREK® (entrectinib)
Ovarian cancer	<i>BRCA1</i> , <i>BRCA2</i> alterations	LYNPARZA® (olaparib)

TABLE CONTINUED ON NEXT PAGE

© 2026 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Leah Commander, M.D. |
Lauren L. Ritterhouse Casariego, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Douglas A. Mata, M.D., M.P.H., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 400 Summer St., Boston, MA 02210 · CLIA: 22D2027531

ORDERED TEST #

APPENDIX
About FoundationOne®CDx
TABLE 1: COMPANION DIAGNOSTIC INDICATIONS CONTINUED

TUMOR TYPE	BIOMARKER(S) DETECTED	THERAPY
Pediatric low-grade glioma	<i>BRAF</i> V600 mutation-positive and <i>BRAF</i> fusions	OJEMDA™ (tovorafenib)
Prostate cancer	<i>BRCA1</i> , <i>BRCA2</i> alterations	AKEEGA® (niraparib + abiraterone acetate)
		LYNPARZA® (olaparib) in combination with abiraterone
	Homologous Recombination Repair (<i>HRR</i>) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>ATR</i> , <i>CDK12</i> , <i>CHEK2</i> , <i>FANCA</i> , <i>MLH1</i> , <i>MRE11A</i> , <i>NBN</i> , <i>PALB2</i> , <i>RAD51C</i>) alterations	TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide)
	Homologous Recombination Repair (<i>HRR</i>) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>BARD1</i> , <i>BRIP1</i> , <i>CDK12</i> , <i>CHEK1</i> , <i>CHEK2</i> , <i>FANCL</i> , <i>PALB2</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RAD54L</i>) alterations	LYNPARZA® (olaparib)
Solid Tumors	<i>MSI</i> -High	KEYTRUDA® (pembrolizumab)
	<i>NTRK1/2/3</i> fusions	ROZLYTREK® (entrectinib)
		VITRAKVI® (larotrectinib)
	<i>RET</i> fusions	RETEVMO® (selpercatinib)
	<i>TMB</i> ≥ 10 mutations per megabase	KEYTRUDA® (pembrolizumab)

*For the most current information about the therapeutic products in this group, go to: <https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm>

The median exon coverage for this sample is 2,240x

ORDERED TEST #

APPENDIX

About FoundationOne®CDx

TEST PRINCIPLE

FoundationOne®CDx (F1CDx) is performed exclusively at Foundation Medicine, Inc. owned and operated sites using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The assay employs CoExtraction, an automated DNA/RNA co-extraction methodology for DNA extraction from routine FFPE biopsy or surgical resection specimens; 50-1000 ng of DNA will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons (refer to Table 2 and Table 3 for the complete list of genes included in F1CDx). In total, the assay detects alterations in a total of 324 genes. Using the Illumina® NovaSeq 6000, hybrid capture-selected libraries are sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data is then processed using a customized analysis pipeline designed to detect all classes of genomic alterations, including base substitutions, indels, copy number alterations (amplifications and homozygous gene deletions), and select genomic rearrangements (e.g., gene fusions). Rearrangements in one of the targeted genes included in Table 3 may be reported along with their uniquely identified genomic partners, which can be any gene in the genome even if not explicitly targeted by the assay. Additionally, genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) are reported.

PERFORMANCE CHARACTERISTICS

Please refer to product label:
foundationmedicine.com/f1cdx

WARNINGS AND PRECAUTIONS

1. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
2. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
3. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an ERBB2 amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical

concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of ERBB2 copy number 4 in breast cancer is estimated to be approximately 2%. HER2 overexpression occurs in 18-20% of breast cancers (Owens et al. 2004 [PMID: 15140287]; Salmon et al. 1987 [PMID: 3798106]; Yaziji et al. 2004 [PMID: 15113815]). Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay.
4. Samples with <25% tumor may have decreased sensitivity for the detection of copy number alterations including *ERBB2*.
5. Clinical performance of Tagrisso® (osimertinib) in patients with an *EGFR* exon 20 T790M mutation detected with an allele fraction <5% is ongoing and has not been established.
6. Due to differences in variant calling between assays and technologies, the FoundationOne CDx assay may not identify and report approximately 16% (10/61) of copy number alterations and approximately 18% (3/17) of rearrangements.
7. Confirmatory testing using a clinically validated assay should be performed for all copy number alterations and rearrangements not associated with CDx claims noted in Table 1 of the Intended Use but used for clinical decision making.
8. For patients with solid tumors whose samples have MSI scores >0.0041 and <0.0124, an MSI "Cannot Be Determined" result is reported. Patients with this result should be retested with a validated orthogonal (alternative) method as these MSI scores represent a range of scores with low reliability. The likelihood of a patient receiving this result is ~3.29% within solid tumors.
9. Patients with solid tumors may also receive an MSI status reported as "Cannot Be Determined" due to a quality control (QC) failure. When all sample-level quality metrics are met, the rate of MSI "Cannot Be Determined" results due to a

QC failure is 8.96%. Patients with this result should consider re-testing with FoundationOne CDx or an orthogonal (alternative) method, if clinically appropriate.

10. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
11. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community.
12. The test is intended to be performed on specific serial number-controlled instruments by Foundation Medicine, Inc.
13. Alterations in polyT homopolymer runs may not be reliably detected in BRCA1/2.
14. Certain large rearrangements in BRCA1/2 including large scale genomic deletions (affecting at least one whole exon), insertions or other deleterious genomic rearrangements including inversions or transversion events, may not be detected in an estimated 5% of ovarian cancer patients with BRCA1/2 mutations by F1CDx.
15. Certain potentially deleterious missense or small in-frame deletions in BRCA1/2 may not

ORDERED TEST

APPENDIX

About FoundationOne®CDx

- be reported under the “CDx associated findings” but may be reported in the “Other alterations and biomarkers identified” section in the patient report.
16. Alterations at allele frequencies below the established limit of detection may not be detected consistently.
 17. While the overall positive percent agreement between trial enrollment assays and F1CDx was 84% (37/44), thirty percent (30%) (6/20) of patients enrolled in the VITRAKVI clinical studies using RNA-based NGS detection were negative for *NTRK* fusions by F1CDx. Four of the six patients (4/6 or 60%) that were negative for *NTRK* fusions by F1CDx had a response to larotrectinib. Therefore, F1CDx may miss a subset of patients with solid tumors with *NTRK1/2/3* fusions who may derive benefit from VITRAKVI.
 18. *NTRK2* fusions per the F1CDx CDx biomarker rules for *NTRK1/2/3* fusions were not well-represented in analytical validation studies.
 19. While the overall positive percent agreement between trial enrollment assays and F1CDx was 63.6% (21/33), 52.4% (11/21) of patients enrolled in the ROZLYTREK clinical studies using RNA-based NGS detection were negative for *NTRK* fusions by F1CDx. 36.4% (4/11) of the patients enrolled using RNA-based NGS detection that were negative for *NTRK* fusions by F1CDx had a response to ROZLYTREK.
 20. While the overall positive percent agreement between trial enrollment assays and F1CDx was 73.9% (34/46), 30.3% (10/33) of patients enrolled in the ROZLYTREK clinical studies using RNA-based NGS detection were negative for *ROS1* fusions by F1CDx. 50% (5/10) of the patients enrolled using RNA-based NGS detection that were negative for *ROS1* fusions by F1CDx had a response to ROZLYTREK.
 21. Due to differences in technology, F1CDx, FISH, and IHC may identify slightly different populations when detecting *ALK* rearrangements. 6.5% of negatives by F1CDx may be positive by both IHC and FISH. See Section 3.4 of the device label for more information.
 22. Certain gene fusions, homozygous deletions and rearrangements including but not limited to *BRCA1*, *BRCA2*, *CDK12*, and indels in *PALB2* were not adequately represented in analytical validation studies and may not be detected consistently by F1CDx.
 23. Due to technological differences in detection, patients who are negative by F1CDx for *RET* fusions may derive benefit from RETEVMO when determined to be positive by other test methods.
 24. Rearrangement detection relies on the breakpoint of the targeted genes listed in Table 3. Rearrangements reported with genomic partners that consist of genes not targeted by the assay have not been validated by the assay.
 25. Additional clinical investigation for *NTRK1/2/3* fusions determined to be negative by F1CDx is recommended for cancers with high *NTRK1/2/3* fusion rates (e.g., soft tissue infantile fibrosarcoma, kidney mesoblastic nephroma, salivary gland secretory carcinoma (MASC), breast secretory carcinoma) such that patients may not forgo a potentially effective therapy.
 26. F1CDx may miss a subset of patients with solid tumors with *NTRK3* fusions due to the design of the test not fully covering the *NTRK3* gene and common fusion partners.
 27. This assay did not detect 24.3% (9/37) of *BRAF* fusions in the clinical validation study supporting this indication. Reduced sensitivity to detect *BRAF* fusions in the clinical validation samples was attributed to sub-optimal quality metrics, including low tumor purity, observed across the whole sample population. Physicians who receive a negative report for *BRAF* fusions for patients with pediatric low-grade glioma should consider following up with another test such that patients may not forgo a potentially effective therapy.
 28. The effect of hemoglobin interference has not been evaluated for the reporting of tumor mutational burden (TMB) with the FoundationOne®CDx assay.

ASSAY CONFIGURATION SPECIFIC TO THIS ISSUED REPORT

MR Suite Version (RG) 9.1.1
MR Reporting Config Version 88
Analysis Pipeline Version v3.45.1
Computational Biology Suite Version 7.3.1
Sequencer Type: NovaSeq 6000
Extraction Method: CoExtraction

ORDERED TEST #

APPENDIX

Genes assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

TABLE 2 | DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B or WTX)	
APC	AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX
AURKA	AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3-3A (H3F3A)
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11 (MRE11A)	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL1 (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	NTRK3
P2RY8	PALB2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)
PDGFRA	PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1
PMS2	POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI
PRKN (PARK2)	PTCH1	PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51
RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10
REL	RET	RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO
SNCAIP	SOC3	SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3
STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)	TYRO3	TET2	TGFBR2
TIPARP	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3	U2AF1	VEGFA
VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703			

TABLE 3 | DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC**	TERT***	TPRSS2

**TERC is an NCRNA

***Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Tumor Mutational Burden (TMB)